Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,19927376,nK(A),"The affinity of HSA and AGP to (+)-THP, expressed as nK(A), were 9.0 x 10(3) M(-1) and 2.34 x 10(5) M(-1), respectively, which were notablely higher than to (-)-THP, with the nK(A) of 3.4 x 10(3) M(-1) and 1.44 x 10(5) M(-1), respectively.","Stereoselective protein binding of tetrahydropalmatine enantiomers in human plasma, HSA, and AGP, but not in rat plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19927376/),1/[M],9.0 x 10(3),308,DB01050,Ibuprofen
,19927376,nK(A),"The affinity of HSA and AGP to (+)-THP, expressed as nK(A), were 9.0 x 10(3) M(-1) and 2.34 x 10(5) M(-1), respectively, which were notablely higher than to (-)-THP, with the nK(A) of 3.4 x 10(3) M(-1) and 1.44 x 10(5) M(-1), respectively.","Stereoselective protein binding of tetrahydropalmatine enantiomers in human plasma, HSA, and AGP, but not in rat plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19927376/),1/[M],2.34 x 10(5),309,DB01050,Ibuprofen
,19927376,nK(A),"The affinity of HSA and AGP to (+)-THP, expressed as nK(A), were 9.0 x 10(3) M(-1) and 2.34 x 10(5) M(-1), respectively, which were notablely higher than to (-)-THP, with the nK(A) of 3.4 x 10(3) M(-1) and 1.44 x 10(5) M(-1), respectively.","Stereoselective protein binding of tetrahydropalmatine enantiomers in human plasma, HSA, and AGP, but not in rat plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19927376/),1/[M],3.4 x 10(3),310,DB01050,Ibuprofen
,19927376,nK(A),"The affinity of HSA and AGP to (+)-THP, expressed as nK(A), were 9.0 x 10(3) M(-1) and 2.34 x 10(5) M(-1), respectively, which were notablely higher than to (-)-THP, with the nK(A) of 3.4 x 10(3) M(-1) and 1.44 x 10(5) M(-1), respectively.","Stereoselective protein binding of tetrahydropalmatine enantiomers in human plasma, HSA, and AGP, but not in rat plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19927376/),1/[M],1.44 x 10(5),311,DB01050,Ibuprofen
,30673916,relative bioavailability,"Though IBU of IBU-PE sustained release bilayer tablet was bioequivalent to the commercial IBU tablet, the relative bioavailability of PE from the bilayer tablets was 87.49 ± 20.00% (90% confidence interval was 72.3 to 102.5%), indicating bioinequivalence probably due to the ""first pass"" effect.",Sustained Release Bilayer Tablet of Ibuprofen and Phenylephrine Hydrochloride: Preparation and Pharmacokinetics in Beagle Dogs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30673916/),%,87.49,975,DB01050,Ibuprofen
,2720131,AUC,The mean AUC and Cmax from rectal administration were 87 per cent and 62 per cent of the corresponding values achieved after oral administration.,Absorption kinetics of rectally and orally administered ibuprofen. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2720131/),%,87,1929,DB01050,Ibuprofen
,2720131,Cmax,The mean AUC and Cmax from rectal administration were 87 per cent and 62 per cent of the corresponding values achieved after oral administration.,Absorption kinetics of rectally and orally administered ibuprofen. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2720131/),%,62,1930,DB01050,Ibuprofen
,8398601,recovery,"The recovery of total KT in bile was significantly higher after administration of (S)-KT than after (R)-KT [90.1 +/- 3.5% vs 68.8 +/- 8.2%, n = 3, P < 0.05].",Stereoselectivity of biliary excretion of 2-arylpropionates in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8398601/),%,90.1,2051,DB01050,Ibuprofen
,8398601,recovery,"The recovery of total KT in bile was significantly higher after administration of (S)-KT than after (R)-KT [90.1 +/- 3.5% vs 68.8 +/- 8.2%, n = 3, P < 0.05].",Stereoselectivity of biliary excretion of 2-arylpropionates in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8398601/),%,68.8,2052,DB01050,Ibuprofen
,8398601,terminal half-life,"In normal rats the terminal half-life of (R)-KT was significantly shorter than that of (S)-KT after administration of (R)-KT (2.2 +/- 0.6 h vs 14.3 +/- 4.9 h, n = 3, P < 0.05).",Stereoselectivity of biliary excretion of 2-arylpropionates in rats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8398601/),h,2.2,2053,DB01050,Ibuprofen
,8398601,terminal half-life,"In normal rats the terminal half-life of (R)-KT was significantly shorter than that of (S)-KT after administration of (R)-KT (2.2 +/- 0.6 h vs 14.3 +/- 4.9 h, n = 3, P < 0.05).",Stereoselectivity of biliary excretion of 2-arylpropionates in rats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8398601/),h,14.3,2054,DB01050,Ibuprofen
,24954342,T1/2,"Diclofenac potassium had the lowest T1/2 and the highest mean Css, muscle/Css, plasma (1.9 hours and 0.85±0.53, respectively).",Concentration of non-steroidal anti-inflammatory drugs in the pelvic floor muscles: an experimental comparative rat model. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24954342/),h,1.9,2086,DB01050,Ibuprofen
,24954342,"Css, muscle/Css","Diclofenac potassium had the lowest T1/2 and the highest mean Css, muscle/Css, plasma (1.9 hours and 0.85±0.53, respectively).",Concentration of non-steroidal anti-inflammatory drugs in the pelvic floor muscles: an experimental comparative rat model. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24954342/),,0.85,2087,DB01050,Ibuprofen
,8032582,half-life,"Furthermore, the similar half-life of both drugs (2-2.5 h) is advantageous for a fixed drug combination.",Pharmacokinetic evaluation of two ibuprofen-codeine combinations. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8032582/),h,2-2.5,2335,DB01050,Ibuprofen
,31202508,Cmax,"After a single-dose administration of ibuprofen acid oral tablets (2 × 200 mg), the total ibuprofen Cmax and AUC0-t (geometric least square [LS] mean) for the Test product was 29.4 μg/mL and 100.6 h/μg/mL, respectively, and for the Reference product it was 30.6 μg/mL and 98.7 h/μg/mL.",Comparative Bioavailability Study of a New Orodispersible Formulation of Ibuprofen Versus Two Existing Oral Tablet Formulations in Healthy Male and Female Volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31202508/),[μg] / [ml],29.4,2541,DB01050,Ibuprofen
,31202508,Cmax,"After a single-dose administration of ibuprofen acid oral tablets (2 × 200 mg), the total ibuprofen Cmax and AUC0-t (geometric least square [LS] mean) for the Test product was 29.4 μg/mL and 100.6 h/μg/mL, respectively, and for the Reference product it was 30.6 μg/mL and 98.7 h/μg/mL.",Comparative Bioavailability Study of a New Orodispersible Formulation of Ibuprofen Versus Two Existing Oral Tablet Formulations in Healthy Male and Female Volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31202508/),[μg] / [ml],30.6,2542,DB01050,Ibuprofen
,31202508,AUC0-t,"After a single-dose administration of ibuprofen acid oral tablets (2 × 200 mg), the total ibuprofen Cmax and AUC0-t (geometric least square [LS] mean) for the Test product was 29.4 μg/mL and 100.6 h/μg/mL, respectively, and for the Reference product it was 30.6 μg/mL and 98.7 h/μg/mL.",Comparative Bioavailability Study of a New Orodispersible Formulation of Ibuprofen Versus Two Existing Oral Tablet Formulations in Healthy Male and Female Volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31202508/),[h] / [ml·μg],100.6,2543,DB01050,Ibuprofen
,31202508,AUC0-t,"After a single-dose administration of ibuprofen acid oral tablets (2 × 200 mg), the total ibuprofen Cmax and AUC0-t (geometric least square [LS] mean) for the Test product was 29.4 μg/mL and 100.6 h/μg/mL, respectively, and for the Reference product it was 30.6 μg/mL and 98.7 h/μg/mL.",Comparative Bioavailability Study of a New Orodispersible Formulation of Ibuprofen Versus Two Existing Oral Tablet Formulations in Healthy Male and Female Volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31202508/),[h] / [ml·μg],98.7,2544,DB01050,Ibuprofen
,29105796,area under the curve (AUC),Celecoxib showed the highest area under the curve (AUC) [146.50 ± 2.75 μg/mL*h] of all NSAID's.,Penetration and pharmacokinetics of non-steroidal anti-inflammatory drugs in rat prostate tissue. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29105796/),[μg] / [h·ml],146.50,2654,DB01050,Ibuprofen
,26723001,AUC(0-∞),Analysis of plasma samples showed higher plasma concentration of (-)-(R)-Etodolacfor both doses (300mg dose: AUC(0-∞)49.80 versus 4.55ugh/mL;400mg dose: AUC(0-∞) 63.90 versus 6.00ugh/mL) with an (R)-(+)/(S)-(-) ratio of approximately 11.,Enantioselective analysis of etodolac in human plasma by LC-MS/MS: Application to clinical pharmacokinetics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26723001/),[ugh] / [ml],49.80,3505,DB01050,Ibuprofen
,26723001,AUC(0-∞),Analysis of plasma samples showed higher plasma concentration of (-)-(R)-Etodolacfor both doses (300mg dose: AUC(0-∞)49.80 versus 4.55ugh/mL;400mg dose: AUC(0-∞) 63.90 versus 6.00ugh/mL) with an (R)-(+)/(S)-(-) ratio of approximately 11.,Enantioselective analysis of etodolac in human plasma by LC-MS/MS: Application to clinical pharmacokinetics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26723001/),[ugh] / [ml],4.55,3506,DB01050,Ibuprofen
,26723001,AUC(0-∞),Analysis of plasma samples showed higher plasma concentration of (-)-(R)-Etodolacfor both doses (300mg dose: AUC(0-∞)49.80 versus 4.55ugh/mL;400mg dose: AUC(0-∞) 63.90 versus 6.00ugh/mL) with an (R)-(+)/(S)-(-) ratio of approximately 11.,Enantioselective analysis of etodolac in human plasma by LC-MS/MS: Application to clinical pharmacokinetics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26723001/),[ugh] / [ml],63.90,3507,DB01050,Ibuprofen
,26723001,AUC(0-∞),Analysis of plasma samples showed higher plasma concentration of (-)-(R)-Etodolacfor both doses (300mg dose: AUC(0-∞)49.80 versus 4.55ugh/mL;400mg dose: AUC(0-∞) 63.90 versus 6.00ugh/mL) with an (R)-(+)/(S)-(-) ratio of approximately 11.,Enantioselective analysis of etodolac in human plasma by LC-MS/MS: Application to clinical pharmacokinetics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26723001/),[ugh] / [ml],6.00,3508,DB01050,Ibuprofen
,26723001,AUC(0-∞),Analysis of plasma samples showed higher plasma concentration of (-)-(R)-Etodolacfor both doses (300mg dose: AUC(0-∞)49.80 versus 4.55ugh/mL;400mg dose: AUC(0-∞) 63.90 versus 6.00ugh/mL) with an (R)-(+)/(S)-(-) ratio of approximately 11.,Enantioselective analysis of etodolac in human plasma by LC-MS/MS: Application to clinical pharmacokinetics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26723001/),,11,3509,DB01050,Ibuprofen
,17063640,AUC(0-infinity),"Values of 154.48 +/- 53.27 microg x h/ml (95 % confidence interval CI: 133.50-177.03) for the test, and 140.86 +/- 44.82 microg x h/ml (95% CI: 122.53-159.16) for the reference preparation AUC(0-infinity) demonstrate a nearly identical extent of drug absorption.",Comparative bioavailability study of two ibuprofen preparations after oral administration in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17063640/),[h·μg] / [ml],154.48,3687,DB01050,Ibuprofen
,17063640,AUC(0-infinity),"Values of 154.48 +/- 53.27 microg x h/ml (95 % confidence interval CI: 133.50-177.03) for the test, and 140.86 +/- 44.82 microg x h/ml (95% CI: 122.53-159.16) for the reference preparation AUC(0-infinity) demonstrate a nearly identical extent of drug absorption.",Comparative bioavailability study of two ibuprofen preparations after oral administration in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17063640/),[h·μg] / [ml],140.86,3688,DB01050,Ibuprofen
,17063640,Maximum plasma concentrations Cmax,Maximum plasma concentrations Cmax of 39.53 +/- 7.11 microg/ml (95 % CI: 35.97-41.78) and 37.71 +/- 8.67 microg/ml (95% CI: 33.37-40.46) achieved for the test and reference preparations did not differ significantly.,Comparative bioavailability study of two ibuprofen preparations after oral administration in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17063640/),[μg] / [ml],39.53,3689,DB01050,Ibuprofen
,17063640,Maximum plasma concentrations Cmax,Maximum plasma concentrations Cmax of 39.53 +/- 7.11 microg/ml (95 % CI: 35.97-41.78) and 37.71 +/- 8.67 microg/ml (95% CI: 33.37-40.46) achieved for the test and reference preparations did not differ significantly.,Comparative bioavailability study of two ibuprofen preparations after oral administration in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17063640/),[μg] / [ml],37.71,3690,DB01050,Ibuprofen
,10707114,elimination half life,There was a significant (p < 0.05) increase in mean elimination half life (2.39 +/- 0.42 to 3.59 +/- 0.35 h) following ibuprofen and diazepam administration compared to ibuprofen alone administered at 22.00 hours.,Time dependent influence of diazepam on the pharmacokinetics of ibuprofen in man. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10707114/),h,2.39,4552,DB01050,Ibuprofen
,10707114,elimination half life,There was a significant (p < 0.05) increase in mean elimination half life (2.39 +/- 0.42 to 3.59 +/- 0.35 h) following ibuprofen and diazepam administration compared to ibuprofen alone administered at 22.00 hours.,Time dependent influence of diazepam on the pharmacokinetics of ibuprofen in man. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10707114/),h,3.59,4553,DB01050,Ibuprofen
,10707114,clearance,The mean clearance of ibuprofen was therefore lowered from 62.7 +/- 8.9 to 41.7 +/- 2.6 ml/h/kg under the influence of diazepam during the night.,Time dependent influence of diazepam on the pharmacokinetics of ibuprofen in man. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10707114/),[ml] / [h·kg],62.7,4554,DB01050,Ibuprofen
,10707114,clearance,The mean clearance of ibuprofen was therefore lowered from 62.7 +/- 8.9 to 41.7 +/- 2.6 ml/h/kg under the influence of diazepam during the night.,Time dependent influence of diazepam on the pharmacokinetics of ibuprofen in man. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10707114/),[ml] / [h·kg],41.7,4555,DB01050,Ibuprofen
,18608465,la,"Increasing the pH value from 2.5 to 6.5 and adding 5 mM beta-CD enhanced the fluorescence signal (lambda(exc) = 224 nm; lambda(em) = 290 nm) by 2.5 and 1.3-fold, respectively, when using standards.",Simple and sensitive HPLC method with fluorescence detection for the measurement of ibuprofen in rat plasma: application to a long-lasting dosage form. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18608465/),nm,224,6428,DB01050,Ibuprofen
less,2040934,peak plasma concentration (Cmax),The dose of ibuprofen was increased if peak plasma concentration (Cmax) was less than 50 micrograms/ml.,Ibuprofen in children with cystic fibrosis: pharmacokinetics and adverse effects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2040934/),[μg] / [ml],50,6544,DB01050,Ibuprofen
,2040934,Peak plasma concentration,"Peak plasma concentration (48 +/- 17 micrograms/ml) was decreased by 27% (p = 0.06), the area under the concentration-time curve (6.1 +/- 1.7 mg.min/ml) was decreased by 46% (p less than 0.001), apparent total clearance (2.3 +/- 0.6 ml/min.kg-1) was increased by 77% (p less than 0.01), and apparent volume of distribution during terminal phase (291 +/- 91 ml/kg) was increased by 84% (p = 0.01) in the children with CF.",Ibuprofen in children with cystic fibrosis: pharmacokinetics and adverse effects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2040934/),[μg] / [ml],48,6545,DB01050,Ibuprofen
,2040934,area under the concentration-time curve,"Peak plasma concentration (48 +/- 17 micrograms/ml) was decreased by 27% (p = 0.06), the area under the concentration-time curve (6.1 +/- 1.7 mg.min/ml) was decreased by 46% (p less than 0.001), apparent total clearance (2.3 +/- 0.6 ml/min.kg-1) was increased by 77% (p less than 0.01), and apparent volume of distribution during terminal phase (291 +/- 91 ml/kg) was increased by 84% (p = 0.01) in the children with CF.",Ibuprofen in children with cystic fibrosis: pharmacokinetics and adverse effects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2040934/),[mg·min] / [ml],6.1,6546,DB01050,Ibuprofen
,2040934,apparent total clearance,"Peak plasma concentration (48 +/- 17 micrograms/ml) was decreased by 27% (p = 0.06), the area under the concentration-time curve (6.1 +/- 1.7 mg.min/ml) was decreased by 46% (p less than 0.001), apparent total clearance (2.3 +/- 0.6 ml/min.kg-1) was increased by 77% (p less than 0.01), and apparent volume of distribution during terminal phase (291 +/- 91 ml/kg) was increased by 84% (p = 0.01) in the children with CF.",Ibuprofen in children with cystic fibrosis: pharmacokinetics and adverse effects. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2040934/),[ml] / [kg·min],2.3,6547,DB01050,Ibuprofen
,2040934,apparent volume of distribution during terminal phase,"Peak plasma concentration (48 +/- 17 micrograms/ml) was decreased by 27% (p = 0.06), the area under the concentration-time curve (6.1 +/- 1.7 mg.min/ml) was decreased by 46% (p less than 0.001), apparent total clearance (2.3 +/- 0.6 ml/min.kg-1) was increased by 77% (p less than 0.01), and apparent volume of distribution during terminal phase (291 +/- 91 ml/kg) was increased by 84% (p = 0.01) in the children with CF.",Ibuprofen in children with cystic fibrosis: pharmacokinetics and adverse effects. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2040934/),[ml] / [kg],291,6548,DB01050,Ibuprofen
,2040934,Time to Cmax,Time to Cmax (66 +/- 20 minutes) and elimination half-life (92 +/- 27 minutes) were not significantly different.,Ibuprofen in children with cystic fibrosis: pharmacokinetics and adverse effects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2040934/),min,66,6549,DB01050,Ibuprofen
,2040934,elimination half-life,Time to Cmax (66 +/- 20 minutes) and elimination half-life (92 +/- 27 minutes) were not significantly different.,Ibuprofen in children with cystic fibrosis: pharmacokinetics and adverse effects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2040934/),min,92,6550,DB01050,Ibuprofen
,9725479,relative bioavailabilities,"The relative bioavailabilities of codeine and ibuprofen (alone or in association) were 106 +/- 24% (mean +/- sd) and 101 +/- 19%, respectively.",Comparative bioavailability study of codeine and ibuprofen after administration of the two products alone or in association to 24 healthy volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9725479/),%,106,6999,DB01050,Ibuprofen
,9725479,relative bioavailabilities,"The relative bioavailabilities of codeine and ibuprofen (alone or in association) were 106 +/- 24% (mean +/- sd) and 101 +/- 19%, respectively.",Comparative bioavailability study of codeine and ibuprofen after administration of the two products alone or in association to 24 healthy volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9725479/),%,101,7000,DB01050,Ibuprofen
,3755554,time required,Tests revealed increased time required for 50% dissolution to take place for Inza tablets (40-47 minutes) relative to Brufen tablets (7 minutes).,Ibuprofen bio-availability. A comparison of Brufen and Inza. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3755554/),min,40-47,7615,DB01050,Ibuprofen
,3755554,time required,Tests revealed increased time required for 50% dissolution to take place for Inza tablets (40-47 minutes) relative to Brufen tablets (7 minutes).,Ibuprofen bio-availability. A comparison of Brufen and Inza. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3755554/),min,7,7616,DB01050,Ibuprofen
,26839733,flow rate,Chromatographic separation was performed on an BDS Hypersil C18 column (250 × 4.6 mm; 5 μm) via gradient elution with mobile phase consisting of 10 mM phosphoric acid (sodium) buffer solution (pH = 2.6 adjusted with 85% orthophosphoric acid) : acetonitrile : methanol with flow rate of 1 mL·min(-1).,"Development and Validation of an HPLC Method for Simultaneous Quantification of Clopidogrel Bisulfate, Its Carboxylic Acid Metabolite, and Atorvastatin in Human Plasma: Application to a Pharmacokinetic Study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26839733/),[ml] / [min],1,8719,DB01050,Ibuprofen
,2109643,AUC0-infinity,"From the results of intravenous injections one can deduce linear ibuprofen pharmacokinetics within the considered dosage range, with corresponding AUC0-infinity values of 3786 micrograms * min ml-1 and 7260 micrograms * min ml-1 for the 200 mg and 400 mg doses, respectively.",Pharmacokinetics and absolute bioavailability of ibuprofen after oral administration of ibuprofen lysine in man. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2109643/),[min·μg] / [ml],3786,8807,DB01050,Ibuprofen
,2109643,AUC0-infinity,"From the results of intravenous injections one can deduce linear ibuprofen pharmacokinetics within the considered dosage range, with corresponding AUC0-infinity values of 3786 micrograms * min ml-1 and 7260 micrograms * min ml-1 for the 200 mg and 400 mg doses, respectively.",Pharmacokinetics and absolute bioavailability of ibuprofen after oral administration of ibuprofen lysine in man. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2109643/),[min·μg] / [ml],7260,8808,DB01050,Ibuprofen
,2109643,peak plasma level (Cmax),"The absorption of orally administered ibuprofen lysine proved to be rapid, resulting in a mean peak plasma level (Cmax) of 31 micrograms ml-1 ibuprofen and in a mean time to peak (tmax) of 45 min.",Pharmacokinetics and absolute bioavailability of ibuprofen after oral administration of ibuprofen lysine in man. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2109643/),[μg] / [ml],31,8809,DB01050,Ibuprofen
,2109643,time to peak (tmax),"The absorption of orally administered ibuprofen lysine proved to be rapid, resulting in a mean peak plasma level (Cmax) of 31 micrograms ml-1 ibuprofen and in a mean time to peak (tmax) of 45 min.",Pharmacokinetics and absolute bioavailability of ibuprofen after oral administration of ibuprofen lysine in man. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2109643/),min,45,8810,DB01050,Ibuprofen
,2109643,absolute bioavailability,"The absolute bioavailability of ibuprofen amounts to 102.7 per cent, indicating a complete absorption of ibuprofen when administered as its lysine salt.",Pharmacokinetics and absolute bioavailability of ibuprofen after oral administration of ibuprofen lysine in man. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2109643/),%,102.7,8811,DB01050,Ibuprofen
,2095133,Cmax,"The ibuprofen concentrations achieved after administration of the test preparation, however, are significantly higher (Cmax = 52.03 micrograms/ml) than those achieved after the reference preparation showing a Cmax of 40.32 micrograms/ml.",[Pharmacokinetics and bioequivalence of two ibuprofen formulations]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2095133/),[μg] / [ml],52.03,9032,DB01050,Ibuprofen
,2095133,Cmax,"The ibuprofen concentrations achieved after administration of the test preparation, however, are significantly higher (Cmax = 52.03 micrograms/ml) than those achieved after the reference preparation showing a Cmax of 40.32 micrograms/ml.",[Pharmacokinetics and bioequivalence of two ibuprofen formulations]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2095133/),[μg] / [ml],40.32,9033,DB01050,Ibuprofen
,2095133,tmax,The tmax of 1.0 h is also significantly shorter than after the reference preparation (tmax = 1.5 h).,[Pharmacokinetics and bioequivalence of two ibuprofen formulations]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2095133/),h,1.0,9034,DB01050,Ibuprofen
,2095133,tmax,The tmax of 1.0 h is also significantly shorter than after the reference preparation (tmax = 1.5 h).,[Pharmacokinetics and bioequivalence of two ibuprofen formulations]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2095133/),h,1.5,9035,DB01050,Ibuprofen
,2095133,t1/2 beta,"The t1/2 beta after both the test and the reference preparation is within the known range, i.e. 1.8 h and 1.4 h, respectively.",[Pharmacokinetics and bioequivalence of two ibuprofen formulations]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2095133/),h,1.8,9036,DB01050,Ibuprofen
,2095133,t1/2 beta,"The t1/2 beta after both the test and the reference preparation is within the known range, i.e. 1.8 h and 1.4 h, respectively.",[Pharmacokinetics and bioequivalence of two ibuprofen formulations]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2095133/),h,1.4,9037,DB01050,Ibuprofen
,1492847,Cmax,When the test preparation was applied maximum ibuprofen levels of 60 +/- 17 micrograms/ml were reached at 27 +/- 17 min p. appl. while Cmax was 52 +/- 12 micrograms/ml at tmax = 94 +/- 27 min after application of the reference preparation.,[Comparative biological availability of two different ibuprofen granules]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1492847/),[μg] / [ml],52,9382,DB01050,Ibuprofen
,1492847,tmax,When the test preparation was applied maximum ibuprofen levels of 60 +/- 17 micrograms/ml were reached at 27 +/- 17 min p. appl. while Cmax was 52 +/- 12 micrograms/ml at tmax = 94 +/- 27 min after application of the reference preparation.,[Comparative biological availability of two different ibuprofen granules]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1492847/),min,94,9383,DB01050,Ibuprofen
,1492847,AUC,"AUC values were 150 +/- 44 microgramsh/ml (test) and 148 +/- 33 microgramsh/ml (reference), respectively.",[Comparative biological availability of two different ibuprofen granules]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1492847/),[μgramsh] / [ml],150,9384,DB01050,Ibuprofen
,1492847,AUC,"AUC values were 150 +/- 44 microgramsh/ml (test) and 148 +/- 33 microgramsh/ml (reference), respectively.",[Comparative biological availability of two different ibuprofen granules]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1492847/),[μgramsh] / [ml],148,9385,DB01050,Ibuprofen
,1492847,relative bioavailability,"Thus, relative bioavailability of ibuprofen was 101.8 +/- 16.3% (or 104.1 +/- 16.7% when the slight differences in doses were corrected for).",[Comparative biological availability of two different ibuprofen granules]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1492847/),%,101.8,9386,DB01050,Ibuprofen
,1492847,relative bioavailability,"Thus, relative bioavailability of ibuprofen was 101.8 +/- 16.3% (or 104.1 +/- 16.7% when the slight differences in doses were corrected for).",[Comparative biological availability of two different ibuprofen granules]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1492847/),%,104.1,9387,DB01050,Ibuprofen
,28677844,flow rate,"Separation of enantiomers was accomplished in a Chiracel OJ-H chiral column based on cellulose tris(4-methylbenzoate) coated on 5 μm silica-gel, 250 x 4.6 mm at 22 °C with a mobile phase composed of n-hexane, 2-propanol, and trifluoroacetic acid that were delivered in gradient elution at a flow rate of 1 ml min-1 .",Enantioselective analysis of ibuprofen enantiomers in mice plasma and tissues by high-performance liquid chromatography with fluorescence detection: Application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28677844/),[ml] / [min],1,12900,DB01050,Ibuprofen
>,15960640,plasma concentrations,Total ibuprofen plasma concentrations >10 mg.l(-1) were seen from 40 min to 8 h.,Perioperative pharmacokinetics of ibuprofen enantiomers after rectal administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15960640/),[mg] / [l],10,13011,DB01050,Ibuprofen
,1810148,steady-state clearances,The mean (+/- SEM) steady-state clearances of (R)-ibuprofen (15.5 +/- 1.1 ml/min/kg) and (S)-ibuprofen (13.6 +/- 1.9 ml/min/kg) were not significantly different from each other (p greater than 0.05) and exceeded the plasma clearance of indocyanine green (4.3 +/- 0.4 ml/min/kg) in a separate group of rabbits (n = 6).,Pharmacokinetics of the enantiomers of ibuprofen in the rabbit. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1810148/),[ml] / [kg·min],15.5,14985,DB01050,Ibuprofen
,1810148,steady-state clearances,The mean (+/- SEM) steady-state clearances of (R)-ibuprofen (15.5 +/- 1.1 ml/min/kg) and (S)-ibuprofen (13.6 +/- 1.9 ml/min/kg) were not significantly different from each other (p greater than 0.05) and exceeded the plasma clearance of indocyanine green (4.3 +/- 0.4 ml/min/kg) in a separate group of rabbits (n = 6).,Pharmacokinetics of the enantiomers of ibuprofen in the rabbit. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1810148/),[ml] / [kg·min],13.6,14986,DB01050,Ibuprofen
,1810148,plasma clearance,The mean (+/- SEM) steady-state clearances of (R)-ibuprofen (15.5 +/- 1.1 ml/min/kg) and (S)-ibuprofen (13.6 +/- 1.9 ml/min/kg) were not significantly different from each other (p greater than 0.05) and exceeded the plasma clearance of indocyanine green (4.3 +/- 0.4 ml/min/kg) in a separate group of rabbits (n = 6).,Pharmacokinetics of the enantiomers of ibuprofen in the rabbit. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1810148/),[ml] / [kg·min],4.3,14987,DB01050,Ibuprofen
,1810148,fi,There was enantiospecific chiral inversion of (R)-ibuprofen to (S)-ibuprofen (fi = 0.30 +/- 0.07) as has been observed in all species so far studied for this 2-arylpropionic acid.,Pharmacokinetics of the enantiomers of ibuprofen in the rabbit. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1810148/),,0.30,14988,DB01050,Ibuprofen
,18959779,Cmax,Detailed analyses showed that Cmax of Eudorlin extra was higher than that of Nurofen forte (36.62 vs. 32.92 microg/ml; p = 0.0014) and that of Migränin (35.94 vs. 30.87 microg/ml; p < 0.0001).,Bioequivalence study of three ibuprofen formulations after single dose administration in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18959779/),[μg] / [ml],36.62,18934,DB01050,Ibuprofen
,18959779,Cmax,Detailed analyses showed that Cmax of Eudorlin extra was higher than that of Nurofen forte (36.62 vs. 32.92 microg/ml; p = 0.0014) and that of Migränin (35.94 vs. 30.87 microg/ml; p < 0.0001).,Bioequivalence study of three ibuprofen formulations after single dose administration in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18959779/),[μg] / [ml],32.92,18935,DB01050,Ibuprofen
,18959779,Cmax,Detailed analyses showed that Cmax of Eudorlin extra was higher than that of Nurofen forte (36.62 vs. 32.92 microg/ml; p = 0.0014) and that of Migränin (35.94 vs. 30.87 microg/ml; p < 0.0001).,Bioequivalence study of three ibuprofen formulations after single dose administration in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18959779/),[μg] / [ml],35.94,18936,DB01050,Ibuprofen
,18959779,Cmax,Detailed analyses showed that Cmax of Eudorlin extra was higher than that of Nurofen forte (36.62 vs. 32.92 microg/ml; p = 0.0014) and that of Migränin (35.94 vs. 30.87 microg/ml; p < 0.0001).,Bioequivalence study of three ibuprofen formulations after single dose administration in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18959779/),[μg] / [ml],30.87,18937,DB01050,Ibuprofen
,18959779,time to maximum plasma concentration (tmax),The time to maximum plasma concentration (tmax) was shorter with Eudorlin extra than with Nurofen forte (1.14 vs. 1.82 h; p < 0.0001) and Migränin (1.13 vs. 1.78 h; p = 0.0031).,Bioequivalence study of three ibuprofen formulations after single dose administration in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18959779/),h,1.14,18938,DB01050,Ibuprofen
,18959779,time to maximum plasma concentration (tmax),The time to maximum plasma concentration (tmax) was shorter with Eudorlin extra than with Nurofen forte (1.14 vs. 1.82 h; p < 0.0001) and Migränin (1.13 vs. 1.78 h; p = 0.0031).,Bioequivalence study of three ibuprofen formulations after single dose administration in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18959779/),h,1.82,18939,DB01050,Ibuprofen
,18959779,time to maximum plasma concentration (tmax),The time to maximum plasma concentration (tmax) was shorter with Eudorlin extra than with Nurofen forte (1.14 vs. 1.82 h; p < 0.0001) and Migränin (1.13 vs. 1.78 h; p = 0.0031).,Bioequivalence study of three ibuprofen formulations after single dose administration in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18959779/),h,1.13,18940,DB01050,Ibuprofen
,18959779,time to maximum plasma concentration (tmax),The time to maximum plasma concentration (tmax) was shorter with Eudorlin extra than with Nurofen forte (1.14 vs. 1.82 h; p < 0.0001) and Migränin (1.13 vs. 1.78 h; p = 0.0031).,Bioequivalence study of three ibuprofen formulations after single dose administration in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18959779/),h,1.78,18941,DB01050,Ibuprofen
,11678782,Peak plasma concentrations,"Peak plasma concentrations of R- and S-ibuprofen were 18.1 and 20 microg ml(-1) (test), and 18.2 and 20 microg ml(-1) (reference).",Simultaneous fitting of R- and S-ibuprofen plasma concentrations after oral administration of the racemate. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11678782/),[μg] / [ml],18.1,19299,DB01050,Ibuprofen
,11678782,Peak plasma concentrations,"Peak plasma concentrations of R- and S-ibuprofen were 18.1 and 20 microg ml(-1) (test), and 18.2 and 20 microg ml(-1) (reference).",Simultaneous fitting of R- and S-ibuprofen plasma concentrations after oral administration of the racemate. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11678782/),[μg] / [ml],20,19300,DB01050,Ibuprofen
,11678782,Peak plasma concentrations,"Peak plasma concentrations of R- and S-ibuprofen were 18.1 and 20 microg ml(-1) (test), and 18.2 and 20 microg ml(-1) (reference).",Simultaneous fitting of R- and S-ibuprofen plasma concentrations after oral administration of the racemate. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11678782/),[μg] / [ml],18.2,19301,DB01050,Ibuprofen
,11678782,Areas under the plasma concentration vs. time curves,"Areas under the plasma concentration vs. time curves were 39.7 and 67.5 microg ml(-1) h (test), and 41.1 and 68.2 microg ml(-1) h (reference).",Simultaneous fitting of R- and S-ibuprofen plasma concentrations after oral administration of the racemate. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11678782/),[h·μg] / [ml],39.7,19302,DB01050,Ibuprofen
,11678782,Areas under the plasma concentration vs. time curves,"Areas under the plasma concentration vs. time curves were 39.7 and 67.5 microg ml(-1) h (test), and 41.1 and 68.2 microg ml(-1) h (reference).",Simultaneous fitting of R- and S-ibuprofen plasma concentrations after oral administration of the racemate. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11678782/),[h·μg] / [ml],67.5,19303,DB01050,Ibuprofen
,11678782,Areas under the plasma concentration vs. time curves,"Areas under the plasma concentration vs. time curves were 39.7 and 67.5 microg ml(-1) h (test), and 41.1 and 68.2 microg ml(-1) h (reference).",Simultaneous fitting of R- and S-ibuprofen plasma concentrations after oral administration of the racemate. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11678782/),[h·μg] / [ml],41.1,19304,DB01050,Ibuprofen
,11678782,Areas under the plasma concentration vs. time curves,"Areas under the plasma concentration vs. time curves were 39.7 and 67.5 microg ml(-1) h (test), and 41.1 and 68.2 microg ml(-1) h (reference).",Simultaneous fitting of R- and S-ibuprofen plasma concentrations after oral administration of the racemate. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11678782/),[h·μg] / [ml],68.2,19305,DB01050,Ibuprofen
,11678782,Clearance,Clearance of R-ibuprofen was 5.2 (test) and 5 l h(-1) (reference).,Simultaneous fitting of R- and S-ibuprofen plasma concentrations after oral administration of the racemate. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11678782/),[l] / [h],5.2,19306,DB01050,Ibuprofen
,11678782,Clearance,Clearance of R-ibuprofen was 5.2 (test) and 5 l h(-1) (reference).,Simultaneous fitting of R- and S-ibuprofen plasma concentrations after oral administration of the racemate. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11678782/),[l] / [h],5,19307,DB01050,Ibuprofen
,11678782,body clearance,"Parameters from compartmental modelling were (given for R-and then for S-ibuprofen): body clearance: 4.9 and 4.64 l h(-1), central volume of distribution: 2.8 and 4.1 l, intercompartment clearance: 5.1 and 5.45 l h(-1), peripheral volume of distribution: 4.1 and 5.2 l.",Simultaneous fitting of R- and S-ibuprofen plasma concentrations after oral administration of the racemate. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11678782/),[l] / [h],4.9,19308,DB01050,Ibuprofen
,11678782,body clearance,"Parameters from compartmental modelling were (given for R-and then for S-ibuprofen): body clearance: 4.9 and 4.64 l h(-1), central volume of distribution: 2.8 and 4.1 l, intercompartment clearance: 5.1 and 5.45 l h(-1), peripheral volume of distribution: 4.1 and 5.2 l.",Simultaneous fitting of R- and S-ibuprofen plasma concentrations after oral administration of the racemate. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11678782/),[l] / [h],4.64,19309,DB01050,Ibuprofen
,11678782,central volume of distribution,"Parameters from compartmental modelling were (given for R-and then for S-ibuprofen): body clearance: 4.9 and 4.64 l h(-1), central volume of distribution: 2.8 and 4.1 l, intercompartment clearance: 5.1 and 5.45 l h(-1), peripheral volume of distribution: 4.1 and 5.2 l.",Simultaneous fitting of R- and S-ibuprofen plasma concentrations after oral administration of the racemate. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11678782/),l,2.8,19310,DB01050,Ibuprofen
,11678782,central volume of distribution,"Parameters from compartmental modelling were (given for R-and then for S-ibuprofen): body clearance: 4.9 and 4.64 l h(-1), central volume of distribution: 2.8 and 4.1 l, intercompartment clearance: 5.1 and 5.45 l h(-1), peripheral volume of distribution: 4.1 and 5.2 l.",Simultaneous fitting of R- and S-ibuprofen plasma concentrations after oral administration of the racemate. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11678782/),l,4.1,19311,DB01050,Ibuprofen
,11678782,intercompartment clearance,"Parameters from compartmental modelling were (given for R-and then for S-ibuprofen): body clearance: 4.9 and 4.64 l h(-1), central volume of distribution: 2.8 and 4.1 l, intercompartment clearance: 5.1 and 5.45 l h(-1), peripheral volume of distribution: 4.1 and 5.2 l.",Simultaneous fitting of R- and S-ibuprofen plasma concentrations after oral administration of the racemate. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11678782/),[l] / [h],5.1,19312,DB01050,Ibuprofen
,11678782,intercompartment clearance,"Parameters from compartmental modelling were (given for R-and then for S-ibuprofen): body clearance: 4.9 and 4.64 l h(-1), central volume of distribution: 2.8 and 4.1 l, intercompartment clearance: 5.1 and 5.45 l h(-1), peripheral volume of distribution: 4.1 and 5.2 l.",Simultaneous fitting of R- and S-ibuprofen plasma concentrations after oral administration of the racemate. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11678782/),[l] / [h],5.45,19313,DB01050,Ibuprofen
,11678782,peripheral volume of distribution,"Parameters from compartmental modelling were (given for R-and then for S-ibuprofen): body clearance: 4.9 and 4.64 l h(-1), central volume of distribution: 2.8 and 4.1 l, intercompartment clearance: 5.1 and 5.45 l h(-1), peripheral volume of distribution: 4.1 and 5.2 l.",Simultaneous fitting of R- and S-ibuprofen plasma concentrations after oral administration of the racemate. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11678782/),l,4.1,19314,DB01050,Ibuprofen
,11678782,peripheral volume of distribution,"Parameters from compartmental modelling were (given for R-and then for S-ibuprofen): body clearance: 4.9 and 4.64 l h(-1), central volume of distribution: 2.8 and 4.1 l, intercompartment clearance: 5.1 and 5.45 l h(-1), peripheral volume of distribution: 4.1 and 5.2 l.",Simultaneous fitting of R- and S-ibuprofen plasma concentrations after oral administration of the racemate. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11678782/),l,5.2,19315,DB01050,Ibuprofen
,11678782,absorption rate constant,"The absorption rate constant was 1.52 h(-1), and the test but not the reference formulation had a lag time of 0.1 h.",Simultaneous fitting of R- and S-ibuprofen plasma concentrations after oral administration of the racemate. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11678782/),1/[h],1.52,19316,DB01050,Ibuprofen
,11678782,lag time,"The absorption rate constant was 1.52 h(-1), and the test but not the reference formulation had a lag time of 0.1 h.",Simultaneous fitting of R- and S-ibuprofen plasma concentrations after oral administration of the racemate. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11678782/),h,0.1,19317,DB01050,Ibuprofen
,21329626,AUC0-t,"Single-dose Mean AUC0-t and AUC0-inf for ER formulation were 116.14 ± 21.54 mg·h/l and 117.60 ± 22.27 mg·h/l, and for IR formulation, were 107.25 ± 23.48 mg·h/l and 108.18 ± 23.93 mg·h/l, with the 90% CI within the limits accepted for bioequivalence.",Pharmacokinetics and bioequivalence of single dose and multiple doses of immediate- and extended-release formulations of dexibuprofen in healthy Chinese subjects. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21329626/),[h·mg] / [l],116.14,19646,DB01050,Ibuprofen
,21329626,AUC0-t,"Single-dose Mean AUC0-t and AUC0-inf for ER formulation were 116.14 ± 21.54 mg·h/l and 117.60 ± 22.27 mg·h/l, and for IR formulation, were 107.25 ± 23.48 mg·h/l and 108.18 ± 23.93 mg·h/l, with the 90% CI within the limits accepted for bioequivalence.",Pharmacokinetics and bioequivalence of single dose and multiple doses of immediate- and extended-release formulations of dexibuprofen in healthy Chinese subjects. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21329626/),[h·mg] / [l],107.25,19647,DB01050,Ibuprofen
,21329626,AUC0-inf,"Single-dose Mean AUC0-t and AUC0-inf for ER formulation were 116.14 ± 21.54 mg·h/l and 117.60 ± 22.27 mg·h/l, and for IR formulation, were 107.25 ± 23.48 mg·h/l and 108.18 ± 23.93 mg·h/l, with the 90% CI within the limits accepted for bioequivalence.",Pharmacokinetics and bioequivalence of single dose and multiple doses of immediate- and extended-release formulations of dexibuprofen in healthy Chinese subjects. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21329626/),[h·mg] / [l],117.60,19648,DB01050,Ibuprofen
,21329626,AUC0-inf,"Single-dose Mean AUC0-t and AUC0-inf for ER formulation were 116.14 ± 21.54 mg·h/l and 117.60 ± 22.27 mg·h/l, and for IR formulation, were 107.25 ± 23.48 mg·h/l and 108.18 ± 23.93 mg·h/l, with the 90% CI within the limits accepted for bioequivalence.",Pharmacokinetics and bioequivalence of single dose and multiple doses of immediate- and extended-release formulations of dexibuprofen in healthy Chinese subjects. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21329626/),[h·mg] / [l],108.18,19649,DB01050,Ibuprofen
,21329626,Cmax,"Mean Cmax for ER and IR formulations were 22.30 ± 5.17 mg/l and 30.26 ± 13.54 mg/l, respectively.",Pharmacokinetics and bioequivalence of single dose and multiple doses of immediate- and extended-release formulations of dexibuprofen in healthy Chinese subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21329626/),[mg] / [l],22.30,19650,DB01050,Ibuprofen
,21329626,Cmax,"Mean Cmax for ER and IR formulations were 22.30 ± 5.17 mg/l and 30.26 ± 13.54 mg/l, respectively.",Pharmacokinetics and bioequivalence of single dose and multiple doses of immediate- and extended-release formulations of dexibuprofen in healthy Chinese subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21329626/),[mg] / [l],30.26,19651,DB01050,Ibuprofen
,21329626,tmax,And median tmax for ER and IR formulations were 4.5 h and 2.0 h.,Pharmacokinetics and bioequivalence of single dose and multiple doses of immediate- and extended-release formulations of dexibuprofen in healthy Chinese subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21329626/),h,4.5,19652,DB01050,Ibuprofen
,21329626,tmax,And median tmax for ER and IR formulations were 4.5 h and 2.0 h.,Pharmacokinetics and bioequivalence of single dose and multiple doses of immediate- and extended-release formulations of dexibuprofen in healthy Chinese subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21329626/),h,2.0,19653,DB01050,Ibuprofen
,21329626,retard quotient (delta R),"The retard quotient (delta R) for ER product was 1.9 ± 0.93, which indicated an intermediate extended release effect.",Pharmacokinetics and bioequivalence of single dose and multiple doses of immediate- and extended-release formulations of dexibuprofen in healthy Chinese subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21329626/),,1.9,19654,DB01050,Ibuprofen
,21329626,AUC0-24,Multiple-dose Mean AUC0-24 for ER formulation was 217.93 ± 41.07 mg·h/l and for IR formulation was 199.33 ± 37.32 mg·h/l.,Pharmacokinetics and bioequivalence of single dose and multiple doses of immediate- and extended-release formulations of dexibuprofen in healthy Chinese subjects. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21329626/),[h·mg] / [l],217.93,19655,DB01050,Ibuprofen
,21329626,AUC0-24,Multiple-dose Mean AUC0-24 for ER formulation was 217.93 ± 41.07 mg·h/l and for IR formulation was 199.33 ± 37.32 mg·h/l.,Pharmacokinetics and bioequivalence of single dose and multiple doses of immediate- and extended-release formulations of dexibuprofen in healthy Chinese subjects. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21329626/),[h·mg] / [l],199.33,19656,DB01050,Ibuprofen
,21329626,tmax,"Other PK parameters of ER and IR formulations were as follows: median tmax were 4.8 h and 2.0 h, Css-max were 20.21 ± 2.69 mg/l and 19.71 ± 3.46 mg/l, Css-min were 2.47 ± 0.99 mg/l and 2.48 ± 0.99 mg/l, Cav were 9.08 ± 1.71 mg/l and 8.31 ± 1.56 mg/l, respectively.",Pharmacokinetics and bioequivalence of single dose and multiple doses of immediate- and extended-release formulations of dexibuprofen in healthy Chinese subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21329626/),h,4.8,19657,DB01050,Ibuprofen
,21329626,tmax,"Other PK parameters of ER and IR formulations were as follows: median tmax were 4.8 h and 2.0 h, Css-max were 20.21 ± 2.69 mg/l and 19.71 ± 3.46 mg/l, Css-min were 2.47 ± 0.99 mg/l and 2.48 ± 0.99 mg/l, Cav were 9.08 ± 1.71 mg/l and 8.31 ± 1.56 mg/l, respectively.",Pharmacokinetics and bioequivalence of single dose and multiple doses of immediate- and extended-release formulations of dexibuprofen in healthy Chinese subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21329626/),h,2.0,19658,DB01050,Ibuprofen
,21329626,Css-max,"Other PK parameters of ER and IR formulations were as follows: median tmax were 4.8 h and 2.0 h, Css-max were 20.21 ± 2.69 mg/l and 19.71 ± 3.46 mg/l, Css-min were 2.47 ± 0.99 mg/l and 2.48 ± 0.99 mg/l, Cav were 9.08 ± 1.71 mg/l and 8.31 ± 1.56 mg/l, respectively.",Pharmacokinetics and bioequivalence of single dose and multiple doses of immediate- and extended-release formulations of dexibuprofen in healthy Chinese subjects. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21329626/),[mg] / [l],20.21,19659,DB01050,Ibuprofen
,21329626,Css-max,"Other PK parameters of ER and IR formulations were as follows: median tmax were 4.8 h and 2.0 h, Css-max were 20.21 ± 2.69 mg/l and 19.71 ± 3.46 mg/l, Css-min were 2.47 ± 0.99 mg/l and 2.48 ± 0.99 mg/l, Cav were 9.08 ± 1.71 mg/l and 8.31 ± 1.56 mg/l, respectively.",Pharmacokinetics and bioequivalence of single dose and multiple doses of immediate- and extended-release formulations of dexibuprofen in healthy Chinese subjects. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21329626/),[mg] / [l],19.71,19660,DB01050,Ibuprofen
,21329626,Css-min,"Other PK parameters of ER and IR formulations were as follows: median tmax were 4.8 h and 2.0 h, Css-max were 20.21 ± 2.69 mg/l and 19.71 ± 3.46 mg/l, Css-min were 2.47 ± 0.99 mg/l and 2.48 ± 0.99 mg/l, Cav were 9.08 ± 1.71 mg/l and 8.31 ± 1.56 mg/l, respectively.",Pharmacokinetics and bioequivalence of single dose and multiple doses of immediate- and extended-release formulations of dexibuprofen in healthy Chinese subjects. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21329626/),[mg] / [l],2.47,19661,DB01050,Ibuprofen
,21329626,Css-min,"Other PK parameters of ER and IR formulations were as follows: median tmax were 4.8 h and 2.0 h, Css-max were 20.21 ± 2.69 mg/l and 19.71 ± 3.46 mg/l, Css-min were 2.47 ± 0.99 mg/l and 2.48 ± 0.99 mg/l, Cav were 9.08 ± 1.71 mg/l and 8.31 ± 1.56 mg/l, respectively.",Pharmacokinetics and bioequivalence of single dose and multiple doses of immediate- and extended-release formulations of dexibuprofen in healthy Chinese subjects. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21329626/),[mg] / [l],2.48,19662,DB01050,Ibuprofen
,21329626,Cav,"Other PK parameters of ER and IR formulations were as follows: median tmax were 4.8 h and 2.0 h, Css-max were 20.21 ± 2.69 mg/l and 19.71 ± 3.46 mg/l, Css-min were 2.47 ± 0.99 mg/l and 2.48 ± 0.99 mg/l, Cav were 9.08 ± 1.71 mg/l and 8.31 ± 1.56 mg/l, respectively.",Pharmacokinetics and bioequivalence of single dose and multiple doses of immediate- and extended-release formulations of dexibuprofen in healthy Chinese subjects. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21329626/),[mg] / [l],9.08,19663,DB01050,Ibuprofen
,21329626,Cav,"Other PK parameters of ER and IR formulations were as follows: median tmax were 4.8 h and 2.0 h, Css-max were 20.21 ± 2.69 mg/l and 19.71 ± 3.46 mg/l, Css-min were 2.47 ± 0.99 mg/l and 2.48 ± 0.99 mg/l, Cav were 9.08 ± 1.71 mg/l and 8.31 ± 1.56 mg/l, respectively.",Pharmacokinetics and bioequivalence of single dose and multiple doses of immediate- and extended-release formulations of dexibuprofen in healthy Chinese subjects. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21329626/),[mg] / [l],8.31,19664,DB01050,Ibuprofen
,2300543,overall drug recovery,"Following oral administration 40 to 41% of the dose were recovered in bile, whereas 16 to 32% of the dose were eliminated in urine, resulting in an overall drug recovery of 66 to 79% within 24 hours.",The biliary elimination and enterohepatic circulation of ibuprofen in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2300543/),%,66 to 79,19866,DB01050,Ibuprofen
,26829518,association constant K(A),"The association constant K(A) (L mol(-1)) of the binding reaches 10(6) order of magnitude, which is significantly stronger than the other components of propolis.",Caffeic acid phenethyl ester exhibiting distinctive binding interaction with human serum albumin implies the pharmacokinetic basis of propolis bioactive components. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26829518/),order,10,22687,DB01050,Ibuprofen
,26829518,binding distance,"Based on the theory of fluorescence resonance energy transfer, the binding distance was calculated as 5.7 nm, which is longer than that of the other components of propolis.",Caffeic acid phenethyl ester exhibiting distinctive binding interaction with human serum albumin implies the pharmacokinetic basis of propolis bioactive components. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26829518/),nm,5.7,22688,DB01050,Ibuprofen
,27569737,C<sub>max</sub>,"After IV administration of single dose, the mean (SD) C<sub>max</sub> value increased from 35.77 (6.98) to 117.12 (19.78) µg/mL, and the mean (SD) AUC<sub>0-t</sub> value increased from 67.63 (10.30) to 230.50 (33.55) µg×h/mL in the range of 0.2-g to 0.8-g dose.","Pharmacokinetics and tolerability of intravenous ibuprofen injection in healthy Chinese volunteers: a randomized, open-label, single- and multiple-dose study . ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27569737/),[μg] / [ml],35.77,25038,DB01050,Ibuprofen
,27569737,C<sub>max</sub>,"After IV administration of single dose, the mean (SD) C<sub>max</sub> value increased from 35.77 (6.98) to 117.12 (19.78) µg/mL, and the mean (SD) AUC<sub>0-t</sub> value increased from 67.63 (10.30) to 230.50 (33.55) µg×h/mL in the range of 0.2-g to 0.8-g dose.","Pharmacokinetics and tolerability of intravenous ibuprofen injection in healthy Chinese volunteers: a randomized, open-label, single- and multiple-dose study . ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27569737/),[μg] / [ml],117.12,25039,DB01050,Ibuprofen
,27569737,AUC<sub>0-t</sub>,"After IV administration of single dose, the mean (SD) C<sub>max</sub> value increased from 35.77 (6.98) to 117.12 (19.78) µg/mL, and the mean (SD) AUC<sub>0-t</sub> value increased from 67.63 (10.30) to 230.50 (33.55) µg×h/mL in the range of 0.2-g to 0.8-g dose.","Pharmacokinetics and tolerability of intravenous ibuprofen injection in healthy Chinese volunteers: a randomized, open-label, single- and multiple-dose study . ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27569737/),[h·μg] / [ml],67.63,25040,DB01050,Ibuprofen
,27569737,AUC<sub>0-t</sub>,"After IV administration of single dose, the mean (SD) C<sub>max</sub> value increased from 35.77 (6.98) to 117.12 (19.78) µg/mL, and the mean (SD) AUC<sub>0-t</sub> value increased from 67.63 (10.30) to 230.50 (33.55) µg×h/mL in the range of 0.2-g to 0.8-g dose.","Pharmacokinetics and tolerability of intravenous ibuprofen injection in healthy Chinese volunteers: a randomized, open-label, single- and multiple-dose study . ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27569737/),[h·μg] / [ml],230.50,25041,DB01050,Ibuprofen
,27569737,terminal half-life,The terminal half-life in plasma was ~ 2.0 hours.,"Pharmacokinetics and tolerability of intravenous ibuprofen injection in healthy Chinese volunteers: a randomized, open-label, single- and multiple-dose study . ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/27569737/),h,2.0,25042,DB01050,Ibuprofen
,27569737,C<sub>max</sub>,"After IV administration of 9 doses of ibuprofen 400 mg every 6 hours, the mean (SD) C<sub>max</sub> was 66.49 (8.49) µg/mL, the AUC<sub>0-t</sub> was 135.65 (26.91) µg×h/mL, the t<sub>1/2</sub> was 2.14 (0.34) hours, the Cl/F was 3.34 (0.68) L/h, and the Vz/F was 10.32 (2.69) L, which were comparable with those after single dosing.","Pharmacokinetics and tolerability of intravenous ibuprofen injection in healthy Chinese volunteers: a randomized, open-label, single- and multiple-dose study . ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27569737/),[μg] / [ml],66.49,25043,DB01050,Ibuprofen
,27569737,AUC<sub>0-t</sub>,"After IV administration of 9 doses of ibuprofen 400 mg every 6 hours, the mean (SD) C<sub>max</sub> was 66.49 (8.49) µg/mL, the AUC<sub>0-t</sub> was 135.65 (26.91) µg×h/mL, the t<sub>1/2</sub> was 2.14 (0.34) hours, the Cl/F was 3.34 (0.68) L/h, and the Vz/F was 10.32 (2.69) L, which were comparable with those after single dosing.","Pharmacokinetics and tolerability of intravenous ibuprofen injection in healthy Chinese volunteers: a randomized, open-label, single- and multiple-dose study . ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27569737/),[h·μg] / [ml],135.65,25044,DB01050,Ibuprofen
,27569737,t<sub>1/2</sub>,"After IV administration of 9 doses of ibuprofen 400 mg every 6 hours, the mean (SD) C<sub>max</sub> was 66.49 (8.49) µg/mL, the AUC<sub>0-t</sub> was 135.65 (26.91) µg×h/mL, the t<sub>1/2</sub> was 2.14 (0.34) hours, the Cl/F was 3.34 (0.68) L/h, and the Vz/F was 10.32 (2.69) L, which were comparable with those after single dosing.","Pharmacokinetics and tolerability of intravenous ibuprofen injection in healthy Chinese volunteers: a randomized, open-label, single- and multiple-dose study . ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27569737/),h,2.14,25045,DB01050,Ibuprofen
,27569737,Cl/F,"After IV administration of 9 doses of ibuprofen 400 mg every 6 hours, the mean (SD) C<sub>max</sub> was 66.49 (8.49) µg/mL, the AUC<sub>0-t</sub> was 135.65 (26.91) µg×h/mL, the t<sub>1/2</sub> was 2.14 (0.34) hours, the Cl/F was 3.34 (0.68) L/h, and the Vz/F was 10.32 (2.69) L, which were comparable with those after single dosing.","Pharmacokinetics and tolerability of intravenous ibuprofen injection in healthy Chinese volunteers: a randomized, open-label, single- and multiple-dose study . ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27569737/),[l] / [h],3.34,25046,DB01050,Ibuprofen
,27569737,Vz/F,"After IV administration of 9 doses of ibuprofen 400 mg every 6 hours, the mean (SD) C<sub>max</sub> was 66.49 (8.49) µg/mL, the AUC<sub>0-t</sub> was 135.65 (26.91) µg×h/mL, the t<sub>1/2</sub> was 2.14 (0.34) hours, the Cl/F was 3.34 (0.68) L/h, and the Vz/F was 10.32 (2.69) L, which were comparable with those after single dosing.","Pharmacokinetics and tolerability of intravenous ibuprofen injection in healthy Chinese volunteers: a randomized, open-label, single- and multiple-dose study . ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27569737/),l,10.32,25047,DB01050,Ibuprofen
,27569737,accumulation index,"The accumulation index was 1.17 (0.06), and the fluctuation was 304.0 (57.7) %.","Pharmacokinetics and tolerability of intravenous ibuprofen injection in healthy Chinese volunteers: a randomized, open-label, single- and multiple-dose study . ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27569737/),,1.17,25048,DB01050,Ibuprofen
,31182538,area under the concentration-time curve from 0 to 24 h [AUC0-24],"The derived vancomycin pharmacokinetic model was subsequently used to propose dose adjustments that yield effective vancomycin exposure (i.e., area under the concentration-time curve from 0 to 24 h [AUC0-24] between 300 to 550 mg·h/liter, with a probability of <0.1 of subtherapeutic exposure) in preterm neonates with patent ductus arteriosus.",Larger Dose Reductions of Vancomycin Required in Neonates with Patent Ductus Arteriosus Receiving Indomethacin versus Ibuprofen. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31182538/),[h·mg] / [l],300 to 550,27592,DB01050,Ibuprofen
,23720246,Cmax,"In the single-dose study, the values of Cmax, tmax, t1/2, AUC0-τ, AUC0-∞ for test and reference formulations were 12.59±2.29 and 12.84±2.79 μg/mL, 4.5±1.1 and 4.3±0.7 h, 4.15±1.37 and 4.03±0.86 h, 83.71±21.01 and 86.32±23.42 μg · h/mL, 86.05±21.37 and 88.99±25.33 μg · h/mL, respectively.",Pharmacokinetics and bioequivalence of two ibuprofen sustained-release formulations after single and multiple doses in healthy chinese male volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23720246/),[μg] / [ml],12.59,27701,DB01050,Ibuprofen
,23720246,tmax,"In the single-dose study, the values of Cmax, tmax, t1/2, AUC0-τ, AUC0-∞ for test and reference formulations were 12.59±2.29 and 12.84±2.79 μg/mL, 4.5±1.1 and 4.3±0.7 h, 4.15±1.37 and 4.03±0.86 h, 83.71±21.01 and 86.32±23.42 μg · h/mL, 86.05±21.37 and 88.99±25.33 μg · h/mL, respectively.",Pharmacokinetics and bioequivalence of two ibuprofen sustained-release formulations after single and multiple doses in healthy chinese male volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23720246/),[h·μg] / [ml],83.71,27702,DB01050,Ibuprofen
,23720246,t1/2,"In the single-dose study, the values of Cmax, tmax, t1/2, AUC0-τ, AUC0-∞ for test and reference formulations were 12.59±2.29 and 12.84±2.79 μg/mL, 4.5±1.1 and 4.3±0.7 h, 4.15±1.37 and 4.03±0.86 h, 83.71±21.01 and 86.32±23.42 μg · h/mL, 86.05±21.37 and 88.99±25.33 μg · h/mL, respectively.",Pharmacokinetics and bioequivalence of two ibuprofen sustained-release formulations after single and multiple doses in healthy chinese male volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23720246/),[μg] / [ml],12.84,27703,DB01050,Ibuprofen
,23720246,t1/2,"In the single-dose study, the values of Cmax, tmax, t1/2, AUC0-τ, AUC0-∞ for test and reference formulations were 12.59±2.29 and 12.84±2.79 μg/mL, 4.5±1.1 and 4.3±0.7 h, 4.15±1.37 and 4.03±0.86 h, 83.71±21.01 and 86.32±23.42 μg · h/mL, 86.05±21.37 and 88.99±25.33 μg · h/mL, respectively.",Pharmacokinetics and bioequivalence of two ibuprofen sustained-release formulations after single and multiple doses in healthy chinese male volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23720246/),[h·μg] / [ml],83.71,27704,DB01050,Ibuprofen
,23720246,AUC0-τ,"In the single-dose study, the values of Cmax, tmax, t1/2, AUC0-τ, AUC0-∞ for test and reference formulations were 12.59±2.29 and 12.84±2.79 μg/mL, 4.5±1.1 and 4.3±0.7 h, 4.15±1.37 and 4.03±0.86 h, 83.71±21.01 and 86.32±23.42 μg · h/mL, 86.05±21.37 and 88.99±25.33 μg · h/mL, respectively.",Pharmacokinetics and bioequivalence of two ibuprofen sustained-release formulations after single and multiple doses in healthy chinese male volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23720246/),[μg] / [ml],12.84,27705,DB01050,Ibuprofen
,23720246,AUC0-τ,"In the single-dose study, the values of Cmax, tmax, t1/2, AUC0-τ, AUC0-∞ for test and reference formulations were 12.59±2.29 and 12.84±2.79 μg/mL, 4.5±1.1 and 4.3±0.7 h, 4.15±1.37 and 4.03±0.86 h, 83.71±21.01 and 86.32±23.42 μg · h/mL, 86.05±21.37 and 88.99±25.33 μg · h/mL, respectively.",Pharmacokinetics and bioequivalence of two ibuprofen sustained-release formulations after single and multiple doses in healthy chinese male volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23720246/),[h·μg] / [ml],83.71,27706,DB01050,Ibuprofen
,23720246,AUC0-τ,"In the single-dose study, the values of Cmax, tmax, t1/2, AUC0-τ, AUC0-∞ for test and reference formulations were 12.59±2.29 and 12.84±2.79 μg/mL, 4.5±1.1 and 4.3±0.7 h, 4.15±1.37 and 4.03±0.86 h, 83.71±21.01 and 86.32±23.42 μg · h/mL, 86.05±21.37 and 88.99±25.33 μg · h/mL, respectively.",Pharmacokinetics and bioequivalence of two ibuprofen sustained-release formulations after single and multiple doses in healthy chinese male volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23720246/),[h·μg] / [ml],86.05,27707,DB01050,Ibuprofen
,23720246,AUC0-∞,"In the single-dose study, the values of Cmax, tmax, t1/2, AUC0-τ, AUC0-∞ for test and reference formulations were 12.59±2.29 and 12.84±2.79 μg/mL, 4.5±1.1 and 4.3±0.7 h, 4.15±1.37 and 4.03±0.86 h, 83.71±21.01 and 86.32±23.42 μg · h/mL, 86.05±21.37 and 88.99±25.33 μg · h/mL, respectively.",Pharmacokinetics and bioequivalence of two ibuprofen sustained-release formulations after single and multiple doses in healthy chinese male volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23720246/),[h·μg] / [ml],86.32,27708,DB01050,Ibuprofen
,23720246,AUC0-∞,"In the single-dose study, the values of Cmax, tmax, t1/2, AUC0-τ, AUC0-∞ for test and reference formulations were 12.59±2.29 and 12.84±2.79 μg/mL, 4.5±1.1 and 4.3±0.7 h, 4.15±1.37 and 4.03±0.86 h, 83.71±21.01 and 86.32±23.42 μg · h/mL, 86.05±21.37 and 88.99±25.33 μg · h/mL, respectively.",Pharmacokinetics and bioequivalence of two ibuprofen sustained-release formulations after single and multiple doses in healthy chinese male volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23720246/),[h·μg] / [ml],86.05,27709,DB01050,Ibuprofen
,23720246,AUC0-∞,"In the single-dose study, the values of Cmax, tmax, t1/2, AUC0-τ, AUC0-∞ for test and reference formulations were 12.59±2.29 and 12.84±2.79 μg/mL, 4.5±1.1 and 4.3±0.7 h, 4.15±1.37 and 4.03±0.86 h, 83.71±21.01 and 86.32±23.42 μg · h/mL, 86.05±21.37 and 88.99±25.33 μg · h/mL, respectively.",Pharmacokinetics and bioequivalence of two ibuprofen sustained-release formulations after single and multiple doses in healthy chinese male volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23720246/),[h·μg] / [ml],88.99,27710,DB01050,Ibuprofen
,23720246,Cmax,"In the multiple-dose study, the values of Cmax, Cmin, tmax, t1/2, AUCss, DF for test and -reference formulations were 14.46±3.08 and 14.00±2.61 μg/mL, 0.47±0.21 and 0.63±0.45 μg/mL, 4.0±0.9 and 4.3±0.9 h, 4.69±1.61 and 4.99±2.16 h, 89.11±19.04 and 89.23±20.56 μg · h/mL, 3.25±0.50 and 3.06±0.71, respectively.",Pharmacokinetics and bioequivalence of two ibuprofen sustained-release formulations after single and multiple doses in healthy chinese male volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23720246/),[μg] / [ml],14.46,27711,DB01050,Ibuprofen
,23720246,Cmin,"In the multiple-dose study, the values of Cmax, Cmin, tmax, t1/2, AUCss, DF for test and -reference formulations were 14.46±3.08 and 14.00±2.61 μg/mL, 0.47±0.21 and 0.63±0.45 μg/mL, 4.0±0.9 and 4.3±0.9 h, 4.69±1.61 and 4.99±2.16 h, 89.11±19.04 and 89.23±20.56 μg · h/mL, 3.25±0.50 and 3.06±0.71, respectively.",Pharmacokinetics and bioequivalence of two ibuprofen sustained-release formulations after single and multiple doses in healthy chinese male volunteers. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23720246/),[μg] / [ml],14.00,27712,DB01050,Ibuprofen
,23720246,tmax,"In the multiple-dose study, the values of Cmax, Cmin, tmax, t1/2, AUCss, DF for test and -reference formulations were 14.46±3.08 and 14.00±2.61 μg/mL, 0.47±0.21 and 0.63±0.45 μg/mL, 4.0±0.9 and 4.3±0.9 h, 4.69±1.61 and 4.99±2.16 h, 89.11±19.04 and 89.23±20.56 μg · h/mL, 3.25±0.50 and 3.06±0.71, respectively.",Pharmacokinetics and bioequivalence of two ibuprofen sustained-release formulations after single and multiple doses in healthy chinese male volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23720246/),[μg] / [ml],14.00,27713,DB01050,Ibuprofen
,23720246,t1/2,"In the multiple-dose study, the values of Cmax, Cmin, tmax, t1/2, AUCss, DF for test and -reference formulations were 14.46±3.08 and 14.00±2.61 μg/mL, 0.47±0.21 and 0.63±0.45 μg/mL, 4.0±0.9 and 4.3±0.9 h, 4.69±1.61 and 4.99±2.16 h, 89.11±19.04 and 89.23±20.56 μg · h/mL, 3.25±0.50 and 3.06±0.71, respectively.",Pharmacokinetics and bioequivalence of two ibuprofen sustained-release formulations after single and multiple doses in healthy chinese male volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23720246/),[μg] / [ml],14.00,27714,DB01050,Ibuprofen
,23720246,AUCss,"In the multiple-dose study, the values of Cmax, Cmin, tmax, t1/2, AUCss, DF for test and -reference formulations were 14.46±3.08 and 14.00±2.61 μg/mL, 0.47±0.21 and 0.63±0.45 μg/mL, 4.0±0.9 and 4.3±0.9 h, 4.69±1.61 and 4.99±2.16 h, 89.11±19.04 and 89.23±20.56 μg · h/mL, 3.25±0.50 and 3.06±0.71, respectively.",Pharmacokinetics and bioequivalence of two ibuprofen sustained-release formulations after single and multiple doses in healthy chinese male volunteers. ,AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23720246/),,3.25,27715,DB01050,Ibuprofen
,23720246,DF,"In the multiple-dose study, the values of Cmax, Cmin, tmax, t1/2, AUCss, DF for test and -reference formulations were 14.46±3.08 and 14.00±2.61 μg/mL, 0.47±0.21 and 0.63±0.45 μg/mL, 4.0±0.9 and 4.3±0.9 h, 4.69±1.61 and 4.99±2.16 h, 89.11±19.04 and 89.23±20.56 μg · h/mL, 3.25±0.50 and 3.06±0.71, respectively.",Pharmacokinetics and bioequivalence of two ibuprofen sustained-release formulations after single and multiple doses in healthy chinese male volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23720246/),[h·μg] / [ml],89.11,27716,DB01050,Ibuprofen
,23720246,DF,"In the multiple-dose study, the values of Cmax, Cmin, tmax, t1/2, AUCss, DF for test and -reference formulations were 14.46±3.08 and 14.00±2.61 μg/mL, 0.47±0.21 and 0.63±0.45 μg/mL, 4.0±0.9 and 4.3±0.9 h, 4.69±1.61 and 4.99±2.16 h, 89.11±19.04 and 89.23±20.56 μg · h/mL, 3.25±0.50 and 3.06±0.71, respectively.",Pharmacokinetics and bioequivalence of two ibuprofen sustained-release formulations after single and multiple doses in healthy chinese male volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23720246/),[h·μg] / [ml],89.23,27717,DB01050,Ibuprofen
,23720246,DF,"In the multiple-dose study, the values of Cmax, Cmin, tmax, t1/2, AUCss, DF for test and -reference formulations were 14.46±3.08 and 14.00±2.61 μg/mL, 0.47±0.21 and 0.63±0.45 μg/mL, 4.0±0.9 and 4.3±0.9 h, 4.69±1.61 and 4.99±2.16 h, 89.11±19.04 and 89.23±20.56 μg · h/mL, 3.25±0.50 and 3.06±0.71, respectively.",Pharmacokinetics and bioequivalence of two ibuprofen sustained-release formulations after single and multiple doses in healthy chinese male volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23720246/),,3.25,27718,DB01050,Ibuprofen
,23720246,DF,"In the multiple-dose study, the values of Cmax, Cmin, tmax, t1/2, AUCss, DF for test and -reference formulations were 14.46±3.08 and 14.00±2.61 μg/mL, 0.47±0.21 and 0.63±0.45 μg/mL, 4.0±0.9 and 4.3±0.9 h, 4.69±1.61 and 4.99±2.16 h, 89.11±19.04 and 89.23±20.56 μg · h/mL, 3.25±0.50 and 3.06±0.71, respectively.",Pharmacokinetics and bioequivalence of two ibuprofen sustained-release formulations after single and multiple doses in healthy chinese male volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23720246/),,3.06,27719,DB01050,Ibuprofen
,23720246,relative bioavailability,Single-dose relative bioavailability were 97.8±10.5% for AUC0-τ and multiple-dose relative bioavailability were 100.6±9.4% for AUCss.,Pharmacokinetics and bioequivalence of two ibuprofen sustained-release formulations after single and multiple doses in healthy chinese male volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23720246/),%,97.8,27720,DB01050,Ibuprofen
,23720246,relative bioavailability,Single-dose relative bioavailability were 97.8±10.5% for AUC0-τ and multiple-dose relative bioavailability were 100.6±9.4% for AUCss.,Pharmacokinetics and bioequivalence of two ibuprofen sustained-release formulations after single and multiple doses in healthy chinese male volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23720246/),%,100.6,27721,DB01050,Ibuprofen
,1492851,flow rate,"The chromatographic separation was performed on a silica gel stationary phase (Zorbax Sil) using n-hexane-chloroform-ethanol (100:10:1, by vol.) as mobile phase (flow rate, 2 ml/min; fluorescence-detection, 305/355 nm; elution order of the derivatives, (-) before (+)).",Studies on the metabolic clearance of ciclotropium to alpha-phenylciclopentylacetic acid using a new enantiospecific metabolite assay. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1492851/),[ml] / [min],2,29086,DB01050,Ibuprofen
,1492851,Limit of quantification,Limit of quantification was 1.0 ng/ml for plasma and 10 ng/ml for urine.,Studies on the metabolic clearance of ciclotropium to alpha-phenylciclopentylacetic acid using a new enantiospecific metabolite assay. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1492851/),[ng] / [ml],1.0,29087,DB01050,Ibuprofen
,1492851,Limit of quantification,Limit of quantification was 1.0 ng/ml for plasma and 10 ng/ml for urine.,Studies on the metabolic clearance of ciclotropium to alpha-phenylciclopentylacetic acid using a new enantiospecific metabolite assay. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1492851/),[ng] / [ml],10,29088,DB01050,Ibuprofen
,11420891,percentage bioinversion,The percentage bioinversion averaged between 35-70% according to the form.,Bioinversion of ibuprofen enantiomers after administration in dogs: estimation of a novel index. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11420891/),%,35-70,29850,DB01050,Ibuprofen
,6970498,detection limit,"As an example, the practical detection limit for naproxen in plasma was about 0.2 microgram ml-1.","HPLC-determination of some antiinflammatory, weak analgesic and uricosuric drugs in human blood plasma and its application to pharmacokinetics. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6970498/),[μg] / [ml],0.2,31759,DB01050,Ibuprofen
,6970498,Vc,"Vc was 0.038 1 kg-1, Vdss 0.138 1 kg-1, t 1/2 (beta) 21.3 hrs, t 1/2 (alpha) 0.99 hr and t 1/2 (ka) 0.67 hr.","HPLC-determination of some antiinflammatory, weak analgesic and uricosuric drugs in human blood plasma and its application to pharmacokinetics. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6970498/),[1] / [kg],0.038,31760,DB01050,Ibuprofen
,6970498,Vdss,"Vc was 0.038 1 kg-1, Vdss 0.138 1 kg-1, t 1/2 (beta) 21.3 hrs, t 1/2 (alpha) 0.99 hr and t 1/2 (ka) 0.67 hr.","HPLC-determination of some antiinflammatory, weak analgesic and uricosuric drugs in human blood plasma and its application to pharmacokinetics. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6970498/),[1] / [kg],0.138,31761,DB01050,Ibuprofen
,6970498,t 1/2 (beta,"Vc was 0.038 1 kg-1, Vdss 0.138 1 kg-1, t 1/2 (beta) 21.3 hrs, t 1/2 (alpha) 0.99 hr and t 1/2 (ka) 0.67 hr.","HPLC-determination of some antiinflammatory, weak analgesic and uricosuric drugs in human blood plasma and its application to pharmacokinetics. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6970498/),h,21.3,31762,DB01050,Ibuprofen
,6970498,t 1/2 (alpha),"Vc was 0.038 1 kg-1, Vdss 0.138 1 kg-1, t 1/2 (beta) 21.3 hrs, t 1/2 (alpha) 0.99 hr and t 1/2 (ka) 0.67 hr.","HPLC-determination of some antiinflammatory, weak analgesic and uricosuric drugs in human blood plasma and its application to pharmacokinetics. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6970498/),h,0.99,31763,DB01050,Ibuprofen
,6970498,t 1/2 (ka),"Vc was 0.038 1 kg-1, Vdss 0.138 1 kg-1, t 1/2 (beta) 21.3 hrs, t 1/2 (alpha) 0.99 hr and t 1/2 (ka) 0.67 hr.","HPLC-determination of some antiinflammatory, weak analgesic and uricosuric drugs in human blood plasma and its application to pharmacokinetics. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6970498/),h,0.67,31764,DB01050,Ibuprofen
,15129975,t50% Cmax,"Both formulations behaved in vivo as sustained release formulations with an HVD(t50% Cmax) value (time span during which the plasma concentration is at least 50% of the Cmax value) of 7.6 and 12.0 h for formulations F-1 and F-2, respectively, whereas a value of 5.2 h was obtained for Ibu-slow.",Bioavailability of ibuprofen from hot-melt extruded mini-matrices. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15129975/),h,7.6,32846,DB01050,Ibuprofen
,15129975,t50% Cmax,"Both formulations behaved in vivo as sustained release formulations with an HVD(t50% Cmax) value (time span during which the plasma concentration is at least 50% of the Cmax value) of 7.6 and 12.0 h for formulations F-1 and F-2, respectively, whereas a value of 5.2 h was obtained for Ibu-slow.",Bioavailability of ibuprofen from hot-melt extruded mini-matrices. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15129975/),h,12.0,32847,DB01050,Ibuprofen
,15129975,t50% Cmax,"Both formulations behaved in vivo as sustained release formulations with an HVD(t50% Cmax) value (time span during which the plasma concentration is at least 50% of the Cmax value) of 7.6 and 12.0 h for formulations F-1 and F-2, respectively, whereas a value of 5.2 h was obtained for Ibu-slow.",Bioavailability of ibuprofen from hot-melt extruded mini-matrices. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15129975/),h,5.2,32848,DB01050,Ibuprofen
,15129975,relative bioavailability,"Although a significantly higher Cmax and AUC(0-24 h) was seen for the reference product, the relative bioavailability of both experimental formulations was about 80%.",Bioavailability of ibuprofen from hot-melt extruded mini-matrices. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15129975/),%,80,32849,DB01050,Ibuprofen
,10223771,relative systemic bioavailability,"The relative systemic bioavailability of ibuprofen gel, based on urine recovery data, was (mean +/- SD) 0.57%+/-0.30%.",Application of microdialysis for the determination of muscle and subcutaneous tissue concentrations after oral and topical ibuprofen administration. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10223771/),%,0.57,33530,DB01050,Ibuprofen
,10223771,areas under the drug concentration-time curves,"Mean values of the dialysate areas under the drug concentration-time curves after topical and oral administration were 731.2+/-605.0 and 176.6+/-122.9 ng x h x mL(-1) for subcutaneous tissue and 63.5+/-90.3 and 213.4+/-117.2 ng x h x mL(-1) for muscle, respectively.",Application of microdialysis for the determination of muscle and subcutaneous tissue concentrations after oral and topical ibuprofen administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10223771/),[h·ng] / [ml],731.2,33531,DB01050,Ibuprofen
,10223771,areas under the drug concentration-time curves,"Mean values of the dialysate areas under the drug concentration-time curves after topical and oral administration were 731.2+/-605.0 and 176.6+/-122.9 ng x h x mL(-1) for subcutaneous tissue and 63.5+/-90.3 and 213.4+/-117.2 ng x h x mL(-1) for muscle, respectively.",Application of microdialysis for the determination of muscle and subcutaneous tissue concentrations after oral and topical ibuprofen administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10223771/),[h·ng] / [ml],176.6,33532,DB01050,Ibuprofen
,10223771,areas under the drug concentration-time curves,"Mean values of the dialysate areas under the drug concentration-time curves after topical and oral administration were 731.2+/-605.0 and 176.6+/-122.9 ng x h x mL(-1) for subcutaneous tissue and 63.5+/-90.3 and 213.4+/-117.2 ng x h x mL(-1) for muscle, respectively.",Application of microdialysis for the determination of muscle and subcutaneous tissue concentrations after oral and topical ibuprofen administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10223771/),[h·ng] / [ml],63.5,33533,DB01050,Ibuprofen
,10223771,areas under the drug concentration-time curves,"Mean values of the dialysate areas under the drug concentration-time curves after topical and oral administration were 731.2+/-605.0 and 176.6+/-122.9 ng x h x mL(-1) for subcutaneous tissue and 63.5+/-90.3 and 213.4+/-117.2 ng x h x mL(-1) for muscle, respectively.",Application of microdialysis for the determination of muscle and subcutaneous tissue concentrations after oral and topical ibuprofen administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10223771/),[h·ng] / [ml],213.4,33534,DB01050,Ibuprofen
,28535819,Withdrawal rate,"Withdrawal rate was 4%, 0%, and 4%, respectively.",Does the placebo effect modulate drug bioavailability? Randomized cross-over studies of three drugs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28535819/),%,4,37188,DB01050,Ibuprofen
,28535819,Withdrawal rate,"Withdrawal rate was 4%, 0%, and 4%, respectively.",Does the placebo effect modulate drug bioavailability? Randomized cross-over studies of three drugs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28535819/),%,0,37189,DB01050,Ibuprofen
,8786978,total body clearance,They differed primarily in total body clearance which was approximately 16 fold greater for diclofenac (213 ml hr-1 per 250 g) than piroxicam (13 ml hr-1 per 250 g).,Regional drug delivery II: relationship between drug targeting index and pharmacokinetic parameters for three non-steroidal anti-inflammatory drugs using the rat air pouch model of inflammation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8786978/),[ml] / [h],213,38036,DB01050,Ibuprofen
,8786978,total body clearance,They differed primarily in total body clearance which was approximately 16 fold greater for diclofenac (213 ml hr-1 per 250 g) than piroxicam (13 ml hr-1 per 250 g).,Regional drug delivery II: relationship between drug targeting index and pharmacokinetic parameters for three non-steroidal anti-inflammatory drugs using the rat air pouch model of inflammation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8786978/),[ml] / [h],13,38037,DB01050,Ibuprofen
,9176996,tmax,"After (+)S-ibuprofen arginine, the following mean pharmacokinetic parameters +/-SD were calculated for (+)S-ibuprofen: tmax 28.6 +/- 28.4 min; Cmax 36.2 +/- 7.7 mg/l; AUC 86.4 +/- 14.9 mg.h/l; t1/2 105.2 +/- 20.4 min.",Preliminary pharmacokinetic study of ibuprofen enantiomers after administration of a new oral formulation (ibuprofen arginine) to healthy male volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9176996/),min,28.6,38182,DB01050,Ibuprofen
,9176996,Cmax,"After (+)S-ibuprofen arginine, the following mean pharmacokinetic parameters +/-SD were calculated for (+)S-ibuprofen: tmax 28.6 +/- 28.4 min; Cmax 36.2 +/- 7.7 mg/l; AUC 86.4 +/- 14.9 mg.h/l; t1/2 105.2 +/- 20.4 min.",Preliminary pharmacokinetic study of ibuprofen enantiomers after administration of a new oral formulation (ibuprofen arginine) to healthy male volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9176996/),[mg] / [l],36.2,38183,DB01050,Ibuprofen
,9176996,AUC,"After (+)S-ibuprofen arginine, the following mean pharmacokinetic parameters +/-SD were calculated for (+)S-ibuprofen: tmax 28.6 +/- 28.4 min; Cmax 36.2 +/- 7.7 mg/l; AUC 86.4 +/- 14.9 mg.h/l; t1/2 105.2 +/- 20.4 min.",Preliminary pharmacokinetic study of ibuprofen enantiomers after administration of a new oral formulation (ibuprofen arginine) to healthy male volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9176996/),[h·mg] / [l],86.4,38184,DB01050,Ibuprofen
,9176996,t1/2,"After (+)S-ibuprofen arginine, the following mean pharmacokinetic parameters +/-SD were calculated for (+)S-ibuprofen: tmax 28.6 +/- 28.4 min; Cmax 36.2 +/- 7.7 mg/l; AUC 86.4 +/- 14.9 mg.h/l; t1/2 105.2 +/- 20.4 min.",Preliminary pharmacokinetic study of ibuprofen enantiomers after administration of a new oral formulation (ibuprofen arginine) to healthy male volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9176996/),min,105.2,38185,DB01050,Ibuprofen
,9176996,tmax,"After (-)R-ibuprofen arginine, the following mean pharmacokinetic parameters were calculated for (+)S-ibuprofen and (-)R-ibuprofen, respectively: tmax 90.0 +/- 17.3 and 50.5 +/- 20.5 min; Cmax 9.7 +/- 3.0 and 35.3 +/- 5.0 mg/l; AUC 47.0 +/- 17.2 and 104.7 +/- 27.7 mg.h/l; t1/2 148.1 +/- 63.6 and 97.7 +/- 23.3 min.",Preliminary pharmacokinetic study of ibuprofen enantiomers after administration of a new oral formulation (ibuprofen arginine) to healthy male volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9176996/),min,90.0,38186,DB01050,Ibuprofen
,9176996,tmax,"After (-)R-ibuprofen arginine, the following mean pharmacokinetic parameters were calculated for (+)S-ibuprofen and (-)R-ibuprofen, respectively: tmax 90.0 +/- 17.3 and 50.5 +/- 20.5 min; Cmax 9.7 +/- 3.0 and 35.3 +/- 5.0 mg/l; AUC 47.0 +/- 17.2 and 104.7 +/- 27.7 mg.h/l; t1/2 148.1 +/- 63.6 and 97.7 +/- 23.3 min.",Preliminary pharmacokinetic study of ibuprofen enantiomers after administration of a new oral formulation (ibuprofen arginine) to healthy male volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9176996/),min,50.5,38187,DB01050,Ibuprofen
,9176996,Cmax,"After (-)R-ibuprofen arginine, the following mean pharmacokinetic parameters were calculated for (+)S-ibuprofen and (-)R-ibuprofen, respectively: tmax 90.0 +/- 17.3 and 50.5 +/- 20.5 min; Cmax 9.7 +/- 3.0 and 35.3 +/- 5.0 mg/l; AUC 47.0 +/- 17.2 and 104.7 +/- 27.7 mg.h/l; t1/2 148.1 +/- 63.6 and 97.7 +/- 23.3 min.",Preliminary pharmacokinetic study of ibuprofen enantiomers after administration of a new oral formulation (ibuprofen arginine) to healthy male volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9176996/),[mg] / [l],9.7,38188,DB01050,Ibuprofen
,9176996,Cmax,"After (-)R-ibuprofen arginine, the following mean pharmacokinetic parameters were calculated for (+)S-ibuprofen and (-)R-ibuprofen, respectively: tmax 90.0 +/- 17.3 and 50.5 +/- 20.5 min; Cmax 9.7 +/- 3.0 and 35.3 +/- 5.0 mg/l; AUC 47.0 +/- 17.2 and 104.7 +/- 27.7 mg.h/l; t1/2 148.1 +/- 63.6 and 97.7 +/- 23.3 min.",Preliminary pharmacokinetic study of ibuprofen enantiomers after administration of a new oral formulation (ibuprofen arginine) to healthy male volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9176996/),[mg] / [l],35.3,38189,DB01050,Ibuprofen
,9176996,AUC,"After (-)R-ibuprofen arginine, the following mean pharmacokinetic parameters were calculated for (+)S-ibuprofen and (-)R-ibuprofen, respectively: tmax 90.0 +/- 17.3 and 50.5 +/- 20.5 min; Cmax 9.7 +/- 3.0 and 35.3 +/- 5.0 mg/l; AUC 47.0 +/- 17.2 and 104.7 +/- 27.7 mg.h/l; t1/2 148.1 +/- 63.6 and 97.7 +/- 23.3 min.",Preliminary pharmacokinetic study of ibuprofen enantiomers after administration of a new oral formulation (ibuprofen arginine) to healthy male volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9176996/),[h·mg] / [l],47.0,38190,DB01050,Ibuprofen
,9176996,AUC,"After (-)R-ibuprofen arginine, the following mean pharmacokinetic parameters were calculated for (+)S-ibuprofen and (-)R-ibuprofen, respectively: tmax 90.0 +/- 17.3 and 50.5 +/- 20.5 min; Cmax 9.7 +/- 3.0 and 35.3 +/- 5.0 mg/l; AUC 47.0 +/- 17.2 and 104.7 +/- 27.7 mg.h/l; t1/2 148.1 +/- 63.6 and 97.7 +/- 23.3 min.",Preliminary pharmacokinetic study of ibuprofen enantiomers after administration of a new oral formulation (ibuprofen arginine) to healthy male volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9176996/),[h·mg] / [l],104.7,38191,DB01050,Ibuprofen
,9176996,t1/2,"After (-)R-ibuprofen arginine, the following mean pharmacokinetic parameters were calculated for (+)S-ibuprofen and (-)R-ibuprofen, respectively: tmax 90.0 +/- 17.3 and 50.5 +/- 20.5 min; Cmax 9.7 +/- 3.0 and 35.3 +/- 5.0 mg/l; AUC 47.0 +/- 17.2 and 104.7 +/- 27.7 mg.h/l; t1/2 148.1 +/- 63.6 and 97.7 +/- 23.3 min.",Preliminary pharmacokinetic study of ibuprofen enantiomers after administration of a new oral formulation (ibuprofen arginine) to healthy male volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9176996/),min,148.1,38192,DB01050,Ibuprofen
,9176996,t1/2,"After (-)R-ibuprofen arginine, the following mean pharmacokinetic parameters were calculated for (+)S-ibuprofen and (-)R-ibuprofen, respectively: tmax 90.0 +/- 17.3 and 50.5 +/- 20.5 min; Cmax 9.7 +/- 3.0 and 35.3 +/- 5.0 mg/l; AUC 47.0 +/- 17.2 and 104.7 +/- 27.7 mg.h/l; t1/2 148.1 +/- 63.6 and 97.7 +/- 23.3 min.",Preliminary pharmacokinetic study of ibuprofen enantiomers after administration of a new oral formulation (ibuprofen arginine) to healthy male volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9176996/),min,97.7,38193,DB01050,Ibuprofen
,9176996,tmax,"After racemic ibuprofen arginine, the following mean pharmacokinetic parameters were calculated for (+)S- and (-)R-ibuprofen, respectively: tmax 30.7 +/- 29.1 and 22.9 +/- 29.8 min; Cmax 29.9 +/- 5.6 and 25.6 +/- 4.4 mg/l; AUC 105.1 +/- 23.0 and 65.3 +/- 15.0 mg.h/l; t1/2 136.6 +/- 20.7 and 128.6 +/- 45.0 min.",Preliminary pharmacokinetic study of ibuprofen enantiomers after administration of a new oral formulation (ibuprofen arginine) to healthy male volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9176996/),min,30.7,38194,DB01050,Ibuprofen
,9176996,tmax,"After racemic ibuprofen arginine, the following mean pharmacokinetic parameters were calculated for (+)S- and (-)R-ibuprofen, respectively: tmax 30.7 +/- 29.1 and 22.9 +/- 29.8 min; Cmax 29.9 +/- 5.6 and 25.6 +/- 4.4 mg/l; AUC 105.1 +/- 23.0 and 65.3 +/- 15.0 mg.h/l; t1/2 136.6 +/- 20.7 and 128.6 +/- 45.0 min.",Preliminary pharmacokinetic study of ibuprofen enantiomers after administration of a new oral formulation (ibuprofen arginine) to healthy male volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9176996/),min,22.9,38195,DB01050,Ibuprofen
,9176996,Cmax,"After racemic ibuprofen arginine, the following mean pharmacokinetic parameters were calculated for (+)S- and (-)R-ibuprofen, respectively: tmax 30.7 +/- 29.1 and 22.9 +/- 29.8 min; Cmax 29.9 +/- 5.6 and 25.6 +/- 4.4 mg/l; AUC 105.1 +/- 23.0 and 65.3 +/- 15.0 mg.h/l; t1/2 136.6 +/- 20.7 and 128.6 +/- 45.0 min.",Preliminary pharmacokinetic study of ibuprofen enantiomers after administration of a new oral formulation (ibuprofen arginine) to healthy male volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9176996/),[mg] / [l],29.9,38196,DB01050,Ibuprofen
,9176996,Cmax,"After racemic ibuprofen arginine, the following mean pharmacokinetic parameters were calculated for (+)S- and (-)R-ibuprofen, respectively: tmax 30.7 +/- 29.1 and 22.9 +/- 29.8 min; Cmax 29.9 +/- 5.6 and 25.6 +/- 4.4 mg/l; AUC 105.1 +/- 23.0 and 65.3 +/- 15.0 mg.h/l; t1/2 136.6 +/- 20.7 and 128.6 +/- 45.0 min.",Preliminary pharmacokinetic study of ibuprofen enantiomers after administration of a new oral formulation (ibuprofen arginine) to healthy male volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9176996/),[mg] / [l],25.6,38197,DB01050,Ibuprofen
,9176996,AUC,"After racemic ibuprofen arginine, the following mean pharmacokinetic parameters were calculated for (+)S- and (-)R-ibuprofen, respectively: tmax 30.7 +/- 29.1 and 22.9 +/- 29.8 min; Cmax 29.9 +/- 5.6 and 25.6 +/- 4.4 mg/l; AUC 105.1 +/- 23.0 and 65.3 +/- 15.0 mg.h/l; t1/2 136.6 +/- 20.7 and 128.6 +/- 45.0 min.",Preliminary pharmacokinetic study of ibuprofen enantiomers after administration of a new oral formulation (ibuprofen arginine) to healthy male volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9176996/),[h·mg] / [l],105.1,38198,DB01050,Ibuprofen
,9176996,AUC,"After racemic ibuprofen arginine, the following mean pharmacokinetic parameters were calculated for (+)S- and (-)R-ibuprofen, respectively: tmax 30.7 +/- 29.1 and 22.9 +/- 29.8 min; Cmax 29.9 +/- 5.6 and 25.6 +/- 4.4 mg/l; AUC 105.1 +/- 23.0 and 65.3 +/- 15.0 mg.h/l; t1/2 136.6 +/- 20.7 and 128.6 +/- 45.0 min.",Preliminary pharmacokinetic study of ibuprofen enantiomers after administration of a new oral formulation (ibuprofen arginine) to healthy male volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9176996/),[h·mg] / [l],65.3,38199,DB01050,Ibuprofen
,9176996,t1/2,"After racemic ibuprofen arginine, the following mean pharmacokinetic parameters were calculated for (+)S- and (-)R-ibuprofen, respectively: tmax 30.7 +/- 29.1 and 22.9 +/- 29.8 min; Cmax 29.9 +/- 5.6 and 25.6 +/- 4.4 mg/l; AUC 105.1 +/- 23.0 and 65.3 +/- 15.0 mg.h/l; t1/2 136.6 +/- 20.7 and 128.6 +/- 45.0 min.",Preliminary pharmacokinetic study of ibuprofen enantiomers after administration of a new oral formulation (ibuprofen arginine) to healthy male volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9176996/),min,136.6,38200,DB01050,Ibuprofen
,9176996,t1/2,"After racemic ibuprofen arginine, the following mean pharmacokinetic parameters were calculated for (+)S- and (-)R-ibuprofen, respectively: tmax 30.7 +/- 29.1 and 22.9 +/- 29.8 min; Cmax 29.9 +/- 5.6 and 25.6 +/- 4.4 mg/l; AUC 105.1 +/- 23.0 and 65.3 +/- 15.0 mg.h/l; t1/2 136.6 +/- 20.7 and 128.6 +/- 45.0 min.",Preliminary pharmacokinetic study of ibuprofen enantiomers after administration of a new oral formulation (ibuprofen arginine) to healthy male volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9176996/),min,128.6,38201,DB01050,Ibuprofen
,9176996,percent bioinversion,The percent bioinversion during the first 30 minutes after (-)R-ibuprofen arginine intake averaged 8.1 +/- 3.9%.,Preliminary pharmacokinetic study of ibuprofen enantiomers after administration of a new oral formulation (ibuprofen arginine) to healthy male volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9176996/),%,8.1,38202,DB01050,Ibuprofen
,9176996,AUC,The mean AUC of (+)S-ibuprofen calculated after 800 mg racemic ibuprofen arginine (105.1 +/- 23.0 mg.h/l) was lower than the mean AUC value obtained by summing the AUCs of (+)S-ibuprofen after administration of 400 mg (+)S-ibuprofen arginine and 400 mg (-)R-ibuprofen arginine (133.4 +/- 26.6 mg.h/l).,Preliminary pharmacokinetic study of ibuprofen enantiomers after administration of a new oral formulation (ibuprofen arginine) to healthy male volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9176996/),[h·mg] / [l],105.1,38203,DB01050,Ibuprofen
,9176996,AUC,The mean AUC of (+)S-ibuprofen calculated after 800 mg racemic ibuprofen arginine (105.1 +/- 23.0 mg.h/l) was lower than the mean AUC value obtained by summing the AUCs of (+)S-ibuprofen after administration of 400 mg (+)S-ibuprofen arginine and 400 mg (-)R-ibuprofen arginine (133.4 +/- 26.6 mg.h/l).,Preliminary pharmacokinetic study of ibuprofen enantiomers after administration of a new oral formulation (ibuprofen arginine) to healthy male volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9176996/),[h·mg] / [l],133.4,38204,DB01050,Ibuprofen
,9176996,AUCs,The mean AUC of (+)S-ibuprofen calculated after 800 mg racemic ibuprofen arginine (105.1 +/- 23.0 mg.h/l) was lower than the mean AUC value obtained by summing the AUCs of (+)S-ibuprofen after administration of 400 mg (+)S-ibuprofen arginine and 400 mg (-)R-ibuprofen arginine (133.4 +/- 26.6 mg.h/l).,Preliminary pharmacokinetic study of ibuprofen enantiomers after administration of a new oral formulation (ibuprofen arginine) to healthy male volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9176996/),[h·mg] / [l],133.4,38205,DB01050,Ibuprofen
,11451637,detection limit,The detection limit of this method was 0.025 microg ml(-1); only 0.5 ml of the plasma sample was required for the determination.,A sensitive method for the determination of gemfibrozil in human plasma samples by RP-LC. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11451637/),[μg] / [ml],0.025,39135,DB01050,Ibuprofen
,11451637,recoveries,Mean recoveries were of 90.15+/-6.9% (C.V.'s<8%) for gemfibrozil and 93.10% for ibuprofen Applicability of the method was demonstrated by a pharmacokinetic study in normal volunteers who received gemfibrozil by oral route.,A sensitive method for the determination of gemfibrozil in human plasma samples by RP-LC. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11451637/),%,90.15,39136,DB01050,Ibuprofen
<,11451637,C.V.'s,Mean recoveries were of 90.15+/-6.9% (C.V.'s<8%) for gemfibrozil and 93.10% for ibuprofen Applicability of the method was demonstrated by a pharmacokinetic study in normal volunteers who received gemfibrozil by oral route.,A sensitive method for the determination of gemfibrozil in human plasma samples by RP-LC. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11451637/),%,8,39137,DB01050,Ibuprofen
,11451637,C.V.'s,Mean recoveries were of 90.15+/-6.9% (C.V.'s<8%) for gemfibrozil and 93.10% for ibuprofen Applicability of the method was demonstrated by a pharmacokinetic study in normal volunteers who received gemfibrozil by oral route.,A sensitive method for the determination of gemfibrozil in human plasma samples by RP-LC. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11451637/),%,93.10,39138,DB01050,Ibuprofen
,9657231,extraction efficiency,"Average extraction efficiency was 96.8+/-6.6% for VM26 between 1 and 25 microg/ml, and 91.4+/-4.3% for internal standard, with both intra- and inter-day coefficients of variation being less than 10%.",Improved high-performance liquid chromatographic analysis of teniposide in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9657231/),%,96.8,41395,DB01050,Ibuprofen
,9657231,extraction efficiency,"Average extraction efficiency was 96.8+/-6.6% for VM26 between 1 and 25 microg/ml, and 91.4+/-4.3% for internal standard, with both intra- and inter-day coefficients of variation being less than 10%.",Improved high-performance liquid chromatographic analysis of teniposide in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9657231/),%,91.4,41396,DB01050,Ibuprofen
,9657231,detection limit,The detection limit with a 100-microl injection was estimated at 0.2 microg/ml with a signal-to-noise ratio of 3 for VM26 in human plasma.,Improved high-performance liquid chromatographic analysis of teniposide in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9657231/),[μg] / [ml],0.2,41397,DB01050,Ibuprofen
,9657231,signal-to-noise ratio,The detection limit with a 100-microl injection was estimated at 0.2 microg/ml with a signal-to-noise ratio of 3 for VM26 in human plasma.,Improved high-performance liquid chromatographic analysis of teniposide in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9657231/),,3,41398,DB01050,Ibuprofen
,21422165,C(max),"After a single oral administration (400 mg/kg) of PI, ibuprofen and ibuprofen glucuronide are the main plasma metabolites of PI; they have, respectively, C(max) of 530 and 215 μM, T(max) of 1 and 2 h, elimination t(1/2) of 7.7 and 5.3 h, and area under the concentration-time curve (0-24 h) of 1816 and 832 μM × h.","Phospho-ibuprofen (MDC-917) is a novel agent against colon cancer: efficacy, metabolism, and pharmacokinetics in mouse models. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21422165/),μM,530,43514,DB01050,Ibuprofen
,21422165,C(max),"After a single oral administration (400 mg/kg) of PI, ibuprofen and ibuprofen glucuronide are the main plasma metabolites of PI; they have, respectively, C(max) of 530 and 215 μM, T(max) of 1 and 2 h, elimination t(1/2) of 7.7 and 5.3 h, and area under the concentration-time curve (0-24 h) of 1816 and 832 μM × h.","Phospho-ibuprofen (MDC-917) is a novel agent against colon cancer: efficacy, metabolism, and pharmacokinetics in mouse models. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21422165/),μM,215,43515,DB01050,Ibuprofen
,21422165,T(max),"After a single oral administration (400 mg/kg) of PI, ibuprofen and ibuprofen glucuronide are the main plasma metabolites of PI; they have, respectively, C(max) of 530 and 215 μM, T(max) of 1 and 2 h, elimination t(1/2) of 7.7 and 5.3 h, and area under the concentration-time curve (0-24 h) of 1816 and 832 μM × h.","Phospho-ibuprofen (MDC-917) is a novel agent against colon cancer: efficacy, metabolism, and pharmacokinetics in mouse models. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21422165/),h,1,43516,DB01050,Ibuprofen
,21422165,T(max),"After a single oral administration (400 mg/kg) of PI, ibuprofen and ibuprofen glucuronide are the main plasma metabolites of PI; they have, respectively, C(max) of 530 and 215 μM, T(max) of 1 and 2 h, elimination t(1/2) of 7.7 and 5.3 h, and area under the concentration-time curve (0-24 h) of 1816 and 832 μM × h.","Phospho-ibuprofen (MDC-917) is a novel agent against colon cancer: efficacy, metabolism, and pharmacokinetics in mouse models. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21422165/),h,2,43517,DB01050,Ibuprofen
,21422165,elimination t(1/2),"After a single oral administration (400 mg/kg) of PI, ibuprofen and ibuprofen glucuronide are the main plasma metabolites of PI; they have, respectively, C(max) of 530 and 215 μM, T(max) of 1 and 2 h, elimination t(1/2) of 7.7 and 5.3 h, and area under the concentration-time curve (0-24 h) of 1816 and 832 μM × h.","Phospho-ibuprofen (MDC-917) is a novel agent against colon cancer: efficacy, metabolism, and pharmacokinetics in mouse models. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21422165/),h,7.7,43518,DB01050,Ibuprofen
,21422165,elimination t(1/2),"After a single oral administration (400 mg/kg) of PI, ibuprofen and ibuprofen glucuronide are the main plasma metabolites of PI; they have, respectively, C(max) of 530 and 215 μM, T(max) of 1 and 2 h, elimination t(1/2) of 7.7 and 5.3 h, and area under the concentration-time curve (0-24 h) of 1816 and 832 μM × h.","Phospho-ibuprofen (MDC-917) is a novel agent against colon cancer: efficacy, metabolism, and pharmacokinetics in mouse models. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21422165/),h,5.3,43519,DB01050,Ibuprofen
,21422165,area under the concentration-time curve (0-24 h),"After a single oral administration (400 mg/kg) of PI, ibuprofen and ibuprofen glucuronide are the main plasma metabolites of PI; they have, respectively, C(max) of 530 and 215 μM, T(max) of 1 and 2 h, elimination t(1/2) of 7.7 and 5.3 h, and area under the concentration-time curve (0-24 h) of 1816 and 832 μM × h.","Phospho-ibuprofen (MDC-917) is a novel agent against colon cancer: efficacy, metabolism, and pharmacokinetics in mouse models. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21422165/),h·μM,1816,43520,DB01050,Ibuprofen
,21422165,area under the concentration-time curve (0-24 h),"After a single oral administration (400 mg/kg) of PI, ibuprofen and ibuprofen glucuronide are the main plasma metabolites of PI; they have, respectively, C(max) of 530 and 215 μM, T(max) of 1 and 2 h, elimination t(1/2) of 7.7 and 5.3 h, and area under the concentration-time curve (0-24 h) of 1816 and 832 μM × h.","Phospho-ibuprofen (MDC-917) is a novel agent against colon cancer: efficacy, metabolism, and pharmacokinetics in mouse models. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21422165/),h·μM,832,43521,DB01050,Ibuprofen
,11302784,oral bioavailability,"In control rats, CEL had an oral bioavailability of 0.59 due mainly to presystemic hepatic metabolism.",Pharmacokinetics of celecoxib in the presence and absence of interferon-induced acute inflammation in the rat: application of a novel HPLC assay. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11302784/),,0.59,44767,DB01050,Ibuprofen
,11302784,terminal t(1/2),"A multi-compartmental disposition kinetics with an average terminal t(1/2) of 2.8 +/- 0.7 h, and volume of distribution of 2.3 +/- 0.6 L/kg were found.",Pharmacokinetics of celecoxib in the presence and absence of interferon-induced acute inflammation in the rat: application of a novel HPLC assay. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11302784/),h,2.8,44768,DB01050,Ibuprofen
,11302784,volume of distribution,"A multi-compartmental disposition kinetics with an average terminal t(1/2) of 2.8 +/- 0.7 h, and volume of distribution of 2.3 +/- 0.6 L/kg were found.",Pharmacokinetics of celecoxib in the presence and absence of interferon-induced acute inflammation in the rat: application of a novel HPLC assay. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11302784/),[l] / [kg],2.3,44769,DB01050,Ibuprofen
,29233194,half-life,Based on PK-modeling we calculated an overall ibuprofen half-life of 17.2 h for the entire observation period over 5 days.,Ibuprofen plasma concentration profile in deliberate ibuprofen overdose with circulatory depression treated with therapeutic plasma exchange: a case report. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29233194/),h,17.2,45923,DB01050,Ibuprofen
,29233194,overall-elimination half-life,"To our knowledge this is the first report of a severe ibuprofen-mono intoxication treated with TPE and providing serial IPCs over a period of five days, indicating an estimated fivefold overall-elimination half-life of 17.2 h.",Ibuprofen plasma concentration profile in deliberate ibuprofen overdose with circulatory depression treated with therapeutic plasma exchange: a case report. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/29233194/),h,17.2,45924,DB01050,Ibuprofen
,1756097,AUC ratios,"Simulated S/R AUC ratios, for administration of the racemate, ranged from 4.0 (presystemic bioinversion) to 1.66 (systemic bioinversion).",An evaluation of ibuprofen bioinversion by simulation. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1756097/),,4.0,46018,DB01050,Ibuprofen
,1756097,AUC ratios,"Simulated S/R AUC ratios, for administration of the racemate, ranged from 4.0 (presystemic bioinversion) to 1.66 (systemic bioinversion).",An evaluation of ibuprofen bioinversion by simulation. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1756097/),,1.66,46019,DB01050,Ibuprofen
,1756097,AUC ratios,"Literature values for S/R AUC ratios averaged 1.53 +/- 0.2 for administration of the racemate; therefore, systemic bioinversion was concluded to be representative of ibuprofen disposition.",An evaluation of ibuprofen bioinversion by simulation. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1756097/),,1.53,46020,DB01050,Ibuprofen
,1756097,AUC ratios,"Additional simulations of S/R AUC ratios, for administration of (-)-(R)-ibuprofen only, ranged from 1.5 (presystemic bioinversion) to 0.66 (systemic bioinversion).",An evaluation of ibuprofen bioinversion by simulation. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1756097/),,1.5,46021,DB01050,Ibuprofen
,1756097,AUC ratios,"Additional simulations of S/R AUC ratios, for administration of (-)-(R)-ibuprofen only, ranged from 1.5 (presystemic bioinversion) to 0.66 (systemic bioinversion).",An evaluation of ibuprofen bioinversion by simulation. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1756097/),,0.66,46022,DB01050,Ibuprofen
,1756097,AUC ratios,"Literature values for S/R AUC ratios averaged 0.50 +/- 0.9 for administration of (-)-(R)-ibuprofen only, which again supported conclusions of systemic bioinversion.",An evaluation of ibuprofen bioinversion by simulation. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1756097/),,0.50,46023,DB01050,Ibuprofen
,28115830,times to maximum concentration,"After a single oral dose of the ibuprofen formulations, the median times to maximum concentration were 0.42, 0.5, and 1.25 hours in ibuprofen arginine, solubilized ibuprofen capsule, and ibuprofen, respectively.",Pharmacokinetic and pharmacodynamic evaluation according to absorption differences in three formulations of ibuprofen. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28115830/),h,0.42,46600,DB01050,Ibuprofen
,28115830,times to maximum concentration,"After a single oral dose of the ibuprofen formulations, the median times to maximum concentration were 0.42, 0.5, and 1.25 hours in ibuprofen arginine, solubilized ibuprofen capsule, and ibuprofen, respectively.",Pharmacokinetic and pharmacodynamic evaluation according to absorption differences in three formulations of ibuprofen. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28115830/),h,0.5,46601,DB01050,Ibuprofen
,28115830,times to maximum concentration,"After a single oral dose of the ibuprofen formulations, the median times to maximum concentration were 0.42, 0.5, and 1.25 hours in ibuprofen arginine, solubilized ibuprofen capsule, and ibuprofen, respectively.",Pharmacokinetic and pharmacodynamic evaluation according to absorption differences in three formulations of ibuprofen. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28115830/),h,1.25,46602,DB01050,Ibuprofen
,15460211,t(max),"Plain ibuprofen acid (Ibu, CAS 15687-27-1) is relatively slowly absorbed after oral administration (t(max) is about 90-120 min).","Comparison of two different preparations of ibuprofen with regard to the time course of their analgesic effect. A randomised, placebo-controlled, double-blind cross-over study using laser somatosensory evoked potentials obtained from UW-irritated skin in healthy volunteers. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15460211/),min,90-120,48205,DB01050,Ibuprofen
,7503838,peak plasma concentrations,Doses were adjusted individually to achieve peak plasma concentrations of 50 to 100 micrograms per milliliter.,Effect of high-dose ibuprofen in patients with cystic fibrosis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7503838/),[μg] / [milliliter],50 to 100,48286,DB01050,Ibuprofen
,29667449,Tlag,"Ibuprofen was absorbed more rapidly from the salt formulations than the reference; Tlag was 3.3-6.4 min for salt formulations compared with 10.9 min for the reference, and 100% of subjects had a Tlag ≤ 5 min for ibuprofen lysine, compared with 61% for ibuprofen liquid capsule, 21% for ibuprofen sodium, and 7% for the reference.","Predicting rapid analgesic onset of ibuprofen salts compared with ibuprofen acid: Tlag, Tlow, Tmed, and a novel parameter, TCmaxRef. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29667449/),min,3.3-6.4,48526,DB01050,Ibuprofen
,29667449,Tlag,"Ibuprofen was absorbed more rapidly from the salt formulations than the reference; Tlag was 3.3-6.4 min for salt formulations compared with 10.9 min for the reference, and 100% of subjects had a Tlag ≤ 5 min for ibuprofen lysine, compared with 61% for ibuprofen liquid capsule, 21% for ibuprofen sodium, and 7% for the reference.","Predicting rapid analgesic onset of ibuprofen salts compared with ibuprofen acid: Tlag, Tlow, Tmed, and a novel parameter, TCmaxRef. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29667449/),min,10.9,48527,DB01050,Ibuprofen
≤,29667449,Tlag,"Ibuprofen was absorbed more rapidly from the salt formulations than the reference; Tlag was 3.3-6.4 min for salt formulations compared with 10.9 min for the reference, and 100% of subjects had a Tlag ≤ 5 min for ibuprofen lysine, compared with 61% for ibuprofen liquid capsule, 21% for ibuprofen sodium, and 7% for the reference.","Predicting rapid analgesic onset of ibuprofen salts compared with ibuprofen acid: Tlag, Tlow, Tmed, and a novel parameter, TCmaxRef. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29667449/),min,5,48528,DB01050,Ibuprofen
,29667449,Tlag,"Ibuprofen was absorbed more rapidly from the salt formulations than the reference; Tlag was 3.3-6.4 min for salt formulations compared with 10.9 min for the reference, and 100% of subjects had a Tlag ≤ 5 min for ibuprofen lysine, compared with 61% for ibuprofen liquid capsule, 21% for ibuprofen sodium, and 7% for the reference.","Predicting rapid analgesic onset of ibuprofen salts compared with ibuprofen acid: Tlag, Tlow, Tmed, and a novel parameter, TCmaxRef. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29667449/),%,61,48529,DB01050,Ibuprofen
,29667449,Tlag,"Ibuprofen was absorbed more rapidly from the salt formulations than the reference; Tlag was 3.3-6.4 min for salt formulations compared with 10.9 min for the reference, and 100% of subjects had a Tlag ≤ 5 min for ibuprofen lysine, compared with 61% for ibuprofen liquid capsule, 21% for ibuprofen sodium, and 7% for the reference.","Predicting rapid analgesic onset of ibuprofen salts compared with ibuprofen acid: Tlag, Tlow, Tmed, and a novel parameter, TCmaxRef. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29667449/),%,21,48530,DB01050,Ibuprofen
,29667449,Tlag,"Ibuprofen was absorbed more rapidly from the salt formulations than the reference; Tlag was 3.3-6.4 min for salt formulations compared with 10.9 min for the reference, and 100% of subjects had a Tlag ≤ 5 min for ibuprofen lysine, compared with 61% for ibuprofen liquid capsule, 21% for ibuprofen sodium, and 7% for the reference.","Predicting rapid analgesic onset of ibuprofen salts compared with ibuprofen acid: Tlag, Tlow, Tmed, and a novel parameter, TCmaxRef. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29667449/),%,7,48531,DB01050,Ibuprofen
,10490073,Half-life of elimination (Kel t1/2),"Half-life of elimination (Kel t1/2) of IV-administered ibuprofen (ie, 10 and 25 mg/kg), was 79 and 108 minutes, maximal serum concentration (C(MAX)) was 82 and 160 microg/ml, and clearance was 0.003 and 0.002 L/kg/min, respectively.",Pharmacokinetics of ibuprofen after intravenous and oral administration and assessment of safety of administration to healthy foals. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10490073/),min,79,51717,DB01050,Ibuprofen
,10490073,Half-life of elimination (Kel t1/2),"Half-life of elimination (Kel t1/2) of IV-administered ibuprofen (ie, 10 and 25 mg/kg), was 79 and 108 minutes, maximal serum concentration (C(MAX)) was 82 and 160 microg/ml, and clearance was 0.003 and 0.002 L/kg/min, respectively.",Pharmacokinetics of ibuprofen after intravenous and oral administration and assessment of safety of administration to healthy foals. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10490073/),min,108,51718,DB01050,Ibuprofen
,10490073,maximal serum concentration (C(MAX)),"Half-life of elimination (Kel t1/2) of IV-administered ibuprofen (ie, 10 and 25 mg/kg), was 79 and 108 minutes, maximal serum concentration (C(MAX)) was 82 and 160 microg/ml, and clearance was 0.003 and 0.002 L/kg/min, respectively.",Pharmacokinetics of ibuprofen after intravenous and oral administration and assessment of safety of administration to healthy foals. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10490073/),[μg] / [ml],82,51719,DB01050,Ibuprofen
,10490073,maximal serum concentration (C(MAX)),"Half-life of elimination (Kel t1/2) of IV-administered ibuprofen (ie, 10 and 25 mg/kg), was 79 and 108 minutes, maximal serum concentration (C(MAX)) was 82 and 160 microg/ml, and clearance was 0.003 and 0.002 L/kg/min, respectively.",Pharmacokinetics of ibuprofen after intravenous and oral administration and assessment of safety of administration to healthy foals. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10490073/),[μg] / [ml],160,51720,DB01050,Ibuprofen
,10490073,clearance,"Half-life of elimination (Kel t1/2) of IV-administered ibuprofen (ie, 10 and 25 mg/kg), was 79 and 108 minutes, maximal serum concentration (C(MAX)) was 82 and 160 microg/ml, and clearance was 0.003 and 0.002 L/kg/min, respectively.",Pharmacokinetics of ibuprofen after intravenous and oral administration and assessment of safety of administration to healthy foals. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10490073/),[l] / [kg·min],0.003,51721,DB01050,Ibuprofen
,10490073,clearance,"Half-life of elimination (Kel t1/2) of IV-administered ibuprofen (ie, 10 and 25 mg/kg), was 79 and 108 minutes, maximal serum concentration (C(MAX)) was 82 and 160 microg/ml, and clearance was 0.003 and 0.002 L/kg/min, respectively.",Pharmacokinetics of ibuprofen after intravenous and oral administration and assessment of safety of administration to healthy foals. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10490073/),[l] / [kg·min],0.002,51722,DB01050,Ibuprofen
,10490073,Kel t1/2,"Ibuprofen given via nasogastric tube resulted in Kel t1/2 of 81 and 100 minutes and C(MAX) of 22 and 52 microg/ml for 10 and 25 mg/kg, respectively.",Pharmacokinetics of ibuprofen after intravenous and oral administration and assessment of safety of administration to healthy foals. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10490073/),min,81,51723,DB01050,Ibuprofen
,10490073,Kel t1/2,"Ibuprofen given via nasogastric tube resulted in Kel t1/2 of 81 and 100 minutes and C(MAX) of 22 and 52 microg/ml for 10 and 25 mg/kg, respectively.",Pharmacokinetics of ibuprofen after intravenous and oral administration and assessment of safety of administration to healthy foals. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10490073/),min,100,51724,DB01050,Ibuprofen
,10490073,C(MAX),"Ibuprofen given via nasogastric tube resulted in Kel t1/2 of 81 and 100 minutes and C(MAX) of 22 and 52 microg/ml for 10 and 25 mg/kg, respectively.",Pharmacokinetics of ibuprofen after intravenous and oral administration and assessment of safety of administration to healthy foals. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10490073/),[μg] / [ml],22,51725,DB01050,Ibuprofen
,10490073,C(MAX),"Ibuprofen given via nasogastric tube resulted in Kel t1/2 of 81 and 100 minutes and C(MAX) of 22 and 52 microg/ml for 10 and 25 mg/kg, respectively.",Pharmacokinetics of ibuprofen after intravenous and oral administration and assessment of safety of administration to healthy foals. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10490073/),[μg] / [ml],52,51726,DB01050,Ibuprofen
,10490073,absorption half-life,"The absorption half-life was 13 minutes, and bioavailability ranged from 71 to 100%.",Pharmacokinetics of ibuprofen after intravenous and oral administration and assessment of safety of administration to healthy foals. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10490073/),min,13,51727,DB01050,Ibuprofen
,10490073,bioavailability,"The absorption half-life was 13 minutes, and bioavailability ranged from 71 to 100%.",Pharmacokinetics of ibuprofen after intravenous and oral administration and assessment of safety of administration to healthy foals. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10490073/),%,71 to 100,51728,DB01050,Ibuprofen
,8498749,volume of distribution at steady state,"Geometric mean (range) volume of distribution at steady state was 0.16 (0.11 to 0.19) and 0.17 (0.15 to 0.19) L/kg, and terminal half-life was 1.08 (0.79 to 1.70) and 1.27 (1.03 to 1.88) hours, for ibuprofen dosages of 14 and 25 mg/kg, respectively.",Pharmacokinetics of ibuprofen in lactating dairy goats. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8498749/),[l] / [kg],0.16,52656,DB01050,Ibuprofen
,8498749,volume of distribution at steady state,"Geometric mean (range) volume of distribution at steady state was 0.16 (0.11 to 0.19) and 0.17 (0.15 to 0.19) L/kg, and terminal half-life was 1.08 (0.79 to 1.70) and 1.27 (1.03 to 1.88) hours, for ibuprofen dosages of 14 and 25 mg/kg, respectively.",Pharmacokinetics of ibuprofen in lactating dairy goats. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8498749/),[l] / [kg],0.17,52657,DB01050,Ibuprofen
,8498749,terminal half-life,"Geometric mean (range) volume of distribution at steady state was 0.16 (0.11 to 0.19) and 0.17 (0.15 to 0.19) L/kg, and terminal half-life was 1.08 (0.79 to 1.70) and 1.27 (1.03 to 1.88) hours, for ibuprofen dosages of 14 and 25 mg/kg, respectively.",Pharmacokinetics of ibuprofen in lactating dairy goats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8498749/),h,1.08,52658,DB01050,Ibuprofen
,8498749,terminal half-life,"Geometric mean (range) volume of distribution at steady state was 0.16 (0.11 to 0.19) and 0.17 (0.15 to 0.19) L/kg, and terminal half-life was 1.08 (0.79 to 1.70) and 1.27 (1.03 to 1.88) hours, for ibuprofen dosages of 14 and 25 mg/kg, respectively.",Pharmacokinetics of ibuprofen in lactating dairy goats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8498749/),h,1.27,52659,DB01050,Ibuprofen
,8498749,bioavailability,"After 50 and 100 mg/kg administered orally, bioavailability was 90.8 and 106%, respectively.",Pharmacokinetics of ibuprofen in lactating dairy goats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8498749/),%,90.8,52660,DB01050,Ibuprofen
,8498749,bioavailability,"After 50 and 100 mg/kg administered orally, bioavailability was 90.8 and 106%, respectively.",Pharmacokinetics of ibuprofen in lactating dairy goats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8498749/),%,106,52661,DB01050,Ibuprofen
,15289789,clearance,"Ibuprofen clearance values were 4.04 L/h (95% confidence interval [CI], 3.61-4.47 L/h), 2.79 L/h (95% CI, 2.07-3.52 L/h), and 0.40 L/h (95% CI, 0.37-0.43 L/h) for carriers of CYP2C8 genotypes *1/*1, *1/*3, and *3/*3, respectively, and 4.43 L/h (95% CI, 3.94-4.92 L/h), 3.26 L/h (95% CI, 2.53-3.99 L/h), 2.91 L/h (95% CI, 1.52-4.30 L/h), 2.05 L/h (95% CI, 0-6.37 L/h), 1.83 L/h (95% CI, 1.24-2.41 L/h), and 1.13 L/h (95% CI, 0.58-1.66 L/h) for carriers of the CYP2C9 genotypes *1/*1, *1/*2, *1/*3, *2/*2, *2/*3, and *3/*3, respectively.",Interindividual variability in ibuprofen pharmacokinetics is related to interaction of cytochrome P450 2C8 and 2C9 amino acid polymorphisms. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15289789/),[l] / [h],4.04,54985,DB01050,Ibuprofen
,15289789,clearance,"Ibuprofen clearance values were 4.04 L/h (95% confidence interval [CI], 3.61-4.47 L/h), 2.79 L/h (95% CI, 2.07-3.52 L/h), and 0.40 L/h (95% CI, 0.37-0.43 L/h) for carriers of CYP2C8 genotypes *1/*1, *1/*3, and *3/*3, respectively, and 4.43 L/h (95% CI, 3.94-4.92 L/h), 3.26 L/h (95% CI, 2.53-3.99 L/h), 2.91 L/h (95% CI, 1.52-4.30 L/h), 2.05 L/h (95% CI, 0-6.37 L/h), 1.83 L/h (95% CI, 1.24-2.41 L/h), and 1.13 L/h (95% CI, 0.58-1.66 L/h) for carriers of the CYP2C9 genotypes *1/*1, *1/*2, *1/*3, *2/*2, *2/*3, and *3/*3, respectively.",Interindividual variability in ibuprofen pharmacokinetics is related to interaction of cytochrome P450 2C8 and 2C9 amino acid polymorphisms. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15289789/),[l] / [h],2.79,54986,DB01050,Ibuprofen
,15289789,clearance,"Ibuprofen clearance values were 4.04 L/h (95% confidence interval [CI], 3.61-4.47 L/h), 2.79 L/h (95% CI, 2.07-3.52 L/h), and 0.40 L/h (95% CI, 0.37-0.43 L/h) for carriers of CYP2C8 genotypes *1/*1, *1/*3, and *3/*3, respectively, and 4.43 L/h (95% CI, 3.94-4.92 L/h), 3.26 L/h (95% CI, 2.53-3.99 L/h), 2.91 L/h (95% CI, 1.52-4.30 L/h), 2.05 L/h (95% CI, 0-6.37 L/h), 1.83 L/h (95% CI, 1.24-2.41 L/h), and 1.13 L/h (95% CI, 0.58-1.66 L/h) for carriers of the CYP2C9 genotypes *1/*1, *1/*2, *1/*3, *2/*2, *2/*3, and *3/*3, respectively.",Interindividual variability in ibuprofen pharmacokinetics is related to interaction of cytochrome P450 2C8 and 2C9 amino acid polymorphisms. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15289789/),[l] / [h],0.40,54987,DB01050,Ibuprofen
,15289789,clearance,"Ibuprofen clearance values were 4.04 L/h (95% confidence interval [CI], 3.61-4.47 L/h), 2.79 L/h (95% CI, 2.07-3.52 L/h), and 0.40 L/h (95% CI, 0.37-0.43 L/h) for carriers of CYP2C8 genotypes *1/*1, *1/*3, and *3/*3, respectively, and 4.43 L/h (95% CI, 3.94-4.92 L/h), 3.26 L/h (95% CI, 2.53-3.99 L/h), 2.91 L/h (95% CI, 1.52-4.30 L/h), 2.05 L/h (95% CI, 0-6.37 L/h), 1.83 L/h (95% CI, 1.24-2.41 L/h), and 1.13 L/h (95% CI, 0.58-1.66 L/h) for carriers of the CYP2C9 genotypes *1/*1, *1/*2, *1/*3, *2/*2, *2/*3, and *3/*3, respectively.",Interindividual variability in ibuprofen pharmacokinetics is related to interaction of cytochrome P450 2C8 and 2C9 amino acid polymorphisms. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15289789/),[l] / [h],4.43,54988,DB01050,Ibuprofen
,15289789,clearance,"Ibuprofen clearance values were 4.04 L/h (95% confidence interval [CI], 3.61-4.47 L/h), 2.79 L/h (95% CI, 2.07-3.52 L/h), and 0.40 L/h (95% CI, 0.37-0.43 L/h) for carriers of CYP2C8 genotypes *1/*1, *1/*3, and *3/*3, respectively, and 4.43 L/h (95% CI, 3.94-4.92 L/h), 3.26 L/h (95% CI, 2.53-3.99 L/h), 2.91 L/h (95% CI, 1.52-4.30 L/h), 2.05 L/h (95% CI, 0-6.37 L/h), 1.83 L/h (95% CI, 1.24-2.41 L/h), and 1.13 L/h (95% CI, 0.58-1.66 L/h) for carriers of the CYP2C9 genotypes *1/*1, *1/*2, *1/*3, *2/*2, *2/*3, and *3/*3, respectively.",Interindividual variability in ibuprofen pharmacokinetics is related to interaction of cytochrome P450 2C8 and 2C9 amino acid polymorphisms. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15289789/),[l] / [h],3.26,54989,DB01050,Ibuprofen
,15289789,clearance,"Ibuprofen clearance values were 4.04 L/h (95% confidence interval [CI], 3.61-4.47 L/h), 2.79 L/h (95% CI, 2.07-3.52 L/h), and 0.40 L/h (95% CI, 0.37-0.43 L/h) for carriers of CYP2C8 genotypes *1/*1, *1/*3, and *3/*3, respectively, and 4.43 L/h (95% CI, 3.94-4.92 L/h), 3.26 L/h (95% CI, 2.53-3.99 L/h), 2.91 L/h (95% CI, 1.52-4.30 L/h), 2.05 L/h (95% CI, 0-6.37 L/h), 1.83 L/h (95% CI, 1.24-2.41 L/h), and 1.13 L/h (95% CI, 0.58-1.66 L/h) for carriers of the CYP2C9 genotypes *1/*1, *1/*2, *1/*3, *2/*2, *2/*3, and *3/*3, respectively.",Interindividual variability in ibuprofen pharmacokinetics is related to interaction of cytochrome P450 2C8 and 2C9 amino acid polymorphisms. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15289789/),[l] / [h],2.91,54990,DB01050,Ibuprofen
,15289789,clearance,"Ibuprofen clearance values were 4.04 L/h (95% confidence interval [CI], 3.61-4.47 L/h), 2.79 L/h (95% CI, 2.07-3.52 L/h), and 0.40 L/h (95% CI, 0.37-0.43 L/h) for carriers of CYP2C8 genotypes *1/*1, *1/*3, and *3/*3, respectively, and 4.43 L/h (95% CI, 3.94-4.92 L/h), 3.26 L/h (95% CI, 2.53-3.99 L/h), 2.91 L/h (95% CI, 1.52-4.30 L/h), 2.05 L/h (95% CI, 0-6.37 L/h), 1.83 L/h (95% CI, 1.24-2.41 L/h), and 1.13 L/h (95% CI, 0.58-1.66 L/h) for carriers of the CYP2C9 genotypes *1/*1, *1/*2, *1/*3, *2/*2, *2/*3, and *3/*3, respectively.",Interindividual variability in ibuprofen pharmacokinetics is related to interaction of cytochrome P450 2C8 and 2C9 amino acid polymorphisms. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15289789/),[l] / [h],2.05,54991,DB01050,Ibuprofen
,15289789,clearance,"Ibuprofen clearance values were 4.04 L/h (95% confidence interval [CI], 3.61-4.47 L/h), 2.79 L/h (95% CI, 2.07-3.52 L/h), and 0.40 L/h (95% CI, 0.37-0.43 L/h) for carriers of CYP2C8 genotypes *1/*1, *1/*3, and *3/*3, respectively, and 4.43 L/h (95% CI, 3.94-4.92 L/h), 3.26 L/h (95% CI, 2.53-3.99 L/h), 2.91 L/h (95% CI, 1.52-4.30 L/h), 2.05 L/h (95% CI, 0-6.37 L/h), 1.83 L/h (95% CI, 1.24-2.41 L/h), and 1.13 L/h (95% CI, 0.58-1.66 L/h) for carriers of the CYP2C9 genotypes *1/*1, *1/*2, *1/*3, *2/*2, *2/*3, and *3/*3, respectively.",Interindividual variability in ibuprofen pharmacokinetics is related to interaction of cytochrome P450 2C8 and 2C9 amino acid polymorphisms. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15289789/),[l] / [h],1.83,54992,DB01050,Ibuprofen
,15289789,clearance,"Ibuprofen clearance values were 4.04 L/h (95% confidence interval [CI], 3.61-4.47 L/h), 2.79 L/h (95% CI, 2.07-3.52 L/h), and 0.40 L/h (95% CI, 0.37-0.43 L/h) for carriers of CYP2C8 genotypes *1/*1, *1/*3, and *3/*3, respectively, and 4.43 L/h (95% CI, 3.94-4.92 L/h), 3.26 L/h (95% CI, 2.53-3.99 L/h), 2.91 L/h (95% CI, 1.52-4.30 L/h), 2.05 L/h (95% CI, 0-6.37 L/h), 1.83 L/h (95% CI, 1.24-2.41 L/h), and 1.13 L/h (95% CI, 0.58-1.66 L/h) for carriers of the CYP2C9 genotypes *1/*1, *1/*2, *1/*3, *2/*2, *2/*3, and *3/*3, respectively.",Interindividual variability in ibuprofen pharmacokinetics is related to interaction of cytochrome P450 2C8 and 2C9 amino acid polymorphisms. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15289789/),[l] / [h],1.13,54993,DB01050,Ibuprofen
,9495875,clearance,The clearance of R-ibuprofen more than doubled in the clofibrate-treated group (mean +/- S.E.M.; 29.4 +/- 4.0 ml/min) as compared to control rats (13.0 +/- 1.4 ml/min; P = .003).,Effect of clofibrate on the chiral disposition of ibuprofen in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9495875/),[ml] / [min],29.4,57428,DB01050,Ibuprofen
,9495875,clearance,The clearance of R-ibuprofen more than doubled in the clofibrate-treated group (mean +/- S.E.M.; 29.4 +/- 4.0 ml/min) as compared to control rats (13.0 +/- 1.4 ml/min; P = .003).,Effect of clofibrate on the chiral disposition of ibuprofen in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9495875/),[ml] / [min],13.0,57429,DB01050,Ibuprofen
,9495875,clearance,"This increase was similarly reflected in the clearance by inversion (treated, 23.2 +/- 3.2 ml/min, untreated, 10.0 +/- 1.2 ml/min; P = .003) and there was also an increase in the rate of inversion (treated, t1/2 inversion, 8.3 +/- 1.6 min; untreated, 13.9 +/- 1.4 min; P = .029).",Effect of clofibrate on the chiral disposition of ibuprofen in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9495875/),[ml] / [min],23.2,57430,DB01050,Ibuprofen
,9495875,clearance,"This increase was similarly reflected in the clearance by inversion (treated, 23.2 +/- 3.2 ml/min, untreated, 10.0 +/- 1.2 ml/min; P = .003) and there was also an increase in the rate of inversion (treated, t1/2 inversion, 8.3 +/- 1.6 min; untreated, 13.9 +/- 1.4 min; P = .029).",Effect of clofibrate on the chiral disposition of ibuprofen in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9495875/),[ml] / [min],10.0,57431,DB01050,Ibuprofen
,9495875,t1/2 inversion,"This increase was similarly reflected in the clearance by inversion (treated, 23.2 +/- 3.2 ml/min, untreated, 10.0 +/- 1.2 ml/min; P = .003) and there was also an increase in the rate of inversion (treated, t1/2 inversion, 8.3 +/- 1.6 min; untreated, 13.9 +/- 1.4 min; P = .029).",Effect of clofibrate on the chiral disposition of ibuprofen in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9495875/),min,8.3,57432,DB01050,Ibuprofen
,9495875,t1/2 inversion,"This increase was similarly reflected in the clearance by inversion (treated, 23.2 +/- 3.2 ml/min, untreated, 10.0 +/- 1.2 ml/min; P = .003) and there was also an increase in the rate of inversion (treated, t1/2 inversion, 8.3 +/- 1.6 min; untreated, 13.9 +/- 1.4 min; P = .029).",Effect of clofibrate on the chiral disposition of ibuprofen in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9495875/),min,13.9,57433,DB01050,Ibuprofen
,9495875,volume of distribution at steady-state,"There was a significant increase in volume of distribution at steady-state (treated, 4.42 +/- 1.12 liter/kg; untreated, 1.03 +/- 0.30 liter/kg; P = .017) observed for the R-enantiomer but not the S-enantiomer (treated, 1.04 +/- 0.13 liter/kg; untreated, 1.10 +/- 0.21 liter/kg).",Effect of clofibrate on the chiral disposition of ibuprofen in rats. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9495875/),[l] / [kg],4.42,57434,DB01050,Ibuprofen
,9495875,volume of distribution at steady-state,"There was a significant increase in volume of distribution at steady-state (treated, 4.42 +/- 1.12 liter/kg; untreated, 1.03 +/- 0.30 liter/kg; P = .017) observed for the R-enantiomer but not the S-enantiomer (treated, 1.04 +/- 0.13 liter/kg; untreated, 1.10 +/- 0.21 liter/kg).",Effect of clofibrate on the chiral disposition of ibuprofen in rats. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9495875/),[l] / [kg],1.03,57435,DB01050,Ibuprofen
,9495875,volume of distribution at steady-state,"There was a significant increase in volume of distribution at steady-state (treated, 4.42 +/- 1.12 liter/kg; untreated, 1.03 +/- 0.30 liter/kg; P = .017) observed for the R-enantiomer but not the S-enantiomer (treated, 1.04 +/- 0.13 liter/kg; untreated, 1.10 +/- 0.21 liter/kg).",Effect of clofibrate on the chiral disposition of ibuprofen in rats. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9495875/),[l] / [kg],1.04,57436,DB01050,Ibuprofen
,9495875,volume of distribution at steady-state,"There was a significant increase in volume of distribution at steady-state (treated, 4.42 +/- 1.12 liter/kg; untreated, 1.03 +/- 0.30 liter/kg; P = .017) observed for the R-enantiomer but not the S-enantiomer (treated, 1.04 +/- 0.13 liter/kg; untreated, 1.10 +/- 0.21 liter/kg).",Effect of clofibrate on the chiral disposition of ibuprofen in rats. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9495875/),[l] / [kg],1.10,57437,DB01050,Ibuprofen
<,26248375,trough,"First, early (before and after second dose) therapeutic drug monitoring (TDM) observations were evaluated for achieving target trough (<3 mg/liter) and peak (>24 mg/liter) levels.",Prospective Evaluation of a Model-Based Dosing Regimen for Amikacin in Preterm and Term Neonates in Clinical Practice. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26248375/),[mg] / [l],3,57472,DB01050,Ibuprofen
>,26248375,peak,"First, early (before and after second dose) therapeutic drug monitoring (TDM) observations were evaluated for achieving target trough (<3 mg/liter) and peak (>24 mg/liter) levels.",Prospective Evaluation of a Model-Based Dosing Regimen for Amikacin in Preterm and Term Neonates in Clinical Practice. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26248375/),[mg] / [l],24,57473,DB01050,Ibuprofen
reached,26248375,early peak levels,"In 579 neonates (median birth body weight, 2,285 [range, 420 to 4,850] g; postnatal age 2 days [range, 1 to 30 days]; gestational age, 34 weeks [range, 24 to 41 weeks]), 90.5% of the observed early peak levels reached 24 mg/liter, and 60.2% of the trough levels were <3 mg/liter (93.4% ≤5 mg/liter).",Prospective Evaluation of a Model-Based Dosing Regimen for Amikacin in Preterm and Term Neonates in Clinical Practice. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26248375/),[mg] / [l],24,57474,DB01050,Ibuprofen
<,26248375,trough levels,"In 579 neonates (median birth body weight, 2,285 [range, 420 to 4,850] g; postnatal age 2 days [range, 1 to 30 days]; gestational age, 34 weeks [range, 24 to 41 weeks]), 90.5% of the observed early peak levels reached 24 mg/liter, and 60.2% of the trough levels were <3 mg/liter (93.4% ≤5 mg/liter).",Prospective Evaluation of a Model-Based Dosing Regimen for Amikacin in Preterm and Term Neonates in Clinical Practice. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26248375/),[mg] / [l],3,57475,DB01050,Ibuprofen
≤,26248375,trough levels,"In 579 neonates (median birth body weight, 2,285 [range, 420 to 4,850] g; postnatal age 2 days [range, 1 to 30 days]; gestational age, 34 weeks [range, 24 to 41 weeks]), 90.5% of the observed early peak levels reached 24 mg/liter, and 60.2% of the trough levels were <3 mg/liter (93.4% ≤5 mg/liter).",Prospective Evaluation of a Model-Based Dosing Regimen for Amikacin in Preterm and Term Neonates in Clinical Practice. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26248375/),[mg] / [l],5,57476,DB01050,Ibuprofen
>,26248375,peak concentrations,Monte Carlo simulations showed that peak concentrations of >24 mg/liter were reached at steady state in almost all patients.,Prospective Evaluation of a Model-Based Dosing Regimen for Amikacin in Preterm and Term Neonates in Clinical Practice. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26248375/),[mg] / [l],24,57477,DB01050,Ibuprofen
<,26248375,Trough,"Trough values of <3 mg/liter at steady state were documented in 78% to 100% and 45% to 96% of simulated cases with and without ibuprofen coadministration, respectively; suboptimal trough levels were found in patients with postnatal age <14 days and current weight of >2,000 g.",Prospective Evaluation of a Model-Based Dosing Regimen for Amikacin in Preterm and Term Neonates in Clinical Practice. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26248375/),[mg] / [at·l·state·steady],3,57478,DB01050,Ibuprofen
,25475358,relative bioavailability,"The relative bioavailability of phenylephrine 10 mg was doubled (Fbio 2.11, 95%CI 1.89, 2.31) when combined with acetaminophen 1000 mg, while the absorption half-time was reduced by 50 %.","Increased bioavailability of phenylephrine by co-administration of acetaminophen: results of four open-label, crossover pharmacokinetic trials in healthy volunteers. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25475358/),,2.11,58874,DB01050,Ibuprofen
,25475358,Fbio,"When combined with 500 mg of acetaminophen, bioavailability increased by 64 % (Fbio 1.64).","Increased bioavailability of phenylephrine by co-administration of acetaminophen: results of four open-label, crossover pharmacokinetic trials in healthy volunteers. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25475358/),,1.64,58875,DB01050,Ibuprofen
,11710578,recovery,"The recovery of diclofenac was 92%, the analysis lasted 7 min with a sensitivity of 5 ng/ml and intra- and inter-day RSDs of 3 and 8%, respectively.",High-performance liquid chromatographic determination of diclofenac in human plasma after solid-phase extraction. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11710578/),%,92,60620,DB01050,Ibuprofen
,28891626,time to reach the maximum plasma concentration(Tmax),"The results indicated that the time to reach the maximum plasma concentration(Tmax) for lignanoids was 0.55-1.42 h, when the maximum plasma concentration(Cmax) could reach 996.36-2 330.96,189.87-1 469.43 μg•L ⁻¹ respectively for magnolol and honokiol.",[Pharmacokinetics of magnolol and honokiol in Weichang'an pill]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28891626/),h,0.55-1.42,60875,DB01050,Ibuprofen
,28891626,maximum plasma concentration(Cmax),"The results indicated that the time to reach the maximum plasma concentration(Tmax) for lignanoids was 0.55-1.42 h, when the maximum plasma concentration(Cmax) could reach 996.36-2 330.96,189.87-1 469.43 μg•L ⁻¹ respectively for magnolol and honokiol.",[Pharmacokinetics of magnolol and honokiol in Weichang'an pill]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28891626/),l·μg·⁻¹,996.36-2 330.96,60876,DB01050,Ibuprofen
,28891626,maximum plasma concentration(Cmax),"The results indicated that the time to reach the maximum plasma concentration(Tmax) for lignanoids was 0.55-1.42 h, when the maximum plasma concentration(Cmax) could reach 996.36-2 330.96,189.87-1 469.43 μg•L ⁻¹ respectively for magnolol and honokiol.",[Pharmacokinetics of magnolol and honokiol in Weichang'an pill]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28891626/),l·μg·⁻¹,189.87-1 469.43,60877,DB01050,Ibuprofen
,21088943,detection limit,"The concentration of ibuprofen in blood plasma was analysed by HPLC, following solid-phase extraction and using indometacin as internal standard (detection limit, 0.05 microg/ml).",In vivo assessment of parenteral formulations of oligo(3-hydroxybutyric Acid) conjugates with the model compound Ibuprofen. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21088943/),[μg] / [ml],0.05,61366,DB01050,Ibuprofen
,21088943,relative bioavailability,"In comparison to the non-conjugated drug in oily solution, the relative bioavailability of ibuprofen conjugates from oily solution, and o/w emulsion was reduced to 17% and 10%, respectively.",In vivo assessment of parenteral formulations of oligo(3-hydroxybutyric Acid) conjugates with the model compound Ibuprofen. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21088943/),%,17,61367,DB01050,Ibuprofen
,21088943,relative bioavailability,"In comparison to the non-conjugated drug in oily solution, the relative bioavailability of ibuprofen conjugates from oily solution, and o/w emulsion was reduced to 17% and 10%, respectively.",In vivo assessment of parenteral formulations of oligo(3-hydroxybutyric Acid) conjugates with the model compound Ibuprofen. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21088943/),%,10,61368,DB01050,Ibuprofen
,2905991,elimination half-life,The elimination half-life of ibuprofen on placebo was 2.04 h.,Do nizatidine and cimetidine interact with ibuprofen? ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2905991/),h,2.04,61733,DB01050,Ibuprofen
,2905991,elimination half-life,The elimination half-life of nizatidine on ibuprofen was 1.72 h and that of cimetidine was 3.54 h.,Do nizatidine and cimetidine interact with ibuprofen? ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2905991/),h,1.72,61734,DB01050,Ibuprofen
,2905991,elimination half-life,The elimination half-life of nizatidine on ibuprofen was 1.72 h and that of cimetidine was 3.54 h.,Do nizatidine and cimetidine interact with ibuprofen? ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2905991/),h,3.54,61735,DB01050,Ibuprofen
,21984391,recoveries,"Average recoveries of ibuprofen at 0.80, 12.0 and 40.0 µg/mL amounted to 98.0 ± 4.2%, 101.2 ± 3.6% and 99.3 ± 5.4%, respectively.",One-step method for plasma determination of ibuprofen by chemiluminescence-coupled ultrafiltration and application in a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21984391/),%,98.0,63000,DB01050,Ibuprofen
,21984391,recoveries,"Average recoveries of ibuprofen at 0.80, 12.0 and 40.0 µg/mL amounted to 98.0 ± 4.2%, 101.2 ± 3.6% and 99.3 ± 5.4%, respectively.",One-step method for plasma determination of ibuprofen by chemiluminescence-coupled ultrafiltration and application in a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21984391/),%,101.2,63001,DB01050,Ibuprofen
,21984391,recoveries,"Average recoveries of ibuprofen at 0.80, 12.0 and 40.0 µg/mL amounted to 98.0 ± 4.2%, 101.2 ± 3.6% and 99.3 ± 5.4%, respectively.",One-step method for plasma determination of ibuprofen by chemiluminescence-coupled ultrafiltration and application in a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21984391/),%,99.3,63002,DB01050,Ibuprofen
,21984391,detection limit,The detection limit for ibuprofen is 10.0 µg/L in plasma samples.,One-step method for plasma determination of ibuprofen by chemiluminescence-coupled ultrafiltration and application in a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21984391/),[μg] / [l],10.0,63003,DB01050,Ibuprofen
,27351190,C max,"The reason of this difference is due to the increase of ibuprofen concentration in rats' plasma: C max of IBU at doses of 20 and 40 mg/kg was found as 0.088 and 0.132 μg/ml, whereas C max of IBU in the complex form was 0.103 and 0.160 μg/ml, respectively.",Supramolecular Complex of Ibuprofen with Larch Polysaccharide Arabinogalactan: Studies on Bioavailability and Pharmacokinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27351190/),[μg] / [ml],0.088,64845,DB01050,Ibuprofen
,27351190,C max,"The reason of this difference is due to the increase of ibuprofen concentration in rats' plasma: C max of IBU at doses of 20 and 40 mg/kg was found as 0.088 and 0.132 μg/ml, whereas C max of IBU in the complex form was 0.103 and 0.160 μg/ml, respectively.",Supramolecular Complex of Ibuprofen with Larch Polysaccharide Arabinogalactan: Studies on Bioavailability and Pharmacokinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27351190/),[μg] / [ml],0.132,64846,DB01050,Ibuprofen
,27351190,C max,"The reason of this difference is due to the increase of ibuprofen concentration in rats' plasma: C max of IBU at doses of 20 and 40 mg/kg was found as 0.088 and 0.132 μg/ml, whereas C max of IBU in the complex form was 0.103 and 0.160 μg/ml, respectively.",Supramolecular Complex of Ibuprofen with Larch Polysaccharide Arabinogalactan: Studies on Bioavailability and Pharmacokinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27351190/),[μg] / [ml],0.103,64847,DB01050,Ibuprofen
,27351190,C max,"The reason of this difference is due to the increase of ibuprofen concentration in rats' plasma: C max of IBU at doses of 20 and 40 mg/kg was found as 0.088 and 0.132 μg/ml, whereas C max of IBU in the complex form was 0.103 and 0.160 μg/ml, respectively.",Supramolecular Complex of Ibuprofen with Larch Polysaccharide Arabinogalactan: Studies on Bioavailability and Pharmacokinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27351190/),[μg] / [ml],0.160,64848,DB01050,Ibuprofen
,7937520,plasma terminal half-life (t1/2),The mean plasma terminal half-life (t1/2) of R(-)ibuprofen was 1.74 hr when intravenously infused as a racemic mixture and was 1.84 hr when intravenously infused alone.,Pharmacokinetics and bioinversion of ibuprofen enantiomers in humans. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7937520/),h,1.74,68389,DB01050,Ibuprofen
,7937520,plasma terminal half-life (t1/2),The mean plasma terminal half-life (t1/2) of R(-)ibuprofen was 1.74 hr when intravenously infused as a racemic mixture and was 1.84 hr when intravenously infused alone.,Pharmacokinetics and bioinversion of ibuprofen enantiomers in humans. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7937520/),h,1.84,68390,DB01050,Ibuprofen
,7937520,t1/2,The mean t1/2 of S(+)ibuprofen was 1.77 hr when dosed as S(+)ibuprofen.,Pharmacokinetics and bioinversion of ibuprofen enantiomers in humans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7937520/),h,1.77,68391,DB01050,Ibuprofen
,7937520,bioavailability,"Because bioinversion of R(-)ibuprofen is not complete, S(+)ibuprofen produced higher bioavailability of S(+)ibuprofen (92.0%) than either racemic ibuprofen (70.7%) or R(-)ibuprofen (57.6%).",Pharmacokinetics and bioinversion of ibuprofen enantiomers in humans. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7937520/),%,92.0,68392,DB01050,Ibuprofen
,7937520,bioavailability,"Because bioinversion of R(-)ibuprofen is not complete, S(+)ibuprofen produced higher bioavailability of S(+)ibuprofen (92.0%) than either racemic ibuprofen (70.7%) or R(-)ibuprofen (57.6%).",Pharmacokinetics and bioinversion of ibuprofen enantiomers in humans. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7937520/),%,70.7,68393,DB01050,Ibuprofen
,7937520,bioavailability,"Because bioinversion of R(-)ibuprofen is not complete, S(+)ibuprofen produced higher bioavailability of S(+)ibuprofen (92.0%) than either racemic ibuprofen (70.7%) or R(-)ibuprofen (57.6%).",Pharmacokinetics and bioinversion of ibuprofen enantiomers in humans. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7937520/),%,57.6,68394,DB01050,Ibuprofen
,7937520,bioavailability,"However, bioavailability of R(-)ibuprofen (83.6%) when dosed alone was not significantly different from when dosed as racemic mixture (80.7%).",Pharmacokinetics and bioinversion of ibuprofen enantiomers in humans. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7937520/),%,83.6,68395,DB01050,Ibuprofen
,7937520,bioavailability,"However, bioavailability of R(-)ibuprofen (83.6%) when dosed alone was not significantly different from when dosed as racemic mixture (80.7%).",Pharmacokinetics and bioinversion of ibuprofen enantiomers in humans. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7937520/),%,80.7,68396,DB01050,Ibuprofen
,15924720,peak blood level,"(1) Animal study: IBU and DZP were both rapidly absorbed from rectum with a peak blood level of (11.7 +/- 1.2) min and (9.4 +/- 2.7) min in rabbits, respectively.",[Animal and clinical studies on rectal administration of a mixed solution of ibuprofen and diazepam]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15924720/),min,11.7,68851,DB01050,Ibuprofen
,15924720,peak blood level,"(1) Animal study: IBU and DZP were both rapidly absorbed from rectum with a peak blood level of (11.7 +/- 1.2) min and (9.4 +/- 2.7) min in rabbits, respectively.",[Animal and clinical studies on rectal administration of a mixed solution of ibuprofen and diazepam]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15924720/),min,9.4,68852,DB01050,Ibuprofen
,15924720,peak values,"The peak values were (57.8 +/- 7.9) mg/L and (450.1 +/- 158.7) microg/L, respectively.",[Animal and clinical studies on rectal administration of a mixed solution of ibuprofen and diazepam]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15924720/),[mg] / [l],57.8,68853,DB01050,Ibuprofen
,15924720,peak values,"The peak values were (57.8 +/- 7.9) mg/L and (450.1 +/- 158.7) microg/L, respectively.",[Animal and clinical studies on rectal administration of a mixed solution of ibuprofen and diazepam]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15924720/),[μg] / [l],450.1,68854,DB01050,Ibuprofen
,22648280,t(1/2abs),Exercise significantly decreased the t(1/2abs) (h) of (S)-ibuprofen (0.26 to 0.17; p = 0.015) and T(max) (h) for both (R)-ibuprofen (0.97 to 0.73; p = 0.008) and (S)-ibuprofen (1.13 to 0.84; p = 0.005).,The effect of operational stressors on ibuprofen pharmacokinetics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22648280/),h,0.26,70710,DB01050,Ibuprofen
less,1640357,tmax,Solutions were absorbed faster (tmax less than 0.25 h) than the tablet (tmax = 2.17 +/- 1.17 h).,Human pharmacokinetics of ibuprofen enantiomers following different doses and formulations: intestinal chiral inversion. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1640357/),h,0.25,71067,DB01050,Ibuprofen
,1640357,tmax,Solutions were absorbed faster (tmax less than 0.25 h) than the tablet (tmax = 2.17 +/- 1.17 h).,Human pharmacokinetics of ibuprofen enantiomers following different doses and formulations: intestinal chiral inversion. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1640357/),h,2.17,71068,DB01050,Ibuprofen
,1640357,AUC ratios,"While the S:R AUC ratios were unaffected by increasing the dose, they were significantly greater after the tablet (1.35 +/- 0.14) as compared with the solutions (1.15 +/- 0.16 to 1.24 +/- 0.26).",Human pharmacokinetics of ibuprofen enantiomers following different doses and formulations: intestinal chiral inversion. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1640357/),,1.35,71069,DB01050,Ibuprofen
,1640357,AUC ratios,"While the S:R AUC ratios were unaffected by increasing the dose, they were significantly greater after the tablet (1.35 +/- 0.14) as compared with the solutions (1.15 +/- 0.16 to 1.24 +/- 0.26).",Human pharmacokinetics of ibuprofen enantiomers following different doses and formulations: intestinal chiral inversion. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1640357/),,1.15,71070,DB01050,Ibuprofen
,1640357,AUC ratios,"While the S:R AUC ratios were unaffected by increasing the dose, they were significantly greater after the tablet (1.35 +/- 0.14) as compared with the solutions (1.15 +/- 0.16 to 1.24 +/- 0.26).",Human pharmacokinetics of ibuprofen enantiomers following different doses and formulations: intestinal chiral inversion. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1640357/),,1.24,71071,DB01050,Ibuprofen
,31989358,AUC0- ∞ (area under the concentration-time curve from time zero to infinity),"Through abdominal route, the AUC0- ∞ (area under the concentration-time curve from time zero to infinity) of uterus was 424.75 μg/g h, which is 3.60 times higher than that of plasma, and was significantly higher than that of other tissues (P < 0.0001).","Transdermal Administration of Ibuprofen-Loaded Gel: Preparation, Pharmacokinetic Profile, and Tissue Distribution. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31989358/),[μg] / [g·h],424.75,72773,DB01050,Ibuprofen
,31989358,Tmax (peak time),"Tmax (peak time) of uterus and plasma was 4 h and 2 h, respectively.","Transdermal Administration of Ibuprofen-Loaded Gel: Preparation, Pharmacokinetic Profile, and Tissue Distribution. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31989358/),h,4,72774,DB01050,Ibuprofen
,31989358,Tmax (peak time),"Tmax (peak time) of uterus and plasma was 4 h and 2 h, respectively.","Transdermal Administration of Ibuprofen-Loaded Gel: Preparation, Pharmacokinetic Profile, and Tissue Distribution. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31989358/),h,2,72775,DB01050,Ibuprofen
,31989358,AUC0-∞,"Upon transdermal application of IBU to the back, the AUC0-∞ of uterus was 75.47 μg/g h, which is 12.63 times lower than that of plasma, while Tmax of uterus and plasma was not lower than 20 h.","Transdermal Administration of Ibuprofen-Loaded Gel: Preparation, Pharmacokinetic Profile, and Tissue Distribution. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31989358/),[μg] / [g·h],75.47,72776,DB01050,Ibuprofen
lower,31989358,Tmax,"Upon transdermal application of IBU to the back, the AUC0-∞ of uterus was 75.47 μg/g h, which is 12.63 times lower than that of plasma, while Tmax of uterus and plasma was not lower than 20 h.","Transdermal Administration of Ibuprofen-Loaded Gel: Preparation, Pharmacokinetic Profile, and Tissue Distribution. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31989358/),h,20,72777,DB01050,Ibuprofen
,21164065,(t(max)),"The maximum plasma concentration (C(max)) of i.v. ibuprofen was approximately twice that of oral ibuprofen, and the (t(max)) of i.v. ibuprofen was 0.11 hour, compared with 1.5 hours for oral ibuprofen.","Pharmacokinetics, safety, and tolerability of a rapid infusion of i.v. ibuprofen in healthy adults. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21164065/),h,0.11,74870,DB01050,Ibuprofen
,21164065,(t(max)),"The maximum plasma concentration (C(max)) of i.v. ibuprofen was approximately twice that of oral ibuprofen, and the (t(max)) of i.v. ibuprofen was 0.11 hour, compared with 1.5 hours for oral ibuprofen.","Pharmacokinetics, safety, and tolerability of a rapid infusion of i.v. ibuprofen in healthy adults. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21164065/),h,1.5,74871,DB01050,Ibuprofen
,21164065,elimination half-life,"However, the elimination half-life of i.v. and oral ibuprofen did not differ, both of which were approximately 2 hours.","Pharmacokinetics, safety, and tolerability of a rapid infusion of i.v. ibuprofen in healthy adults. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21164065/),h,2,74872,DB01050,Ibuprofen
,21383341,EC50,"Maximum pain relief score by ibuprofen was 1.8 units greater than placebo, with an EC50 (effect-site) for ibuprofen concentration of 10.2 µg·mL(-1).",Modeling the onset and offset of dental pain relief by ibuprofen. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21383341/),[μg] / [ml],10.2,75481,DB01050,Ibuprofen
,22493811,absolute bioavailabilities,"Oral administration of ibuprofen arginate resulted in a very rapid absorption of (S)-(+)-ibuprofen (eutomer), and the absolute bioavailabilities of (S)-(+)-ibuprofen and (R)-(-)-ibuprofen were about 100% and 80%, respectively.",Pharmacokinetics of ibuprofen enantiomers in rats after intravenous and oral administration of ibuprofen arginate. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22493811/),%,100,77234,DB01050,Ibuprofen
,22493811,absolute bioavailabilities,"Oral administration of ibuprofen arginate resulted in a very rapid absorption of (S)-(+)-ibuprofen (eutomer), and the absolute bioavailabilities of (S)-(+)-ibuprofen and (R)-(-)-ibuprofen were about 100% and 80%, respectively.",Pharmacokinetics of ibuprofen enantiomers in rats after intravenous and oral administration of ibuprofen arginate. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22493811/),%,80,77235,DB01050,Ibuprofen
,1820883,MRT,"Ibuprofen absorption was much slower with aluminium hydroxide capsules (MRT 5.3, Tmax 3.1 h, Cmax 25.6 mg l-1, lag time 37.5 min) than with sodium bicarbonate capsules of the previous study (MRT 2.6 h, tmax 0.4 h, Cmax 51.4 mg l-1), lag time 0 min).",Effects of pH regulators used as additives on the bioavailability of ibuprofen from hard gelatin capsules. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1820883/),,5.3,78792,DB01050,Ibuprofen
,1820883,Tmax,"Ibuprofen absorption was much slower with aluminium hydroxide capsules (MRT 5.3, Tmax 3.1 h, Cmax 25.6 mg l-1, lag time 37.5 min) than with sodium bicarbonate capsules of the previous study (MRT 2.6 h, tmax 0.4 h, Cmax 51.4 mg l-1), lag time 0 min).",Effects of pH regulators used as additives on the bioavailability of ibuprofen from hard gelatin capsules. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1820883/),h,3.1,78793,DB01050,Ibuprofen
,1820883,Cmax,"Ibuprofen absorption was much slower with aluminium hydroxide capsules (MRT 5.3, Tmax 3.1 h, Cmax 25.6 mg l-1, lag time 37.5 min) than with sodium bicarbonate capsules of the previous study (MRT 2.6 h, tmax 0.4 h, Cmax 51.4 mg l-1), lag time 0 min).",Effects of pH regulators used as additives on the bioavailability of ibuprofen from hard gelatin capsules. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1820883/),[mg] / [l],25.6,78794,DB01050,Ibuprofen
,1820883,lag time,"Ibuprofen absorption was much slower with aluminium hydroxide capsules (MRT 5.3, Tmax 3.1 h, Cmax 25.6 mg l-1, lag time 37.5 min) than with sodium bicarbonate capsules of the previous study (MRT 2.6 h, tmax 0.4 h, Cmax 51.4 mg l-1), lag time 0 min).",Effects of pH regulators used as additives on the bioavailability of ibuprofen from hard gelatin capsules. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1820883/),min,37.5,78795,DB01050,Ibuprofen
,1820883,MRT,"Ibuprofen absorption was much slower with aluminium hydroxide capsules (MRT 5.3, Tmax 3.1 h, Cmax 25.6 mg l-1, lag time 37.5 min) than with sodium bicarbonate capsules of the previous study (MRT 2.6 h, tmax 0.4 h, Cmax 51.4 mg l-1), lag time 0 min).",Effects of pH regulators used as additives on the bioavailability of ibuprofen from hard gelatin capsules. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1820883/),h,2.6,78796,DB01050,Ibuprofen
,1820883,tmax,"Ibuprofen absorption was much slower with aluminium hydroxide capsules (MRT 5.3, Tmax 3.1 h, Cmax 25.6 mg l-1, lag time 37.5 min) than with sodium bicarbonate capsules of the previous study (MRT 2.6 h, tmax 0.4 h, Cmax 51.4 mg l-1), lag time 0 min).",Effects of pH regulators used as additives on the bioavailability of ibuprofen from hard gelatin capsules. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1820883/),h,0.4,78797,DB01050,Ibuprofen
,1820883,Cmax,"Ibuprofen absorption was much slower with aluminium hydroxide capsules (MRT 5.3, Tmax 3.1 h, Cmax 25.6 mg l-1, lag time 37.5 min) than with sodium bicarbonate capsules of the previous study (MRT 2.6 h, tmax 0.4 h, Cmax 51.4 mg l-1), lag time 0 min).",Effects of pH regulators used as additives on the bioavailability of ibuprofen from hard gelatin capsules. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1820883/),[mg] / [l],51.4,78798,DB01050,Ibuprofen
,1820883,lag time,"Ibuprofen absorption was much slower with aluminium hydroxide capsules (MRT 5.3, Tmax 3.1 h, Cmax 25.6 mg l-1, lag time 37.5 min) than with sodium bicarbonate capsules of the previous study (MRT 2.6 h, tmax 0.4 h, Cmax 51.4 mg l-1), lag time 0 min).",Effects of pH regulators used as additives on the bioavailability of ibuprofen from hard gelatin capsules. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1820883/),min,0,78799,DB01050,Ibuprofen
,1820883,MRT,"The corresponding values for calcium carbonate and tartaric acid capsules were: MRT 3.7 h and 3.9 h, Tmax 1.7 h and 2.0 h, Cmax 32.2 mg l-1 and 30.8 mg l-1 and lag time 3.1 min and 7.6 min.",Effects of pH regulators used as additives on the bioavailability of ibuprofen from hard gelatin capsules. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1820883/),h,3.7,78800,DB01050,Ibuprofen
,1820883,MRT,"The corresponding values for calcium carbonate and tartaric acid capsules were: MRT 3.7 h and 3.9 h, Tmax 1.7 h and 2.0 h, Cmax 32.2 mg l-1 and 30.8 mg l-1 and lag time 3.1 min and 7.6 min.",Effects of pH regulators used as additives on the bioavailability of ibuprofen from hard gelatin capsules. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1820883/),h,3.9,78801,DB01050,Ibuprofen
,1820883,Tmax,"The corresponding values for calcium carbonate and tartaric acid capsules were: MRT 3.7 h and 3.9 h, Tmax 1.7 h and 2.0 h, Cmax 32.2 mg l-1 and 30.8 mg l-1 and lag time 3.1 min and 7.6 min.",Effects of pH regulators used as additives on the bioavailability of ibuprofen from hard gelatin capsules. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1820883/),h,1.7,78802,DB01050,Ibuprofen
,1820883,Tmax,"The corresponding values for calcium carbonate and tartaric acid capsules were: MRT 3.7 h and 3.9 h, Tmax 1.7 h and 2.0 h, Cmax 32.2 mg l-1 and 30.8 mg l-1 and lag time 3.1 min and 7.6 min.",Effects of pH regulators used as additives on the bioavailability of ibuprofen from hard gelatin capsules. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1820883/),h,2.0,78803,DB01050,Ibuprofen
,1820883,Cmax,"The corresponding values for calcium carbonate and tartaric acid capsules were: MRT 3.7 h and 3.9 h, Tmax 1.7 h and 2.0 h, Cmax 32.2 mg l-1 and 30.8 mg l-1 and lag time 3.1 min and 7.6 min.",Effects of pH regulators used as additives on the bioavailability of ibuprofen from hard gelatin capsules. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1820883/),[mg] / [l],32.2,78804,DB01050,Ibuprofen
,1820883,Cmax,"The corresponding values for calcium carbonate and tartaric acid capsules were: MRT 3.7 h and 3.9 h, Tmax 1.7 h and 2.0 h, Cmax 32.2 mg l-1 and 30.8 mg l-1 and lag time 3.1 min and 7.6 min.",Effects of pH regulators used as additives on the bioavailability of ibuprofen from hard gelatin capsules. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1820883/),[mg] / [l],30.8,78805,DB01050,Ibuprofen
,1820883,lag time,"The corresponding values for calcium carbonate and tartaric acid capsules were: MRT 3.7 h and 3.9 h, Tmax 1.7 h and 2.0 h, Cmax 32.2 mg l-1 and 30.8 mg l-1 and lag time 3.1 min and 7.6 min.",Effects of pH regulators used as additives on the bioavailability of ibuprofen from hard gelatin capsules. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1820883/),min,3.1,78806,DB01050,Ibuprofen
,1820883,lag time,"The corresponding values for calcium carbonate and tartaric acid capsules were: MRT 3.7 h and 3.9 h, Tmax 1.7 h and 2.0 h, Cmax 32.2 mg l-1 and 30.8 mg l-1 and lag time 3.1 min and 7.6 min.",Effects of pH regulators used as additives on the bioavailability of ibuprofen from hard gelatin capsules. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1820883/),min,7.6,78807,DB01050,Ibuprofen
,1904749,maximum percentage inhibition,"3. The maximum percentage inhibition of TXB2 generation increased significantly with dose from a mean +/- s.d. of 93.4 +/- 1.2% after the 200 mg dose to 98.8 +/- 0.3% after the 1200 mg dose, and there was an increase with dose in the duration of inhibition of TXB2 generation.",Effect of racemic ibuprofen dose on the magnitude and duration of platelet cyclo-oxygenase inhibition: relationship between inhibition of thromboxane production and the plasma unbound concentration of S(+)-ibuprofen. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1904749/),%,93.4,79716,DB01050,Ibuprofen
,1904749,maximum percentage inhibition,"3. The maximum percentage inhibition of TXB2 generation increased significantly with dose from a mean +/- s.d. of 93.4 +/- 1.2% after the 200 mg dose to 98.8 +/- 0.3% after the 1200 mg dose, and there was an increase with dose in the duration of inhibition of TXB2 generation.",Effect of racemic ibuprofen dose on the magnitude and duration of platelet cyclo-oxygenase inhibition: relationship between inhibition of thromboxane production and the plasma unbound concentration of S(+)-ibuprofen. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1904749/),%,98.8,79717,DB01050,Ibuprofen
,1904749,plasma unbound concentration,The mean plasma unbound concentration of S(+)-ibuprofen required to inhibit platelet TXB2 generation by 50% (EC50) was 9.8 +/- 1.0 micrograms l-1.,Effect of racemic ibuprofen dose on the magnitude and duration of platelet cyclo-oxygenase inhibition: relationship between inhibition of thromboxane production and the plasma unbound concentration of S(+)-ibuprofen. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1904749/),[μg] / [l],9.8,79718,DB01050,Ibuprofen
,1904749,EC50),The mean plasma unbound concentration of S(+)-ibuprofen required to inhibit platelet TXB2 generation by 50% (EC50) was 9.8 +/- 1.0 micrograms l-1.,Effect of racemic ibuprofen dose on the magnitude and duration of platelet cyclo-oxygenase inhibition: relationship between inhibition of thromboxane production and the plasma unbound concentration of S(+)-ibuprofen. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1904749/),[μg] / [l],9.8,79719,DB01050,Ibuprofen
,4064467,peak serum ibuprofen concentration,"Compared with the control state, cimetidine increased the peak serum ibuprofen concentration (64 vs. 56 micrograms/ml), but the value during ranitidine dosing (57 micrograms/ml) was indistinguishable from the control value.",Interaction of ibuprofen with the H-2 receptor antagonists ranitidine and cimetidine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4064467/),[μg] / [ml],64,80890,DB01050,Ibuprofen
,4064467,peak serum ibuprofen concentration,"Compared with the control state, cimetidine increased the peak serum ibuprofen concentration (64 vs. 56 micrograms/ml), but the value during ranitidine dosing (57 micrograms/ml) was indistinguishable from the control value.",Interaction of ibuprofen with the H-2 receptor antagonists ranitidine and cimetidine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4064467/),[μg] / [ml],56,80891,DB01050,Ibuprofen
,4064467,peak serum ibuprofen concentration,"Compared with the control state, cimetidine increased the peak serum ibuprofen concentration (64 vs. 56 micrograms/ml), but the value during ranitidine dosing (57 micrograms/ml) was indistinguishable from the control value.",Interaction of ibuprofen with the H-2 receptor antagonists ranitidine and cimetidine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4064467/),[μg] / [ml],57,80892,DB01050,Ibuprofen
,4064467,elimination t1/2,"There were no significant differences between control, cimetidine, and ranitidine conditions in ibuprofen elimination t1/2 (2.1, 2.1, and 2.0 hours, respectively).",Interaction of ibuprofen with the H-2 receptor antagonists ranitidine and cimetidine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/4064467/),h,2.1,80893,DB01050,Ibuprofen
,4064467,elimination t1/2,"There were no significant differences between control, cimetidine, and ranitidine conditions in ibuprofen elimination t1/2 (2.1, 2.1, and 2.0 hours, respectively).",Interaction of ibuprofen with the H-2 receptor antagonists ranitidine and cimetidine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/4064467/),h,2.0,80894,DB01050,Ibuprofen
,4064467,oral clearance,"Overall there was a significant difference among the control, cimetidine, and ranitidine conditions in ibuprofen oral clearance (52.8, 48.3, and 54.1 ml/min, respectively), but individual differences in cimetidine vs. control and between ranitidine vs. control were not statistically significant.",Interaction of ibuprofen with the H-2 receptor antagonists ranitidine and cimetidine. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4064467/),[ml] / [min],52.8,80895,DB01050,Ibuprofen
,4064467,oral clearance,"Overall there was a significant difference among the control, cimetidine, and ranitidine conditions in ibuprofen oral clearance (52.8, 48.3, and 54.1 ml/min, respectively), but individual differences in cimetidine vs. control and between ranitidine vs. control were not statistically significant.",Interaction of ibuprofen with the H-2 receptor antagonists ranitidine and cimetidine. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4064467/),[ml] / [min],48.3,80896,DB01050,Ibuprofen
,4064467,oral clearance,"Overall there was a significant difference among the control, cimetidine, and ranitidine conditions in ibuprofen oral clearance (52.8, 48.3, and 54.1 ml/min, respectively), but individual differences in cimetidine vs. control and between ranitidine vs. control were not statistically significant.",Interaction of ibuprofen with the H-2 receptor antagonists ranitidine and cimetidine. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4064467/),[ml] / [min],54.1,80897,DB01050,Ibuprofen
,19961574,Tmax,"Tmax for sodium ibuprofen was less than half that of standard ibuprofen (median 35 min vs 90 min, respectively; P=0.0002) and Cmax was significantly higher (41.47 microg/mL vs 31.88 microg/mL; ratio test/reference=130.06%, 90% CI 118.86-142.32%).","Bioavailability of ibuprofen following oral administration of standard ibuprofen, sodium ibuprofen or ibuprofen acid incorporating poloxamer in healthy volunteers. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19961574/),min,35,81213,DB01050,Ibuprofen
,19961574,Tmax,"Tmax for sodium ibuprofen was less than half that of standard ibuprofen (median 35 min vs 90 min, respectively; P=0.0002) and Cmax was significantly higher (41.47 microg/mL vs 31.88 microg/mL; ratio test/reference=130.06%, 90% CI 118.86-142.32%).","Bioavailability of ibuprofen following oral administration of standard ibuprofen, sodium ibuprofen or ibuprofen acid incorporating poloxamer in healthy volunteers. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19961574/),min,90,81214,DB01050,Ibuprofen
,19961574,Cmax,"Tmax for sodium ibuprofen was less than half that of standard ibuprofen (median 35 min vs 90 min, respectively; P=0.0002) and Cmax was significantly higher (41.47 microg/mL vs 31.88 microg/mL; ratio test/reference=130.06%, 90% CI 118.86-142.32%).","Bioavailability of ibuprofen following oral administration of standard ibuprofen, sodium ibuprofen or ibuprofen acid incorporating poloxamer in healthy volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19961574/),[μg] / [ml],41.47,81215,DB01050,Ibuprofen
,19961574,Cmax,"Tmax for sodium ibuprofen was less than half that of standard ibuprofen (median 35 min vs 90 min, respectively; P=0.0002) and Cmax was significantly higher (41.47 microg/mL vs 31.88 microg/mL; ratio test/reference=130.06%, 90% CI 118.86-142.32%).","Bioavailability of ibuprofen following oral administration of standard ibuprofen, sodium ibuprofen or ibuprofen acid incorporating poloxamer in healthy volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19961574/),[μg] / [ml],31.88,81216,DB01050,Ibuprofen
,19961574,Tmax,"Ibuprofen/poloxamer was bioequivalent to the standard ibuprofen formulation, despite its Tmax being on average 20 minutes shorter than standard ibuprofen (median 75 mins vs 90 mins, respectively; P=0.1913), as the ratio of test/reference=110.48% (CI 100.96-120.89%), which fell within the 80-125% limit of the CPMP and FDA guidelines for bioequivalence.","Bioavailability of ibuprofen following oral administration of standard ibuprofen, sodium ibuprofen or ibuprofen acid incorporating poloxamer in healthy volunteers. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19961574/),min,75,81217,DB01050,Ibuprofen
,19961574,Tmax,"Ibuprofen/poloxamer was bioequivalent to the standard ibuprofen formulation, despite its Tmax being on average 20 minutes shorter than standard ibuprofen (median 75 mins vs 90 mins, respectively; P=0.1913), as the ratio of test/reference=110.48% (CI 100.96-120.89%), which fell within the 80-125% limit of the CPMP and FDA guidelines for bioequivalence.","Bioavailability of ibuprofen following oral administration of standard ibuprofen, sodium ibuprofen or ibuprofen acid incorporating poloxamer in healthy volunteers. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19961574/),min,90,81218,DB01050,Ibuprofen
,2084127,limit of detection,"The limit of detection was 0.1 micrograms/ml for the enantiomers of ketoprofen and ibuprofen, and 0.25 micrograms/ml for the enantiomers of fenoprofen.","Stereoselective high-performance liquid chromatographic determination of ketoprofen, ibuprofen and fenoprofen in plasma using a chiral alpha 1-acid glycoprotein column. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2084127/),[μg] / [ml],0.1,81250,DB01050,Ibuprofen
,2084127,limit of detection,"The limit of detection was 0.1 micrograms/ml for the enantiomers of ketoprofen and ibuprofen, and 0.25 micrograms/ml for the enantiomers of fenoprofen.","Stereoselective high-performance liquid chromatographic determination of ketoprofen, ibuprofen and fenoprofen in plasma using a chiral alpha 1-acid glycoprotein column. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2084127/),[μg] / [ml],0.25,81251,DB01050,Ibuprofen
,8300702,half-life,"The half-life varied from 1.4 to 5.1 hours, depending on the site of administration and/or the presence of solid food.",The pharmacokinetics of ibuprofen after burn injury. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8300702/),h,1.4 to 5.1,81493,DB01050,Ibuprofen
,8300702,half-life,The reported half-life for ibuprofen suspension is 1.8 to 2 hours.,The pharmacokinetics of ibuprofen after burn injury. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8300702/),h,1.8 to 2,81494,DB01050,Ibuprofen
,8300702,Time to maximal temperature reduction,Time to maximal temperature reduction was between 2 and 3 hours after drug administration.,The pharmacokinetics of ibuprofen after burn injury. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8300702/),h,2 and 3,81495,DB01050,Ibuprofen
,1479559,apparent corneal permeability coefficients,"R3 and R4 each had apparent corneal permeability coefficients of 6 x 10(-6) cm/sec, whereas ibufenac and ibuprofen yielded values of about 22 x 10(-6) cm/sec.","Biopharmaceutical evaluation of ibufenac, ibuprofen, and their hydroxyethoxy analogs in the rabbit eye. ",Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1479559/),[cm] / [s],6 x 10(-6),81796,DB01050,Ibuprofen
,1479559,apparent corneal permeability coefficients,"R3 and R4 each had apparent corneal permeability coefficients of 6 x 10(-6) cm/sec, whereas ibufenac and ibuprofen yielded values of about 22 x 10(-6) cm/sec.","Biopharmaceutical evaluation of ibufenac, ibuprofen, and their hydroxyethoxy analogs in the rabbit eye. ",Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1479559/),[cm] / [s],22 x 10(-6),81797,DB01050,Ibuprofen
,14581080,flow rate,"The HPLC chiral resolution of IBU was obtained using a chiral stationary phase based on a tris-(3,5-dimethylphenylcarbamate) amylose derivative, under reversed phase conditions (CHIRALPAK AD-RH column), using a mobile phase consisting of methanol:water (8:2, v/v), containing 0.1% of an aqueous solution of phosphoric acid at pH 2, at a flow rate of 0.6 ml/min.",Enantioselective determination of ibuprofen in plasma by high-performance liquid chromatography-electrospray mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14581080/),[ml] / [min],0.6,81822,DB01050,Ibuprofen
,8906081,peak ibuprofen concentration,"To be effective, peak ibuprofen concentration of 50 to 100 mg/L has to be achieved.",Use of a rapid HPLC assay for determination of pharmacokinetic parameters of ibuprofen in patients with cystic fibrosis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8906081/),[mg] / [l],50 to 100,82187,DB01050,Ibuprofen
,8906081,recovery,"The assay possessed linearity up to 500 mg/L, sensitivity to 1 mg/L, average recovery of 98%, and run-to-run precision (n = 23) of 3%.",Use of a rapid HPLC assay for determination of pharmacokinetic parameters of ibuprofen in patients with cystic fibrosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8906081/),%,98,82188,DB01050,Ibuprofen
,8906081,time to peak concentration,"Observed time to peak concentration varied significantly between those receiving ibuprofen tablets (mean + SD, 94 +/- 29 min, n = 16) and syrup (30 +/- 0 min, n = 4) (P < 0.0001).",Use of a rapid HPLC assay for determination of pharmacokinetic parameters of ibuprofen in patients with cystic fibrosis. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8906081/),min,94,82189,DB01050,Ibuprofen
,8906081,time to peak concentration,"Observed time to peak concentration varied significantly between those receiving ibuprofen tablets (mean + SD, 94 +/- 29 min, n = 16) and syrup (30 +/- 0 min, n = 4) (P < 0.0001).",Use of a rapid HPLC assay for determination of pharmacokinetic parameters of ibuprofen in patients with cystic fibrosis. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8906081/),min,30,82190,DB01050,Ibuprofen
,13680850,recovery,"Mean recovery was determined as 101.0% by analysis of plasma standard samples containing 0.0424, 0.424, 2.12 and 4.24 microg/mL of 3-n-butylphthalide.",Determination of 3-n-butylphthalide in rabbit plasma by HPLC with fluorescence detection and its application in pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/13680850/),%,101.0,82276,DB01050,Ibuprofen
,7787132,relative bioavailability,"The relative bioavailability of ibuprofen and naproxen, following oral administration of ibudice and napdice, was 96% and 74%, respectively, and the rate of absorption was not significantly different from that obtained following oral dosing of the parent compound.",Pharmacokinetic analysis of diethylcarbonate prodrugs of ibuprofen and naproxen. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7787132/),%,96,83137,DB01050,Ibuprofen
,7787132,relative bioavailability,"The relative bioavailability of ibuprofen and naproxen, following oral administration of ibudice and napdice, was 96% and 74%, respectively, and the rate of absorption was not significantly different from that obtained following oral dosing of the parent compound.",Pharmacokinetic analysis of diethylcarbonate prodrugs of ibuprofen and naproxen. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7787132/),%,74,83138,DB01050,Ibuprofen
,28933113,relative bioavailability,"In comparison with negative control (no PE was added), the relative bioavailability values with the addition of Chuanxiong oil, Angelica oil, Cinnamon oil and Azone as PE were determined to be 161.87%, 171.05%, 151.37% and 148.66%, respectively.",[Evaluation of pharmacokinetics and in vitro/in vivo correlation of ibuprofen with essential oils as penetration enhancer following transdermal administration]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28933113/),%,161.87,85572,DB01050,Ibuprofen
,28933113,relative bioavailability,"In comparison with negative control (no PE was added), the relative bioavailability values with the addition of Chuanxiong oil, Angelica oil, Cinnamon oil and Azone as PE were determined to be 161.87%, 171.05%, 151.37% and 148.66%, respectively.",[Evaluation of pharmacokinetics and in vitro/in vivo correlation of ibuprofen with essential oils as penetration enhancer following transdermal administration]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28933113/),%,171.05,85573,DB01050,Ibuprofen
,28933113,relative bioavailability,"In comparison with negative control (no PE was added), the relative bioavailability values with the addition of Chuanxiong oil, Angelica oil, Cinnamon oil and Azone as PE were determined to be 161.87%, 171.05%, 151.37% and 148.66%, respectively.",[Evaluation of pharmacokinetics and in vitro/in vivo correlation of ibuprofen with essential oils as penetration enhancer following transdermal administration]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28933113/),%,151.37,85574,DB01050,Ibuprofen
,28933113,relative bioavailability,"In comparison with negative control (no PE was added), the relative bioavailability values with the addition of Chuanxiong oil, Angelica oil, Cinnamon oil and Azone as PE were determined to be 161.87%, 171.05%, 151.37% and 148.66%, respectively.",[Evaluation of pharmacokinetics and in vitro/in vivo correlation of ibuprofen with essential oils as penetration enhancer following transdermal administration]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28933113/),%,148.66,85575,DB01050,Ibuprofen
,23937590,relative bioavailability,"Formula TF5 tablets comprising lyophilized micelles (F5; DXI: Pluronic F127 in 1:1 ratio and 0.25% mannitol) showed higher Cmax and earlier tmax values than those of the commercial formula, where the relative bioavailability was calculated to be 160.15%.","Adoption of polymeric micelles to enhance the oral bioavailability of dexibuprofen: formulation, in-vitro evaluation and in-vivo pharmacokinetic study in healthy human volunteers. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23937590/),%,160.15,86069,DB01050,Ibuprofen
,1748537,tmax,IP was absorbed rapidly (tmax 0.6-1.9 h).,Relative pharmacokinetics of three oral 400 mg ibuprofen dosage forms in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1748537/),h,0.6-1.9,87295,DB01050,Ibuprofen
,28569515,globule size,The optimized formulation produced a microemulsion with a globule size of 177.5 nm.,"Self-emulsifying drug delivery system (SEDDS) of Ibuprofen: formulation, in vitro and in vivo evaluation. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28569515/),,177.5,87649,DB01050,Ibuprofen
,11978144,half-life,"Following intravitreal administration, fomivirsen is slowly cleared from vitreous with a half-life of approximately 55 hours in humans.",Fomivirsen: clinical pharmacology and potential drug interactions. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11978144/),h,55,90169,DB01050,Ibuprofen
,11978144,half-life for clearance,The estimated half-life for clearance of fomivirsen from retina was 78 hours in monkeys following a 115-microg dose.,Fomivirsen: clinical pharmacology and potential drug interactions. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11978144/),h,78,90170,DB01050,Ibuprofen
,20602760,Mean plasma levels,"Mean plasma levels at 10 and 20 minutes were 6.64 microg x mL(-1) and 16.81 microg x mL(-1), respectively, for ibuprofen from the combination, compared with 0.58 microg x mL(-1) and 9.00 microg x mL-1, respectively, for monotherapy.",The pharmacokinetic profile of a novel fixed-dose combination tablet of ibuprofen and paracetamol. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20602760/),[μg] / [ml],6.64,91110,DB01050,Ibuprofen
,20602760,Mean plasma levels,"Mean plasma levels at 10 and 20 minutes were 6.64 microg x mL(-1) and 16.81 microg x mL(-1), respectively, for ibuprofen from the combination, compared with 0.58 microg x mL(-1) and 9.00 microg x mL-1, respectively, for monotherapy.",The pharmacokinetic profile of a novel fixed-dose combination tablet of ibuprofen and paracetamol. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20602760/),[μg] / [ml],16.81,91111,DB01050,Ibuprofen
,20602760,Mean plasma levels,"Mean plasma levels at 10 and 20 minutes were 6.64 microg x mL(-1) and 16.81 microg x mL(-1), respectively, for ibuprofen from the combination, compared with 0.58 microg x mL(-1) and 9.00 microg x mL-1, respectively, for monotherapy.",The pharmacokinetic profile of a novel fixed-dose combination tablet of ibuprofen and paracetamol. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20602760/),[μg] / [ml],0.58,91112,DB01050,Ibuprofen
,20602760,Mean plasma levels,"Mean plasma levels at 10 and 20 minutes were 6.64 microg x mL(-1) and 16.81 microg x mL(-1), respectively, for ibuprofen from the combination, compared with 0.58 microg x mL(-1) and 9.00 microg x mL-1, respectively, for monotherapy.",The pharmacokinetic profile of a novel fixed-dose combination tablet of ibuprofen and paracetamol. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20602760/),[μg] / [ml],9.00,91113,DB01050,Ibuprofen
,20602760,mean,"For paracetamol, mean plasma levels at 10 and 20 minutes were 5.43 microg x mL(-1) and 14.54 microg x mL(-, respectively, for the combination compared with 0.33 microg x mL(-1) and 9.19 microg x mL(-1), respectively, for monotherapy.",The pharmacokinetic profile of a novel fixed-dose combination tablet of ibuprofen and paracetamol. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20602760/),[μg] / [ml],5.43,91114,DB01050,Ibuprofen
,20602760,mean,"For paracetamol, mean plasma levels at 10 and 20 minutes were 5.43 microg x mL(-1) and 14.54 microg x mL(-, respectively, for the combination compared with 0.33 microg x mL(-1) and 9.19 microg x mL(-1), respectively, for monotherapy.",The pharmacokinetic profile of a novel fixed-dose combination tablet of ibuprofen and paracetamol. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20602760/),[μg] / [ml],9.19,91115,DB01050,Ibuprofen
,20602760,plasma levels,"For paracetamol, mean plasma levels at 10 and 20 minutes were 5.43 microg x mL(-1) and 14.54 microg x mL(-, respectively, for the combination compared with 0.33 microg x mL(-1) and 9.19 microg x mL(-1), respectively, for monotherapy.",The pharmacokinetic profile of a novel fixed-dose combination tablet of ibuprofen and paracetamol. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20602760/),[μg] / [ml],5.43,91116,DB01050,Ibuprofen
,20602760,plasma levels,"For paracetamol, mean plasma levels at 10 and 20 minutes were 5.43 microg x mL(-1) and 14.54 microg x mL(-, respectively, for the combination compared with 0.33 microg x mL(-1) and 9.19 microg x mL(-1), respectively, for monotherapy.",The pharmacokinetic profile of a novel fixed-dose combination tablet of ibuprofen and paracetamol. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20602760/),ml(-·μg,14.54,91117,DB01050,Ibuprofen
,20602760,plasma levels,"For paracetamol, mean plasma levels at 10 and 20 minutes were 5.43 microg x mL(-1) and 14.54 microg x mL(-, respectively, for the combination compared with 0.33 microg x mL(-1) and 9.19 microg x mL(-1), respectively, for monotherapy.",The pharmacokinetic profile of a novel fixed-dose combination tablet of ibuprofen and paracetamol. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20602760/),[μg] / [ml],0.33,91118,DB01050,Ibuprofen
,20602760,plasma levels,"For paracetamol, mean plasma levels at 10 and 20 minutes were 5.43 microg x mL(-1) and 14.54 microg x mL(-, respectively, for the combination compared with 0.33 microg x mL(-1) and 9.19 microg x mL(-1), respectively, for monotherapy.",The pharmacokinetic profile of a novel fixed-dose combination tablet of ibuprofen and paracetamol. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20602760/),[μg] / [ml],9.19,91119,DB01050,Ibuprofen
,15967300,flow rate,"Chromatographic separation was performed on a Diamonsil C18 column with a C18 guard column using a binary mixture of acetonitrile and 0.02 mol/l phosphate buffer (pH 6.5) (35:65, v/v) delivered at a flow rate of 1.2 ml/min.",Determination of ibuprofen in dog plasma by liquid chromatography and application in pharmacokinetic studies of an ibuprofen prodrug in dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15967300/),[ml] / [min],1.2,93719,DB01050,Ibuprofen
,15967300,extraction recoveries,"The mean extraction recoveries of ibuprofen determined over the concentrations of 1.0, 10.0, and 40.0 microg/ml were (100.5+/-1.8)%, (99.8+/-1.0)%, and (99.2+/-2.3)%.",Determination of ibuprofen in dog plasma by liquid chromatography and application in pharmacokinetic studies of an ibuprofen prodrug in dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15967300/),%,100.5,93720,DB01050,Ibuprofen
,15967300,extraction recoveries,"The mean extraction recoveries of ibuprofen determined over the concentrations of 1.0, 10.0, and 40.0 microg/ml were (100.5+/-1.8)%, (99.8+/-1.0)%, and (99.2+/-2.3)%.",Determination of ibuprofen in dog plasma by liquid chromatography and application in pharmacokinetic studies of an ibuprofen prodrug in dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15967300/),%,99.8,93721,DB01050,Ibuprofen
,15967300,extraction recoveries,"The mean extraction recoveries of ibuprofen determined over the concentrations of 1.0, 10.0, and 40.0 microg/ml were (100.5+/-1.8)%, (99.8+/-1.0)%, and (99.2+/-2.3)%.",Determination of ibuprofen in dog plasma by liquid chromatography and application in pharmacokinetic studies of an ibuprofen prodrug in dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15967300/),%,99.2,93722,DB01050,Ibuprofen
,28444716,relative bioavailability,"The highest peak plasma concentration was observed after 3 chews, and the relative bioavailability was approximately 8% higher compared to 8 chews.",The Relative Bioavailability of Ibuprofen After Administration With a Novel Soft Chewable Drug Formulation. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28444716/),%,8,93789,DB01050,Ibuprofen
,9725480,t(max),If the whole dose was incorporated in the core the absorption curve has only one clear t(max) value at about 10 h.,Biopharmaceutical evaluation of time-controlled press-coated tablets containing polymers to adjust drug release. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9725480/),h,10,97617,DB01050,Ibuprofen
,8477555,bioavailabilities,"The bioavailabilities of (R)-ibuprofen and total ibuprofen were 0.92 +/- 0.11 and 0.95 +/- 0.08, respectively.",Lack of presystemic inversion of (R)- to (S)-ibuprofen in humans. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8477555/),,0.92,97709,DB01050,Ibuprofen
,8477555,bioavailabilities,"The bioavailabilities of (R)-ibuprofen and total ibuprofen were 0.92 +/- 0.11 and 0.95 +/- 0.08, respectively.",Lack of presystemic inversion of (R)- to (S)-ibuprofen in humans. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8477555/),,0.95,97710,DB01050,Ibuprofen
,11897978,peak concentrations,Therapeutic drug monitoring has been recommended to maintain peak concentrations within the range of 50 to 100 mg/L to ensure efficacy.,Development of population pharmacokinetic models and optimal sampling times for ibuprofen tablet and suspension formulations in children with cystic fibrosis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11897978/),[mg] / [l],50 to 100,99136,DB01050,Ibuprofen
,11897978,sampling times,"D-optimal sampling times for the suspension and tablet formulations are 0, 0.25 to 0.5, 1, and 3 to 4 hours and 0, 0.25 to 0.5, 1 to 1.5, and 5 hours respectively.",Development of population pharmacokinetic models and optimal sampling times for ibuprofen tablet and suspension formulations in children with cystic fibrosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11897978/),h,0,99137,DB01050,Ibuprofen
,11897978,sampling times,"D-optimal sampling times for the suspension and tablet formulations are 0, 0.25 to 0.5, 1, and 3 to 4 hours and 0, 0.25 to 0.5, 1 to 1.5, and 5 hours respectively.",Development of population pharmacokinetic models and optimal sampling times for ibuprofen tablet and suspension formulations in children with cystic fibrosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11897978/),h,0.25 to 0.5,99138,DB01050,Ibuprofen
,11897978,sampling times,"D-optimal sampling times for the suspension and tablet formulations are 0, 0.25 to 0.5, 1, and 3 to 4 hours and 0, 0.25 to 0.5, 1 to 1.5, and 5 hours respectively.",Development of population pharmacokinetic models and optimal sampling times for ibuprofen tablet and suspension formulations in children with cystic fibrosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11897978/),h,1,99139,DB01050,Ibuprofen
,11897978,sampling times,"D-optimal sampling times for the suspension and tablet formulations are 0, 0.25 to 0.5, 1, and 3 to 4 hours and 0, 0.25 to 0.5, 1 to 1.5, and 5 hours respectively.",Development of population pharmacokinetic models and optimal sampling times for ibuprofen tablet and suspension formulations in children with cystic fibrosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11897978/),h,3 to 4,99140,DB01050,Ibuprofen
,11897978,sampling times,"D-optimal sampling times for the suspension and tablet formulations are 0, 0.25 to 0.5, 1, and 3 to 4 hours and 0, 0.25 to 0.5, 1 to 1.5, and 5 hours respectively.",Development of population pharmacokinetic models and optimal sampling times for ibuprofen tablet and suspension formulations in children with cystic fibrosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11897978/),h,1 to 1.5,99141,DB01050,Ibuprofen
,11897978,sampling times,"D-optimal sampling times for the suspension and tablet formulations are 0, 0.25 to 0.5, 1, and 3 to 4 hours and 0, 0.25 to 0.5, 1 to 1.5, and 5 hours respectively.",Development of population pharmacokinetic models and optimal sampling times for ibuprofen tablet and suspension formulations in children with cystic fibrosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11897978/),h,5,99142,DB01050,Ibuprofen
,3317799,half-life,A pharmacokinetic study showed a half-life for tenoxicam of 45 h in synovial fluid when the half-life was 42 h in plasma.,Clinical experience with tenoxicam: a review. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3317799/),h,45,101536,DB01050,Ibuprofen
,3317799,half-life,A pharmacokinetic study showed a half-life for tenoxicam of 45 h in synovial fluid when the half-life was 42 h in plasma.,Clinical experience with tenoxicam: a review. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3317799/),h,42,101537,DB01050,Ibuprofen
,3317799,peak plasma levels,A single and multiple oral dose pharmacokinetic study of tenoxicam in the elderly showed no progressive accumulation with peak plasma levels of 2.6 micrograms/ml after the single dose and 12.4 micrograms/ml at steady state.,Clinical experience with tenoxicam: a review. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3317799/),[μg] / [ml],2.6,101538,DB01050,Ibuprofen
,3317799,peak plasma levels,A single and multiple oral dose pharmacokinetic study of tenoxicam in the elderly showed no progressive accumulation with peak plasma levels of 2.6 micrograms/ml after the single dose and 12.4 micrograms/ml at steady state.,Clinical experience with tenoxicam: a review. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3317799/),[μg] / [ml],12.4,101539,DB01050,Ibuprofen
,6662976,volume of distribution,"Between drug-free control and ibuprofen coadministration trials, there was no significant difference in antipyrine volume of distribution (0.69 vs. 0.69 liter/kg), elimination half-life (12.2 vs. 12.5 hours), or total metabolic clearance (0.69 vs. 0.70 ml/min/kg).",Ibuprofen does not impair antipyrine clearance. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6662976/),[l] / [kg],0.69,101570,DB01050,Ibuprofen
,6662976,elimination half-life,"Between drug-free control and ibuprofen coadministration trials, there was no significant difference in antipyrine volume of distribution (0.69 vs. 0.69 liter/kg), elimination half-life (12.2 vs. 12.5 hours), or total metabolic clearance (0.69 vs. 0.70 ml/min/kg).",Ibuprofen does not impair antipyrine clearance. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6662976/),h,12.2,101571,DB01050,Ibuprofen
,6662976,elimination half-life,"Between drug-free control and ibuprofen coadministration trials, there was no significant difference in antipyrine volume of distribution (0.69 vs. 0.69 liter/kg), elimination half-life (12.2 vs. 12.5 hours), or total metabolic clearance (0.69 vs. 0.70 ml/min/kg).",Ibuprofen does not impair antipyrine clearance. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6662976/),h,12.5,101572,DB01050,Ibuprofen
,6662976,total metabolic clearance,"Between drug-free control and ibuprofen coadministration trials, there was no significant difference in antipyrine volume of distribution (0.69 vs. 0.69 liter/kg), elimination half-life (12.2 vs. 12.5 hours), or total metabolic clearance (0.69 vs. 0.70 ml/min/kg).",Ibuprofen does not impair antipyrine clearance. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6662976/),[ml] / [kg·min],0.69,101573,DB01050,Ibuprofen
,6662976,total metabolic clearance,"Between drug-free control and ibuprofen coadministration trials, there was no significant difference in antipyrine volume of distribution (0.69 vs. 0.69 liter/kg), elimination half-life (12.2 vs. 12.5 hours), or total metabolic clearance (0.69 vs. 0.70 ml/min/kg).",Ibuprofen does not impair antipyrine clearance. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6662976/),[ml] / [kg·min],0.70,101574,DB01050,Ibuprofen
,24733245,lag time,"The pharmacokinetic modeling outcomes indicate that following a ∼25-minute lag time, ibuprofen is rapidly absorbed to the central compartment and rapidly equilibrates with the CSF, resulting in the total ibuprofen concentration in the CSF versus plasma (CCSF /Cplasma ) of 0.011 ± 0.007.",Plasma and cerebrospinal fluid concentrations of ibuprofen in pediatric patients and antipyretic effect: Pharmacokinetic-pharmacodynamic modeling analysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24733245/),,∼25,102286,DB01050,Ibuprofen
,24733245,total ibuprofen concentration in the CSF versus,"The pharmacokinetic modeling outcomes indicate that following a ∼25-minute lag time, ibuprofen is rapidly absorbed to the central compartment and rapidly equilibrates with the CSF, resulting in the total ibuprofen concentration in the CSF versus plasma (CCSF /Cplasma ) of 0.011 ± 0.007.",Plasma and cerebrospinal fluid concentrations of ibuprofen in pediatric patients and antipyretic effect: Pharmacokinetic-pharmacodynamic modeling analysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24733245/),,0.011,102287,DB01050,Ibuprofen
,17944539,half-life,"The stability studies revealed the half-life of M1 to be about 0.85 h in HSA, 1.82 h in human plasma, and 4.48 h in phosphate-buffered saline (PBS) as determined by first-order approximation.",Irreversible alkylation of human serum albumin by zileuton metabolite 2-acetylbenzothiophene-S-oxide: a potential model for hepatotoxicity. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17944539/),h,0.85,103134,DB01050,Ibuprofen
,17944539,half-life,"The stability studies revealed the half-life of M1 to be about 0.85 h in HSA, 1.82 h in human plasma, and 4.48 h in phosphate-buffered saline (PBS) as determined by first-order approximation.",Irreversible alkylation of human serum albumin by zileuton metabolite 2-acetylbenzothiophene-S-oxide: a potential model for hepatotoxicity. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17944539/),h,1.82,103135,DB01050,Ibuprofen
,17944539,half-life,"The stability studies revealed the half-life of M1 to be about 0.85 h in HSA, 1.82 h in human plasma, and 4.48 h in phosphate-buffered saline (PBS) as determined by first-order approximation.",Irreversible alkylation of human serum albumin by zileuton metabolite 2-acetylbenzothiophene-S-oxide: a potential model for hepatotoxicity. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17944539/),h,4.48,103136,DB01050,Ibuprofen
,17944539,rate constant k,The alkylation rate constant k for HSA was 20 M(-1) min(-1).,Irreversible alkylation of human serum albumin by zileuton metabolite 2-acetylbenzothiophene-S-oxide: a potential model for hepatotoxicity. ,Kinact-Q14,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17944539/),1/[M·min],20,103137,DB01050,Ibuprofen
,20356918,oral clearance (Cl/F),"For ibuprofen, oral clearance (Cl/F) was 77.5 + or - 16.4 mL/kg/h and volume of distribution (Vd/F) was 0.147 + or - 0.037 L/kg.",Multiple-dose pharmacokinetics and safety of an ibuprofen-pseudoephedrine cold suspension in children. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20356918/),[ml] / [h·kg],77.5,104154,DB01050,Ibuprofen
,20356918,volume of distribution (Vd/F),"For ibuprofen, oral clearance (Cl/F) was 77.5 + or - 16.4 mL/kg/h and volume of distribution (Vd/F) was 0.147 + or - 0.037 L/kg.",Multiple-dose pharmacokinetics and safety of an ibuprofen-pseudoephedrine cold suspension in children. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20356918/),[l] / [kg],0.147,104155,DB01050,Ibuprofen
,20356918,Cl/F,"For pseudoephedrine, Cl/F was 12.3 + or - 2.2 mL/kg/min and Vd/F was 2.52 + or - 0.47 L/kg.",Multiple-dose pharmacokinetics and safety of an ibuprofen-pseudoephedrine cold suspension in children. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20356918/),[ml] / [kg·min],12.3,104156,DB01050,Ibuprofen
,20356918,Vd/F,"For pseudoephedrine, Cl/F was 12.3 + or - 2.2 mL/kg/min and Vd/F was 2.52 + or - 0.47 L/kg.",Multiple-dose pharmacokinetics and safety of an ibuprofen-pseudoephedrine cold suspension in children. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20356918/),[l] / [kg],2.52,104157,DB01050,Ibuprofen
,10536246,Time to peak concentration,"Time to peak concentration was 6 h after morning administration, 4 h after evening administration.",Morning versus evening dosing of ibuprofen using conventional and time-controlled release formulations. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10536246/),h,6,104402,DB01050,Ibuprofen
,10536246,Time to peak concentration,"Time to peak concentration was 6 h after morning administration, 4 h after evening administration.",Morning versus evening dosing of ibuprofen using conventional and time-controlled release formulations. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10536246/),h,4,104403,DB01050,Ibuprofen
,10877012,Elimination half-life,Elimination half-life ranged from 9.9 h to 17.5 h after multiple dosing with an accumulation ratio close to 2 for all doses.,"Pharmacokinetics, COX-2 specificity, and tolerability of supratherapeutic doses of rofecoxib in humans. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10877012/),h,9.9,106237,DB01050,Ibuprofen
,10877012,Elimination half-life,Elimination half-life ranged from 9.9 h to 17.5 h after multiple dosing with an accumulation ratio close to 2 for all doses.,"Pharmacokinetics, COX-2 specificity, and tolerability of supratherapeutic doses of rofecoxib in humans. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10877012/),h,17.5,106238,DB01050,Ibuprofen
,10877012,accumulation ratio,Elimination half-life ranged from 9.9 h to 17.5 h after multiple dosing with an accumulation ratio close to 2 for all doses.,"Pharmacokinetics, COX-2 specificity, and tolerability of supratherapeutic doses of rofecoxib in humans. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10877012/),,2,106239,DB01050,Ibuprofen
,8803878,volume of distribution at steady-state (Vd(ss)),"After intravenous administration, the volume of distribution at steady-state (Vd(ss)), the total systemic clearance (ClB), the elimination half-life (t1/2 beta) and the MRT were 0.303 L/kg, 482.3 ml/h.kg, 2.71 h and 1.02 h, respectively.",Bioavailability and pharmacokinetics of ibuprofen in the broiler chicken. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8803878/),[l] / [kg],0.303,107394,DB01050,Ibuprofen
,8803878,total systemic clearance (ClB),"After intravenous administration, the volume of distribution at steady-state (Vd(ss)), the total systemic clearance (ClB), the elimination half-life (t1/2 beta) and the MRT were 0.303 L/kg, 482.3 ml/h.kg, 2.71 h and 1.02 h, respectively.",Bioavailability and pharmacokinetics of ibuprofen in the broiler chicken. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8803878/),[ml] / [h·kg],482.3,107395,DB01050,Ibuprofen
,8803878,total systemic clearance (ClB),"After intravenous administration, the volume of distribution at steady-state (Vd(ss)), the total systemic clearance (ClB), the elimination half-life (t1/2 beta) and the MRT were 0.303 L/kg, 482.3 ml/h.kg, 2.71 h and 1.02 h, respectively.",Bioavailability and pharmacokinetics of ibuprofen in the broiler chicken. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8803878/),h,2.71,107396,DB01050,Ibuprofen
,8803878,elimination half-life (t1/2 beta),"After intravenous administration, the volume of distribution at steady-state (Vd(ss)), the total systemic clearance (ClB), the elimination half-life (t1/2 beta) and the MRT were 0.303 L/kg, 482.3 ml/h.kg, 2.71 h and 1.02 h, respectively.",Bioavailability and pharmacokinetics of ibuprofen in the broiler chicken. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8803878/),[ml] / [h·kg],482.3,107397,DB01050,Ibuprofen
,8803878,elimination half-life (t1/2 beta),"After intravenous administration, the volume of distribution at steady-state (Vd(ss)), the total systemic clearance (ClB), the elimination half-life (t1/2 beta) and the MRT were 0.303 L/kg, 482.3 ml/h.kg, 2.71 h and 1.02 h, respectively.",Bioavailability and pharmacokinetics of ibuprofen in the broiler chicken. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8803878/),h,2.71,107398,DB01050,Ibuprofen
,8803878,MRT,"After intravenous administration, the volume of distribution at steady-state (Vd(ss)), the total systemic clearance (ClB), the elimination half-life (t1/2 beta) and the MRT were 0.303 L/kg, 482.3 ml/h.kg, 2.71 h and 1.02 h, respectively.",Bioavailability and pharmacokinetics of ibuprofen in the broiler chicken. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8803878/),h,1.02,107399,DB01050,Ibuprofen
,8803878,tmax,"After intramuscular administration of ibuprofen, the tmax and Cmax were 0.37 h, and 42.2 micrograms/mL, respectively, with an estimated bioavailability of 46.7%.",Bioavailability and pharmacokinetics of ibuprofen in the broiler chicken. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8803878/),h,0.37,107400,DB01050,Ibuprofen
,8803878,Cmax,"After intramuscular administration of ibuprofen, the tmax and Cmax were 0.37 h, and 42.2 micrograms/mL, respectively, with an estimated bioavailability of 46.7%.",Bioavailability and pharmacokinetics of ibuprofen in the broiler chicken. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8803878/),[μg] / [ml],42.2,107401,DB01050,Ibuprofen
,8803878,bioavailability,"After intramuscular administration of ibuprofen, the tmax and Cmax were 0.37 h, and 42.2 micrograms/mL, respectively, with an estimated bioavailability of 46.7%.",Bioavailability and pharmacokinetics of ibuprofen in the broiler chicken. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8803878/),%,46.7,107402,DB01050,Ibuprofen
,8803878,tmax,"After oral administration of ibuprofen, the tmax and Cmax were 0.31 h and 23.91 micrograms/mL, respectively, with an estimated bioavailability of 24.2%.",Bioavailability and pharmacokinetics of ibuprofen in the broiler chicken. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8803878/),h,0.31,107403,DB01050,Ibuprofen
,8803878,Cmax,"After oral administration of ibuprofen, the tmax and Cmax were 0.31 h and 23.91 micrograms/mL, respectively, with an estimated bioavailability of 24.2%.",Bioavailability and pharmacokinetics of ibuprofen in the broiler chicken. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8803878/),[μg] / [ml],23.91,107404,DB01050,Ibuprofen
,8803878,bioavailability,"After oral administration of ibuprofen, the tmax and Cmax were 0.31 h and 23.91 micrograms/mL, respectively, with an estimated bioavailability of 24.2%.",Bioavailability and pharmacokinetics of ibuprofen in the broiler chicken. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8803878/),%,24.2,107405,DB01050,Ibuprofen
up to,20942639,maximum solubility,"The optimal formulation consists of 17% Labrafil M 1944CS, 28% Cremophor RH40/Transcutol P (3:1, w/w), and 55% water, with a maximum solubility of ibuprofen up to 60.3 mg/ml.",Preparation and evaluation of ibuprofen-loaded microemulsion for improvement of oral bioavailability. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20942639/),[mg] / [ml],60.3,110487,DB01050,Ibuprofen
,20942639,droplet size,The mean droplet size of microemulsion was 57 nm.,Preparation and evaluation of ibuprofen-loaded microemulsion for improvement of oral bioavailability. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20942639/),,57,110488,DB01050,Ibuprofen
,8894512,"""","The ""lymphatic clearance"" differed substantially between the investigated compounds (mean +/- SD: R-ibuprofen, 19.8 +/- 9.4; S-ibuprofen, 9.6 +/- 3.6; tenoxicam, 32.5 +/- 31.3; nabumetone, 133.6 +/- 75.2; 6MNA, 18.3 +/- 8.5 microliters/min/kg).",Transfer of different nonsteroidal antiinflammatory drugs via the lymphatic system in the rat. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8894512/),[μl] / [kg·min],19.8,111072,DB01050,Ibuprofen
,8894512,lymphatic clearance,"The ""lymphatic clearance"" differed substantially between the investigated compounds (mean +/- SD: R-ibuprofen, 19.8 +/- 9.4; S-ibuprofen, 9.6 +/- 3.6; tenoxicam, 32.5 +/- 31.3; nabumetone, 133.6 +/- 75.2; 6MNA, 18.3 +/- 8.5 microliters/min/kg).",Transfer of different nonsteroidal antiinflammatory drugs via the lymphatic system in the rat. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8894512/),[μl] / [kg·min],19.8,111073,DB01050,Ibuprofen
,8894512,lymphatic clearance,"The ""lymphatic clearance"" differed substantially between the investigated compounds (mean +/- SD: R-ibuprofen, 19.8 +/- 9.4; S-ibuprofen, 9.6 +/- 3.6; tenoxicam, 32.5 +/- 31.3; nabumetone, 133.6 +/- 75.2; 6MNA, 18.3 +/- 8.5 microliters/min/kg).",Transfer of different nonsteroidal antiinflammatory drugs via the lymphatic system in the rat. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8894512/),[μl] / [kg·min],9.6,111074,DB01050,Ibuprofen
,8894512,lymphatic clearance,"The ""lymphatic clearance"" differed substantially between the investigated compounds (mean +/- SD: R-ibuprofen, 19.8 +/- 9.4; S-ibuprofen, 9.6 +/- 3.6; tenoxicam, 32.5 +/- 31.3; nabumetone, 133.6 +/- 75.2; 6MNA, 18.3 +/- 8.5 microliters/min/kg).",Transfer of different nonsteroidal antiinflammatory drugs via the lymphatic system in the rat. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8894512/),[μl] / [kg·min],32.5,111075,DB01050,Ibuprofen
,8894512,lymphatic clearance,"The ""lymphatic clearance"" differed substantially between the investigated compounds (mean +/- SD: R-ibuprofen, 19.8 +/- 9.4; S-ibuprofen, 9.6 +/- 3.6; tenoxicam, 32.5 +/- 31.3; nabumetone, 133.6 +/- 75.2; 6MNA, 18.3 +/- 8.5 microliters/min/kg).",Transfer of different nonsteroidal antiinflammatory drugs via the lymphatic system in the rat. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8894512/),[μl] / [kg·min],133.6,111076,DB01050,Ibuprofen
,8894512,lymphatic clearance,"The ""lymphatic clearance"" differed substantially between the investigated compounds (mean +/- SD: R-ibuprofen, 19.8 +/- 9.4; S-ibuprofen, 9.6 +/- 3.6; tenoxicam, 32.5 +/- 31.3; nabumetone, 133.6 +/- 75.2; 6MNA, 18.3 +/- 8.5 microliters/min/kg).",Transfer of different nonsteroidal antiinflammatory drugs via the lymphatic system in the rat. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8894512/),[μl] / [kg·min],18.3,111077,DB01050,Ibuprofen
not exceed,8894512,Overall recovery,Overall recovery of the investigated compounds in lymph did not exceed 5% of the doses given.,Transfer of different nonsteroidal antiinflammatory drugs via the lymphatic system in the rat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8894512/),%,5,111078,DB01050,Ibuprofen
,8403739,elimination half-life (t1/2),"Compared with the elimination half-life (t1/2) of (-)-R- and (+)-S-ibuprofen in 8 healthy age-matched controls (1.7 +/- 0.3h and 1.8 +/- 0.5h, respectively), t1/2 was prolonged significantly (p < 0.045 and < 0.001, respectively) in patients with cirrhosis (t1/2 = 3.1 +/- 1.7h and 3.4 +/- 1.0h, respectively).",Disposition of ibuprofen in patients with liver cirrhosis. Stereochemical considerations. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8403739/),h,1.7,111101,DB01050,Ibuprofen
,8403739,elimination half-life (t1/2),"Compared with the elimination half-life (t1/2) of (-)-R- and (+)-S-ibuprofen in 8 healthy age-matched controls (1.7 +/- 0.3h and 1.8 +/- 0.5h, respectively), t1/2 was prolonged significantly (p < 0.045 and < 0.001, respectively) in patients with cirrhosis (t1/2 = 3.1 +/- 1.7h and 3.4 +/- 1.0h, respectively).",Disposition of ibuprofen in patients with liver cirrhosis. Stereochemical considerations. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8403739/),h,1.8,111102,DB01050,Ibuprofen
,8403739,t1/2,"Compared with the elimination half-life (t1/2) of (-)-R- and (+)-S-ibuprofen in 8 healthy age-matched controls (1.7 +/- 0.3h and 1.8 +/- 0.5h, respectively), t1/2 was prolonged significantly (p < 0.045 and < 0.001, respectively) in patients with cirrhosis (t1/2 = 3.1 +/- 1.7h and 3.4 +/- 1.0h, respectively).",Disposition of ibuprofen in patients with liver cirrhosis. Stereochemical considerations. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8403739/),h,3.1,111103,DB01050,Ibuprofen
,8403739,t1/2,"Compared with the elimination half-life (t1/2) of (-)-R- and (+)-S-ibuprofen in 8 healthy age-matched controls (1.7 +/- 0.3h and 1.8 +/- 0.5h, respectively), t1/2 was prolonged significantly (p < 0.045 and < 0.001, respectively) in patients with cirrhosis (t1/2 = 3.1 +/- 1.7h and 3.4 +/- 1.0h, respectively).",Disposition of ibuprofen in patients with liver cirrhosis. Stereochemical considerations. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8403739/),h,3.4,111104,DB01050,Ibuprofen
,8403739,t1/2,Elimination of this enantiomer was slightly impaired as could be seen from the prolonged t1/2 (1.6 +/- 0.1h vs 2.6 +/- 0.5h; p < 0.001) and the increase in AUC (101 +/- 35 vs 144 +/- 41 mg/L.h; p = 0.041).,Disposition of ibuprofen in patients with liver cirrhosis. Stereochemical considerations. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8403739/),h,1.6,111105,DB01050,Ibuprofen
,8403739,t1/2,Elimination of this enantiomer was slightly impaired as could be seen from the prolonged t1/2 (1.6 +/- 0.1h vs 2.6 +/- 0.5h; p < 0.001) and the increase in AUC (101 +/- 35 vs 144 +/- 41 mg/L.h; p = 0.041).,Disposition of ibuprofen in patients with liver cirrhosis. Stereochemical considerations. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8403739/),h,2.6,111106,DB01050,Ibuprofen
,8403739,AUC,Elimination of this enantiomer was slightly impaired as could be seen from the prolonged t1/2 (1.6 +/- 0.1h vs 2.6 +/- 0.5h; p < 0.001) and the increase in AUC (101 +/- 35 vs 144 +/- 41 mg/L.h; p = 0.041).,Disposition of ibuprofen in patients with liver cirrhosis. Stereochemical considerations. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8403739/),[mg] / [h·l],101,111107,DB01050,Ibuprofen
,8403739,AUC,Elimination of this enantiomer was slightly impaired as could be seen from the prolonged t1/2 (1.6 +/- 0.1h vs 2.6 +/- 0.5h; p < 0.001) and the increase in AUC (101 +/- 35 vs 144 +/- 41 mg/L.h; p = 0.041).,Disposition of ibuprofen in patients with liver cirrhosis. Stereochemical considerations. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8403739/),[mg] / [h·l],144,111108,DB01050,Ibuprofen
,18755258,relative bioavailability,The relative bioavailability of ibuprofen gel compared to the two marketed products was 228.8% and 181.0%.,Optimization of ibuprofen gel formulations using experimental design technique for enhanced transdermal penetration. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18755258/),%,228.8,111317,DB01050,Ibuprofen
,18755258,relative bioavailability,The relative bioavailability of ibuprofen gel compared to the two marketed products was 228.8% and 181.0%.,Optimization of ibuprofen gel formulations using experimental design technique for enhanced transdermal penetration. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18755258/),%,181.0,111318,DB01050,Ibuprofen
,16813969,plasma half-life,"The drug has prolonged elimination (plasma half-life = ca 23 hours), suggesting that once daily dosing is appropriate.",Systematic review: intravenous Ibuprofen in preterm newborns. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16813969/),h,23,111519,DB01050,Ibuprofen
,25088343,%,"The %PDA closed by ibuprofen (n=24) and indomethacin (n=24) is 77.7±14.1 and 77.3±11.0, respectively.",Clinical pharmacology of ibuprofen and indomethacin in preterm infants with patent ductus arteriosus. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25088343/),,77.7,115576,DB01050,Ibuprofen
,25088343,%,"The %PDA closed by ibuprofen (n=24) and indomethacin (n=24) is 77.7±14.1 and 77.3±11.0, respectively.",Clinical pharmacology of ibuprofen and indomethacin in preterm infants with patent ductus arteriosus. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25088343/),,77.3,115577,DB01050,Ibuprofen
,9356198,maximal effect,"The maximal effect lasted 12 and 36 h following 10 and 20 mg kg-1 doses, respectively.",Toxicokinetics of indomethacin-induced intestinal permeability in the rat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9356198/),h,12,116211,DB01050,Ibuprofen
,9356198,maximal effect,"The maximal effect lasted 12 and 36 h following 10 and 20 mg kg-1 doses, respectively.",Toxicokinetics of indomethacin-induced intestinal permeability in the rat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9356198/),h,36,116212,DB01050,Ibuprofen
,31363393,times to maximum concentration,"After a single oral dose of ibuprofen formulations, the median times to maximum concentration were 60 and 240 minutes in ibuprofen tablet (200 mg) and enteric-coated capsule, respectively.",New formulation of ibuprofen on absorption-rate: A comparative bioavailability study in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31363393/),min,60,117318,DB01050,Ibuprofen
,31363393,times to maximum concentration,"After a single oral dose of ibuprofen formulations, the median times to maximum concentration were 60 and 240 minutes in ibuprofen tablet (200 mg) and enteric-coated capsule, respectively.",New formulation of ibuprofen on absorption-rate: A comparative bioavailability study in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31363393/),min,240,117319,DB01050,Ibuprofen
,31363393,maximum levels,"The maximum levels for the participants receiving ibuprofen tablet and enteric-coated capsule were 11.71±1.3 and 10.32±4.19 µg/mL, respectively.",New formulation of ibuprofen on absorption-rate: A comparative bioavailability study in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31363393/),[μg] / [ml],11.71,117320,DB01050,Ibuprofen
,31363393,maximum levels,"The maximum levels for the participants receiving ibuprofen tablet and enteric-coated capsule were 11.71±1.3 and 10.32±4.19 µg/mL, respectively.",New formulation of ibuprofen on absorption-rate: A comparative bioavailability study in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31363393/),[μg] / [ml],10.32,117321,DB01050,Ibuprofen
,31363393,area under curve (AUC),"The pharmacokinetic (PK) modeling data showed the area under curve (AUC) to be 61.51 hours & 86.62 hours for the group receiving the tablet and the capsule, respectively.",New formulation of ibuprofen on absorption-rate: A comparative bioavailability study in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31363393/),h,61.51,117322,DB01050,Ibuprofen
,31363393,area under curve (AUC),"The pharmacokinetic (PK) modeling data showed the area under curve (AUC) to be 61.51 hours & 86.62 hours for the group receiving the tablet and the capsule, respectively.",New formulation of ibuprofen on absorption-rate: A comparative bioavailability study in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31363393/),h,86.62,117323,DB01050,Ibuprofen
,6737251,half-lives,"The elimination of serum ibuprofen followed first-order kinetics, with mean half-lives of 2.51 +/- 1.10 and 2.81 +/- 0.72 h in normal and nephrectomized dogs, respectively.",Disposition of ibuprofen in nephrectomized dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6737251/),h,2.51,117338,DB01050,Ibuprofen
,6737251,half-lives,"The elimination of serum ibuprofen followed first-order kinetics, with mean half-lives of 2.51 +/- 1.10 and 2.81 +/- 0.72 h in normal and nephrectomized dogs, respectively.",Disposition of ibuprofen in nephrectomized dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6737251/),h,2.81,117339,DB01050,Ibuprofen
,6737251,serum clearance,"Mean serum clearance of ibuprofen in nephrectomized dogs, 31.0 +/- 5.2 mL/h/kg, was higher than that in normal dogs, 12.2 +/- 8.6 mL/h/kg, (p less than 0.02).",Disposition of ibuprofen in nephrectomized dogs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6737251/),[ml] / [h·kg],31.0,117340,DB01050,Ibuprofen
,6737251,serum clearance,"Mean serum clearance of ibuprofen in nephrectomized dogs, 31.0 +/- 5.2 mL/h/kg, was higher than that in normal dogs, 12.2 +/- 8.6 mL/h/kg, (p less than 0.02).",Disposition of ibuprofen in nephrectomized dogs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6737251/),[ml] / [h·kg],12.2,117341,DB01050,Ibuprofen
,6737251,volume of distribution,"The difference may be attributed to the greater volume of distribution for ibuprofen in nephrectomized dogs, 125.2 +/- 39.0 (88.8-160.4) mL/kg as compared with 53.4 +/- 57.8 (26.0-119.9) mL/kg in the normal group (p less than 0.2).",Disposition of ibuprofen in nephrectomized dogs. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6737251/),[ml] / [kg],125.2,117342,DB01050,Ibuprofen
,6737251,volume of distribution,"The difference may be attributed to the greater volume of distribution for ibuprofen in nephrectomized dogs, 125.2 +/- 39.0 (88.8-160.4) mL/kg as compared with 53.4 +/- 57.8 (26.0-119.9) mL/kg in the normal group (p less than 0.2).",Disposition of ibuprofen in nephrectomized dogs. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6737251/),[ml] / [kg],53.4,117343,DB01050,Ibuprofen
,12884255,C(max),"The in vivo study showed that C(max), AUC(0-8), and the absolute bioavailability for the granules (49.0 microg/mL, 57.0 h x microg/mL and 80.6%, respectively) were almost one and half times that of the physical mixture (32.2 microg/mL, 38.4 h x microg/mL and 53.1%, respectively).",Enhanced bioavailability of process-induced fast-dissolving ibuprofen cogranulated with beta-cyclodextrin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12884255/),[μg] / [ml],49.0,117949,DB01050,Ibuprofen
,12884255,AUC(0-8),"The in vivo study showed that C(max), AUC(0-8), and the absolute bioavailability for the granules (49.0 microg/mL, 57.0 h x microg/mL and 80.6%, respectively) were almost one and half times that of the physical mixture (32.2 microg/mL, 38.4 h x microg/mL and 53.1%, respectively).",Enhanced bioavailability of process-induced fast-dissolving ibuprofen cogranulated with beta-cyclodextrin. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12884255/),[h·μg] / [ml],57.0,117950,DB01050,Ibuprofen
,12884255,AUC(0-8),"The in vivo study showed that C(max), AUC(0-8), and the absolute bioavailability for the granules (49.0 microg/mL, 57.0 h x microg/mL and 80.6%, respectively) were almost one and half times that of the physical mixture (32.2 microg/mL, 38.4 h x microg/mL and 53.1%, respectively).",Enhanced bioavailability of process-induced fast-dissolving ibuprofen cogranulated with beta-cyclodextrin. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12884255/),[μg] / [ml],32.2,117951,DB01050,Ibuprofen
,12884255,AUC(0-8),"The in vivo study showed that C(max), AUC(0-8), and the absolute bioavailability for the granules (49.0 microg/mL, 57.0 h x microg/mL and 80.6%, respectively) were almost one and half times that of the physical mixture (32.2 microg/mL, 38.4 h x microg/mL and 53.1%, respectively).",Enhanced bioavailability of process-induced fast-dissolving ibuprofen cogranulated with beta-cyclodextrin. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12884255/),[h·μg] / [ml],38.4,117952,DB01050,Ibuprofen
,12884255,absolute bioavailability,"The in vivo study showed that C(max), AUC(0-8), and the absolute bioavailability for the granules (49.0 microg/mL, 57.0 h x microg/mL and 80.6%, respectively) were almost one and half times that of the physical mixture (32.2 microg/mL, 38.4 h x microg/mL and 53.1%, respectively).",Enhanced bioavailability of process-induced fast-dissolving ibuprofen cogranulated with beta-cyclodextrin. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12884255/),%,80.6,117953,DB01050,Ibuprofen
,12884255,absolute bioavailability,"The in vivo study showed that C(max), AUC(0-8), and the absolute bioavailability for the granules (49.0 microg/mL, 57.0 h x microg/mL and 80.6%, respectively) were almost one and half times that of the physical mixture (32.2 microg/mL, 38.4 h x microg/mL and 53.1%, respectively).",Enhanced bioavailability of process-induced fast-dissolving ibuprofen cogranulated with beta-cyclodextrin. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12884255/),%,53.1,117954,DB01050,Ibuprofen
,12884255,C(max),"However, in bile duct-ligated rats, lower C(max) and AUC(0-8) (15.9 microg/mL and 14.4 h x microg/mL, respectively) were obtained for the granules.",Enhanced bioavailability of process-induced fast-dissolving ibuprofen cogranulated with beta-cyclodextrin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12884255/),[μg] / [ml],15.9,117955,DB01050,Ibuprofen
,12884255,AUC(0-8),"However, in bile duct-ligated rats, lower C(max) and AUC(0-8) (15.9 microg/mL and 14.4 h x microg/mL, respectively) were obtained for the granules.",Enhanced bioavailability of process-induced fast-dissolving ibuprofen cogranulated with beta-cyclodextrin. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12884255/),[h·μg] / [ml],14.4,117956,DB01050,Ibuprofen
,14527090,C(max),"The C(max), AUC(0-6 hr) and Ka for ibuprofen increased from 38 +/- 0.70 microg/ml to 42 +/- 0.98 microg/ml (p > 0.05); and 28.03 +/- 2.40 microg/ml x hr to 56.51 +/- 0.16 microg/ml x hr (p < 0.05) and 1.048 +/- 0.02hr(-1) to 2.781 +/- 0.11 hr(-1) (p < 0.05) respectively.",Effect of Tamarindus indica. L on the bioavailability of ibuprofen in healthy human volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14527090/),[μg] / [ml],38,119145,DB01050,Ibuprofen
,14527090,AUC(0-6 hr),"The C(max), AUC(0-6 hr) and Ka for ibuprofen increased from 38 +/- 0.70 microg/ml to 42 +/- 0.98 microg/ml (p > 0.05); and 28.03 +/- 2.40 microg/ml x hr to 56.51 +/- 0.16 microg/ml x hr (p < 0.05) and 1.048 +/- 0.02hr(-1) to 2.781 +/- 0.11 hr(-1) (p < 0.05) respectively.",Effect of Tamarindus indica. L on the bioavailability of ibuprofen in healthy human volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14527090/),[μg] / [ml],42,119146,DB01050,Ibuprofen
,14527090,AUC(0-6 hr),"The C(max), AUC(0-6 hr) and Ka for ibuprofen increased from 38 +/- 0.70 microg/ml to 42 +/- 0.98 microg/ml (p > 0.05); and 28.03 +/- 2.40 microg/ml x hr to 56.51 +/- 0.16 microg/ml x hr (p < 0.05) and 1.048 +/- 0.02hr(-1) to 2.781 +/- 0.11 hr(-1) (p < 0.05) respectively.",Effect of Tamarindus indica. L on the bioavailability of ibuprofen in healthy human volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14527090/),[μg] / [h·ml],28.03,119147,DB01050,Ibuprofen
,14527090,AUC(0-6 hr),"The C(max), AUC(0-6 hr) and Ka for ibuprofen increased from 38 +/- 0.70 microg/ml to 42 +/- 0.98 microg/ml (p > 0.05); and 28.03 +/- 2.40 microg/ml x hr to 56.51 +/- 0.16 microg/ml x hr (p < 0.05) and 1.048 +/- 0.02hr(-1) to 2.781 +/- 0.11 hr(-1) (p < 0.05) respectively.",Effect of Tamarindus indica. L on the bioavailability of ibuprofen in healthy human volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14527090/),[μg] / [h·ml],56.51,119148,DB01050,Ibuprofen
,14527090,AUC(0-6 hr),"The C(max), AUC(0-6 hr) and Ka for ibuprofen increased from 38 +/- 0.70 microg/ml to 42 +/- 0.98 microg/ml (p > 0.05); and 28.03 +/- 2.40 microg/ml x hr to 56.51 +/- 0.16 microg/ml x hr (p < 0.05) and 1.048 +/- 0.02hr(-1) to 2.781 +/- 0.11 hr(-1) (p < 0.05) respectively.",Effect of Tamarindus indica. L on the bioavailability of ibuprofen in healthy human volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14527090/),1/[hr],1.048,119149,DB01050,Ibuprofen
,14527090,AUC(0-6 hr),"The C(max), AUC(0-6 hr) and Ka for ibuprofen increased from 38 +/- 0.70 microg/ml to 42 +/- 0.98 microg/ml (p > 0.05); and 28.03 +/- 2.40 microg/ml x hr to 56.51 +/- 0.16 microg/ml x hr (p < 0.05) and 1.048 +/- 0.02hr(-1) to 2.781 +/- 0.11 hr(-1) (p < 0.05) respectively.",Effect of Tamarindus indica. L on the bioavailability of ibuprofen in healthy human volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14527090/),1/[hr],2.781,119150,DB01050,Ibuprofen
,14527090,Ka,"The C(max), AUC(0-6 hr) and Ka for ibuprofen increased from 38 +/- 0.70 microg/ml to 42 +/- 0.98 microg/ml (p > 0.05); and 28.03 +/- 2.40 microg/ml x hr to 56.51 +/- 0.16 microg/ml x hr (p < 0.05) and 1.048 +/- 0.02hr(-1) to 2.781 +/- 0.11 hr(-1) (p < 0.05) respectively.",Effect of Tamarindus indica. L on the bioavailability of ibuprofen in healthy human volunteers. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14527090/),[μg] / [h·ml],56.51,119151,DB01050,Ibuprofen
,14527090,Ka,"The C(max), AUC(0-6 hr) and Ka for ibuprofen increased from 38 +/- 0.70 microg/ml to 42 +/- 0.98 microg/ml (p > 0.05); and 28.03 +/- 2.40 microg/ml x hr to 56.51 +/- 0.16 microg/ml x hr (p < 0.05) and 1.048 +/- 0.02hr(-1) to 2.781 +/- 0.11 hr(-1) (p < 0.05) respectively.",Effect of Tamarindus indica. L on the bioavailability of ibuprofen in healthy human volunteers. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14527090/),1/[hr],1.048,119152,DB01050,Ibuprofen
,14527090,Ka,"The C(max), AUC(0-6 hr) and Ka for ibuprofen increased from 38 +/- 0.70 microg/ml to 42 +/- 0.98 microg/ml (p > 0.05); and 28.03 +/- 2.40 microg/ml x hr to 56.51 +/- 0.16 microg/ml x hr (p < 0.05) and 1.048 +/- 0.02hr(-1) to 2.781 +/- 0.11 hr(-1) (p < 0.05) respectively.",Effect of Tamarindus indica. L on the bioavailability of ibuprofen in healthy human volunteers. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14527090/),1/[hr],2.781,119153,DB01050,Ibuprofen
,14527090,t(max),There was no change in the t(max) (120.00 +/- 0.43m) but there was a decrease in the k(el) from 0.63 +/- 0.20 hr(-1) to 0.46 +/- 0.11 hr(-1) (p<0.05).,Effect of Tamarindus indica. L on the bioavailability of ibuprofen in healthy human volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14527090/),m,120.00,119154,DB01050,Ibuprofen
,14527090,k(el),There was no change in the t(max) (120.00 +/- 0.43m) but there was a decrease in the k(el) from 0.63 +/- 0.20 hr(-1) to 0.46 +/- 0.11 hr(-1) (p<0.05).,Effect of Tamarindus indica. L on the bioavailability of ibuprofen in healthy human volunteers. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14527090/),1/[hr],0.63,119155,DB01050,Ibuprofen
,14527090,k(el),There was no change in the t(max) (120.00 +/- 0.43m) but there was a decrease in the k(el) from 0.63 +/- 0.20 hr(-1) to 0.46 +/- 0.11 hr(-1) (p<0.05).,Effect of Tamarindus indica. L on the bioavailability of ibuprofen in healthy human volunteers. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14527090/),1/[hr],0.46,119156,DB01050,Ibuprofen
,14527090,C(max),"Similarly the C(max), AUC(0-6 h) and Ka for hydroxy-ibuprofen rose from 43 +/- 0.76 microg/ml to 45 +/- 0.16 microg/ml (p < 0.05); 39.04 +/- 2.30 microg/ml x hr to 59.49 +/- 2.39 microg/ml.hr in (p < 0.05) and 1.498 +/- 0.79hr(-1) to 3.442 +/- 0.23 hr(-1) (p < 0.05) respectively; while the C(max), AUC(0-6 h) and Ka for carboxy-ibuprofen rose from 48 +/- 0.7 microg/ml to 51 +/- 0.16 microg/ml (p < 0.05); 41.972 +/- 0.68 microg/ml x hr to 63.948 +/- 0.12 microg/ml x hr (p < 0.05) and 1.649 +/- 0.08 hr(-1) to 4.187 +/- 0.42 hr(-1) (p < 0.05) respectively.",Effect of Tamarindus indica. L on the bioavailability of ibuprofen in healthy human volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14527090/),[μg] / [ml],43,119157,DB01050,Ibuprofen
,14527090,AUC(0-6 h),"Similarly the C(max), AUC(0-6 h) and Ka for hydroxy-ibuprofen rose from 43 +/- 0.76 microg/ml to 45 +/- 0.16 microg/ml (p < 0.05); 39.04 +/- 2.30 microg/ml x hr to 59.49 +/- 2.39 microg/ml.hr in (p < 0.05) and 1.498 +/- 0.79hr(-1) to 3.442 +/- 0.23 hr(-1) (p < 0.05) respectively; while the C(max), AUC(0-6 h) and Ka for carboxy-ibuprofen rose from 48 +/- 0.7 microg/ml to 51 +/- 0.16 microg/ml (p < 0.05); 41.972 +/- 0.68 microg/ml x hr to 63.948 +/- 0.12 microg/ml x hr (p < 0.05) and 1.649 +/- 0.08 hr(-1) to 4.187 +/- 0.42 hr(-1) (p < 0.05) respectively.",Effect of Tamarindus indica. L on the bioavailability of ibuprofen in healthy human volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14527090/),[μg] / [ml],45,119158,DB01050,Ibuprofen
,14527090,AUC(0-6 h),"Similarly the C(max), AUC(0-6 h) and Ka for hydroxy-ibuprofen rose from 43 +/- 0.76 microg/ml to 45 +/- 0.16 microg/ml (p < 0.05); 39.04 +/- 2.30 microg/ml x hr to 59.49 +/- 2.39 microg/ml.hr in (p < 0.05) and 1.498 +/- 0.79hr(-1) to 3.442 +/- 0.23 hr(-1) (p < 0.05) respectively; while the C(max), AUC(0-6 h) and Ka for carboxy-ibuprofen rose from 48 +/- 0.7 microg/ml to 51 +/- 0.16 microg/ml (p < 0.05); 41.972 +/- 0.68 microg/ml x hr to 63.948 +/- 0.12 microg/ml x hr (p < 0.05) and 1.649 +/- 0.08 hr(-1) to 4.187 +/- 0.42 hr(-1) (p < 0.05) respectively.",Effect of Tamarindus indica. L on the bioavailability of ibuprofen in healthy human volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14527090/),[μg] / [h·ml],39.04,119159,DB01050,Ibuprofen
,14527090,AUC(0-6 h),"Similarly the C(max), AUC(0-6 h) and Ka for hydroxy-ibuprofen rose from 43 +/- 0.76 microg/ml to 45 +/- 0.16 microg/ml (p < 0.05); 39.04 +/- 2.30 microg/ml x hr to 59.49 +/- 2.39 microg/ml.hr in (p < 0.05) and 1.498 +/- 0.79hr(-1) to 3.442 +/- 0.23 hr(-1) (p < 0.05) respectively; while the C(max), AUC(0-6 h) and Ka for carboxy-ibuprofen rose from 48 +/- 0.7 microg/ml to 51 +/- 0.16 microg/ml (p < 0.05); 41.972 +/- 0.68 microg/ml x hr to 63.948 +/- 0.12 microg/ml x hr (p < 0.05) and 1.649 +/- 0.08 hr(-1) to 4.187 +/- 0.42 hr(-1) (p < 0.05) respectively.",Effect of Tamarindus indica. L on the bioavailability of ibuprofen in healthy human volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14527090/),[μg] / [h·ml],59.49,119160,DB01050,Ibuprofen
,14527090,AUC(0-6 h),"Similarly the C(max), AUC(0-6 h) and Ka for hydroxy-ibuprofen rose from 43 +/- 0.76 microg/ml to 45 +/- 0.16 microg/ml (p < 0.05); 39.04 +/- 2.30 microg/ml x hr to 59.49 +/- 2.39 microg/ml.hr in (p < 0.05) and 1.498 +/- 0.79hr(-1) to 3.442 +/- 0.23 hr(-1) (p < 0.05) respectively; while the C(max), AUC(0-6 h) and Ka for carboxy-ibuprofen rose from 48 +/- 0.7 microg/ml to 51 +/- 0.16 microg/ml (p < 0.05); 41.972 +/- 0.68 microg/ml x hr to 63.948 +/- 0.12 microg/ml x hr (p < 0.05) and 1.649 +/- 0.08 hr(-1) to 4.187 +/- 0.42 hr(-1) (p < 0.05) respectively.",Effect of Tamarindus indica. L on the bioavailability of ibuprofen in healthy human volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14527090/),1/[hr],1.498,119161,DB01050,Ibuprofen
,14527090,Ka,"Similarly the C(max), AUC(0-6 h) and Ka for hydroxy-ibuprofen rose from 43 +/- 0.76 microg/ml to 45 +/- 0.16 microg/ml (p < 0.05); 39.04 +/- 2.30 microg/ml x hr to 59.49 +/- 2.39 microg/ml.hr in (p < 0.05) and 1.498 +/- 0.79hr(-1) to 3.442 +/- 0.23 hr(-1) (p < 0.05) respectively; while the C(max), AUC(0-6 h) and Ka for carboxy-ibuprofen rose from 48 +/- 0.7 microg/ml to 51 +/- 0.16 microg/ml (p < 0.05); 41.972 +/- 0.68 microg/ml x hr to 63.948 +/- 0.12 microg/ml x hr (p < 0.05) and 1.649 +/- 0.08 hr(-1) to 4.187 +/- 0.42 hr(-1) (p < 0.05) respectively.",Effect of Tamarindus indica. L on the bioavailability of ibuprofen in healthy human volunteers. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14527090/),1/[hr],3.442,119162,DB01050,Ibuprofen
,14527090,C(max),"Similarly the C(max), AUC(0-6 h) and Ka for hydroxy-ibuprofen rose from 43 +/- 0.76 microg/ml to 45 +/- 0.16 microg/ml (p < 0.05); 39.04 +/- 2.30 microg/ml x hr to 59.49 +/- 2.39 microg/ml.hr in (p < 0.05) and 1.498 +/- 0.79hr(-1) to 3.442 +/- 0.23 hr(-1) (p < 0.05) respectively; while the C(max), AUC(0-6 h) and Ka for carboxy-ibuprofen rose from 48 +/- 0.7 microg/ml to 51 +/- 0.16 microg/ml (p < 0.05); 41.972 +/- 0.68 microg/ml x hr to 63.948 +/- 0.12 microg/ml x hr (p < 0.05) and 1.649 +/- 0.08 hr(-1) to 4.187 +/- 0.42 hr(-1) (p < 0.05) respectively.",Effect of Tamarindus indica. L on the bioavailability of ibuprofen in healthy human volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14527090/),[μg] / [ml],48,119163,DB01050,Ibuprofen
,14527090,AUC(0-6 h),"Similarly the C(max), AUC(0-6 h) and Ka for hydroxy-ibuprofen rose from 43 +/- 0.76 microg/ml to 45 +/- 0.16 microg/ml (p < 0.05); 39.04 +/- 2.30 microg/ml x hr to 59.49 +/- 2.39 microg/ml.hr in (p < 0.05) and 1.498 +/- 0.79hr(-1) to 3.442 +/- 0.23 hr(-1) (p < 0.05) respectively; while the C(max), AUC(0-6 h) and Ka for carboxy-ibuprofen rose from 48 +/- 0.7 microg/ml to 51 +/- 0.16 microg/ml (p < 0.05); 41.972 +/- 0.68 microg/ml x hr to 63.948 +/- 0.12 microg/ml x hr (p < 0.05) and 1.649 +/- 0.08 hr(-1) to 4.187 +/- 0.42 hr(-1) (p < 0.05) respectively.",Effect of Tamarindus indica. L on the bioavailability of ibuprofen in healthy human volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14527090/),[μg] / [ml],51,119164,DB01050,Ibuprofen
,14527090,AUC(0-6 h),"Similarly the C(max), AUC(0-6 h) and Ka for hydroxy-ibuprofen rose from 43 +/- 0.76 microg/ml to 45 +/- 0.16 microg/ml (p < 0.05); 39.04 +/- 2.30 microg/ml x hr to 59.49 +/- 2.39 microg/ml.hr in (p < 0.05) and 1.498 +/- 0.79hr(-1) to 3.442 +/- 0.23 hr(-1) (p < 0.05) respectively; while the C(max), AUC(0-6 h) and Ka for carboxy-ibuprofen rose from 48 +/- 0.7 microg/ml to 51 +/- 0.16 microg/ml (p < 0.05); 41.972 +/- 0.68 microg/ml x hr to 63.948 +/- 0.12 microg/ml x hr (p < 0.05) and 1.649 +/- 0.08 hr(-1) to 4.187 +/- 0.42 hr(-1) (p < 0.05) respectively.",Effect of Tamarindus indica. L on the bioavailability of ibuprofen in healthy human volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14527090/),[μg] / [h·ml],41.972,119165,DB01050,Ibuprofen
,14527090,AUC(0-6 h),"Similarly the C(max), AUC(0-6 h) and Ka for hydroxy-ibuprofen rose from 43 +/- 0.76 microg/ml to 45 +/- 0.16 microg/ml (p < 0.05); 39.04 +/- 2.30 microg/ml x hr to 59.49 +/- 2.39 microg/ml.hr in (p < 0.05) and 1.498 +/- 0.79hr(-1) to 3.442 +/- 0.23 hr(-1) (p < 0.05) respectively; while the C(max), AUC(0-6 h) and Ka for carboxy-ibuprofen rose from 48 +/- 0.7 microg/ml to 51 +/- 0.16 microg/ml (p < 0.05); 41.972 +/- 0.68 microg/ml x hr to 63.948 +/- 0.12 microg/ml x hr (p < 0.05) and 1.649 +/- 0.08 hr(-1) to 4.187 +/- 0.42 hr(-1) (p < 0.05) respectively.",Effect of Tamarindus indica. L on the bioavailability of ibuprofen in healthy human volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14527090/),[μg] / [h·ml],63.948,119166,DB01050,Ibuprofen
,14527090,Ka,"Similarly the C(max), AUC(0-6 h) and Ka for hydroxy-ibuprofen rose from 43 +/- 0.76 microg/ml to 45 +/- 0.16 microg/ml (p < 0.05); 39.04 +/- 2.30 microg/ml x hr to 59.49 +/- 2.39 microg/ml.hr in (p < 0.05) and 1.498 +/- 0.79hr(-1) to 3.442 +/- 0.23 hr(-1) (p < 0.05) respectively; while the C(max), AUC(0-6 h) and Ka for carboxy-ibuprofen rose from 48 +/- 0.7 microg/ml to 51 +/- 0.16 microg/ml (p < 0.05); 41.972 +/- 0.68 microg/ml x hr to 63.948 +/- 0.12 microg/ml x hr (p < 0.05) and 1.649 +/- 0.08 hr(-1) to 4.187 +/- 0.42 hr(-1) (p < 0.05) respectively.",Effect of Tamarindus indica. L on the bioavailability of ibuprofen in healthy human volunteers. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14527090/),[μg] / [h·ml],41.972,119167,DB01050,Ibuprofen
,14527090,Ka,"Similarly the C(max), AUC(0-6 h) and Ka for hydroxy-ibuprofen rose from 43 +/- 0.76 microg/ml to 45 +/- 0.16 microg/ml (p < 0.05); 39.04 +/- 2.30 microg/ml x hr to 59.49 +/- 2.39 microg/ml.hr in (p < 0.05) and 1.498 +/- 0.79hr(-1) to 3.442 +/- 0.23 hr(-1) (p < 0.05) respectively; while the C(max), AUC(0-6 h) and Ka for carboxy-ibuprofen rose from 48 +/- 0.7 microg/ml to 51 +/- 0.16 microg/ml (p < 0.05); 41.972 +/- 0.68 microg/ml x hr to 63.948 +/- 0.12 microg/ml x hr (p < 0.05) and 1.649 +/- 0.08 hr(-1) to 4.187 +/- 0.42 hr(-1) (p < 0.05) respectively.",Effect of Tamarindus indica. L on the bioavailability of ibuprofen in healthy human volunteers. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14527090/),[μg] / [h·ml],63.948,119168,DB01050,Ibuprofen
,2010508,limit of detection,The limit of detection for ibuprofen (in human plasma) is 25 ng/mL for a 100-microL injection volume.,Assay of ibuprofen in human plasma by rapid and sensitive reversed-phase high-performance liquid chromatography:application to a single dose pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2010508/),[ng] / [ml],25,120098,DB01050,Ibuprofen
less,2010508,completion time of,The completion time of assay is less than 20 minutes.,Assay of ibuprofen in human plasma by rapid and sensitive reversed-phase high-performance liquid chromatography:application to a single dose pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2010508/),min,20,120099,DB01050,Ibuprofen
,16390350,volume of distribution (V),The population parameter estimate for volume of distribution (V) was 40.2 l per 70 kg.,Limited predictability of amikacin clearance in extreme premature neonates at birth. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16390350/),[l] / [70·kg],40.2,120128,DB01050,Ibuprofen
,16390350,Clearance (CL),Clearance (CL) increased from 0.486 l h(-1) per 70 kg at 24 weeks PCA to 0.940 l h(-1) per 70 kg by 30 weeks PCA.,Limited predictability of amikacin clearance in extreme premature neonates at birth. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16390350/),[l] / [70·h·kg],0.486,120129,DB01050,Ibuprofen
,16390350,Clearance (CL),Clearance (CL) increased from 0.486 l h(-1) per 70 kg at 24 weeks PCA to 0.940 l h(-1) per 70 kg by 30 weeks PCA.,Limited predictability of amikacin clearance in extreme premature neonates at birth. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16390350/),[l] / [70·h·kg],0.940,120130,DB01050,Ibuprofen
,19048790,Tmax,The Tmax of IBU-ISG and reference formulation were (1.8 +/- 0.6) and (0.4 +/- 0. 1) h.,[Preparation of in situ gel systems for the oral delivery of ibuprofen and its pharmacokinetics study in beagle dogs]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19048790/),h,1.8,122493,DB01050,Ibuprofen
,19048790,Tmax,The Tmax of IBU-ISG and reference formulation were (1.8 +/- 0.6) and (0.4 +/- 0. 1) h.,[Preparation of in situ gel systems for the oral delivery of ibuprofen and its pharmacokinetics study in beagle dogs]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19048790/),h,0.4,122494,DB01050,Ibuprofen
,19048790,Cmax,The Cmax values were (29.2 +/- 7.6) and (37.8 +/- 2.2) microg x mL(-1).,[Preparation of in situ gel systems for the oral delivery of ibuprofen and its pharmacokinetics study in beagle dogs]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19048790/),[μg] / [ml],29.2,122495,DB01050,Ibuprofen
,19048790,Cmax,The Cmax values were (29.2 +/- 7.6) and (37.8 +/- 2.2) microg x mL(-1).,[Preparation of in situ gel systems for the oral delivery of ibuprofen and its pharmacokinetics study in beagle dogs]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19048790/),[μg] / [ml],37.8,122496,DB01050,Ibuprofen
,19048790,T(1/2),"The T(1/2) were (2.3 +/- 0.5) and (2.0 +/- 0.9) h, and the AUC(0-t) were (131.0 +/- 38.6) and (117.3 +/- 23.1) microg x mL(-1) x h, respectively.",[Preparation of in situ gel systems for the oral delivery of ibuprofen and its pharmacokinetics study in beagle dogs]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19048790/),h,2.3,122497,DB01050,Ibuprofen
,19048790,T(1/2),"The T(1/2) were (2.3 +/- 0.5) and (2.0 +/- 0.9) h, and the AUC(0-t) were (131.0 +/- 38.6) and (117.3 +/- 23.1) microg x mL(-1) x h, respectively.",[Preparation of in situ gel systems for the oral delivery of ibuprofen and its pharmacokinetics study in beagle dogs]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19048790/),h,2.0,122498,DB01050,Ibuprofen
,19048790,AUC(0-t),"The T(1/2) were (2.3 +/- 0.5) and (2.0 +/- 0.9) h, and the AUC(0-t) were (131.0 +/- 38.6) and (117.3 +/- 23.1) microg x mL(-1) x h, respectively.",[Preparation of in situ gel systems for the oral delivery of ibuprofen and its pharmacokinetics study in beagle dogs]. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19048790/),[h·μg] / [ml],131.0,122499,DB01050,Ibuprofen
,19048790,AUC(0-t),"The T(1/2) were (2.3 +/- 0.5) and (2.0 +/- 0.9) h, and the AUC(0-t) were (131.0 +/- 38.6) and (117.3 +/- 23.1) microg x mL(-1) x h, respectively.",[Preparation of in situ gel systems for the oral delivery of ibuprofen and its pharmacokinetics study in beagle dogs]. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19048790/),[h·μg] / [ml],117.3,122500,DB01050,Ibuprofen
,10606790,AUC,The AUC values determined were 527.00 (piroxicam) 269. 45 (ketoprofen) 258.65 (naproxen) 243.22 (indomethacin) and 88.09 (ibuprofen) microg/ml per h.,The influence of the physicochemical characteristics and pharmacokinetic properties of selected NSAID's on their transdermal absorption. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10606790/),[μg] / [h·ml],527.00,122561,DB01050,Ibuprofen
,10606790,AUC,The AUC values determined were 527.00 (piroxicam) 269. 45 (ketoprofen) 258.65 (naproxen) 243.22 (indomethacin) and 88.09 (ibuprofen) microg/ml per h.,The influence of the physicochemical characteristics and pharmacokinetic properties of selected NSAID's on their transdermal absorption. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10606790/),[μg] / [h·ml],269. 45,122562,DB01050,Ibuprofen
,10606790,AUC,The AUC values determined were 527.00 (piroxicam) 269. 45 (ketoprofen) 258.65 (naproxen) 243.22 (indomethacin) and 88.09 (ibuprofen) microg/ml per h.,The influence of the physicochemical characteristics and pharmacokinetic properties of selected NSAID's on their transdermal absorption. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10606790/),[μg] / [h·ml],258.65,122563,DB01050,Ibuprofen
,10606790,AUC,The AUC values determined were 527.00 (piroxicam) 269. 45 (ketoprofen) 258.65 (naproxen) 243.22 (indomethacin) and 88.09 (ibuprofen) microg/ml per h.,The influence of the physicochemical characteristics and pharmacokinetic properties of selected NSAID's on their transdermal absorption. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10606790/),[μg] / [h·ml],243.22,122564,DB01050,Ibuprofen
,10606790,AUC,The AUC values determined were 527.00 (piroxicam) 269. 45 (ketoprofen) 258.65 (naproxen) 243.22 (indomethacin) and 88.09 (ibuprofen) microg/ml per h.,The influence of the physicochemical characteristics and pharmacokinetic properties of selected NSAID's on their transdermal absorption. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10606790/),[μg] / [h·ml],88.09,122565,DB01050,Ibuprofen
,28971375,particle size,"In the end, we acquired the optimal formulation of ibuprofen cationic liposomes (Ibu-CL) by orthogonal test design, and the particle size and entrapment efficiency (EE%) were 121.0 ± 3.5 nm and 72.9 ± 3.4%, respectively.",In vitro and In vivo Studies on a Novel Bioadhesive Colloidal System: Cationic Liposomes of Ibuprofen. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28971375/),nm,121.0,123423,DB01050,Ibuprofen
,28971375,entrapment efficiency (EE%),"In the end, we acquired the optimal formulation of ibuprofen cationic liposomes (Ibu-CL) by orthogonal test design, and the particle size and entrapment efficiency (EE%) were 121.0 ± 3.5 nm and 72.9 ± 3.4%, respectively.",In vitro and In vivo Studies on a Novel Bioadhesive Colloidal System: Cationic Liposomes of Ibuprofen. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28971375/),%,72.9,123424,DB01050,Ibuprofen
,18358504,IC(50),RIAA inhibited LPS-stimulated PGE(2) formation with >200-fold selectivity of COX-2 (IC(50)=1.3 microg/ml) over COX-1 (IC(50)>289 microg/ml).,"Safety, efficacy and anti-inflammatory activity of rho iso-alpha-acids from hops. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18358504/),[μg] / [ml],1.3,123772,DB01050,Ibuprofen
>,18358504,IC(50),RIAA inhibited LPS-stimulated PGE(2) formation with >200-fold selectivity of COX-2 (IC(50)=1.3 microg/ml) over COX-1 (IC(50)>289 microg/ml).,"Safety, efficacy and anti-inflammatory activity of rho iso-alpha-acids from hops. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18358504/),[μg] / [ml],289,123773,DB01050,Ibuprofen
,18358504,IC(50),"In support, we found RIAA showed minimal PGE(2) inhibition (IC(50)=21mug/ml) relative to celecoxib (IC(50)=0.024 microg/ml), aspirin (IC(50)=0.52 microg/ml) or ibuprofen (IC(50)=0.57 microg/ml) in the AGS gastric mucosal model, where COX-1 and -2 are expressed constitutively.","Safety, efficacy and anti-inflammatory activity of rho iso-alpha-acids from hops. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18358504/),[μg] / [ml],21,123774,DB01050,Ibuprofen
,18358504,IC(50),"In support, we found RIAA showed minimal PGE(2) inhibition (IC(50)=21mug/ml) relative to celecoxib (IC(50)=0.024 microg/ml), aspirin (IC(50)=0.52 microg/ml) or ibuprofen (IC(50)=0.57 microg/ml) in the AGS gastric mucosal model, where COX-1 and -2 are expressed constitutively.","Safety, efficacy and anti-inflammatory activity of rho iso-alpha-acids from hops. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18358504/),[μg] / [ml],0.024,123775,DB01050,Ibuprofen
,18358504,IC(50),"In support, we found RIAA showed minimal PGE(2) inhibition (IC(50)=21mug/ml) relative to celecoxib (IC(50)=0.024 microg/ml), aspirin (IC(50)=0.52 microg/ml) or ibuprofen (IC(50)=0.57 microg/ml) in the AGS gastric mucosal model, where COX-1 and -2 are expressed constitutively.","Safety, efficacy and anti-inflammatory activity of rho iso-alpha-acids from hops. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18358504/),[μg] / [ml],0.52,123776,DB01050,Ibuprofen
,18358504,IC(50),"In support, we found RIAA showed minimal PGE(2) inhibition (IC(50)=21mug/ml) relative to celecoxib (IC(50)=0.024 microg/ml), aspirin (IC(50)=0.52 microg/ml) or ibuprofen (IC(50)=0.57 microg/ml) in the AGS gastric mucosal model, where COX-1 and -2 are expressed constitutively.","Safety, efficacy and anti-inflammatory activity of rho iso-alpha-acids from hops. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18358504/),[μg] / [ml],0.57,123777,DB01050,Ibuprofen
,32250464,clearance,"We found that S-ibuprofen clearance (CLS , 3.98 mL/h [relative standard error {RSE} 8%]) increases with PNA and GA, with exponents of 2.25 (RSE 6%) and 5.81 (RSE 15%), respectively.",Enantiomer specific pharmacokinetics of ibuprofen in preterm neonates with patent ductus arteriosus. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32250464/),[ml] / [h],3.98,124099,DB01050,Ibuprofen
,32250464,Clearance,"Clearance of R-ibuprofen was found to be high compared to CLS (18 mL/h [RSE 24%]), resulting in a low contribution of R-ibuprofen to total ibuprofen exposure.",Enantiomer specific pharmacokinetics of ibuprofen in preterm neonates with patent ductus arteriosus. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32250464/),[ml] / [h],18,124100,DB01050,Ibuprofen
,1642682,peak plasma concentration,The mean values of peak plasma concentration (microgram/ml) were 26.1 and 56.4 after treatment with 200 and 400 mg sachets respectively vs. 16.3 and 43.0 after treatment with 200 and 400 mg tablets.,Activity and pharmacokinetics of a new oral dosage form of soluble ibuprofen. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1642682/),[μg] / [ml],26.1,124215,DB01050,Ibuprofen
,1642682,peak plasma concentration,The mean values of peak plasma concentration (microgram/ml) were 26.1 and 56.4 after treatment with 200 and 400 mg sachets respectively vs. 16.3 and 43.0 after treatment with 200 and 400 mg tablets.,Activity and pharmacokinetics of a new oral dosage form of soluble ibuprofen. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1642682/),[μg] / [ml],56.4,124216,DB01050,Ibuprofen
,1642682,peak plasma concentration,The mean values of peak plasma concentration (microgram/ml) were 26.1 and 56.4 after treatment with 200 and 400 mg sachets respectively vs. 16.3 and 43.0 after treatment with 200 and 400 mg tablets.,Activity and pharmacokinetics of a new oral dosage form of soluble ibuprofen. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1642682/),[μg] / [ml],16.3,124217,DB01050,Ibuprofen
,1642682,peak plasma concentration,The mean values of peak plasma concentration (microgram/ml) were 26.1 and 56.4 after treatment with 200 and 400 mg sachets respectively vs. 16.3 and 43.0 after treatment with 200 and 400 mg tablets.,Activity and pharmacokinetics of a new oral dosage form of soluble ibuprofen. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1642682/),[μg] / [ml],43.0,124218,DB01050,Ibuprofen
,1642682,peak time,The mean values of peak time were 16.9 and 24.4 min after treatment with 200 and 400 mg sachets respectively vs. 90.0 and 63.7 min after treatment with 200 and 400 mg tablets.,Activity and pharmacokinetics of a new oral dosage form of soluble ibuprofen. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1642682/),min,16.9,124219,DB01050,Ibuprofen
,1642682,peak time,The mean values of peak time were 16.9 and 24.4 min after treatment with 200 and 400 mg sachets respectively vs. 90.0 and 63.7 min after treatment with 200 and 400 mg tablets.,Activity and pharmacokinetics of a new oral dosage form of soluble ibuprofen. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1642682/),min,24.4,124220,DB01050,Ibuprofen
,1642682,peak time,The mean values of peak time were 16.9 and 24.4 min after treatment with 200 and 400 mg sachets respectively vs. 90.0 and 63.7 min after treatment with 200 and 400 mg tablets.,Activity and pharmacokinetics of a new oral dosage form of soluble ibuprofen. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1642682/),min,90.0,124221,DB01050,Ibuprofen
,1642682,peak time,The mean values of peak time were 16.9 and 24.4 min after treatment with 200 and 400 mg sachets respectively vs. 90.0 and 63.7 min after treatment with 200 and 400 mg tablets.,Activity and pharmacokinetics of a new oral dosage form of soluble ibuprofen. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1642682/),min,63.7,124222,DB01050,Ibuprofen
,1642682,relative bioavailability index,The shortening in the absorption time and the increase in the plasma concentrations did not involve a quicker drug elimination nor cause any changes in the bioavailability (mean values of the relative bioavailability indexes of 0.98 for 200 mg dosage form and 1.02 for the 400 mg one).,Activity and pharmacokinetics of a new oral dosage form of soluble ibuprofen. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1642682/),,0.98,124223,DB01050,Ibuprofen
,1642682,relative bioavailability index,The shortening in the absorption time and the increase in the plasma concentrations did not involve a quicker drug elimination nor cause any changes in the bioavailability (mean values of the relative bioavailability indexes of 0.98 for 200 mg dosage form and 1.02 for the 400 mg one).,Activity and pharmacokinetics of a new oral dosage form of soluble ibuprofen. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1642682/),,1.02,124224,DB01050,Ibuprofen
,3804520,peak levels,"Mean peak levels of 25.1 micrograms/ml for preparation A (2 X 300 mg), 31.3 micrograms/ml for preparation B (2 X 400 mg) and 68.5 micrograms/ml for preparation C (2 X 400 mg) were reached at 5.3, 3 and 2 hours respectively, after ingestion of the drugs.",Evaluation of the absorption from three ibuprofen formulations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3804520/),[μg] / [ml],25.1,125064,DB01050,Ibuprofen
,3804520,peak levels,"Mean peak levels of 25.1 micrograms/ml for preparation A (2 X 300 mg), 31.3 micrograms/ml for preparation B (2 X 400 mg) and 68.5 micrograms/ml for preparation C (2 X 400 mg) were reached at 5.3, 3 and 2 hours respectively, after ingestion of the drugs.",Evaluation of the absorption from three ibuprofen formulations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3804520/),[μg] / [ml],31.3,125065,DB01050,Ibuprofen
,3804520,peak levels,"Mean peak levels of 25.1 micrograms/ml for preparation A (2 X 300 mg), 31.3 micrograms/ml for preparation B (2 X 400 mg) and 68.5 micrograms/ml for preparation C (2 X 400 mg) were reached at 5.3, 3 and 2 hours respectively, after ingestion of the drugs.",Evaluation of the absorption from three ibuprofen formulations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3804520/),[μg] / [ml],68.5,125066,DB01050,Ibuprofen
,3804520,relative bioavailability,The relative bioavailability was very close to 100% in almost all subjects (coefficient of variation 14% and 17%).,Evaluation of the absorption from three ibuprofen formulations. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3804520/),%,100,125067,DB01050,Ibuprofen
,3804520,relative bioavailability,The relative bioavailability was very close to 100% in almost all subjects (coefficient of variation 14% and 17%).,Evaluation of the absorption from three ibuprofen formulations. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3804520/),%,14,125068,DB01050,Ibuprofen
,3804520,relative bioavailability,The relative bioavailability was very close to 100% in almost all subjects (coefficient of variation 14% and 17%).,Evaluation of the absorption from three ibuprofen formulations. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3804520/),%,17,125069,DB01050,Ibuprofen
,1586023,absolute bioavailability,Both formulations had an absolute bioavailability of about 80%.,Bioavailability of two ibuprofen oral paste formulations in fed or nonfed ponies. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1586023/),%,80,126410,DB01050,Ibuprofen
,17976261,area under the curve of the plasma concentration-time curve (AUC,The area under the curve of the plasma concentration-time curve (AUC; (mean+/-s.d.) values for rac-ibuprofen were 192.90+/-43.47 for the SR preparation and 195.90+/-31.69 microg h mL(-1) for the IR preparation.,Effect of absorption rate on pharmacokinetics of ibuprofen in relation to chiral inversion in humans. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17976261/),[h·μg] / [ml],192.90,128846,DB01050,Ibuprofen
,17976261,area under the curve of the plasma concentration-time curve (AUC,The area under the curve of the plasma concentration-time curve (AUC; (mean+/-s.d.) values for rac-ibuprofen were 192.90+/-43.47 for the SR preparation and 195.90+/-31.69 microg h mL(-1) for the IR preparation.,Effect of absorption rate on pharmacokinetics of ibuprofen in relation to chiral inversion in humans. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17976261/),[h·μg] / [ml],195.90,128847,DB01050,Ibuprofen
,17976261,AUC,"AUC values for the enantiomers after administration of the SR formulation were 55.38+/-17.79 and 92.51+/-30.68 microg h mL(-1) for R- and S-ibuprofen, respectively, and were 65.94+/-20.06 and 100.81+/-32.28 microg h mL(-1) for R- and S-ibuprofen after administration of the IR preparation.",Effect of absorption rate on pharmacokinetics of ibuprofen in relation to chiral inversion in humans. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17976261/),[h·μg] / [ml],55.38,128848,DB01050,Ibuprofen
,17976261,AUC,"AUC values for the enantiomers after administration of the SR formulation were 55.38+/-17.79 and 92.51+/-30.68 microg h mL(-1) for R- and S-ibuprofen, respectively, and were 65.94+/-20.06 and 100.81+/-32.28 microg h mL(-1) for R- and S-ibuprofen after administration of the IR preparation.",Effect of absorption rate on pharmacokinetics of ibuprofen in relation to chiral inversion in humans. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17976261/),[h·μg] / [ml],92.51,128849,DB01050,Ibuprofen
,17976261,AUC,"AUC values for the enantiomers after administration of the SR formulation were 55.38+/-17.79 and 92.51+/-30.68 microg h mL(-1) for R- and S-ibuprofen, respectively, and were 65.94+/-20.06 and 100.81+/-32.28 microg h mL(-1) for R- and S-ibuprofen after administration of the IR preparation.",Effect of absorption rate on pharmacokinetics of ibuprofen in relation to chiral inversion in humans. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17976261/),[h·μg] / [ml],65.94,128850,DB01050,Ibuprofen
,17976261,AUC,"AUC values for the enantiomers after administration of the SR formulation were 55.38+/-17.79 and 92.51+/-30.68 microg h mL(-1) for R- and S-ibuprofen, respectively, and were 65.94+/-20.06 and 100.81+/-32.28 microg h mL(-1) for R- and S-ibuprofen after administration of the IR preparation.",Effect of absorption rate on pharmacokinetics of ibuprofen in relation to chiral inversion in humans. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17976261/),[h·μg] / [ml],100.81,128851,DB01050,Ibuprofen
,17976261,C(max),"C(max) values were significantly decreased with the SR preparation: 25.11+/-5.71, 12.24+/-3.79 and 12.38+/-3.55 microg h mL(-1) for rac-, R-, and S-ibuprofen, respectively, after administration of the SR preparation, vs 46.21+/-8.20, 20.82+/-5.90 and 23.46+/-7.30 microg h mL(-1) for rac-, R-, and S-ibuprofen, respectively, after administration of the IR preparation.",Effect of absorption rate on pharmacokinetics of ibuprofen in relation to chiral inversion in humans. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17976261/),[h·μg] / [ml],25.11,128852,DB01050,Ibuprofen
,17976261,C(max),"C(max) values were significantly decreased with the SR preparation: 25.11+/-5.71, 12.24+/-3.79 and 12.38+/-3.55 microg h mL(-1) for rac-, R-, and S-ibuprofen, respectively, after administration of the SR preparation, vs 46.21+/-8.20, 20.82+/-5.90 and 23.46+/-7.30 microg h mL(-1) for rac-, R-, and S-ibuprofen, respectively, after administration of the IR preparation.",Effect of absorption rate on pharmacokinetics of ibuprofen in relation to chiral inversion in humans. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17976261/),[h·μg] / [ml],12.24,128853,DB01050,Ibuprofen
,17976261,C(max),"C(max) values were significantly decreased with the SR preparation: 25.11+/-5.71, 12.24+/-3.79 and 12.38+/-3.55 microg h mL(-1) for rac-, R-, and S-ibuprofen, respectively, after administration of the SR preparation, vs 46.21+/-8.20, 20.82+/-5.90 and 23.46+/-7.30 microg h mL(-1) for rac-, R-, and S-ibuprofen, respectively, after administration of the IR preparation.",Effect of absorption rate on pharmacokinetics of ibuprofen in relation to chiral inversion in humans. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17976261/),[h·μg] / [ml],12.38,128854,DB01050,Ibuprofen
,17976261,C(max),"C(max) values were significantly decreased with the SR preparation: 25.11+/-5.71, 12.24+/-3.79 and 12.38+/-3.55 microg h mL(-1) for rac-, R-, and S-ibuprofen, respectively, after administration of the SR preparation, vs 46.21+/-8.20, 20.82+/-5.90 and 23.46+/-7.30 microg h mL(-1) for rac-, R-, and S-ibuprofen, respectively, after administration of the IR preparation.",Effect of absorption rate on pharmacokinetics of ibuprofen in relation to chiral inversion in humans. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17976261/),[h·μg] / [ml],46.21,128855,DB01050,Ibuprofen
,17976261,C(max),"C(max) values were significantly decreased with the SR preparation: 25.11+/-5.71, 12.24+/-3.79 and 12.38+/-3.55 microg h mL(-1) for rac-, R-, and S-ibuprofen, respectively, after administration of the SR preparation, vs 46.21+/-8.20, 20.82+/-5.90 and 23.46+/-7.30 microg h mL(-1) for rac-, R-, and S-ibuprofen, respectively, after administration of the IR preparation.",Effect of absorption rate on pharmacokinetics of ibuprofen in relation to chiral inversion in humans. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17976261/),[h·μg] / [ml],20.82,128856,DB01050,Ibuprofen
,17976261,C(max),"C(max) values were significantly decreased with the SR preparation: 25.11+/-5.71, 12.24+/-3.79 and 12.38+/-3.55 microg h mL(-1) for rac-, R-, and S-ibuprofen, respectively, after administration of the SR preparation, vs 46.21+/-8.20, 20.82+/-5.90 and 23.46+/-7.30 microg h mL(-1) for rac-, R-, and S-ibuprofen, respectively, after administration of the IR preparation.",Effect of absorption rate on pharmacokinetics of ibuprofen in relation to chiral inversion in humans. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17976261/),[h·μg] / [ml],23.46,128857,DB01050,Ibuprofen
,17976261,Mean residence time,"Mean residence time was significantly increased: 7.01+/-1.29, 5.52+/-1.25 and 7.04+/-1.30 h for rac-, R-, and S-ibuprofen, respectively, after administration of the SR preparation vs 4.34+/-0.89, 3.43+/-0.64 and 4.51+/-0.79 h for rac-, R-, and S-ibuprofen, respectively, after administration of the IR preparation.",Effect of absorption rate on pharmacokinetics of ibuprofen in relation to chiral inversion in humans. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17976261/),h,7.01,128858,DB01050,Ibuprofen
,17976261,Mean residence time,"Mean residence time was significantly increased: 7.01+/-1.29, 5.52+/-1.25 and 7.04+/-1.30 h for rac-, R-, and S-ibuprofen, respectively, after administration of the SR preparation vs 4.34+/-0.89, 3.43+/-0.64 and 4.51+/-0.79 h for rac-, R-, and S-ibuprofen, respectively, after administration of the IR preparation.",Effect of absorption rate on pharmacokinetics of ibuprofen in relation to chiral inversion in humans. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17976261/),h,5.52,128859,DB01050,Ibuprofen
,17976261,Mean residence time,"Mean residence time was significantly increased: 7.01+/-1.29, 5.52+/-1.25 and 7.04+/-1.30 h for rac-, R-, and S-ibuprofen, respectively, after administration of the SR preparation vs 4.34+/-0.89, 3.43+/-0.64 and 4.51+/-0.79 h for rac-, R-, and S-ibuprofen, respectively, after administration of the IR preparation.",Effect of absorption rate on pharmacokinetics of ibuprofen in relation to chiral inversion in humans. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17976261/),h,7.04,128860,DB01050,Ibuprofen
,17976261,Mean residence time,"Mean residence time was significantly increased: 7.01+/-1.29, 5.52+/-1.25 and 7.04+/-1.30 h for rac-, R-, and S-ibuprofen, respectively, after administration of the SR preparation vs 4.34+/-0.89, 3.43+/-0.64 and 4.51+/-0.79 h for rac-, R-, and S-ibuprofen, respectively, after administration of the IR preparation.",Effect of absorption rate on pharmacokinetics of ibuprofen in relation to chiral inversion in humans. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17976261/),h,4.34,128861,DB01050,Ibuprofen
,17976261,Mean residence time,"Mean residence time was significantly increased: 7.01+/-1.29, 5.52+/-1.25 and 7.04+/-1.30 h for rac-, R-, and S-ibuprofen, respectively, after administration of the SR preparation vs 4.34+/-0.89, 3.43+/-0.64 and 4.51+/-0.79 h for rac-, R-, and S-ibuprofen, respectively, after administration of the IR preparation.",Effect of absorption rate on pharmacokinetics of ibuprofen in relation to chiral inversion in humans. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17976261/),h,3.43,128862,DB01050,Ibuprofen
,17976261,Mean residence time,"Mean residence time was significantly increased: 7.01+/-1.29, 5.52+/-1.25 and 7.04+/-1.30 h for rac-, R-, and S-ibuprofen, respectively, after administration of the SR preparation vs 4.34+/-0.89, 3.43+/-0.64 and 4.51+/-0.79 h for rac-, R-, and S-ibuprofen, respectively, after administration of the IR preparation.",Effect of absorption rate on pharmacokinetics of ibuprofen in relation to chiral inversion in humans. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17976261/),h,4.51,128863,DB01050,Ibuprofen
,18307541,elimination clearance CL,Mean population pharmacokinetic estimates with corresponding intersubject variabilities (%) were: elimination clearance CL = 9.49 ml h(-1) (62%) and volume of distribution V = 375 ml (72%).,"An optimized ibuprofen dosing scheme for preterm neonates with patent ductus arteriosus, based on a population pharmacokinetic and pharmacodynamic study. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18307541/),[ml] / [h],9.49,129104,DB01050,Ibuprofen
,18307541,volume of distribution V,Mean population pharmacokinetic estimates with corresponding intersubject variabilities (%) were: elimination clearance CL = 9.49 ml h(-1) (62%) and volume of distribution V = 375 ml (72%).,"An optimized ibuprofen dosing scheme for preterm neonates with patent ductus arteriosus, based on a population pharmacokinetic and pharmacodynamic study. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18307541/),ml,375,129105,DB01050,Ibuprofen
<,18307541,AUC1,PDA closure was observed in 50% of the neonates when AUC1D < 600 mg l(-1) h (or AUC3D < 900 mg l(-1) h) and in 91% when AUC1D > 600 mg l(-1) h (or AUC3D > 900 mg l(-1) h) (P = 0.006).,"An optimized ibuprofen dosing scheme for preterm neonates with patent ductus arteriosus, based on a population pharmacokinetic and pharmacodynamic study. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18307541/),,600,129106,DB01050,Ibuprofen
>,18307541,AUC1D,PDA closure was observed in 50% of the neonates when AUC1D < 600 mg l(-1) h (or AUC3D < 900 mg l(-1) h) and in 91% when AUC1D > 600 mg l(-1) h (or AUC3D > 900 mg l(-1) h) (P = 0.006).,"An optimized ibuprofen dosing scheme for preterm neonates with patent ductus arteriosus, based on a population pharmacokinetic and pharmacodynamic study. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18307541/),[h·mg] / [l],600,129107,DB01050,Ibuprofen
>,18307541,AUC3D,PDA closure was observed in 50% of the neonates when AUC1D < 600 mg l(-1) h (or AUC3D < 900 mg l(-1) h) and in 91% when AUC1D > 600 mg l(-1) h (or AUC3D > 900 mg l(-1) h) (P = 0.006).,"An optimized ibuprofen dosing scheme for preterm neonates with patent ductus arteriosus, based on a population pharmacokinetic and pharmacodynamic study. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18307541/),[h·mg] / [l],900,129108,DB01050,Ibuprofen
,3350204,maximum plasma concentrations,"The mean maximum plasma concentrations of ibuprofen were 58, 45 and 54 micrograms/ml after administration of Brufen, Burana and Ibumetin, respectively, the time to reach this being 1.4, 2.1 and 1.6 h, respectively, after administration.",Bioavailability of three commercial preparations of ibuprofen 600 mg. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3350204/),[μg] / [ml],58,130343,DB01050,Ibuprofen
,3350204,maximum plasma concentrations,"The mean maximum plasma concentrations of ibuprofen were 58, 45 and 54 micrograms/ml after administration of Brufen, Burana and Ibumetin, respectively, the time to reach this being 1.4, 2.1 and 1.6 h, respectively, after administration.",Bioavailability of three commercial preparations of ibuprofen 600 mg. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3350204/),[μg] / [ml],45,130344,DB01050,Ibuprofen
,3350204,maximum plasma concentrations,"The mean maximum plasma concentrations of ibuprofen were 58, 45 and 54 micrograms/ml after administration of Brufen, Burana and Ibumetin, respectively, the time to reach this being 1.4, 2.1 and 1.6 h, respectively, after administration.",Bioavailability of three commercial preparations of ibuprofen 600 mg. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3350204/),[μg] / [ml],54,130345,DB01050,Ibuprofen
,3350204,time to reach this,"The mean maximum plasma concentrations of ibuprofen were 58, 45 and 54 micrograms/ml after administration of Brufen, Burana and Ibumetin, respectively, the time to reach this being 1.4, 2.1 and 1.6 h, respectively, after administration.",Bioavailability of three commercial preparations of ibuprofen 600 mg. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3350204/),h,1.4,130346,DB01050,Ibuprofen
,3350204,time to reach this,"The mean maximum plasma concentrations of ibuprofen were 58, 45 and 54 micrograms/ml after administration of Brufen, Burana and Ibumetin, respectively, the time to reach this being 1.4, 2.1 and 1.6 h, respectively, after administration.",Bioavailability of three commercial preparations of ibuprofen 600 mg. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3350204/),h,2.1,130347,DB01050,Ibuprofen
,3350204,time to reach this,"The mean maximum plasma concentrations of ibuprofen were 58, 45 and 54 micrograms/ml after administration of Brufen, Burana and Ibumetin, respectively, the time to reach this being 1.4, 2.1 and 1.6 h, respectively, after administration.",Bioavailability of three commercial preparations of ibuprofen 600 mg. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3350204/),h,1.6,130348,DB01050,Ibuprofen
,3350204,relative bioavailability,The relative bioavailability was very similar between Brufen and Burana but about 8% lower for Ibumetin and this difference between Brufen and Ibumetin was significant.,Bioavailability of three commercial preparations of ibuprofen 600 mg. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3350204/),%,8,130349,DB01050,Ibuprofen
,10911512,clearance (CL),"There were no significant differences between zaleplon monotherapy and combination therapy in mean +/- SD, of zaleplon clearance (CL) (2.80 +/- 0.72 versus 2.72 +/- 0.89 L/hr/kg, respectively), maximum plasma concentration (Cmax) (37.1 +/- 17.9 versus 39.8 +/- 20.0 ng/mL), or area under the concentration-versus-time curve (AUC) (56.7 +/- 22.8 versus 59.2 +/- 22.0 ng.hr/mL).",Absence of an interaction between ibuprofen and zaleplon. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10911512/),[l] / [h·kg],2.80,131739,DB01050,Ibuprofen
,10911512,clearance (CL),"There were no significant differences between zaleplon monotherapy and combination therapy in mean +/- SD, of zaleplon clearance (CL) (2.80 +/- 0.72 versus 2.72 +/- 0.89 L/hr/kg, respectively), maximum plasma concentration (Cmax) (37.1 +/- 17.9 versus 39.8 +/- 20.0 ng/mL), or area under the concentration-versus-time curve (AUC) (56.7 +/- 22.8 versus 59.2 +/- 22.0 ng.hr/mL).",Absence of an interaction between ibuprofen and zaleplon. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10911512/),[l] / [h·kg],2.72,131740,DB01050,Ibuprofen
,10911512,maximum plasma concentration (Cmax),"There were no significant differences between zaleplon monotherapy and combination therapy in mean +/- SD, of zaleplon clearance (CL) (2.80 +/- 0.72 versus 2.72 +/- 0.89 L/hr/kg, respectively), maximum plasma concentration (Cmax) (37.1 +/- 17.9 versus 39.8 +/- 20.0 ng/mL), or area under the concentration-versus-time curve (AUC) (56.7 +/- 22.8 versus 59.2 +/- 22.0 ng.hr/mL).",Absence of an interaction between ibuprofen and zaleplon. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10911512/),[ng] / [ml],37.1,131741,DB01050,Ibuprofen
,10911512,maximum plasma concentration (Cmax),"There were no significant differences between zaleplon monotherapy and combination therapy in mean +/- SD, of zaleplon clearance (CL) (2.80 +/- 0.72 versus 2.72 +/- 0.89 L/hr/kg, respectively), maximum plasma concentration (Cmax) (37.1 +/- 17.9 versus 39.8 +/- 20.0 ng/mL), or area under the concentration-versus-time curve (AUC) (56.7 +/- 22.8 versus 59.2 +/- 22.0 ng.hr/mL).",Absence of an interaction between ibuprofen and zaleplon. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10911512/),[ng] / [ml],39.8,131742,DB01050,Ibuprofen
,10911512,area under the concentration-versus-time curve (AUC),"There were no significant differences between zaleplon monotherapy and combination therapy in mean +/- SD, of zaleplon clearance (CL) (2.80 +/- 0.72 versus 2.72 +/- 0.89 L/hr/kg, respectively), maximum plasma concentration (Cmax) (37.1 +/- 17.9 versus 39.8 +/- 20.0 ng/mL), or area under the concentration-versus-time curve (AUC) (56.7 +/- 22.8 versus 59.2 +/- 22.0 ng.hr/mL).",Absence of an interaction between ibuprofen and zaleplon. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10911512/),[h·ng] / [ml],56.7,131743,DB01050,Ibuprofen
,10911512,area under the concentration-versus-time curve (AUC),"There were no significant differences between zaleplon monotherapy and combination therapy in mean +/- SD, of zaleplon clearance (CL) (2.80 +/- 0.72 versus 2.72 +/- 0.89 L/hr/kg, respectively), maximum plasma concentration (Cmax) (37.1 +/- 17.9 versus 39.8 +/- 20.0 ng/mL), or area under the concentration-versus-time curve (AUC) (56.7 +/- 22.8 versus 59.2 +/- 22.0 ng.hr/mL).",Absence of an interaction between ibuprofen and zaleplon. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10911512/),[h·ng] / [ml],59.2,131744,DB01050,Ibuprofen
,10911512,CL,"There were no significant differences between ibuprofen monotherapy and combination therapy in ibuprofen CL (71.6 +/- 17.0 versus 71.7 +/- 14.9 L/hr/kg), Cmax (40.8 +/- 10.2 versus 40.4 +/- 10.0 micrograms/mL), or AUC (127.6 +/- 29.6 versus 126.4 +/- 29.7 micrograms.hr/mL).",Absence of an interaction between ibuprofen and zaleplon. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10911512/),[l] / [h·kg],71.6,131745,DB01050,Ibuprofen
,10911512,CL,"There were no significant differences between ibuprofen monotherapy and combination therapy in ibuprofen CL (71.6 +/- 17.0 versus 71.7 +/- 14.9 L/hr/kg), Cmax (40.8 +/- 10.2 versus 40.4 +/- 10.0 micrograms/mL), or AUC (127.6 +/- 29.6 versus 126.4 +/- 29.7 micrograms.hr/mL).",Absence of an interaction between ibuprofen and zaleplon. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10911512/),[l] / [h·kg],71.7,131746,DB01050,Ibuprofen
,10911512,Cmax,"There were no significant differences between ibuprofen monotherapy and combination therapy in ibuprofen CL (71.6 +/- 17.0 versus 71.7 +/- 14.9 L/hr/kg), Cmax (40.8 +/- 10.2 versus 40.4 +/- 10.0 micrograms/mL), or AUC (127.6 +/- 29.6 versus 126.4 +/- 29.7 micrograms.hr/mL).",Absence of an interaction between ibuprofen and zaleplon. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10911512/),[μg] / [ml],40.8,131747,DB01050,Ibuprofen
,10911512,Cmax,"There were no significant differences between ibuprofen monotherapy and combination therapy in ibuprofen CL (71.6 +/- 17.0 versus 71.7 +/- 14.9 L/hr/kg), Cmax (40.8 +/- 10.2 versus 40.4 +/- 10.0 micrograms/mL), or AUC (127.6 +/- 29.6 versus 126.4 +/- 29.7 micrograms.hr/mL).",Absence of an interaction between ibuprofen and zaleplon. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10911512/),[μg] / [ml],40.4,131748,DB01050,Ibuprofen
,10911512,AUC,"There were no significant differences between ibuprofen monotherapy and combination therapy in ibuprofen CL (71.6 +/- 17.0 versus 71.7 +/- 14.9 L/hr/kg), Cmax (40.8 +/- 10.2 versus 40.4 +/- 10.0 micrograms/mL), or AUC (127.6 +/- 29.6 versus 126.4 +/- 29.7 micrograms.hr/mL).",Absence of an interaction between ibuprofen and zaleplon. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10911512/),[h·μg] / [ml],127.6,131749,DB01050,Ibuprofen
,10911512,AUC,"There were no significant differences between ibuprofen monotherapy and combination therapy in ibuprofen CL (71.6 +/- 17.0 versus 71.7 +/- 14.9 L/hr/kg), Cmax (40.8 +/- 10.2 versus 40.4 +/- 10.0 micrograms/mL), or AUC (127.6 +/- 29.6 versus 126.4 +/- 29.7 micrograms.hr/mL).",Absence of an interaction between ibuprofen and zaleplon. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10911512/),[h·μg] / [ml],126.4,131750,DB01050,Ibuprofen
,25841571,Solubility,"Solubility of ibuprofen in the mixed oils was unexpectedly and remarkably increased (almost 300mg/mL) compared with that (around 100mg/mL) of the single oil (GTCC), which also resulted in greatly increased solubility of ibuprofen in mixed oils-containing microemulsions.",Optimized mixed oils remarkably reduce the amount of surfactants in microemulsions without affecting oral bioavailability of ibuprofen by simultaneously enlarging microemulsion areas and enhancing drug solubility. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25841571/),[mg] / [ml],300,132951,DB01050,Ibuprofen
,25841571,Solubility,"Solubility of ibuprofen in the mixed oils was unexpectedly and remarkably increased (almost 300mg/mL) compared with that (around 100mg/mL) of the single oil (GTCC), which also resulted in greatly increased solubility of ibuprofen in mixed oils-containing microemulsions.",Optimized mixed oils remarkably reduce the amount of surfactants in microemulsions without affecting oral bioavailability of ibuprofen by simultaneously enlarging microemulsion areas and enhancing drug solubility. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25841571/),[mg] / [ml],100,132952,DB01050,Ibuprofen
,15567287,maximum solubility,"The poloxamer gel with menthol/ibuprofen ratio of 1:9 and higher than 15% poloxamer 188 showed the maximum solubility of ibuprofen, 1.2mg/ml.",Preparation of ibuprofen-loaded liquid suppository using eutectic mixture system with menthol. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15567287/),[mg] / [ml],1.2,133042,DB01050,Ibuprofen
,15567287,solubility,The ibuprofen-loaded liquid suppository [P 188/menthol/ibuprofen (15/0.25/2.5%)] with the maximum ibuprofen solubility of 1.2mg/ml was administered easily to the anus and to remain at the administered site without leakage after the dose.,Preparation of ibuprofen-loaded liquid suppository using eutectic mixture system with menthol. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15567287/),[mg] / [ml],1.2,133043,DB01050,Ibuprofen
,21864907,AUC(0-t),"In the single-dose study, the mean (SD) AUC(0-t) was 155.60 (40.94) μg/h/mL for the CR formulation and 161.11 (37.50) μg/h/mL for the IR formulation; the mean (SD) C(max) values were 22.71 (6.64) and 23.77 (4.91) μg/mL, respectively; and the median T(max) values were 2.01 hours and 2.00 hours, respectively.",Pharmacokinetic comparison of controlled- and immediate-release formulations of dexibuprofen after single and multiple oral doses in fasting healthy male Korean volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21864907/),[μg] / [h·ml],155.60,133134,DB01050,Ibuprofen
,21864907,AUC(0-t),"In the single-dose study, the mean (SD) AUC(0-t) was 155.60 (40.94) μg/h/mL for the CR formulation and 161.11 (37.50) μg/h/mL for the IR formulation; the mean (SD) C(max) values were 22.71 (6.64) and 23.77 (4.91) μg/mL, respectively; and the median T(max) values were 2.01 hours and 2.00 hours, respectively.",Pharmacokinetic comparison of controlled- and immediate-release formulations of dexibuprofen after single and multiple oral doses in fasting healthy male Korean volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21864907/),[μg] / [h·ml],161.11,133135,DB01050,Ibuprofen
,21864907,C(max),"In the single-dose study, the mean (SD) AUC(0-t) was 155.60 (40.94) μg/h/mL for the CR formulation and 161.11 (37.50) μg/h/mL for the IR formulation; the mean (SD) C(max) values were 22.71 (6.64) and 23.77 (4.91) μg/mL, respectively; and the median T(max) values were 2.01 hours and 2.00 hours, respectively.",Pharmacokinetic comparison of controlled- and immediate-release formulations of dexibuprofen after single and multiple oral doses in fasting healthy male Korean volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21864907/),[μg] / [ml],22.71,133136,DB01050,Ibuprofen
,21864907,C(max),"In the single-dose study, the mean (SD) AUC(0-t) was 155.60 (40.94) μg/h/mL for the CR formulation and 161.11 (37.50) μg/h/mL for the IR formulation; the mean (SD) C(max) values were 22.71 (6.64) and 23.77 (4.91) μg/mL, respectively; and the median T(max) values were 2.01 hours and 2.00 hours, respectively.",Pharmacokinetic comparison of controlled- and immediate-release formulations of dexibuprofen after single and multiple oral doses in fasting healthy male Korean volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21864907/),[μg] / [ml],23.77,133137,DB01050,Ibuprofen
,21864907,T(max),"In the single-dose study, the mean (SD) AUC(0-t) was 155.60 (40.94) μg/h/mL for the CR formulation and 161.11 (37.50) μg/h/mL for the IR formulation; the mean (SD) C(max) values were 22.71 (6.64) and 23.77 (4.91) μg/mL, respectively; and the median T(max) values were 2.01 hours and 2.00 hours, respectively.",Pharmacokinetic comparison of controlled- and immediate-release formulations of dexibuprofen after single and multiple oral doses in fasting healthy male Korean volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21864907/),h,2.01,133138,DB01050,Ibuprofen
,21864907,T(max),"In the single-dose study, the mean (SD) AUC(0-t) was 155.60 (40.94) μg/h/mL for the CR formulation and 161.11 (37.50) μg/h/mL for the IR formulation; the mean (SD) C(max) values were 22.71 (6.64) and 23.77 (4.91) μg/mL, respectively; and the median T(max) values were 2.01 hours and 2.00 hours, respectively.",Pharmacokinetic comparison of controlled- and immediate-release formulations of dexibuprofen after single and multiple oral doses in fasting healthy male Korean volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21864907/),h,2.00,133139,DB01050,Ibuprofen
,21864907,AUC(0-τ),"In the multiple-dose study, the mean (SD) AUC(0-τ) values for CR and IR were 129.70 (23.72) μg/h/mL and 150.04 (27.09) μg/h/mL, respectively; the mean (SD) C(max,ss) values were 24.51 (5.12) and 21.69 (5.21) μg/mL, respectively; and the median T(max.",Pharmacokinetic comparison of controlled- and immediate-release formulations of dexibuprofen after single and multiple oral doses in fasting healthy male Korean volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21864907/),[μg] / [h·ml],129.70,133140,DB01050,Ibuprofen
,21864907,AUC(0-τ),"In the multiple-dose study, the mean (SD) AUC(0-τ) values for CR and IR were 129.70 (23.72) μg/h/mL and 150.04 (27.09) μg/h/mL, respectively; the mean (SD) C(max,ss) values were 24.51 (5.12) and 21.69 (5.21) μg/mL, respectively; and the median T(max.",Pharmacokinetic comparison of controlled- and immediate-release formulations of dexibuprofen after single and multiple oral doses in fasting healthy male Korean volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21864907/),[μg] / [h·ml],150.04,133141,DB01050,Ibuprofen
,21864907,"C(max,ss)","In the multiple-dose study, the mean (SD) AUC(0-τ) values for CR and IR were 129.70 (23.72) μg/h/mL and 150.04 (27.09) μg/h/mL, respectively; the mean (SD) C(max,ss) values were 24.51 (5.12) and 21.69 (5.21) μg/mL, respectively; and the median T(max.",Pharmacokinetic comparison of controlled- and immediate-release formulations of dexibuprofen after single and multiple oral doses in fasting healthy male Korean volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21864907/),[μg] / [ml],24.51,133142,DB01050,Ibuprofen
,21864907,"C(max,ss)","In the multiple-dose study, the mean (SD) AUC(0-τ) values for CR and IR were 129.70 (23.72) μg/h/mL and 150.04 (27.09) μg/h/mL, respectively; the mean (SD) C(max,ss) values were 24.51 (5.12) and 21.69 (5.21) μg/mL, respectively; and the median T(max.",Pharmacokinetic comparison of controlled- and immediate-release formulations of dexibuprofen after single and multiple oral doses in fasting healthy male Korean volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21864907/),[μg] / [ml],21.69,133143,DB01050,Ibuprofen
,21864907,ss),"ss) values were 2.51 hours and 5.25 hours, respectively.",Pharmacokinetic comparison of controlled- and immediate-release formulations of dexibuprofen after single and multiple oral doses in fasting healthy male Korean volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21864907/),h,2.51,133144,DB01050,Ibuprofen
,21864907,ss),"ss) values were 2.51 hours and 5.25 hours, respectively.",Pharmacokinetic comparison of controlled- and immediate-release formulations of dexibuprofen after single and multiple oral doses in fasting healthy male Korean volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21864907/),h,5.25,133145,DB01050,Ibuprofen
,15785936,clearance,"Mean amikacin clearance was lower (0.48 to 0.59 ml/kg/min, P <0.001) in infants co-treated with ibuprofen.",The impact of ibuprofen on renal clearance in preterm infants is independent of the gestational age. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15785936/),[ml] / [kg·min],0.48 to 0.59,135151,DB01050,Ibuprofen
,15785936,clearance,Absolute decrease in mean amikacin clearance (0.10 to 0.14 ml/kg/min) was similar in all four cohorts.,The impact of ibuprofen on renal clearance in preterm infants is independent of the gestational age. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15785936/),[ml] / [kg·min],0.10 to 0.14,135152,DB01050,Ibuprofen
,1807089,Minimal detectable concentration,Minimal detectable concentration of serum piroxicam by using HPLC reported in literature was mostly around 50 ng.,[A HPLC method for determining piroxicam in body fluids]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1807089/),ng,50,135527,DB01050,Ibuprofen
,1807089,detection limit,"A new HPLC method providing a detection limit of 0.75 ng, sensitive enough to quantify low concentrations of serum piroxicam down to 5 ng.",[A HPLC method for determining piroxicam in body fluids]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1807089/),ng,0.75,135528,DB01050,Ibuprofen
,1807089,flow rate,A mixture of methanol and ammonium acetate 0.1 mol.L-1 (1:0.9 vol.vol-1) was selected as mobile phase with a flow rate of 1 ml.min-1. 0.025% tetramethyl ethylene diamine was added to ammonium acetate solution and adjusted to pH 4.5 with citric acid before mixing.,[A HPLC method for determining piroxicam in body fluids]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1807089/),[ml] / [min],1,135529,DB01050,Ibuprofen
,1807089,recoveries,"The within-day and day-to-day precisions (CV) of this method were 2.88% and 2.89% respectively, with average recoveries of 96.0-102.4% (10-5,000 ng.ml-1).",[A HPLC method for determining piroxicam in body fluids]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1807089/),%,96.0-102.4,135530,DB01050,Ibuprofen
,1807089,recoveries,"The within-day and day-to-day precisions (CV) of this method were 2.88% and 2.89% respectively, with average recoveries of 96.0-102.4% (10-5,000 ng.ml-1).",[A HPLC method for determining piroxicam in body fluids]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1807089/),[ng] / [ml],"10-5,000",135531,DB01050,Ibuprofen
,25864706,detected plasma concentration,"Furthermore, detected plasma concentration of boeravinone B was two times higher in RRF-PC (75 ng/mL) as compared with RRF (40 ng/mL).",Anti-inflammatory potential of a lipid-based formulation of a rotenoid-rich fraction prepared from Boerhavia diffusa. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25864706/),[ng] / [ml],75,136662,DB01050,Ibuprofen
,25864706,detected plasma concentration,"Furthermore, detected plasma concentration of boeravinone B was two times higher in RRF-PC (75 ng/mL) as compared with RRF (40 ng/mL).",Anti-inflammatory potential of a lipid-based formulation of a rotenoid-rich fraction prepared from Boerhavia diffusa. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25864706/),[ng] / [ml],40,136663,DB01050,Ibuprofen
,29323795,maximum steady-state drug concentration,"The maximum steady-state drug concentration and area under the concentration curve from time 0 on day 5 (t = 0) to the 24-hours sample on day 6 were 514 ng/mL (95% CI 439 to 603 ng/mL) and 9.78 kg·h/mL (95% CI 8.43 to 11.4 kg·h/mL), respectively.",A Pharmacokinetic Study of an Ibuprofen Topical Patch in Healthy Male and Female Adult Volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29323795/),[ng] / [ml],514,137631,DB01050,Ibuprofen
,29323795,area under the concentration curve from time 0,"The maximum steady-state drug concentration and area under the concentration curve from time 0 on day 5 (t = 0) to the 24-hours sample on day 6 were 514 ng/mL (95% CI 439 to 603 ng/mL) and 9.78 kg·h/mL (95% CI 8.43 to 11.4 kg·h/mL), respectively.",A Pharmacokinetic Study of an Ibuprofen Topical Patch in Healthy Male and Female Adult Volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29323795/),[h·kg] / [ml],9.78,137632,DB01050,Ibuprofen
,18840026,apparent volume of distribution,"Etoricoxib is extensively protein bound, primarily to plasma albumin, and has an apparent volume of distribution of 120 L in humans.",Clinical pharmacokinetic and pharmacodynamic profile of etoricoxib. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18840026/),l,120,139735,DB01050,Ibuprofen
,18840026,elimination half-life,The elimination half-life of approximately 20 hours in healthy subjects enables once-daily dosing.,Clinical pharmacokinetic and pharmacodynamic profile of etoricoxib. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/18840026/),h,20,139736,DB01050,Ibuprofen
up to,12207314,recoveries,The mean recoveries for ibuprofen enantiomers were up to 85%.,Enantioselective analysis of ibuprofen in human plasma by anionic cyclodextrin-modified electrokinetic chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12207314/),%,85,140179,DB01050,Ibuprofen
,12207314,maximum plasma level,"The analysis of real plasma samples obtained from a healthy volunteer after administration of 600 mg of racemic ibuprofen showed a maximum plasma level of 29.6 and 39.9 microg mL(-1) of (-)-(R)- and (+)-(S)-ibuprofen, respectively, and the area under plasma concentration-time curve AUC(0-infinity) (+)-(S)/AUC(0-infinity) (-)-(R) ratio was 1.87.",Enantioselective analysis of ibuprofen in human plasma by anionic cyclodextrin-modified electrokinetic chromatography. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12207314/),[μg] / [ml],29.6,140180,DB01050,Ibuprofen
,12207314,maximum plasma level,"The analysis of real plasma samples obtained from a healthy volunteer after administration of 600 mg of racemic ibuprofen showed a maximum plasma level of 29.6 and 39.9 microg mL(-1) of (-)-(R)- and (+)-(S)-ibuprofen, respectively, and the area under plasma concentration-time curve AUC(0-infinity) (+)-(S)/AUC(0-infinity) (-)-(R) ratio was 1.87.",Enantioselective analysis of ibuprofen in human plasma by anionic cyclodextrin-modified electrokinetic chromatography. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12207314/),[μg] / [ml],39.9,140181,DB01050,Ibuprofen
,12207314,area under plasma concentration-time curve AUC(0-infinity),"The analysis of real plasma samples obtained from a healthy volunteer after administration of 600 mg of racemic ibuprofen showed a maximum plasma level of 29.6 and 39.9 microg mL(-1) of (-)-(R)- and (+)-(S)-ibuprofen, respectively, and the area under plasma concentration-time curve AUC(0-infinity) (+)-(S)/AUC(0-infinity) (-)-(R) ratio was 1.87.",Enantioselective analysis of ibuprofen in human plasma by anionic cyclodextrin-modified electrokinetic chromatography. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12207314/),,1.87,140182,DB01050,Ibuprofen
,27381612,area under the concentration-time curve (AUC0~24),"The area under the concentration-time curve (AUC0~24) of IBU-PC and Motrin were 366±115 and 391±105 μg/h/ml, respectively.",Evaluation of a Non-aqueous Ibuprofen-Phospholipid Complex Formulation in Rats. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27381612/),[μg] / [h·ml],366,140359,DB01050,Ibuprofen
,27381612,area under the concentration-time curve (AUC0~24),"The area under the concentration-time curve (AUC0~24) of IBU-PC and Motrin were 366±115 and 391±105 μg/h/ml, respectively.",Evaluation of a Non-aqueous Ibuprofen-Phospholipid Complex Formulation in Rats. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27381612/),[μg] / [h·ml],391,140360,DB01050,Ibuprofen
,27381612,relative bioavailability,The relative bioavailability of IBU-PC was 94.2%.,Evaluation of a Non-aqueous Ibuprofen-Phospholipid Complex Formulation in Rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27381612/),%,94.2,140361,DB01050,Ibuprofen
<,10701434,run times,"The method has a lower limit of quantification (LLOQ) adequate for sensitive pharmacokinetic studies ( < or = 0.05 microg/ml), has run times of < or = 15 min, and uses aliquot volumes adequate for pediatric studies (0.25 ml).","A rapid, sensitive HPLC method for the determination of ganciclovir in human plasma and serum. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10701434/),min,15,140499,DB01050,Ibuprofen
,10701434,lambda(ex),Detection and quantification of ganciclovir is by fluorescence (lambda(ex) = 278 nm; lambda(em) = 380 nm).,"A rapid, sensitive HPLC method for the determination of ganciclovir in human plasma and serum. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10701434/),,278,140500,DB01050,Ibuprofen
,10701434,lambda(em),Detection and quantification of ganciclovir is by fluorescence (lambda(ex) = 278 nm; lambda(em) = 380 nm).,"A rapid, sensitive HPLC method for the determination of ganciclovir in human plasma and serum. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10701434/),,380,140501,DB01050,Ibuprofen
<,10701434,% C.V.,All intra- and inter-assay % C.V. values were < 8%; all recoveries (accuracy) were within 7% of nominal values.,"A rapid, sensitive HPLC method for the determination of ganciclovir in human plasma and serum. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10701434/),%,8,140502,DB01050,Ibuprofen
,1447669,elimination rate constant from the effect compartment,"The mean elimination rate constant from the effect compartment was 0.6 hour-1, corresponding to a half-life of drug in the effect compartment of 1.1 hours.",Effect of age on ibuprofen pharmacokinetics and antipyretic response. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1447669/),1/[h],0.6,144348,DB01050,Ibuprofen
,1447669,half-life of drug in the effect compartment,"The mean elimination rate constant from the effect compartment was 0.6 hour-1, corresponding to a half-life of drug in the effect compartment of 1.1 hours.",Effect of age on ibuprofen pharmacokinetics and antipyretic response. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1447669/),h,1.1,144349,DB01050,Ibuprofen
,15193725,R,"The calculated electrophoretic parameters of the analytes were as follows: electrophoretic mobility, micorep(-)-R = -0.75 x 10(-4) to -0.30 x 10(-4) cm2/Vs; micorep(+)-S = -0.83 -(-0.38) cm2/Vs and electroosmotic mobility, microEOF = 2.35 x 10(-4) cm2/Vs, migration times, tmigr R = 12.55 - 16.07 min; tmigr s = 13.08 - 16.9 min, resolution factors, RS = 1.88 - 3.70 and chiral selectivity, alpha = 1.16 - 1.34.",High performance capillary electrophoresis for determination of the enantiomers of 2-arylpropionic acid derivatives in human serum. Pharmacokinetic studies of ketoprofen enantiomers following administration of standard and sustained release tablets. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15193725/),min,12.55 - 16.07,145171,DB01050,Ibuprofen
,15193725,tmigr s,"The calculated electrophoretic parameters of the analytes were as follows: electrophoretic mobility, micorep(-)-R = -0.75 x 10(-4) to -0.30 x 10(-4) cm2/Vs; micorep(+)-S = -0.83 -(-0.38) cm2/Vs and electroosmotic mobility, microEOF = 2.35 x 10(-4) cm2/Vs, migration times, tmigr R = 12.55 - 16.07 min; tmigr s = 13.08 - 16.9 min, resolution factors, RS = 1.88 - 3.70 and chiral selectivity, alpha = 1.16 - 1.34.",High performance capillary electrophoresis for determination of the enantiomers of 2-arylpropionic acid derivatives in human serum. Pharmacokinetic studies of ketoprofen enantiomers following administration of standard and sustained release tablets. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15193725/),min,13.08 - 16.9,145172,DB01050,Ibuprofen
,15193725,Recovery,Recovery of the enantiomers from serum was about 90%.,High performance capillary electrophoresis for determination of the enantiomers of 2-arylpropionic acid derivatives in human serum. Pharmacokinetic studies of ketoprofen enantiomers following administration of standard and sustained release tablets. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15193725/),%,90,145173,DB01050,Ibuprofen
,8054251,oral clearance (CLo),"In the non-NSAID control portion of the study, MTX oral clearance (CLo) was 11.0 +/- 3.9 l h-1, renal clearance (CLR) was 7.9 +/- 2.8 l h-1, percent excreted unchanged was 72 +2- 19% and fraction unbound (fu) was 0.54 +/- 0.11.","Methotrexate disposition following concomitant administration of ketoprofen, piroxicam and flurbiprofen in patients with rheumatoid arthritis. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8054251/),[l] / [h],11.0,145184,DB01050,Ibuprofen
,8054251,renal clearance (CLR),"In the non-NSAID control portion of the study, MTX oral clearance (CLo) was 11.0 +/- 3.9 l h-1, renal clearance (CLR) was 7.9 +/- 2.8 l h-1, percent excreted unchanged was 72 +2- 19% and fraction unbound (fu) was 0.54 +/- 0.11.","Methotrexate disposition following concomitant administration of ketoprofen, piroxicam and flurbiprofen in patients with rheumatoid arthritis. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8054251/),[l] / [h],7.9,145185,DB01050,Ibuprofen
,8054251,percent excreted unchanged,"In the non-NSAID control portion of the study, MTX oral clearance (CLo) was 11.0 +/- 3.9 l h-1, renal clearance (CLR) was 7.9 +/- 2.8 l h-1, percent excreted unchanged was 72 +2- 19% and fraction unbound (fu) was 0.54 +/- 0.11.","Methotrexate disposition following concomitant administration of ketoprofen, piroxicam and flurbiprofen in patients with rheumatoid arthritis. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8054251/),%,72,145186,DB01050,Ibuprofen
,8054251,fraction unbound (fu),"In the non-NSAID control portion of the study, MTX oral clearance (CLo) was 11.0 +/- 3.9 l h-1, renal clearance (CLR) was 7.9 +/- 2.8 l h-1, percent excreted unchanged was 72 +2- 19% and fraction unbound (fu) was 0.54 +/- 0.11.","Methotrexate disposition following concomitant administration of ketoprofen, piroxicam and flurbiprofen in patients with rheumatoid arthritis. ",fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8054251/),,0.54,145187,DB01050,Ibuprofen
,2882970,systemic plasma clearance (CLtot),The systemic plasma clearance (CLtot) of ibuprofen was dose-dependent and decreased from 0.29 to 0.14 liter/hr/kg primarily as a result of a 65% decrease in the partial metabolic clearance to OH-ibuprofen while the average mean residence time (MRTtot) increased approximately 35% over the 10-50 mg/kg dosage range.,Dose-dependent pharmacokinetics of ibuprofen in the rat. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2882970/),[l] / [h·kg],0.29,145725,DB01050,Ibuprofen
,2882970,systemic plasma clearance (CLtot),The systemic plasma clearance (CLtot) of ibuprofen was dose-dependent and decreased from 0.29 to 0.14 liter/hr/kg primarily as a result of a 65% decrease in the partial metabolic clearance to OH-ibuprofen while the average mean residence time (MRTtot) increased approximately 35% over the 10-50 mg/kg dosage range.,Dose-dependent pharmacokinetics of ibuprofen in the rat. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2882970/),[l] / [h·kg],0.14,145726,DB01050,Ibuprofen
,2882970,half-life,"Since there were no dose-dependent changes in the apparent steady state volume of distribution (Vss,tot), the mean harmonic half-life increased from 1.7-2.8 hr over the dosage range studied.",Dose-dependent pharmacokinetics of ibuprofen in the rat. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2882970/),h,1.7-2.8,145727,DB01050,Ibuprofen
,2882970,free fraction,"The binding of ibuprofen to plasma proteins was relatively independent of concentration up to 90 mg/liter (mean free fraction approximately 5.5%), but became markedly concentration-dependent thereafter (free fraction up to 25.4% at 411 mg/liter).",Dose-dependent pharmacokinetics of ibuprofen in the rat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2882970/),%,5.5,145728,DB01050,Ibuprofen
up to,2882970,free fraction,"The binding of ibuprofen to plasma proteins was relatively independent of concentration up to 90 mg/liter (mean free fraction approximately 5.5%), but became markedly concentration-dependent thereafter (free fraction up to 25.4% at 411 mg/liter).",Dose-dependent pharmacokinetics of ibuprofen in the rat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2882970/),%,25.4,145729,DB01050,Ibuprofen
,24847268,Cmax,"For the test formulation, the ibuprofen gMean Cmax was 17.0 μg/mL (vs. 18.1 μg/mL for reference-A), AUC0-t was 57.1 (vs. 60.0 μg·h/mL), and AUC0-∞ was 59.9 μg·h/mL (vs. 63.1 μg·h/mL).","Pharmacokinetics and bioavailability of single dose ibuprofen and pseudoephedrine alone or in combination: a randomized three-period, cross-over trial in healthy Indian volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24847268/),[μg] / [ml],17.0,146298,DB01050,Ibuprofen
,24847268,Cmax,"For the test formulation, the ibuprofen gMean Cmax was 17.0 μg/mL (vs. 18.1 μg/mL for reference-A), AUC0-t was 57.1 (vs. 60.0 μg·h/mL), and AUC0-∞ was 59.9 μg·h/mL (vs. 63.1 μg·h/mL).","Pharmacokinetics and bioavailability of single dose ibuprofen and pseudoephedrine alone or in combination: a randomized three-period, cross-over trial in healthy Indian volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24847268/),[μg] / [ml],18.1,146299,DB01050,Ibuprofen
,24847268,AUC0-t,"For the test formulation, the ibuprofen gMean Cmax was 17.0 μg/mL (vs. 18.1 μg/mL for reference-A), AUC0-t was 57.1 (vs. 60.0 μg·h/mL), and AUC0-∞ was 59.9 μg·h/mL (vs. 63.1 μg·h/mL).","Pharmacokinetics and bioavailability of single dose ibuprofen and pseudoephedrine alone or in combination: a randomized three-period, cross-over trial in healthy Indian volunteers. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24847268/),[h·μg] / [ml],57.1,146300,DB01050,Ibuprofen
,24847268,AUC0-t,"For the test formulation, the ibuprofen gMean Cmax was 17.0 μg/mL (vs. 18.1 μg/mL for reference-A), AUC0-t was 57.1 (vs. 60.0 μg·h/mL), and AUC0-∞ was 59.9 μg·h/mL (vs. 63.1 μg·h/mL).","Pharmacokinetics and bioavailability of single dose ibuprofen and pseudoephedrine alone or in combination: a randomized three-period, cross-over trial in healthy Indian volunteers. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24847268/),[h·μg] / [ml],60.0,146301,DB01050,Ibuprofen
,24847268,AUC0-∞,"For the test formulation, the ibuprofen gMean Cmax was 17.0 μg/mL (vs. 18.1 μg/mL for reference-A), AUC0-t was 57.1 (vs. 60.0 μg·h/mL), and AUC0-∞ was 59.9 μg·h/mL (vs. 63.1 μg·h/mL).","Pharmacokinetics and bioavailability of single dose ibuprofen and pseudoephedrine alone or in combination: a randomized three-period, cross-over trial in healthy Indian volunteers. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24847268/),[h·μg] / [ml],59.9,146302,DB01050,Ibuprofen
,24847268,AUC0-∞,"For the test formulation, the ibuprofen gMean Cmax was 17.0 μg/mL (vs. 18.1 μg/mL for reference-A), AUC0-t was 57.1 (vs. 60.0 μg·h/mL), and AUC0-∞ was 59.9 μg·h/mL (vs. 63.1 μg·h/mL).","Pharmacokinetics and bioavailability of single dose ibuprofen and pseudoephedrine alone or in combination: a randomized three-period, cross-over trial in healthy Indian volunteers. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24847268/),[h·μg] / [ml],63.1,146303,DB01050,Ibuprofen
,24847268,Cmax,"For pseudoephedrine, the gMean Cmax for the test formulation was 97.2 ng/mL (vs. 98.5 ng/mL for reference-B), AUC0-t was 878.4 (vs. 842.8 ng·h/mL) and AUC0-∞ was 907.8 ng·h/mL (vs. 868.3 ng·h/mL).","Pharmacokinetics and bioavailability of single dose ibuprofen and pseudoephedrine alone or in combination: a randomized three-period, cross-over trial in healthy Indian volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24847268/),[ng] / [ml],97.2,146304,DB01050,Ibuprofen
,24847268,Cmax,"For pseudoephedrine, the gMean Cmax for the test formulation was 97.2 ng/mL (vs. 98.5 ng/mL for reference-B), AUC0-t was 878.4 (vs. 842.8 ng·h/mL) and AUC0-∞ was 907.8 ng·h/mL (vs. 868.3 ng·h/mL).","Pharmacokinetics and bioavailability of single dose ibuprofen and pseudoephedrine alone or in combination: a randomized three-period, cross-over trial in healthy Indian volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24847268/),[ng] / [ml],98.5,146305,DB01050,Ibuprofen
,24847268,AUC0-t,"For pseudoephedrine, the gMean Cmax for the test formulation was 97.2 ng/mL (vs. 98.5 ng/mL for reference-B), AUC0-t was 878.4 (vs. 842.8 ng·h/mL) and AUC0-∞ was 907.8 ng·h/mL (vs. 868.3 ng·h/mL).","Pharmacokinetics and bioavailability of single dose ibuprofen and pseudoephedrine alone or in combination: a randomized three-period, cross-over trial in healthy Indian volunteers. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24847268/),[h·ng] / [ml],878.4,146306,DB01050,Ibuprofen
,24847268,AUC0-t,"For pseudoephedrine, the gMean Cmax for the test formulation was 97.2 ng/mL (vs. 98.5 ng/mL for reference-B), AUC0-t was 878.4 (vs. 842.8 ng·h/mL) and AUC0-∞ was 907.8 ng·h/mL (vs. 868.3 ng·h/mL).","Pharmacokinetics and bioavailability of single dose ibuprofen and pseudoephedrine alone or in combination: a randomized three-period, cross-over trial in healthy Indian volunteers. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24847268/),[h·ng] / [ml],842.8,146307,DB01050,Ibuprofen
,24847268,AUC0-∞,"For pseudoephedrine, the gMean Cmax for the test formulation was 97.2 ng/mL (vs. 98.5 ng/mL for reference-B), AUC0-t was 878.4 (vs. 842.8 ng·h/mL) and AUC0-∞ was 907.8 ng·h/mL (vs. 868.3 ng·h/mL).","Pharmacokinetics and bioavailability of single dose ibuprofen and pseudoephedrine alone or in combination: a randomized three-period, cross-over trial in healthy Indian volunteers. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24847268/),[h·ng] / [ml],907.8,146308,DB01050,Ibuprofen
,24847268,AUC0-∞,"For pseudoephedrine, the gMean Cmax for the test formulation was 97.2 ng/mL (vs. 98.5 ng/mL for reference-B), AUC0-t was 878.4 (vs. 842.8 ng·h/mL) and AUC0-∞ was 907.8 ng·h/mL (vs. 868.3 ng·h/mL).","Pharmacokinetics and bioavailability of single dose ibuprofen and pseudoephedrine alone or in combination: a randomized three-period, cross-over trial in healthy Indian volunteers. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24847268/),[h·ng] / [ml],868.3,146309,DB01050,Ibuprofen
,8922555,time to maximum plasma concentration (tmax),"Dexketoprofen trometamol, given as a tablet, is rapidly absorbed, with a time to maximum plasma concentration (tmax) of between 0.25 and 0.75 hours, whereas the tmax for the S-enantiomer after the racemic drug, administered as tablets or capsules prepared with the free acid, is between 0.5 and 3 hours.",Preclinical and clinical development of dexketoprofen. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8922555/),h,0.25 and 0.75,147498,DB01050,Ibuprofen
,8922555,tmax,"Dexketoprofen trometamol, given as a tablet, is rapidly absorbed, with a time to maximum plasma concentration (tmax) of between 0.25 and 0.75 hours, whereas the tmax for the S-enantiomer after the racemic drug, administered as tablets or capsules prepared with the free acid, is between 0.5 and 3 hours.",Preclinical and clinical development of dexketoprofen. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8922555/),h,0.5 and 3,147499,DB01050,Ibuprofen
,8922555,Peak plasma concentrations,"Peak plasma concentrations of 1.4 and 3.1 mg/L are reached after administration of dexketoprofen trometamol 12.5 and 25 mg, respectively.",Preclinical and clinical development of dexketoprofen. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8922555/),[mg] / [l],1.4,147500,DB01050,Ibuprofen
,8922555,Peak plasma concentrations,"Peak plasma concentrations of 1.4 and 3.1 mg/L are reached after administration of dexketoprofen trometamol 12.5 and 25 mg, respectively.",Preclinical and clinical development of dexketoprofen. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8922555/),[mg] / [l],3.1,147501,DB01050,Ibuprofen
,20195587,t(max),"The samples from a bioequivalence study of two ibuprofen 2% oral suspensions that had shown bioequivalence for AUC and C(max), but not for t(max) (medians of 2.0 and 0.75 h) with a non-chiral method were assayed with a chiral method to investigate whether there was an actual difference in the rate of absorption within the limits of C(max) and AUC bioequivalence.",Rationale and conditions for the requirement of chiral bioanalytical methods in bioequivalence studies. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20195587/),h,2.0,150052,DB01050,Ibuprofen
,20195587,t(max),"The samples from a bioequivalence study of two ibuprofen 2% oral suspensions that had shown bioequivalence for AUC and C(max), but not for t(max) (medians of 2.0 and 0.75 h) with a non-chiral method were assayed with a chiral method to investigate whether there was an actual difference in the rate of absorption within the limits of C(max) and AUC bioequivalence.",Rationale and conditions for the requirement of chiral bioanalytical methods in bioequivalence studies. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20195587/),h,0.75,150053,DB01050,Ibuprofen
,32110819,Cmax,Mean Cmax values showed a significant (p value 0.035) decrease from 44.14±2.3 to 33.1±0.8 μg/mL.,Effect of an Al/Mg Hydroxide Antacid and Food on the Pharmacokinetics of Dexibuprofen. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32110819/),[μg] / [ml],44.14,150635,DB01050,Ibuprofen
,32110819,Cmax,Mean Cmax values showed a significant (p value 0.035) decrease from 44.14±2.3 to 33.1±0.8 μg/mL.,Effect of an Al/Mg Hydroxide Antacid and Food on the Pharmacokinetics of Dexibuprofen. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32110819/),[μg] / [ml],33.1,150636,DB01050,Ibuprofen
,32110819,AUC,AUC increased from 195.7±8.9 μg.hr/mL to 222.8±14.7 μg.hr/mL.,Effect of an Al/Mg Hydroxide Antacid and Food on the Pharmacokinetics of Dexibuprofen. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32110819/),[h·μg] / [ml],195.7,150637,DB01050,Ibuprofen
,32110819,AUC,AUC increased from 195.7±8.9 μg.hr/mL to 222.8±14.7 μg.hr/mL.,Effect of an Al/Mg Hydroxide Antacid and Food on the Pharmacokinetics of Dexibuprofen. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32110819/),[h·μg] / [ml],222.8,150638,DB01050,Ibuprofen
,32110819,t1/2,t1/2 increased significantly from 4.505±0.19 hrs to 6.216±0.36 hrs whereas Ke reduced from 0.159±0.00 to 0.116±0.006 hrs-1.,Effect of an Al/Mg Hydroxide Antacid and Food on the Pharmacokinetics of Dexibuprofen. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32110819/),h,4.505,150639,DB01050,Ibuprofen
,32110819,t1/2,t1/2 increased significantly from 4.505±0.19 hrs to 6.216±0.36 hrs whereas Ke reduced from 0.159±0.00 to 0.116±0.006 hrs-1.,Effect of an Al/Mg Hydroxide Antacid and Food on the Pharmacokinetics of Dexibuprofen. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32110819/),h,6.216,150640,DB01050,Ibuprofen
,32110819,Ke,t1/2 increased significantly from 4.505±0.19 hrs to 6.216±0.36 hrs whereas Ke reduced from 0.159±0.00 to 0.116±0.006 hrs-1.,Effect of an Al/Mg Hydroxide Antacid and Food on the Pharmacokinetics of Dexibuprofen. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32110819/),1/[h],0.159,150641,DB01050,Ibuprofen
,32110819,Ke,t1/2 increased significantly from 4.505±0.19 hrs to 6.216±0.36 hrs whereas Ke reduced from 0.159±0.00 to 0.116±0.006 hrs-1.,Effect of an Al/Mg Hydroxide Antacid and Food on the Pharmacokinetics of Dexibuprofen. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32110819/),1/[h],0.116,150642,DB01050,Ibuprofen
,32110819,Cmax,Cmax increased from 44.877±2.263 to 51.721±0.096 μg/mL.,Effect of an Al/Mg Hydroxide Antacid and Food on the Pharmacokinetics of Dexibuprofen. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32110819/),[μg] / [ml],44.877,150643,DB01050,Ibuprofen
,32110819,Cmax,Cmax increased from 44.877±2.263 to 51.721±0.096 μg/mL.,Effect of an Al/Mg Hydroxide Antacid and Food on the Pharmacokinetics of Dexibuprofen. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32110819/),[μg] / [ml],51.721,150644,DB01050,Ibuprofen
,25244773,elution,"Using Aglient C18 column (2.1 mm x 50 mm,1.7 microm) was chromatographed, using methanol-5 mmol x L(-1) ammonium formate mobile phase gradient, elution 0.3 mL x min(-1).",[Simultaneous determination of 9 major components of dachengqi tang in rat plasma by UPLC-MS/MS]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25244773/),[ml] / [min],0.3,151232,DB01050,Ibuprofen
,12814452,unbound clearance,"In contrast, the free fraction of S-ibuprofen was significantly greater [33%; young 0.48 +/- 0.10%; elderly 0.64 +/- 0.20%] mean difference -0.16; 95% confidence interval (CI) -0.05, -0.27; P < 0.01; and the unbound clearance of the drug enantiomer was significantly lower (28%; young 15.9 +/- 2.2 l min-1; elderly 11.5 +/- 4.1 l min-1; mean difference 4.4; 95% CI 2.12, 6.68; P < 0.001) in the elderly.",Influence of age on the enantiomeric disposition of ibuprofen in healthy volunteers. ,CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12814452/),[l] / [min],15.9,153255,DB01050,Ibuprofen
,12814452,unbound clearance,"In contrast, the free fraction of S-ibuprofen was significantly greater [33%; young 0.48 +/- 0.10%; elderly 0.64 +/- 0.20%] mean difference -0.16; 95% confidence interval (CI) -0.05, -0.27; P < 0.01; and the unbound clearance of the drug enantiomer was significantly lower (28%; young 15.9 +/- 2.2 l min-1; elderly 11.5 +/- 4.1 l min-1; mean difference 4.4; 95% CI 2.12, 6.68; P < 0.001) in the elderly.",Influence of age on the enantiomeric disposition of ibuprofen in healthy volunteers. ,CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12814452/),[l] / [min],11.5,153256,DB01050,Ibuprofen
,15025856,total body clearance,"The total body clearance values calculated by compartmental model analysis (0.65 +/- 0.21 for R-(-)-ibuprofen and 0.63 +/- 0.34 for S-(+)-ibuprofen) after intravenous administration of the racemate of ibuprofen were significantly smaller than those of individual enantiomers (0.95 +/- 0.23 for R-(-)-ibuprofen and 1.03 +/- 0.23 for S-(+)-ibuprofen), indicating that the enantiomer-enantiomer interaction results in a mutual inhibition.",Pharmacokinetic interaction of ibuprofen enantiomers in rabbits. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15025856/),,0.65,153306,DB01050,Ibuprofen
,15025856,total body clearance,"The total body clearance values calculated by compartmental model analysis (0.65 +/- 0.21 for R-(-)-ibuprofen and 0.63 +/- 0.34 for S-(+)-ibuprofen) after intravenous administration of the racemate of ibuprofen were significantly smaller than those of individual enantiomers (0.95 +/- 0.23 for R-(-)-ibuprofen and 1.03 +/- 0.23 for S-(+)-ibuprofen), indicating that the enantiomer-enantiomer interaction results in a mutual inhibition.",Pharmacokinetic interaction of ibuprofen enantiomers in rabbits. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15025856/),,0.63,153307,DB01050,Ibuprofen
,15025856,total body clearance,"The total body clearance values calculated by compartmental model analysis (0.65 +/- 0.21 for R-(-)-ibuprofen and 0.63 +/- 0.34 for S-(+)-ibuprofen) after intravenous administration of the racemate of ibuprofen were significantly smaller than those of individual enantiomers (0.95 +/- 0.23 for R-(-)-ibuprofen and 1.03 +/- 0.23 for S-(+)-ibuprofen), indicating that the enantiomer-enantiomer interaction results in a mutual inhibition.",Pharmacokinetic interaction of ibuprofen enantiomers in rabbits. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15025856/),,0.95,153308,DB01050,Ibuprofen
,15025856,total body clearance,"The total body clearance values calculated by compartmental model analysis (0.65 +/- 0.21 for R-(-)-ibuprofen and 0.63 +/- 0.34 for S-(+)-ibuprofen) after intravenous administration of the racemate of ibuprofen were significantly smaller than those of individual enantiomers (0.95 +/- 0.23 for R-(-)-ibuprofen and 1.03 +/- 0.23 for S-(+)-ibuprofen), indicating that the enantiomer-enantiomer interaction results in a mutual inhibition.",Pharmacokinetic interaction of ibuprofen enantiomers in rabbits. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15025856/),,1.03,153309,DB01050,Ibuprofen
,12956898,inversion ratios,"R-(-) enantiomer to S-(+) enantiomer inversion ratios after intraduodenal administration of the powder form and the sustained-release form, and after intravenous injection were calculated to be 1.63, 1.94 and 1.19, respectively, indicating that pharmacological effects may depend on the absorption rate in rabbits.",Effects of absorption rate on the pre-systemic chiral inversion of ibuprofen in rabbits. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12956898/),,1.63,154263,DB01050,Ibuprofen
,12956898,inversion ratios,"R-(-) enantiomer to S-(+) enantiomer inversion ratios after intraduodenal administration of the powder form and the sustained-release form, and after intravenous injection were calculated to be 1.63, 1.94 and 1.19, respectively, indicating that pharmacological effects may depend on the absorption rate in rabbits.",Effects of absorption rate on the pre-systemic chiral inversion of ibuprofen in rabbits. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12956898/),,1.94,154264,DB01050,Ibuprofen
,12956898,inversion ratios,"R-(-) enantiomer to S-(+) enantiomer inversion ratios after intraduodenal administration of the powder form and the sustained-release form, and after intravenous injection were calculated to be 1.63, 1.94 and 1.19, respectively, indicating that pharmacological effects may depend on the absorption rate in rabbits.",Effects of absorption rate on the pre-systemic chiral inversion of ibuprofen in rabbits. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12956898/),,1.19,154265,DB01050,Ibuprofen
,8595072,Cmax,"For percutaneous application of 500 mg ibuprofen (10 g 5% gel on the back, area of 20 x 20 cm) with occlusion for 2 h, a Cmax of 7.1 +/- 4.4 micrograms/ml (95% confidence interval (CI): 5.0-9.1) was obtained at 2.4 +/- 0.8 h (95% CI: 2.0-2.8).",Pharmacokinetics and bioavailability of percutaneous ibuprofen. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8595072/),[μg] / [ml],7.1,155230,DB01050,Ibuprofen
,8595072,Cmax,"For oral administration of 400 mg, Cmax was 36.7 +/- 7.5 micrograms/ml (95% CI: 33.2-40.1) at 1.1 +/- 0.8 h (95% CI: 0.7-1.5).",Pharmacokinetics and bioavailability of percutaneous ibuprofen. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8595072/),[μg] / [ml],36.7,155231,DB01050,Ibuprofen
,8595072,relative bioavailability,The (dose-corrected) relative bioavailability of the topical ibuprofen was found to be 22 +/- 12% (95% CI: 14-30%) of that after oral administration.,Pharmacokinetics and bioavailability of percutaneous ibuprofen. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8595072/),%,22,155232,DB01050,Ibuprofen
,8595072,plasma elimination half-life,"The plasma elimination half-life was 2.5 +/- 1.4 h (95% CI: 1.9-3.2) for topical administration, and 1.8 +/- 0.5 h (95% CI: 1.6-2.1) after oral administration (not significant, p > 0.05).",Pharmacokinetics and bioavailability of percutaneous ibuprofen. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8595072/),h,2.5,155233,DB01050,Ibuprofen
,8595072,plasma elimination half-life,"The plasma elimination half-life was 2.5 +/- 1.4 h (95% CI: 1.9-3.2) for topical administration, and 1.8 +/- 0.5 h (95% CI: 1.6-2.1) after oral administration (not significant, p > 0.05).",Pharmacokinetics and bioavailability of percutaneous ibuprofen. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8595072/),h,1.8,155234,DB01050,Ibuprofen
,17679510,peak serum concentrations,"Six-milligram/kilogram dosages resulted in peak serum concentrations of 5.91 +/- 2.17 microg/ml R(-) and 14.82 +/- 9.71 microg/ml S(+) in African elephants, and 5.72 +/- 1.60 microg/ml R(-) and 18.32 +/- 10.35 microg/ml S(+) in Asian elephants.",Pharmacokinetics of orally administered ibuprofen in African and Asian elephants (Loxodonta africana and Elephas maximus). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17679510/),[μg] / [ml],5.91,155530,DB01050,Ibuprofen
,17679510,peak serum concentrations,"Six-milligram/kilogram dosages resulted in peak serum concentrations of 5.91 +/- 2.17 microg/ml R(-) and 14.82 +/- 9.71 microg/ml S(+) in African elephants, and 5.72 +/- 1.60 microg/ml R(-) and 18.32 +/- 10.35 microg/ml S(+) in Asian elephants.",Pharmacokinetics of orally administered ibuprofen in African and Asian elephants (Loxodonta africana and Elephas maximus). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17679510/),[μg] / [ml],14.82,155531,DB01050,Ibuprofen
,17679510,peak serum concentrations,"Six-milligram/kilogram dosages resulted in peak serum concentrations of 5.91 +/- 2.17 microg/ml R(-) and 14.82 +/- 9.71 microg/ml S(+) in African elephants, and 5.72 +/- 1.60 microg/ml R(-) and 18.32 +/- 10.35 microg/ml S(+) in Asian elephants.",Pharmacokinetics of orally administered ibuprofen in African and Asian elephants (Loxodonta africana and Elephas maximus). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17679510/),[μg] / [ml],5.72,155532,DB01050,Ibuprofen
,17679510,peak serum concentrations,"Six-milligram/kilogram dosages resulted in peak serum concentrations of 5.91 +/- 2.17 microg/ml R(-) and 14.82 +/- 9.71 microg/ml S(+) in African elephants, and 5.72 +/- 1.60 microg/ml R(-) and 18.32 +/- 10.35 microg/ml S(+) in Asian elephants.",Pharmacokinetics of orally administered ibuprofen in African and Asian elephants (Loxodonta africana and Elephas maximus). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17679510/),[μg] / [ml],18.32,155533,DB01050,Ibuprofen
,17679510,half-life,Ibuprofen was eliminated with first-order kinetics characteristic of a single-compartment model with a half-life of 2.2-2.4 hr R(-) and 4.5-5.1 hr S(+) in African elephants and 2.4-2.9 hr R(-) and 5.9-7.7 hr S(+) in Asian elephants.,Pharmacokinetics of orally administered ibuprofen in African and Asian elephants (Loxodonta africana and Elephas maximus). ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17679510/),h,2.2-2.4,155534,DB01050,Ibuprofen
,17679510,half-life,Ibuprofen was eliminated with first-order kinetics characteristic of a single-compartment model with a half-life of 2.2-2.4 hr R(-) and 4.5-5.1 hr S(+) in African elephants and 2.4-2.9 hr R(-) and 5.9-7.7 hr S(+) in Asian elephants.,Pharmacokinetics of orally administered ibuprofen in African and Asian elephants (Loxodonta africana and Elephas maximus). ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17679510/),h,4.5-5.1,155535,DB01050,Ibuprofen
,17679510,half-life,Ibuprofen was eliminated with first-order kinetics characteristic of a single-compartment model with a half-life of 2.2-2.4 hr R(-) and 4.5-5.1 hr S(+) in African elephants and 2.4-2.9 hr R(-) and 5.9-7.7 hr S(+) in Asian elephants.,Pharmacokinetics of orally administered ibuprofen in African and Asian elephants (Loxodonta africana and Elephas maximus). ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17679510/),h,2.4-2.9,155536,DB01050,Ibuprofen
,17679510,half-life,Ibuprofen was eliminated with first-order kinetics characteristic of a single-compartment model with a half-life of 2.2-2.4 hr R(-) and 4.5-5.1 hr S(+) in African elephants and 2.4-2.9 hr R(-) and 5.9-7.7 hr S(+) in Asian elephants.,Pharmacokinetics of orally administered ibuprofen in African and Asian elephants (Loxodonta africana and Elephas maximus). ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17679510/),h,5.9-7.7,155537,DB01050,Ibuprofen
,17679510,volume of distribution,The volume of distribution was estimated to be between 322 and 356 ml/kg R(-) and 133 and 173 ml/kg S(+) in Asian elephants and 360-431 ml/kg R(-) and 179-207 ml/kg S(+) in African elephants.,Pharmacokinetics of orally administered ibuprofen in African and Asian elephants (Loxodonta africana and Elephas maximus). ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17679510/),[ml] / [kg],322 and 356,155538,DB01050,Ibuprofen
,17679510,volume of distribution,The volume of distribution was estimated to be between 322 and 356 ml/kg R(-) and 133 and 173 ml/kg S(+) in Asian elephants and 360-431 ml/kg R(-) and 179-207 ml/kg S(+) in African elephants.,Pharmacokinetics of orally administered ibuprofen in African and Asian elephants (Loxodonta africana and Elephas maximus). ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17679510/),[ml] / [kg],133 and 173,155539,DB01050,Ibuprofen
,17679510,volume of distribution,The volume of distribution was estimated to be between 322 and 356 ml/kg R(-) and 133 and 173 ml/kg S(+) in Asian elephants and 360-431 ml/kg R(-) and 179-207 ml/kg S(+) in African elephants.,Pharmacokinetics of orally administered ibuprofen in African and Asian elephants (Loxodonta africana and Elephas maximus). ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17679510/),[ml] / [kg],360-431,155540,DB01050,Ibuprofen
,17679510,volume of distribution,The volume of distribution was estimated to be between 322 and 356 ml/kg R(-) and 133 and 173 ml/kg S(+) in Asian elephants and 360-431 ml/kg R(-) and 179-207 ml/kg S(+) in African elephants.,Pharmacokinetics of orally administered ibuprofen in African and Asian elephants (Loxodonta africana and Elephas maximus). ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17679510/),[ml] / [kg],179-207,155541,DB01050,Ibuprofen
,17679510,Steady-state serum concentrations,Steady-state serum concentrations of ibuprofen ranged from 2.2 to 10.5 microg/ml R(-) and 5.5 to 32.0 microg/ml S(+) (mean: 5.17 +/- 0.7 R(-) and 13.95 +/- 0.9 S(+) microg/ml in African elephants and 5.0 +/- 1.09 microg/ml R(-) and 14.1 +/- 2.8 microg/ml S(+) in Asian elephants).,Pharmacokinetics of orally administered ibuprofen in African and Asian elephants (Loxodonta africana and Elephas maximus). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17679510/),[μg] / [ml],2.2 to 10.5,155542,DB01050,Ibuprofen
,17679510,Steady-state serum concentrations,Steady-state serum concentrations of ibuprofen ranged from 2.2 to 10.5 microg/ml R(-) and 5.5 to 32.0 microg/ml S(+) (mean: 5.17 +/- 0.7 R(-) and 13.95 +/- 0.9 S(+) microg/ml in African elephants and 5.0 +/- 1.09 microg/ml R(-) and 14.1 +/- 2.8 microg/ml S(+) in Asian elephants).,Pharmacokinetics of orally administered ibuprofen in African and Asian elephants (Loxodonta africana and Elephas maximus). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17679510/),[μg] / [ml],5.5 to 32.0,155543,DB01050,Ibuprofen
,17679510,Steady-state serum concentrations,Steady-state serum concentrations of ibuprofen ranged from 2.2 to 10.5 microg/ml R(-) and 5.5 to 32.0 microg/ml S(+) (mean: 5.17 +/- 0.7 R(-) and 13.95 +/- 0.9 S(+) microg/ml in African elephants and 5.0 +/- 1.09 microg/ml R(-) and 14.1 +/- 2.8 microg/ml S(+) in Asian elephants).,Pharmacokinetics of orally administered ibuprofen in African and Asian elephants (Loxodonta africana and Elephas maximus). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17679510/),[μg] / [ml],5.17,155544,DB01050,Ibuprofen
,17679510,Steady-state serum concentrations,Steady-state serum concentrations of ibuprofen ranged from 2.2 to 10.5 microg/ml R(-) and 5.5 to 32.0 microg/ml S(+) (mean: 5.17 +/- 0.7 R(-) and 13.95 +/- 0.9 S(+) microg/ml in African elephants and 5.0 +/- 1.09 microg/ml R(-) and 14.1 +/- 2.8 microg/ml S(+) in Asian elephants).,Pharmacokinetics of orally administered ibuprofen in African and Asian elephants (Loxodonta africana and Elephas maximus). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17679510/),[μg] / [ml],13.95,155545,DB01050,Ibuprofen
,17679510,Steady-state serum concentrations,Steady-state serum concentrations of ibuprofen ranged from 2.2 to 10.5 microg/ml R(-) and 5.5 to 32.0 microg/ml S(+) (mean: 5.17 +/- 0.7 R(-) and 13.95 +/- 0.9 S(+) microg/ml in African elephants and 5.0 +/- 1.09 microg/ml R(-) and 14.1 +/- 2.8 microg/ml S(+) in Asian elephants).,Pharmacokinetics of orally administered ibuprofen in African and Asian elephants (Loxodonta africana and Elephas maximus). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17679510/),[μg] / [ml],5.0,155546,DB01050,Ibuprofen
,17679510,Steady-state serum concentrations,Steady-state serum concentrations of ibuprofen ranged from 2.2 to 10.5 microg/ml R(-) and 5.5 to 32.0 microg/ml S(+) (mean: 5.17 +/- 0.7 R(-) and 13.95 +/- 0.9 S(+) microg/ml in African elephants and 5.0 +/- 1.09 microg/ml R(-) and 14.1 +/- 2.8 microg/ml S(+) in Asian elephants).,Pharmacokinetics of orally administered ibuprofen in African and Asian elephants (Loxodonta africana and Elephas maximus). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17679510/),[μg] / [ml],14.1,155547,DB01050,Ibuprofen
,1981899,mean absorption time (MAT),"The mean absorption time (MAT) from water-soluble gelatin preparations was about 0.7 h, while the MAT from commercial tablets and common gelatin tablets was about 1.2 h.",Rapidly absorbed solid oral formulations of ibuprofen using water-soluble gelatin. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1981899/),h,0.7,157094,DB01050,Ibuprofen
,1981899,MAT,"The mean absorption time (MAT) from water-soluble gelatin preparations was about 0.7 h, while the MAT from commercial tablets and common gelatin tablets was about 1.2 h.",Rapidly absorbed solid oral formulations of ibuprofen using water-soluble gelatin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1981899/),h,1.2,157095,DB01050,Ibuprofen
,16028097,time to equilibrium,"The time to equilibrium was established to be within 5 h, and the mean unbound fraction of MS-275 (f (u)) over a presumed therapeutic concentration range in healthy volunteer human plasma was 0.188 +/- 0.0075 as compared to 0.168 +/- 0.0144 in cancer patients.","Interspecies differences in plasma protein binding of MS-275, a novel histone deacetylase inhibitor. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16028097/),h,5,158186,DB01050,Ibuprofen
,16028097,unbound fraction of MS-275 (f (u)),"The time to equilibrium was established to be within 5 h, and the mean unbound fraction of MS-275 (f (u)) over a presumed therapeutic concentration range in healthy volunteer human plasma was 0.188 +/- 0.0075 as compared to 0.168 +/- 0.0144 in cancer patients.","Interspecies differences in plasma protein binding of MS-275, a novel histone deacetylase inhibitor. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16028097/),,0.188,158187,DB01050,Ibuprofen
,16028097,unbound fraction of MS-275 (f (u)),"The time to equilibrium was established to be within 5 h, and the mean unbound fraction of MS-275 (f (u)) over a presumed therapeutic concentration range in healthy volunteer human plasma was 0.188 +/- 0.0075 as compared to 0.168 +/- 0.0144 in cancer patients.","Interspecies differences in plasma protein binding of MS-275, a novel histone deacetylase inhibitor. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16028097/),,0.168,158188,DB01050,Ibuprofen
,16028097,f (u),"Among 19 tested drugs, a slightly increased f (u) was observed in the presence of only ibuprofen (f (u), 0.236 +/- 0.001) and metoclopramide (f (u), 0.270 +/- 0.042), suggesting weakly competitive displacement from protein-binding sites (P < 0.01).","Interspecies differences in plasma protein binding of MS-275, a novel histone deacetylase inhibitor. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16028097/),,0.236,158189,DB01050,Ibuprofen
,16028097,f (u),"Among 19 tested drugs, a slightly increased f (u) was observed in the presence of only ibuprofen (f (u), 0.236 +/- 0.001) and metoclopramide (f (u), 0.270 +/- 0.042), suggesting weakly competitive displacement from protein-binding sites (P < 0.01).","Interspecies differences in plasma protein binding of MS-275, a novel histone deacetylase inhibitor. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16028097/),,0.270,158190,DB01050,Ibuprofen
,31472084,Mature clearance,"Mature clearance was 3.81 (CV 15.5%, 95%CI 3.72, 3.92) L/h/70 kg.",A target concentration strategy to determine ibuprofen dosing in children. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31472084/),[l] / [70·h·kg],3.81,159334,DB01050,Ibuprofen
,31472084,maturation half-time,"The maturation half-time was 36.8 (CV 9.2%, 95%CI 34.7, 40.9) weeks postmenstrual age and the Hill coefficient 11.5 (95%CI 8.1, 15).",A target concentration strategy to determine ibuprofen dosing in children. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31472084/),weeks,36.8,159335,DB01050,Ibuprofen
,31472084,Hill coefficient,"The maturation half-time was 36.8 (CV 9.2%, 95%CI 34.7, 40.9) weeks postmenstrual age and the Hill coefficient 11.5 (95%CI 8.1, 15).",A target concentration strategy to determine ibuprofen dosing in children. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31472084/),,11.5,159336,DB01050,Ibuprofen
,31472084,effect site concentration,A target effect of four units (visual analogue scale 0-10) correlated with an effect site concentration of 6.3 mg/L: a concentration achieved at trough after 400 mg 8 hourly in adults.,A target concentration strategy to determine ibuprofen dosing in children. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31472084/),[mg] / [l],6.3,159337,DB01050,Ibuprofen
,1762067,clearances,"For racemic ibuprofen, the mean clearances (+/- S.D.) of S-ibuprofen, R-ibuprofen inversion and R-ibuprofen noninversion were 87.4 +/- 25.9, 57.3 +/- 31.0 and 56.3 +/- 29.0 ml/min, respectively.","Stereoselective metabolism of ibuprofen in humans: administration of R-, S- and racemic ibuprofen. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1762067/),[ml] / [min],87.4,159998,DB01050,Ibuprofen
,1762067,clearances,"For racemic ibuprofen, the mean clearances (+/- S.D.) of S-ibuprofen, R-ibuprofen inversion and R-ibuprofen noninversion were 87.4 +/- 25.9, 57.3 +/- 31.0 and 56.3 +/- 29.0 ml/min, respectively.","Stereoselective metabolism of ibuprofen in humans: administration of R-, S- and racemic ibuprofen. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1762067/),[ml] / [min],57.3,159999,DB01050,Ibuprofen
,1762067,clearances,"For racemic ibuprofen, the mean clearances (+/- S.D.) of S-ibuprofen, R-ibuprofen inversion and R-ibuprofen noninversion were 87.4 +/- 25.9, 57.3 +/- 31.0 and 56.3 +/- 29.0 ml/min, respectively.","Stereoselective metabolism of ibuprofen in humans: administration of R-, S- and racemic ibuprofen. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1762067/),[ml] / [min],56.3,160000,DB01050,Ibuprofen
,24435507,overall closure rate,"The overall closure rate of PDA was 60 and 65.7 % in the ibuprofen and indomethacin groups, respectively.",Comparison of oral ibuprofen with oral indomethacin for PDA closure in Indian preterm neonates: a randomized controlled trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24435507/),%,60,162314,DB01050,Ibuprofen
,24435507,overall closure rate,"The overall closure rate of PDA was 60 and 65.7 % in the ibuprofen and indomethacin groups, respectively.",Comparison of oral ibuprofen with oral indomethacin for PDA closure in Indian preterm neonates: a randomized controlled trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24435507/),%,65.7,162315,DB01050,Ibuprofen
,24435507,Closure rate,"Closure rate was significantly higher when the drugs were administered at an early postnatal age (<8 days) (83.3 % [p = 0.02] in the indomethacin group and 75 % [p = 0.03] in the ibuprofen group) in neonates >28 weeks (ibuprofen group 66.7 % [p = 0.02]; indomethacin group 65.5 % [p = 0.04]) and in babies with birth weight >1,000 g (ibuprofen group 62.2 %; indomethacin group 70 % [p = 0.04 in both groups]).",Comparison of oral ibuprofen with oral indomethacin for PDA closure in Indian preterm neonates: a randomized controlled trial. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24435507/),,83,162316,DB01050,Ibuprofen
,24435507,Closure rate,"Closure rate was significantly higher when the drugs were administered at an early postnatal age (<8 days) (83.3 % [p = 0.02] in the indomethacin group and 75 % [p = 0.03] in the ibuprofen group) in neonates >28 weeks (ibuprofen group 66.7 % [p = 0.02]; indomethacin group 65.5 % [p = 0.04]) and in babies with birth weight >1,000 g (ibuprofen group 62.2 %; indomethacin group 70 % [p = 0.04 in both groups]).",Comparison of oral ibuprofen with oral indomethacin for PDA closure in Indian preterm neonates: a randomized controlled trial. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24435507/),,75,162317,DB01050,Ibuprofen
,24435507,Closure rate,"Closure rate was significantly higher when the drugs were administered at an early postnatal age (<8 days) (83.3 % [p = 0.02] in the indomethacin group and 75 % [p = 0.03] in the ibuprofen group) in neonates >28 weeks (ibuprofen group 66.7 % [p = 0.02]; indomethacin group 65.5 % [p = 0.04]) and in babies with birth weight >1,000 g (ibuprofen group 62.2 %; indomethacin group 70 % [p = 0.04 in both groups]).",Comparison of oral ibuprofen with oral indomethacin for PDA closure in Indian preterm neonates: a randomized controlled trial. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24435507/),,66,162318,DB01050,Ibuprofen
,24435507,Closure rate,"Closure rate was significantly higher when the drugs were administered at an early postnatal age (<8 days) (83.3 % [p = 0.02] in the indomethacin group and 75 % [p = 0.03] in the ibuprofen group) in neonates >28 weeks (ibuprofen group 66.7 % [p = 0.02]; indomethacin group 65.5 % [p = 0.04]) and in babies with birth weight >1,000 g (ibuprofen group 62.2 %; indomethacin group 70 % [p = 0.04 in both groups]).",Comparison of oral ibuprofen with oral indomethacin for PDA closure in Indian preterm neonates: a randomized controlled trial. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24435507/),,65,162319,DB01050,Ibuprofen
,18796580,clearance,"Estimated clearance and volume of distribution were 3.5 mL/h/kg and 173 mL/kg, respectively, with a calculated half-life (t((1/2))) of 34.3 hours for S-ibuprofen.",Population pharmacokinetic analysis of Ibuprofen enantiomers in preterm newborn infants. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18796580/),[ml] / [h·kg],3.5,162721,DB01050,Ibuprofen
,18796580,volume of distribution,"Estimated clearance and volume of distribution were 3.5 mL/h/kg and 173 mL/kg, respectively, with a calculated half-life (t((1/2))) of 34.3 hours for S-ibuprofen.",Population pharmacokinetic analysis of Ibuprofen enantiomers in preterm newborn infants. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18796580/),[ml] / [kg],173,162722,DB01050,Ibuprofen
,18796580,half-life (t((1/2))),"Estimated clearance and volume of distribution were 3.5 mL/h/kg and 173 mL/kg, respectively, with a calculated half-life (t((1/2))) of 34.3 hours for S-ibuprofen.",Population pharmacokinetic analysis of Ibuprofen enantiomers in preterm newborn infants. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18796580/),h,34.3,162723,DB01050,Ibuprofen
,18796580,clearance,Estimated clearance at birth and volume of distribution were 25.5 mL/h/kg and 306 mL/kg with a t((1/2)) at birth of 8.3 hours for R-ibuprofen.,Population pharmacokinetic analysis of Ibuprofen enantiomers in preterm newborn infants. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18796580/),[ml] / [h·kg],25.5,162724,DB01050,Ibuprofen
,18796580,volume of distribution,Estimated clearance at birth and volume of distribution were 25.5 mL/h/kg and 306 mL/kg with a t((1/2)) at birth of 8.3 hours for R-ibuprofen.,Population pharmacokinetic analysis of Ibuprofen enantiomers in preterm newborn infants. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18796580/),[ml] / [kg],306,162725,DB01050,Ibuprofen
,18796580,t((1/2)),Estimated clearance at birth and volume of distribution were 25.5 mL/h/kg and 306 mL/kg with a t((1/2)) at birth of 8.3 hours for R-ibuprofen.,Population pharmacokinetic analysis of Ibuprofen enantiomers in preterm newborn infants. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18796580/),h,8.3,162726,DB01050,Ibuprofen
,9880911,Tmax,"The Tmax of the CIB layer tablet was about 52 min, while that of the commercial tablet was about 103 min.",Absorption of ibuprofen coated by anhydrous silicic acid. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9880911/),min,52,166800,DB01050,Ibuprofen
,9880911,Tmax,"The Tmax of the CIB layer tablet was about 52 min, while that of the commercial tablet was about 103 min.",Absorption of ibuprofen coated by anhydrous silicic acid. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9880911/),min,103,166801,DB01050,Ibuprofen
,33849297,ζ potential,"Key findings: Core-shell-shaped mixed PLNs were successfully prepared, with sizes in the nano range (193.3 ± 0.70 to 795.8 ± 0.70 nm) and ζ potential (-26.8 ± 0.45 to -42.8 ± 0.30 mV).",Enhanced oral bioavailability and gastroprotective effect of ibuprofen through mixed polymer-lipid nanoparticles. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33849297/),mv,-,170905,DB01050,Ibuprofen
,33849297,ζ potential,"Key findings: Core-shell-shaped mixed PLNs were successfully prepared, with sizes in the nano range (193.3 ± 0.70 to 795.8 ± 0.70 nm) and ζ potential (-26.8 ± 0.45 to -42.8 ± 0.30 mV).",Enhanced oral bioavailability and gastroprotective effect of ibuprofen through mixed polymer-lipid nanoparticles. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33849297/),mv,26.8,170906,DB01050,Ibuprofen
,33849297,ζ potential,"Key findings: Core-shell-shaped mixed PLNs were successfully prepared, with sizes in the nano range (193.3 ± 0.70 to 795.8 ± 0.70 nm) and ζ potential (-26.8 ± 0.45 to -42.8 ± 0.30 mV).",Enhanced oral bioavailability and gastroprotective effect of ibuprofen through mixed polymer-lipid nanoparticles. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33849297/),mv,42.8,170907,DB01050,Ibuprofen
,33849297,Entrapment efficiency,Entrapment efficiency ranged from 80.3 to 93.6%.,Enhanced oral bioavailability and gastroprotective effect of ibuprofen through mixed polymer-lipid nanoparticles. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33849297/),%,80.3 to,170908,DB01050,Ibuprofen
,33849297,Entrapment efficiency,Entrapment efficiency ranged from 80.3 to 93.6%.,Enhanced oral bioavailability and gastroprotective effect of ibuprofen through mixed polymer-lipid nanoparticles. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33849297/),%,93,170909,DB01050,Ibuprofen
,27554088,maximum plasma concentration (C max),"After single doses of 200, 400 and 800 mg and multiple doses of 400 mg intravenous ibuprofen, the main pharmacokinetic parameters obtained were: maximum plasma concentration (C max) 23.05 ± 2.96, 41.90 ± 3.22, 76.06 ± 8.70, and 49.53 ± 3.92 μg/ml, respectively, which were achieved immediately at the end of the infusion; area under the plasma concentration-time curve from time zero to the time of last quantifiable concentration (AUC0-t ) 49.82 ± 10.92, 88.79 ± 12.43, 152.34 ± 25.23, and 106.68 ± 18.94 µg·h/mL, respectively; AUC from time zero to infinity (AUC0-∞) 51.91 ± 10.67, 91.46 ± 12.06, 155.04 ± 25.70, and 108.58 ± 19.49 µg·h/ml, respectively; half-life (t ½) 1.87 ± 0.30, 1.93 ± 0.24, 2.02 ± 0.38, and 1.74 ± 0.26 h, respectively.",Pharmacokinetic Properties of Intravenous Ibuprofen in Healthy Chinese Volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27554088/),[μg] / [ml],23.05,177114,DB01050,Ibuprofen
,27554088,maximum plasma concentration (C max),"After single doses of 200, 400 and 800 mg and multiple doses of 400 mg intravenous ibuprofen, the main pharmacokinetic parameters obtained were: maximum plasma concentration (C max) 23.05 ± 2.96, 41.90 ± 3.22, 76.06 ± 8.70, and 49.53 ± 3.92 μg/ml, respectively, which were achieved immediately at the end of the infusion; area under the plasma concentration-time curve from time zero to the time of last quantifiable concentration (AUC0-t ) 49.82 ± 10.92, 88.79 ± 12.43, 152.34 ± 25.23, and 106.68 ± 18.94 µg·h/mL, respectively; AUC from time zero to infinity (AUC0-∞) 51.91 ± 10.67, 91.46 ± 12.06, 155.04 ± 25.70, and 108.58 ± 19.49 µg·h/ml, respectively; half-life (t ½) 1.87 ± 0.30, 1.93 ± 0.24, 2.02 ± 0.38, and 1.74 ± 0.26 h, respectively.",Pharmacokinetic Properties of Intravenous Ibuprofen in Healthy Chinese Volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27554088/),[μg] / [ml],41.90,177115,DB01050,Ibuprofen
,27554088,maximum plasma concentration (C max),"After single doses of 200, 400 and 800 mg and multiple doses of 400 mg intravenous ibuprofen, the main pharmacokinetic parameters obtained were: maximum plasma concentration (C max) 23.05 ± 2.96, 41.90 ± 3.22, 76.06 ± 8.70, and 49.53 ± 3.92 μg/ml, respectively, which were achieved immediately at the end of the infusion; area under the plasma concentration-time curve from time zero to the time of last quantifiable concentration (AUC0-t ) 49.82 ± 10.92, 88.79 ± 12.43, 152.34 ± 25.23, and 106.68 ± 18.94 µg·h/mL, respectively; AUC from time zero to infinity (AUC0-∞) 51.91 ± 10.67, 91.46 ± 12.06, 155.04 ± 25.70, and 108.58 ± 19.49 µg·h/ml, respectively; half-life (t ½) 1.87 ± 0.30, 1.93 ± 0.24, 2.02 ± 0.38, and 1.74 ± 0.26 h, respectively.",Pharmacokinetic Properties of Intravenous Ibuprofen in Healthy Chinese Volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27554088/),[μg] / [ml],76.06,177116,DB01050,Ibuprofen
,27554088,maximum plasma concentration (C max),"After single doses of 200, 400 and 800 mg and multiple doses of 400 mg intravenous ibuprofen, the main pharmacokinetic parameters obtained were: maximum plasma concentration (C max) 23.05 ± 2.96, 41.90 ± 3.22, 76.06 ± 8.70, and 49.53 ± 3.92 μg/ml, respectively, which were achieved immediately at the end of the infusion; area under the plasma concentration-time curve from time zero to the time of last quantifiable concentration (AUC0-t ) 49.82 ± 10.92, 88.79 ± 12.43, 152.34 ± 25.23, and 106.68 ± 18.94 µg·h/mL, respectively; AUC from time zero to infinity (AUC0-∞) 51.91 ± 10.67, 91.46 ± 12.06, 155.04 ± 25.70, and 108.58 ± 19.49 µg·h/ml, respectively; half-life (t ½) 1.87 ± 0.30, 1.93 ± 0.24, 2.02 ± 0.38, and 1.74 ± 0.26 h, respectively.",Pharmacokinetic Properties of Intravenous Ibuprofen in Healthy Chinese Volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27554088/),[μg] / [ml],49.53,177117,DB01050,Ibuprofen
,27554088,area under the plasma concentration-time curve from time zero to the time of last quantifiable concentration (AUC0-t ),"After single doses of 200, 400 and 800 mg and multiple doses of 400 mg intravenous ibuprofen, the main pharmacokinetic parameters obtained were: maximum plasma concentration (C max) 23.05 ± 2.96, 41.90 ± 3.22, 76.06 ± 8.70, and 49.53 ± 3.92 μg/ml, respectively, which were achieved immediately at the end of the infusion; area under the plasma concentration-time curve from time zero to the time of last quantifiable concentration (AUC0-t ) 49.82 ± 10.92, 88.79 ± 12.43, 152.34 ± 25.23, and 106.68 ± 18.94 µg·h/mL, respectively; AUC from time zero to infinity (AUC0-∞) 51.91 ± 10.67, 91.46 ± 12.06, 155.04 ± 25.70, and 108.58 ± 19.49 µg·h/ml, respectively; half-life (t ½) 1.87 ± 0.30, 1.93 ± 0.24, 2.02 ± 0.38, and 1.74 ± 0.26 h, respectively.",Pharmacokinetic Properties of Intravenous Ibuprofen in Healthy Chinese Volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27554088/),[h·μg] / [ml],49.82,177118,DB01050,Ibuprofen
,27554088,area under the plasma concentration-time curve from time zero to the time of last quantifiable concentration (AUC0-t ),"After single doses of 200, 400 and 800 mg and multiple doses of 400 mg intravenous ibuprofen, the main pharmacokinetic parameters obtained were: maximum plasma concentration (C max) 23.05 ± 2.96, 41.90 ± 3.22, 76.06 ± 8.70, and 49.53 ± 3.92 μg/ml, respectively, which were achieved immediately at the end of the infusion; area under the plasma concentration-time curve from time zero to the time of last quantifiable concentration (AUC0-t ) 49.82 ± 10.92, 88.79 ± 12.43, 152.34 ± 25.23, and 106.68 ± 18.94 µg·h/mL, respectively; AUC from time zero to infinity (AUC0-∞) 51.91 ± 10.67, 91.46 ± 12.06, 155.04 ± 25.70, and 108.58 ± 19.49 µg·h/ml, respectively; half-life (t ½) 1.87 ± 0.30, 1.93 ± 0.24, 2.02 ± 0.38, and 1.74 ± 0.26 h, respectively.",Pharmacokinetic Properties of Intravenous Ibuprofen in Healthy Chinese Volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27554088/),[h·μg] / [ml],88.79,177119,DB01050,Ibuprofen
,27554088,area under the plasma concentration-time curve from time zero to the time of last quantifiable concentration (AUC0-t ),"After single doses of 200, 400 and 800 mg and multiple doses of 400 mg intravenous ibuprofen, the main pharmacokinetic parameters obtained were: maximum plasma concentration (C max) 23.05 ± 2.96, 41.90 ± 3.22, 76.06 ± 8.70, and 49.53 ± 3.92 μg/ml, respectively, which were achieved immediately at the end of the infusion; area under the plasma concentration-time curve from time zero to the time of last quantifiable concentration (AUC0-t ) 49.82 ± 10.92, 88.79 ± 12.43, 152.34 ± 25.23, and 106.68 ± 18.94 µg·h/mL, respectively; AUC from time zero to infinity (AUC0-∞) 51.91 ± 10.67, 91.46 ± 12.06, 155.04 ± 25.70, and 108.58 ± 19.49 µg·h/ml, respectively; half-life (t ½) 1.87 ± 0.30, 1.93 ± 0.24, 2.02 ± 0.38, and 1.74 ± 0.26 h, respectively.",Pharmacokinetic Properties of Intravenous Ibuprofen in Healthy Chinese Volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27554088/),[h·μg] / [ml],152.34,177120,DB01050,Ibuprofen
,27554088,area under the plasma concentration-time curve from time zero to the time of last quantifiable concentration (AUC0-t ),"After single doses of 200, 400 and 800 mg and multiple doses of 400 mg intravenous ibuprofen, the main pharmacokinetic parameters obtained were: maximum plasma concentration (C max) 23.05 ± 2.96, 41.90 ± 3.22, 76.06 ± 8.70, and 49.53 ± 3.92 μg/ml, respectively, which were achieved immediately at the end of the infusion; area under the plasma concentration-time curve from time zero to the time of last quantifiable concentration (AUC0-t ) 49.82 ± 10.92, 88.79 ± 12.43, 152.34 ± 25.23, and 106.68 ± 18.94 µg·h/mL, respectively; AUC from time zero to infinity (AUC0-∞) 51.91 ± 10.67, 91.46 ± 12.06, 155.04 ± 25.70, and 108.58 ± 19.49 µg·h/ml, respectively; half-life (t ½) 1.87 ± 0.30, 1.93 ± 0.24, 2.02 ± 0.38, and 1.74 ± 0.26 h, respectively.",Pharmacokinetic Properties of Intravenous Ibuprofen in Healthy Chinese Volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27554088/),[h·μg] / [ml],106.68,177121,DB01050,Ibuprofen
,27554088,AUC from time zero to infinity (AUC0-∞),"After single doses of 200, 400 and 800 mg and multiple doses of 400 mg intravenous ibuprofen, the main pharmacokinetic parameters obtained were: maximum plasma concentration (C max) 23.05 ± 2.96, 41.90 ± 3.22, 76.06 ± 8.70, and 49.53 ± 3.92 μg/ml, respectively, which were achieved immediately at the end of the infusion; area under the plasma concentration-time curve from time zero to the time of last quantifiable concentration (AUC0-t ) 49.82 ± 10.92, 88.79 ± 12.43, 152.34 ± 25.23, and 106.68 ± 18.94 µg·h/mL, respectively; AUC from time zero to infinity (AUC0-∞) 51.91 ± 10.67, 91.46 ± 12.06, 155.04 ± 25.70, and 108.58 ± 19.49 µg·h/ml, respectively; half-life (t ½) 1.87 ± 0.30, 1.93 ± 0.24, 2.02 ± 0.38, and 1.74 ± 0.26 h, respectively.",Pharmacokinetic Properties of Intravenous Ibuprofen in Healthy Chinese Volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27554088/),[h·μg] / [ml],51.91,177122,DB01050,Ibuprofen
,27554088,AUC from time zero to infinity (AUC0-∞),"After single doses of 200, 400 and 800 mg and multiple doses of 400 mg intravenous ibuprofen, the main pharmacokinetic parameters obtained were: maximum plasma concentration (C max) 23.05 ± 2.96, 41.90 ± 3.22, 76.06 ± 8.70, and 49.53 ± 3.92 μg/ml, respectively, which were achieved immediately at the end of the infusion; area under the plasma concentration-time curve from time zero to the time of last quantifiable concentration (AUC0-t ) 49.82 ± 10.92, 88.79 ± 12.43, 152.34 ± 25.23, and 106.68 ± 18.94 µg·h/mL, respectively; AUC from time zero to infinity (AUC0-∞) 51.91 ± 10.67, 91.46 ± 12.06, 155.04 ± 25.70, and 108.58 ± 19.49 µg·h/ml, respectively; half-life (t ½) 1.87 ± 0.30, 1.93 ± 0.24, 2.02 ± 0.38, and 1.74 ± 0.26 h, respectively.",Pharmacokinetic Properties of Intravenous Ibuprofen in Healthy Chinese Volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27554088/),[h·μg] / [ml],91.46,177123,DB01050,Ibuprofen
,27554088,AUC from time zero to infinity (AUC0-∞),"After single doses of 200, 400 and 800 mg and multiple doses of 400 mg intravenous ibuprofen, the main pharmacokinetic parameters obtained were: maximum plasma concentration (C max) 23.05 ± 2.96, 41.90 ± 3.22, 76.06 ± 8.70, and 49.53 ± 3.92 μg/ml, respectively, which were achieved immediately at the end of the infusion; area under the plasma concentration-time curve from time zero to the time of last quantifiable concentration (AUC0-t ) 49.82 ± 10.92, 88.79 ± 12.43, 152.34 ± 25.23, and 106.68 ± 18.94 µg·h/mL, respectively; AUC from time zero to infinity (AUC0-∞) 51.91 ± 10.67, 91.46 ± 12.06, 155.04 ± 25.70, and 108.58 ± 19.49 µg·h/ml, respectively; half-life (t ½) 1.87 ± 0.30, 1.93 ± 0.24, 2.02 ± 0.38, and 1.74 ± 0.26 h, respectively.",Pharmacokinetic Properties of Intravenous Ibuprofen in Healthy Chinese Volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27554088/),[h·μg] / [ml],155.04,177124,DB01050,Ibuprofen
,27554088,AUC from time zero to infinity (AUC0-∞),"After single doses of 200, 400 and 800 mg and multiple doses of 400 mg intravenous ibuprofen, the main pharmacokinetic parameters obtained were: maximum plasma concentration (C max) 23.05 ± 2.96, 41.90 ± 3.22, 76.06 ± 8.70, and 49.53 ± 3.92 μg/ml, respectively, which were achieved immediately at the end of the infusion; area under the plasma concentration-time curve from time zero to the time of last quantifiable concentration (AUC0-t ) 49.82 ± 10.92, 88.79 ± 12.43, 152.34 ± 25.23, and 106.68 ± 18.94 µg·h/mL, respectively; AUC from time zero to infinity (AUC0-∞) 51.91 ± 10.67, 91.46 ± 12.06, 155.04 ± 25.70, and 108.58 ± 19.49 µg·h/ml, respectively; half-life (t ½) 1.87 ± 0.30, 1.93 ± 0.24, 2.02 ± 0.38, and 1.74 ± 0.26 h, respectively.",Pharmacokinetic Properties of Intravenous Ibuprofen in Healthy Chinese Volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27554088/),[h·μg] / [ml],108.58,177125,DB01050,Ibuprofen
,27554088,half-life (t ½),"After single doses of 200, 400 and 800 mg and multiple doses of 400 mg intravenous ibuprofen, the main pharmacokinetic parameters obtained were: maximum plasma concentration (C max) 23.05 ± 2.96, 41.90 ± 3.22, 76.06 ± 8.70, and 49.53 ± 3.92 μg/ml, respectively, which were achieved immediately at the end of the infusion; area under the plasma concentration-time curve from time zero to the time of last quantifiable concentration (AUC0-t ) 49.82 ± 10.92, 88.79 ± 12.43, 152.34 ± 25.23, and 106.68 ± 18.94 µg·h/mL, respectively; AUC from time zero to infinity (AUC0-∞) 51.91 ± 10.67, 91.46 ± 12.06, 155.04 ± 25.70, and 108.58 ± 19.49 µg·h/ml, respectively; half-life (t ½) 1.87 ± 0.30, 1.93 ± 0.24, 2.02 ± 0.38, and 1.74 ± 0.26 h, respectively.",Pharmacokinetic Properties of Intravenous Ibuprofen in Healthy Chinese Volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27554088/),,1.87,177126,DB01050,Ibuprofen
,27554088,half-life (t ½),"After single doses of 200, 400 and 800 mg and multiple doses of 400 mg intravenous ibuprofen, the main pharmacokinetic parameters obtained were: maximum plasma concentration (C max) 23.05 ± 2.96, 41.90 ± 3.22, 76.06 ± 8.70, and 49.53 ± 3.92 μg/ml, respectively, which were achieved immediately at the end of the infusion; area under the plasma concentration-time curve from time zero to the time of last quantifiable concentration (AUC0-t ) 49.82 ± 10.92, 88.79 ± 12.43, 152.34 ± 25.23, and 106.68 ± 18.94 µg·h/mL, respectively; AUC from time zero to infinity (AUC0-∞) 51.91 ± 10.67, 91.46 ± 12.06, 155.04 ± 25.70, and 108.58 ± 19.49 µg·h/ml, respectively; half-life (t ½) 1.87 ± 0.30, 1.93 ± 0.24, 2.02 ± 0.38, and 1.74 ± 0.26 h, respectively.",Pharmacokinetic Properties of Intravenous Ibuprofen in Healthy Chinese Volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27554088/),,1.93,177127,DB01050,Ibuprofen
,27554088,half-life (t ½),"After single doses of 200, 400 and 800 mg and multiple doses of 400 mg intravenous ibuprofen, the main pharmacokinetic parameters obtained were: maximum plasma concentration (C max) 23.05 ± 2.96, 41.90 ± 3.22, 76.06 ± 8.70, and 49.53 ± 3.92 μg/ml, respectively, which were achieved immediately at the end of the infusion; area under the plasma concentration-time curve from time zero to the time of last quantifiable concentration (AUC0-t ) 49.82 ± 10.92, 88.79 ± 12.43, 152.34 ± 25.23, and 106.68 ± 18.94 µg·h/mL, respectively; AUC from time zero to infinity (AUC0-∞) 51.91 ± 10.67, 91.46 ± 12.06, 155.04 ± 25.70, and 108.58 ± 19.49 µg·h/ml, respectively; half-life (t ½) 1.87 ± 0.30, 1.93 ± 0.24, 2.02 ± 0.38, and 1.74 ± 0.26 h, respectively.",Pharmacokinetic Properties of Intravenous Ibuprofen in Healthy Chinese Volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27554088/),,2.02,177128,DB01050,Ibuprofen
,27554088,accumulation index (AI),The accumulation index (AI) was 1.22 ± 0.17 after multiple doses.,Pharmacokinetic Properties of Intravenous Ibuprofen in Healthy Chinese Volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27554088/),,1.22,177129,DB01050,Ibuprofen
,25417559,flow rate,"Chromatographic separation was performed by pumping the mobile phase containing acetonitrile, water and formic acid (89.2:11.7:0.1) for 2.0 min at a flow rate of 0.25 μL/min into a Hypersil-Gold C18 column, 20 × 2.0 mm (1.9 µm) from Thermoscientific, New York, USA.","Development and validation of a sensitive UHPLC-MS/MS method for the simultaneous analysis of tramadol, dextromethorphan chlorpheniramine and their major metabolites in human plasma in forensic context: application to pharmacokinetics. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25417559/),[μl] / [min],0.25,178279,DB01050,Ibuprofen
,7899229,synovial fluid exit rate constant,"The single dose mean +/- S.D. synovial fluid exit rate constant for diclofenac was 0.39 +/- 0.33 hr-1 (n = 6), which was not significantly different from that determined by method 2; which was 0.49 +/- 0.52 hr-1.",Transsynovial drug distribution: synovial mean transit time of diclofenac and other nonsteroidal antiinflammatory drugs. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7899229/),1/[h],0.39,178926,DB01050,Ibuprofen
,7899229,synovial fluid exit rate constant,"The single dose mean +/- S.D. synovial fluid exit rate constant for diclofenac was 0.39 +/- 0.33 hr-1 (n = 6), which was not significantly different from that determined by method 2; which was 0.49 +/- 0.52 hr-1.",Transsynovial drug distribution: synovial mean transit time of diclofenac and other nonsteroidal antiinflammatory drugs. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7899229/),1/[h],0.49,178927,DB01050,Ibuprofen
,7899229,steady state mean,"The steady state mean +/- S.D. diclofenac synovial fluid exit rate constants for methods 1 and 2 were 0.43 +/- 0.18 and 0.54 +/- 0.71 hr-1 (n = 8), respectively, which were not significantly different.",Transsynovial drug distribution: synovial mean transit time of diclofenac and other nonsteroidal antiinflammatory drugs. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7899229/),1/[h],0.43,178928,DB01050,Ibuprofen
,7899229,steady state mean,"The steady state mean +/- S.D. diclofenac synovial fluid exit rate constants for methods 1 and 2 were 0.43 +/- 0.18 and 0.54 +/- 0.71 hr-1 (n = 8), respectively, which were not significantly different.",Transsynovial drug distribution: synovial mean transit time of diclofenac and other nonsteroidal antiinflammatory drugs. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7899229/),1/[h],0.54,178929,DB01050,Ibuprofen
,7899229,s,"The steady state mean +/- S.D. diclofenac synovial fluid exit rate constants for methods 1 and 2 were 0.43 +/- 0.18 and 0.54 +/- 0.71 hr-1 (n = 8), respectively, which were not significantly different.",Transsynovial drug distribution: synovial mean transit time of diclofenac and other nonsteroidal antiinflammatory drugs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7899229/),1/[h],0.43,178930,DB01050,Ibuprofen
,7899229,s,"The steady state mean +/- S.D. diclofenac synovial fluid exit rate constants for methods 1 and 2 were 0.43 +/- 0.18 and 0.54 +/- 0.71 hr-1 (n = 8), respectively, which were not significantly different.",Transsynovial drug distribution: synovial mean transit time of diclofenac and other nonsteroidal antiinflammatory drugs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7899229/),1/[h],0.54,178931,DB01050,Ibuprofen
,22613269,Ductal closure rates,"Ductal closure rates were 100% and 97.6%, respectively, in the oral and intravenous groups.",Comparison of oral and intravenous Ibuprofen for medical closure of patent ductus arteriosus: which one is better? ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22613269/),%,100,180169,DB01050,Ibuprofen
,22613269,Ductal closure rates,"Ductal closure rates were 100% and 97.6%, respectively, in the oral and intravenous groups.",Comparison of oral and intravenous Ibuprofen for medical closure of patent ductus arteriosus: which one is better? ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22613269/),%,97.6,180170,DB01050,Ibuprofen
,8263108,flow-rate,The resultant diastereomers corresponding to IB and I.S. were chromatographed at ambient temperature on a 100 mm x 4.6 mm I.D. C18 reversed-phase column using acetonitrile-water-acetic acid-triethylamine (60:40:0.1:0.02) as the mobile phase pumped at a flow-rate of 1.2 ml/min.,Stereospecific high-performance liquid chromatographic assay of ibuprofen: improved sensitivity and sample processing efficiency. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8263108/),[ml] / [min],1.2,180616,DB01050,Ibuprofen
,12877565,Cmax,"The Cmax, AUC0-6hr and Ka for ibuprofen decreased from 38.04 +/- 0.70microg/ml to 20.06 +/- 1.21microg/ml (p<0.05); 28.030 +/- 2.40microg/ml.hr to 14.180 +/- 1.12microg/ml.hr (p<0.05) and 1.048 +/- 0.02hr(-1) to 0.602 +/- 0.03hr(-1).",Effect of sodium/potassium salt (potash) on the bioavailability of ibuprofen in healthy human volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12877565/),[μg] / [ml],38.04,182193,DB01050,Ibuprofen
,12877565,AUC0-6hr,"The Cmax, AUC0-6hr and Ka for ibuprofen decreased from 38.04 +/- 0.70microg/ml to 20.06 +/- 1.21microg/ml (p<0.05); 28.030 +/- 2.40microg/ml.hr to 14.180 +/- 1.12microg/ml.hr (p<0.05) and 1.048 +/- 0.02hr(-1) to 0.602 +/- 0.03hr(-1).",Effect of sodium/potassium salt (potash) on the bioavailability of ibuprofen in healthy human volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12877565/),[μg] / [h·ml],28.030,182194,DB01050,Ibuprofen
,12877565,AUC0-6hr,"The Cmax, AUC0-6hr and Ka for ibuprofen decreased from 38.04 +/- 0.70microg/ml to 20.06 +/- 1.21microg/ml (p<0.05); 28.030 +/- 2.40microg/ml.hr to 14.180 +/- 1.12microg/ml.hr (p<0.05) and 1.048 +/- 0.02hr(-1) to 0.602 +/- 0.03hr(-1).",Effect of sodium/potassium salt (potash) on the bioavailability of ibuprofen in healthy human volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12877565/),[μg] / [h·ml],14.180,182195,DB01050,Ibuprofen
,12877565,AUC0-6hr,"The Cmax, AUC0-6hr and Ka for ibuprofen decreased from 38.04 +/- 0.70microg/ml to 20.06 +/- 1.21microg/ml (p<0.05); 28.030 +/- 2.40microg/ml.hr to 14.180 +/- 1.12microg/ml.hr (p<0.05) and 1.048 +/- 0.02hr(-1) to 0.602 +/- 0.03hr(-1).",Effect of sodium/potassium salt (potash) on the bioavailability of ibuprofen in healthy human volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12877565/),1/[hr],1.048,182196,DB01050,Ibuprofen
,12877565,AUC0-6hr,"The Cmax, AUC0-6hr and Ka for ibuprofen decreased from 38.04 +/- 0.70microg/ml to 20.06 +/- 1.21microg/ml (p<0.05); 28.030 +/- 2.40microg/ml.hr to 14.180 +/- 1.12microg/ml.hr (p<0.05) and 1.048 +/- 0.02hr(-1) to 0.602 +/- 0.03hr(-1).",Effect of sodium/potassium salt (potash) on the bioavailability of ibuprofen in healthy human volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12877565/),1/[hr],0.602,182197,DB01050,Ibuprofen
,12877565,Ka,"The Cmax, AUC0-6hr and Ka for ibuprofen decreased from 38.04 +/- 0.70microg/ml to 20.06 +/- 1.21microg/ml (p<0.05); 28.030 +/- 2.40microg/ml.hr to 14.180 +/- 1.12microg/ml.hr (p<0.05) and 1.048 +/- 0.02hr(-1) to 0.602 +/- 0.03hr(-1).",Effect of sodium/potassium salt (potash) on the bioavailability of ibuprofen in healthy human volunteers. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12877565/),1/[hr],1.048,182198,DB01050,Ibuprofen
,12877565,Ka,"The Cmax, AUC0-6hr and Ka for ibuprofen decreased from 38.04 +/- 0.70microg/ml to 20.06 +/- 1.21microg/ml (p<0.05); 28.030 +/- 2.40microg/ml.hr to 14.180 +/- 1.12microg/ml.hr (p<0.05) and 1.048 +/- 0.02hr(-1) to 0.602 +/- 0.03hr(-1).",Effect of sodium/potassium salt (potash) on the bioavailability of ibuprofen in healthy human volunteers. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12877565/),1/[hr],0.602,182199,DB01050,Ibuprofen
,12877565,Cmax,"Similarly, the Cmax for hydroxy-ibuprofen and carboxy-ibuprofen decreases from 43.04 +/- 0.76microg/ml to 27.21 +/- 0.24microg/ml (p<0.05) and 48 +/- 0.71microg/ml to 31.08 +/- 0.12microg/ml (p<0.05) respectively; while AUC0-6hr for hydroxy-ibuprofen decreased from 34.120 +/- 0.49microg/ml.hr to 16.410 +/- 0.27microg/ml.hr while that of carboxy-ibuprofen decreased from 36.121 +/- 1.97microg/ml.hr to 19.278 +/- 0.92microg/ml.hr respectively.",Effect of sodium/potassium salt (potash) on the bioavailability of ibuprofen in healthy human volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12877565/),[μg] / [ml],43.04,182200,DB01050,Ibuprofen
,12877565,Cmax,"Similarly, the Cmax for hydroxy-ibuprofen and carboxy-ibuprofen decreases from 43.04 +/- 0.76microg/ml to 27.21 +/- 0.24microg/ml (p<0.05) and 48 +/- 0.71microg/ml to 31.08 +/- 0.12microg/ml (p<0.05) respectively; while AUC0-6hr for hydroxy-ibuprofen decreased from 34.120 +/- 0.49microg/ml.hr to 16.410 +/- 0.27microg/ml.hr while that of carboxy-ibuprofen decreased from 36.121 +/- 1.97microg/ml.hr to 19.278 +/- 0.92microg/ml.hr respectively.",Effect of sodium/potassium salt (potash) on the bioavailability of ibuprofen in healthy human volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12877565/),[μg] / [ml],27.21,182201,DB01050,Ibuprofen
,12877565,Cmax,"Similarly, the Cmax for hydroxy-ibuprofen and carboxy-ibuprofen decreases from 43.04 +/- 0.76microg/ml to 27.21 +/- 0.24microg/ml (p<0.05) and 48 +/- 0.71microg/ml to 31.08 +/- 0.12microg/ml (p<0.05) respectively; while AUC0-6hr for hydroxy-ibuprofen decreased from 34.120 +/- 0.49microg/ml.hr to 16.410 +/- 0.27microg/ml.hr while that of carboxy-ibuprofen decreased from 36.121 +/- 1.97microg/ml.hr to 19.278 +/- 0.92microg/ml.hr respectively.",Effect of sodium/potassium salt (potash) on the bioavailability of ibuprofen in healthy human volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12877565/),[μg] / [ml],48,182202,DB01050,Ibuprofen
,12877565,Cmax,"Similarly, the Cmax for hydroxy-ibuprofen and carboxy-ibuprofen decreases from 43.04 +/- 0.76microg/ml to 27.21 +/- 0.24microg/ml (p<0.05) and 48 +/- 0.71microg/ml to 31.08 +/- 0.12microg/ml (p<0.05) respectively; while AUC0-6hr for hydroxy-ibuprofen decreased from 34.120 +/- 0.49microg/ml.hr to 16.410 +/- 0.27microg/ml.hr while that of carboxy-ibuprofen decreased from 36.121 +/- 1.97microg/ml.hr to 19.278 +/- 0.92microg/ml.hr respectively.",Effect of sodium/potassium salt (potash) on the bioavailability of ibuprofen in healthy human volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12877565/),[μg] / [ml],31.08,182203,DB01050,Ibuprofen
,12877565,AUC0-6hr,"Similarly, the Cmax for hydroxy-ibuprofen and carboxy-ibuprofen decreases from 43.04 +/- 0.76microg/ml to 27.21 +/- 0.24microg/ml (p<0.05) and 48 +/- 0.71microg/ml to 31.08 +/- 0.12microg/ml (p<0.05) respectively; while AUC0-6hr for hydroxy-ibuprofen decreased from 34.120 +/- 0.49microg/ml.hr to 16.410 +/- 0.27microg/ml.hr while that of carboxy-ibuprofen decreased from 36.121 +/- 1.97microg/ml.hr to 19.278 +/- 0.92microg/ml.hr respectively.",Effect of sodium/potassium salt (potash) on the bioavailability of ibuprofen in healthy human volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12877565/),[μg] / [h·ml],34.120,182204,DB01050,Ibuprofen
,12877565,AUC0-6hr,"Similarly, the Cmax for hydroxy-ibuprofen and carboxy-ibuprofen decreases from 43.04 +/- 0.76microg/ml to 27.21 +/- 0.24microg/ml (p<0.05) and 48 +/- 0.71microg/ml to 31.08 +/- 0.12microg/ml (p<0.05) respectively; while AUC0-6hr for hydroxy-ibuprofen decreased from 34.120 +/- 0.49microg/ml.hr to 16.410 +/- 0.27microg/ml.hr while that of carboxy-ibuprofen decreased from 36.121 +/- 1.97microg/ml.hr to 19.278 +/- 0.92microg/ml.hr respectively.",Effect of sodium/potassium salt (potash) on the bioavailability of ibuprofen in healthy human volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12877565/),[μg] / [h·ml],16.410,182205,DB01050,Ibuprofen
,12877565,AUC0-6hr,"Similarly, the Cmax for hydroxy-ibuprofen and carboxy-ibuprofen decreases from 43.04 +/- 0.76microg/ml to 27.21 +/- 0.24microg/ml (p<0.05) and 48 +/- 0.71microg/ml to 31.08 +/- 0.12microg/ml (p<0.05) respectively; while AUC0-6hr for hydroxy-ibuprofen decreased from 34.120 +/- 0.49microg/ml.hr to 16.410 +/- 0.27microg/ml.hr while that of carboxy-ibuprofen decreased from 36.121 +/- 1.97microg/ml.hr to 19.278 +/- 0.92microg/ml.hr respectively.",Effect of sodium/potassium salt (potash) on the bioavailability of ibuprofen in healthy human volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12877565/),[μg] / [h·ml],36.121,182206,DB01050,Ibuprofen
,12877565,AUC0-6hr,"Similarly, the Cmax for hydroxy-ibuprofen and carboxy-ibuprofen decreases from 43.04 +/- 0.76microg/ml to 27.21 +/- 0.24microg/ml (p<0.05) and 48 +/- 0.71microg/ml to 31.08 +/- 0.12microg/ml (p<0.05) respectively; while AUC0-6hr for hydroxy-ibuprofen decreased from 34.120 +/- 0.49microg/ml.hr to 16.410 +/- 0.27microg/ml.hr while that of carboxy-ibuprofen decreased from 36.121 +/- 1.97microg/ml.hr to 19.278 +/- 0.92microg/ml.hr respectively.",Effect of sodium/potassium salt (potash) on the bioavailability of ibuprofen in healthy human volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12877565/),[μg] / [h·ml],19.278,182207,DB01050,Ibuprofen
,12877565,Kel,The Kel for hydroxy-ibuprofen increased from 0.71 +/- 0.94 hr(-1) to 0.81 +/- 0.21 hr(-1) (p<0.05) respectively.,Effect of sodium/potassium salt (potash) on the bioavailability of ibuprofen in healthy human volunteers. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12877565/),1/[hr],0.71,182208,DB01050,Ibuprofen
,12877565,Kel,The Kel for hydroxy-ibuprofen increased from 0.71 +/- 0.94 hr(-1) to 0.81 +/- 0.21 hr(-1) (p<0.05) respectively.,Effect of sodium/potassium salt (potash) on the bioavailability of ibuprofen in healthy human volunteers. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12877565/),1/[hr],0.81,182209,DB01050,Ibuprofen
,2050181,maximum observed serum concentrations,The maximum observed serum concentrations of ibuprofen ranged from 17-42 micrograms.,Pharmacokinetics of ibuprofen in febrile children. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2050181/),μg,17-42,185095,DB01050,Ibuprofen
,2050181,tmax,"Mean tmax, oral clearance and elimination half life were 1.1 h, 1.2 ml.min-1.kg-1, and 1.6 h, respectively in patients at 5 mg.",Pharmacokinetics of ibuprofen in febrile children. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2050181/),h,1.1,185096,DB01050,Ibuprofen
,2050181,oral clearance,"Mean tmax, oral clearance and elimination half life were 1.1 h, 1.2 ml.min-1.kg-1, and 1.6 h, respectively in patients at 5 mg.",Pharmacokinetics of ibuprofen in febrile children. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2050181/),[ml] / [kg·min],1.2,185097,DB01050,Ibuprofen
,2050181,elimination half life,"Mean tmax, oral clearance and elimination half life were 1.1 h, 1.2 ml.min-1.kg-1, and 1.6 h, respectively in patients at 5 mg.",Pharmacokinetics of ibuprofen in febrile children. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2050181/),h,1.6,185098,DB01050,Ibuprofen
,3665393,AUC,"The ranges of mean (+/- S.D.) values were 113.97 +/- 21.5 to 127.53 +/- 29.3 micrograms.hr/mL for AUC, 35.30 +/- 6.40 to 41.00 +/- 10.00 micrograms/mL for Cmax, 0.95 +/- 0.30 to 1.28 +/- 0.54 hr for tmax, and 0.346 +/- 0.026 to 0.388 +/- 0.040 hr-1 for k.",Effect of antacid suspension on the pharmacokinetics of ibuprofen. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3665393/),[h·μg] / [ml],113.97,187949,DB01050,Ibuprofen
,3665393,AUC,"The ranges of mean (+/- S.D.) values were 113.97 +/- 21.5 to 127.53 +/- 29.3 micrograms.hr/mL for AUC, 35.30 +/- 6.40 to 41.00 +/- 10.00 micrograms/mL for Cmax, 0.95 +/- 0.30 to 1.28 +/- 0.54 hr for tmax, and 0.346 +/- 0.026 to 0.388 +/- 0.040 hr-1 for k.",Effect of antacid suspension on the pharmacokinetics of ibuprofen. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3665393/),[h·μg] / [ml],127.53,187950,DB01050,Ibuprofen
,3665393,Cmax,"The ranges of mean (+/- S.D.) values were 113.97 +/- 21.5 to 127.53 +/- 29.3 micrograms.hr/mL for AUC, 35.30 +/- 6.40 to 41.00 +/- 10.00 micrograms/mL for Cmax, 0.95 +/- 0.30 to 1.28 +/- 0.54 hr for tmax, and 0.346 +/- 0.026 to 0.388 +/- 0.040 hr-1 for k.",Effect of antacid suspension on the pharmacokinetics of ibuprofen. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3665393/),[μg] / [ml],35.30,187951,DB01050,Ibuprofen
,3665393,Cmax,"The ranges of mean (+/- S.D.) values were 113.97 +/- 21.5 to 127.53 +/- 29.3 micrograms.hr/mL for AUC, 35.30 +/- 6.40 to 41.00 +/- 10.00 micrograms/mL for Cmax, 0.95 +/- 0.30 to 1.28 +/- 0.54 hr for tmax, and 0.346 +/- 0.026 to 0.388 +/- 0.040 hr-1 for k.",Effect of antacid suspension on the pharmacokinetics of ibuprofen. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3665393/),[μg] / [ml],41.00,187952,DB01050,Ibuprofen
,3665393,tmax,"The ranges of mean (+/- S.D.) values were 113.97 +/- 21.5 to 127.53 +/- 29.3 micrograms.hr/mL for AUC, 35.30 +/- 6.40 to 41.00 +/- 10.00 micrograms/mL for Cmax, 0.95 +/- 0.30 to 1.28 +/- 0.54 hr for tmax, and 0.346 +/- 0.026 to 0.388 +/- 0.040 hr-1 for k.",Effect of antacid suspension on the pharmacokinetics of ibuprofen. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3665393/),h,0.95,187953,DB01050,Ibuprofen
,3665393,tmax,"The ranges of mean (+/- S.D.) values were 113.97 +/- 21.5 to 127.53 +/- 29.3 micrograms.hr/mL for AUC, 35.30 +/- 6.40 to 41.00 +/- 10.00 micrograms/mL for Cmax, 0.95 +/- 0.30 to 1.28 +/- 0.54 hr for tmax, and 0.346 +/- 0.026 to 0.388 +/- 0.040 hr-1 for k.",Effect of antacid suspension on the pharmacokinetics of ibuprofen. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3665393/),h,1.28,187954,DB01050,Ibuprofen
,3665393,k,"The ranges of mean (+/- S.D.) values were 113.97 +/- 21.5 to 127.53 +/- 29.3 micrograms.hr/mL for AUC, 35.30 +/- 6.40 to 41.00 +/- 10.00 micrograms/mL for Cmax, 0.95 +/- 0.30 to 1.28 +/- 0.54 hr for tmax, and 0.346 +/- 0.026 to 0.388 +/- 0.040 hr-1 for k.",Effect of antacid suspension on the pharmacokinetics of ibuprofen. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3665393/),1/[h],0.346,187955,DB01050,Ibuprofen
,3665393,k,"The ranges of mean (+/- S.D.) values were 113.97 +/- 21.5 to 127.53 +/- 29.3 micrograms.hr/mL for AUC, 35.30 +/- 6.40 to 41.00 +/- 10.00 micrograms/mL for Cmax, 0.95 +/- 0.30 to 1.28 +/- 0.54 hr for tmax, and 0.346 +/- 0.026 to 0.388 +/- 0.040 hr-1 for k.",Effect of antacid suspension on the pharmacokinetics of ibuprofen. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3665393/),1/[h],0.388,187956,DB01050,Ibuprofen
,28926295,AUC0-72h,The ibuprofen medicated plaster was associated with a reduction in pain on movement (POM) based on lower VAS AUC0-72h (2399.4 mm*h) compared with placebo (4078.9 mm*h) (least squares mean difference: - 1679.5 mm*h; P < 0.0001).,Efficacy and safety assessment of acute sports-related traumatic soft tissue injuries using a new ibuprofen medicated plaster: results from a randomized controlled clinical trial. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28926295/),h·mm,2399.4,190963,DB01050,Ibuprofen
,28926295,AUC0-72h,The ibuprofen medicated plaster was associated with a reduction in pain on movement (POM) based on lower VAS AUC0-72h (2399.4 mm*h) compared with placebo (4078.9 mm*h) (least squares mean difference: - 1679.5 mm*h; P < 0.0001).,Efficacy and safety assessment of acute sports-related traumatic soft tissue injuries using a new ibuprofen medicated plaster: results from a randomized controlled clinical trial. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28926295/),h·mm,4078.9,190964,DB01050,Ibuprofen
,22197608,flow rate,"Following extraction, the analytes were separated on a Phenomenex Gemini C18 column (150 mm×2.0 mm, 5 μm), using a gradient of ammonium acetate 10 mM and acetonitrile with a flow rate of 300 μL/min.",Development and validation of a sensitive solid-phase-extraction (SPE) method using high-performance liquid chromatography/tandem mass spectrometry (LC-MS/MS) for determination of risedronate concentrations in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22197608/),[μl] / [min],300,191493,DB01050,Ibuprofen
,22197608,recovery,Mean recovery was 54% for risedronate and 51% for the internal standard.,Development and validation of a sensitive solid-phase-extraction (SPE) method using high-performance liquid chromatography/tandem mass spectrometry (LC-MS/MS) for determination of risedronate concentrations in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22197608/),%,54,191494,DB01050,Ibuprofen
,22197608,recovery,Mean recovery was 54% for risedronate and 51% for the internal standard.,Development and validation of a sensitive solid-phase-extraction (SPE) method using high-performance liquid chromatography/tandem mass spectrometry (LC-MS/MS) for determination of risedronate concentrations in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22197608/),%,51,191495,DB01050,Ibuprofen
,12182253,remedication times,"Median remedication times with both doses of ibuprofen arginate were similar to those with both doses of ibuprofen, ranging from 4.0 to 5.2 hours.","A randomized, double-blind, placebo-controlled comparison of the analgesic efficacy, onset of action, and tolerability of ibuprofen arginate and ibuprofen in postoperative dental pain. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12182253/),h,4.0 to 5.2,191813,DB01050,Ibuprofen
,12182253,time to meaningful pain relief,"Ibuprofen arginate was effective in this population of patients experiencing moderate to severe pain after surgical extraction of > or = 1 impacted third molar, with 16 to 24 minutes' faster time to meaningful pain relief than with ibuprofen.","A randomized, double-blind, placebo-controlled comparison of the analgesic efficacy, onset of action, and tolerability of ibuprofen arginate and ibuprofen in postoperative dental pain. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12182253/),minutes',16 to 24,191814,DB01050,Ibuprofen
,24482408,flow rate,"Separation was accomplished in a Chirex® 3005 (250 × 4.6 mm, 5 μm) column at 25°C with a mobile phase that consisted of 0.01 M ammonium acetate in methanol at a flow rate of 1.1 mL/min.",Analysis of ibuprofen enantiomers in rat plasma by liquid chromatography with tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24482408/),[ml] / [min],1.1,192667,DB01050,Ibuprofen
,15342612,t(1/2),"R- and S-ibuprofen t(1/2) were about 10 hours and 25.5 hours, respectively.",Population pharmacokinetics of ibuprofen enantiomers in very premature neonates. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15342612/),h,10,194275,DB01050,Ibuprofen
,15342612,t(1/2),"R- and S-ibuprofen t(1/2) were about 10 hours and 25.5 hours, respectively.",Population pharmacokinetics of ibuprofen enantiomers in very premature neonates. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15342612/),h,25.5,194276,DB01050,Ibuprofen
,15342612,CLR,"After prophylactic treatment, the mean clearance of R-ibuprofen (CLR = 12.7 mL/h) was about 2.5-fold higher than for S-ibuprofen (CLS = 5.0 mL/h).",Population pharmacokinetics of ibuprofen enantiomers in very premature neonates. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15342612/),[ml] / [h],12.7,194277,DB01050,Ibuprofen
,15342612,CLS,"After prophylactic treatment, the mean clearance of R-ibuprofen (CLR = 12.7 mL/h) was about 2.5-fold higher than for S-ibuprofen (CLS = 5.0 mL/h).",Population pharmacokinetics of ibuprofen enantiomers in very premature neonates. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15342612/),[ml] / [h],5.0,194278,DB01050,Ibuprofen
,3958223,extraction efficiencies,Mean extraction efficiencies were 0.16 (hydroxy) and 0.15 (carboxy).,The influence of hemodialysis on the pharmacokinetics of ibuprofen and its major metabolites. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3958223/),,0.16,197282,DB01050,Ibuprofen
,3958223,extraction efficiencies,Mean extraction efficiencies were 0.16 (hydroxy) and 0.15 (carboxy).,The influence of hemodialysis on the pharmacokinetics of ibuprofen and its major metabolites. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3958223/),,0.15,197283,DB01050,Ibuprofen
,27169284,recovery rate,The recovery rate was 93.1% to 100.4%.,[Plasma ibuprofen enantiomers and their pharmacokinetics in Beagle dogs determined by HPLC]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27169284/),%,93.1,199121,DB01050,Ibuprofen
,27169284,recovery rate,The recovery rate was 93.1% to 100.4%.,[Plasma ibuprofen enantiomers and their pharmacokinetics in Beagle dogs determined by HPLC]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27169284/),%,100.4,199122,DB01050,Ibuprofen
,27169284,C(max),"The C(max) of S-ibuprofen in Beagle dog plasma after a single intravenous administration of racemic-ibuprofen, S-ibuprofen and R-ibuprofen were 30.8 ± 4.7, 46.1 ± 5.9 and 20.0 ± 2.6 μg x mL(-1), respectively.",[Plasma ibuprofen enantiomers and their pharmacokinetics in Beagle dogs determined by HPLC]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27169284/),[μg] / [ml],30.8,199123,DB01050,Ibuprofen
,27169284,C(max),"The C(max) of S-ibuprofen in Beagle dog plasma after a single intravenous administration of racemic-ibuprofen, S-ibuprofen and R-ibuprofen were 30.8 ± 4.7, 46.1 ± 5.9 and 20.0 ± 2.6 μg x mL(-1), respectively.",[Plasma ibuprofen enantiomers and their pharmacokinetics in Beagle dogs determined by HPLC]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27169284/),[μg] / [ml],46.1,199124,DB01050,Ibuprofen
,27169284,C(max),"The C(max) of S-ibuprofen in Beagle dog plasma after a single intravenous administration of racemic-ibuprofen, S-ibuprofen and R-ibuprofen were 30.8 ± 4.7, 46.1 ± 5.9 and 20.0 ± 2.6 μg x mL(-1), respectively.",[Plasma ibuprofen enantiomers and their pharmacokinetics in Beagle dogs determined by HPLC]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27169284/),[μg] / [ml],20.0,199125,DB01050,Ibuprofen
,27169284,chiral inversion,"Comparing the pharmacokinetic parameters at different doses, chiral inversion were 70.1% ± 36.6% and 76.4% ± 36.2%, respectively, after intravenous administration of racemic- and R-ibuprofen.",[Plasma ibuprofen enantiomers and their pharmacokinetics in Beagle dogs determined by HPLC]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27169284/),%,70.1,199126,DB01050,Ibuprofen
,27169284,chiral inversion,"Comparing the pharmacokinetic parameters at different doses, chiral inversion were 70.1% ± 36.6% and 76.4% ± 36.2%, respectively, after intravenous administration of racemic- and R-ibuprofen.",[Plasma ibuprofen enantiomers and their pharmacokinetics in Beagle dogs determined by HPLC]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27169284/),%,76.4,199127,DB01050,Ibuprofen
,2339107,t1/2,Sustained-release ibuprofen tablets containing 0.18% of 170Er2O3 (greater than 96% 170Er) in the bulk formulation were manufactured under pilot-scale conditions and were radiolabeled utilizing a neutron activation procedure which converted stable 170Er to radioactive 171Er (t1/2 = 7.5 hr).,The effect of food on gastrointestinal (GI) transit of sustained-release ibuprofen tablets as evaluated by gamma scintigraphy. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2339107/),h,7.5,199969,DB01050,Ibuprofen
,2339107,gastric residence time,"In the remaining three subjects, the intact tablet was ejected from the stomach and a gastric residence time of approximately 4 hr was measured.",The effect of food on gastrointestinal (GI) transit of sustained-release ibuprofen tablets as evaluated by gamma scintigraphy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2339107/),h,4,199970,DB01050,Ibuprofen
,2339107,gastric retention time,This is in marked contrast to a previous study conducted in fasted volunteers in which gastric retention time ranged from 10 to 60 min.,The effect of food on gastrointestinal (GI) transit of sustained-release ibuprofen tablets as evaluated by gamma scintigraphy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2339107/),min,10 to 60,199971,DB01050,Ibuprofen
,12971028,elimination half-life (t1/2),"There was a large interindividual variability observed for plasma concentrations, elimination half-life (t1/2) (15.72 +/- 3.76 h), and area under the plasma concentration-time curve (AUC0-infinity) (402.60 +/- 79.67 micrograms.h/mL) in these babies.",Pharmacokinetics of oral ibuprofen in premature infants. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12971028/),h,15.72,200922,DB01050,Ibuprofen
,12971028,area under the plasma concentration-time curve (AUC0-infinity),"There was a large interindividual variability observed for plasma concentrations, elimination half-life (t1/2) (15.72 +/- 3.76 h), and area under the plasma concentration-time curve (AUC0-infinity) (402.60 +/- 79.67 micrograms.h/mL) in these babies.",Pharmacokinetics of oral ibuprofen in premature infants. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12971028/),[h·μg] / [ml],402.60,200923,DB01050,Ibuprofen
,12152005,clearances,"The pharmacokinetics of racemic and of S-ibuprofen depended on the CYP2C9 isoleucine359leucine amino acid polymorphism: population mean S-ibuprofen clearances were 3.25 L/h (95% confidence interval [CI], 2.84 to 3.73), 2.38 L/h (95% CI, 2.09 to 2.73), and 1.52 L/h (95% CI, 1.33 to 1.74) in carriers of the CYP2C9 genotypes *1/*1, *1/*3, and *3/*3, respectively.",Enantiospecific effects of cytochrome P450 2C9 amino acid variants on ibuprofen pharmacokinetics and on the inhibition of cyclooxygenases 1 and 2. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12152005/),[l] / [h],3.25,202163,DB01050,Ibuprofen
,12152005,clearances,"The pharmacokinetics of racemic and of S-ibuprofen depended on the CYP2C9 isoleucine359leucine amino acid polymorphism: population mean S-ibuprofen clearances were 3.25 L/h (95% confidence interval [CI], 2.84 to 3.73), 2.38 L/h (95% CI, 2.09 to 2.73), and 1.52 L/h (95% CI, 1.33 to 1.74) in carriers of the CYP2C9 genotypes *1/*1, *1/*3, and *3/*3, respectively.",Enantiospecific effects of cytochrome P450 2C9 amino acid variants on ibuprofen pharmacokinetics and on the inhibition of cyclooxygenases 1 and 2. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12152005/),[l] / [h],2.38,202164,DB01050,Ibuprofen
,12152005,clearances,"The pharmacokinetics of racemic and of S-ibuprofen depended on the CYP2C9 isoleucine359leucine amino acid polymorphism: population mean S-ibuprofen clearances were 3.25 L/h (95% confidence interval [CI], 2.84 to 3.73), 2.38 L/h (95% CI, 2.09 to 2.73), and 1.52 L/h (95% CI, 1.33 to 1.74) in carriers of the CYP2C9 genotypes *1/*1, *1/*3, and *3/*3, respectively.",Enantiospecific effects of cytochrome P450 2C9 amino acid variants on ibuprofen pharmacokinetics and on the inhibition of cyclooxygenases 1 and 2. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12152005/),[l] / [h],1.52,202165,DB01050,Ibuprofen
,25047517,area under the curve for 0-24 hours,Intravenous administration of PI-PEG resulted in significant levels in blood and in colon cancer xenografts (xenograft values in parentheses): area under the curve for 0-24 hours = 2351 (2621) (nmol/g) × h; Cmax = 1965 (886) nmol/g; Tmax = 0.08 (2) hour.,Pegylation improves the pharmacokinetics and bioavailability of small-molecule drugs hydrolyzable by esterases: a study of phospho-Ibuprofen. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25047517/),[nmol] / [g)·h],2351,203825,DB01050,Ibuprofen
,25047517,Cmax,Intravenous administration of PI-PEG resulted in significant levels in blood and in colon cancer xenografts (xenograft values in parentheses): area under the curve for 0-24 hours = 2351 (2621) (nmol/g) × h; Cmax = 1965 (886) nmol/g; Tmax = 0.08 (2) hour.,Pegylation improves the pharmacokinetics and bioavailability of small-molecule drugs hydrolyzable by esterases: a study of phospho-Ibuprofen. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25047517/),[nM] / [g],1965,203826,DB01050,Ibuprofen
,25047517,Tmax,Intravenous administration of PI-PEG resulted in significant levels in blood and in colon cancer xenografts (xenograft values in parentheses): area under the curve for 0-24 hours = 2351 (2621) (nmol/g) × h; Cmax = 1965 (886) nmol/g; Tmax = 0.08 (2) hour.,Pegylation improves the pharmacokinetics and bioavailability of small-molecule drugs hydrolyzable by esterases: a study of phospho-Ibuprofen. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25047517/),h,0.08,203827,DB01050,Ibuprofen
,9167225,lymphatic clearance,"The ""lymphatic clearance"" substantially differed between the investigated compounds (mean +/- SD: R-ibuprofen 6.71 +/- 3.15 microliters/min, S-ibuprofen 3.24 +/- 1.20 microliters/min, tenoxicam 8.74 +/- 8.11 microliters/min, nabumetone 46.05 +/- 26.08 microliters/min and 6MNA 6.32 +/- 2.96 microliters/min).",Lymph distribution of different non-steroidal anti-inflammatory drugs assessed by microsurgical cannulation of the thoracic duct in rat. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9167225/),[μl] / [min],6.71,203929,DB01050,Ibuprofen
,9167225,lymphatic clearance,"The ""lymphatic clearance"" substantially differed between the investigated compounds (mean +/- SD: R-ibuprofen 6.71 +/- 3.15 microliters/min, S-ibuprofen 3.24 +/- 1.20 microliters/min, tenoxicam 8.74 +/- 8.11 microliters/min, nabumetone 46.05 +/- 26.08 microliters/min and 6MNA 6.32 +/- 2.96 microliters/min).",Lymph distribution of different non-steroidal anti-inflammatory drugs assessed by microsurgical cannulation of the thoracic duct in rat. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9167225/),[μl] / [min],3.24,203930,DB01050,Ibuprofen
,9167225,lymphatic clearance,"The ""lymphatic clearance"" substantially differed between the investigated compounds (mean +/- SD: R-ibuprofen 6.71 +/- 3.15 microliters/min, S-ibuprofen 3.24 +/- 1.20 microliters/min, tenoxicam 8.74 +/- 8.11 microliters/min, nabumetone 46.05 +/- 26.08 microliters/min and 6MNA 6.32 +/- 2.96 microliters/min).",Lymph distribution of different non-steroidal anti-inflammatory drugs assessed by microsurgical cannulation of the thoracic duct in rat. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9167225/),[μl] / [min],8.74,203931,DB01050,Ibuprofen
,9167225,lymphatic clearance,"The ""lymphatic clearance"" substantially differed between the investigated compounds (mean +/- SD: R-ibuprofen 6.71 +/- 3.15 microliters/min, S-ibuprofen 3.24 +/- 1.20 microliters/min, tenoxicam 8.74 +/- 8.11 microliters/min, nabumetone 46.05 +/- 26.08 microliters/min and 6MNA 6.32 +/- 2.96 microliters/min).",Lymph distribution of different non-steroidal anti-inflammatory drugs assessed by microsurgical cannulation of the thoracic duct in rat. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9167225/),[μl] / [min],46.05,203932,DB01050,Ibuprofen
,9167225,lymphatic clearance,"The ""lymphatic clearance"" substantially differed between the investigated compounds (mean +/- SD: R-ibuprofen 6.71 +/- 3.15 microliters/min, S-ibuprofen 3.24 +/- 1.20 microliters/min, tenoxicam 8.74 +/- 8.11 microliters/min, nabumetone 46.05 +/- 26.08 microliters/min and 6MNA 6.32 +/- 2.96 microliters/min).",Lymph distribution of different non-steroidal anti-inflammatory drugs assessed by microsurgical cannulation of the thoracic duct in rat. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9167225/),[μl] / [min],6.32,203933,DB01050,Ibuprofen
not exceed,9167225,overall recovery,The overall recovery of the investigated compounds in lymph did not exceed 5% of the doses given.,Lymph distribution of different non-steroidal anti-inflammatory drugs assessed by microsurgical cannulation of the thoracic duct in rat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9167225/),%,5,203934,DB01050,Ibuprofen
>,33975823,AUC0-72h,Association between ibuprofen plasma concentrations measured at various sampling time points on the first day of treatment and attainment of the target exposure over the first 3 days of treatment (AUC0-72h >900 mg·hour/L).,Novel strategy to personalise use of ibuprofen for closure of patent ductus arteriosus in preterm neonates. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33975823/),[h·mg] / [l],900,206356,DB01050,Ibuprofen
>,33975823,AUC0-72h,We designed a novel and practical TDM strategy and have shown that the chance of reaching the target exposure (AUC0-72h >900 mg·hour/L) can be predicted with a single sample collection on the first day of treatment.,Novel strategy to personalise use of ibuprofen for closure of patent ductus arteriosus in preterm neonates. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33975823/),[h·mg] / [l],900,206357,DB01050,Ibuprofen
,9726693,tmax,"Dexibuprofen was absorbed rapidly (tmax 2.1 - 2.2 hours) reaching maximum concentrations of 12.4 microg/ml (200 mg), respectively 12.0 microg/ml (400 mg dose adjusted).",Pharmacokinetics of dexibuprofen administered as 200 mg and 400 mg film-coated tablets in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9726693/),h,2.1 - 2.2,206512,DB01050,Ibuprofen
,9726693,maximum concentrations,"Dexibuprofen was absorbed rapidly (tmax 2.1 - 2.2 hours) reaching maximum concentrations of 12.4 microg/ml (200 mg), respectively 12.0 microg/ml (400 mg dose adjusted).",Pharmacokinetics of dexibuprofen administered as 200 mg and 400 mg film-coated tablets in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9726693/),[μg] / [ml],12.4,206513,DB01050,Ibuprofen
,9726693,maximum concentrations,"Dexibuprofen was absorbed rapidly (tmax 2.1 - 2.2 hours) reaching maximum concentrations of 12.4 microg/ml (200 mg), respectively 12.0 microg/ml (400 mg dose adjusted).",Pharmacokinetics of dexibuprofen administered as 200 mg and 400 mg film-coated tablets in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9726693/),[μg] / [ml],12.0,206514,DB01050,Ibuprofen
,9726693,AUC(0-12h),"For the characteristics AUC(0-12h) and AUC(0-infinity) arithmetic means of 49.2 (microg) x (h/ml)(200 mg) and 48.2 (microg) x (h/ml)(400 mg dose-adjusted), respectively 50.5 (microg) x (h/ml)(200 mg), and 49.2 (microg) x (h/ml)(400 mg) were calculated.",Pharmacokinetics of dexibuprofen administered as 200 mg and 400 mg film-coated tablets in healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9726693/),[h·μg] / [ml],49.2,206515,DB01050,Ibuprofen
,9726693,AUC(0-12h),"For the characteristics AUC(0-12h) and AUC(0-infinity) arithmetic means of 49.2 (microg) x (h/ml)(200 mg) and 48.2 (microg) x (h/ml)(400 mg dose-adjusted), respectively 50.5 (microg) x (h/ml)(200 mg), and 49.2 (microg) x (h/ml)(400 mg) were calculated.",Pharmacokinetics of dexibuprofen administered as 200 mg and 400 mg film-coated tablets in healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9726693/),[h·μg] / [ml],50.5,206516,DB01050,Ibuprofen
,9726693,AUC(0-infinity),"For the characteristics AUC(0-12h) and AUC(0-infinity) arithmetic means of 49.2 (microg) x (h/ml)(200 mg) and 48.2 (microg) x (h/ml)(400 mg dose-adjusted), respectively 50.5 (microg) x (h/ml)(200 mg), and 49.2 (microg) x (h/ml)(400 mg) were calculated.",Pharmacokinetics of dexibuprofen administered as 200 mg and 400 mg film-coated tablets in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9726693/),[h·μg] / [ml],48.2,206517,DB01050,Ibuprofen
,9726693,AUC(0-infinity),"For the characteristics AUC(0-12h) and AUC(0-infinity) arithmetic means of 49.2 (microg) x (h/ml)(200 mg) and 48.2 (microg) x (h/ml)(400 mg dose-adjusted), respectively 50.5 (microg) x (h/ml)(200 mg), and 49.2 (microg) x (h/ml)(400 mg) were calculated.",Pharmacokinetics of dexibuprofen administered as 200 mg and 400 mg film-coated tablets in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9726693/),μg,49.2,206518,DB01050,Ibuprofen
,21329049,Cmax,Ibuprofen plasma concentration reached a Cmax of 74.11 +/- 18.52 microg/ml 2 hours post application on rat skin.,Ibuprofen transdermal ethosomal gel: characterization and efficiency in animal models. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21329049/),[μg] / [ml],74.11,206611,DB01050,Ibuprofen
,28856569,maximum observed concentration (C max),"For cromolyn, the mean (±SD) maximum observed concentration (C max) in plasma was 46.69 ± 32.97 and 96.75 ± 46.22 ng/ml after single- and double-dose inhalation, respectively [time to C max (t max) ~22 min for each; terminal elimination half-life (t ½) ~1.8 h for each].",Pharmacokinetics of Cromolyn and Ibuprofen in Healthy Elderly Volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28856569/),[ng] / [ml],46.69,206660,DB01050,Ibuprofen
,28856569,maximum observed concentration (C max),"For cromolyn, the mean (±SD) maximum observed concentration (C max) in plasma was 46.69 ± 32.97 and 96.75 ± 46.22 ng/ml after single- and double-dose inhalation, respectively [time to C max (t max) ~22 min for each; terminal elimination half-life (t ½) ~1.8 h for each].",Pharmacokinetics of Cromolyn and Ibuprofen in Healthy Elderly Volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28856569/),[ng] / [ml],96.75,206661,DB01050,Ibuprofen
,28856569,time to C max (t max),"For cromolyn, the mean (±SD) maximum observed concentration (C max) in plasma was 46.69 ± 32.97 and 96.75 ± 46.22 ng/ml after single- and double-dose inhalation, respectively [time to C max (t max) ~22 min for each; terminal elimination half-life (t ½) ~1.8 h for each].",Pharmacokinetics of Cromolyn and Ibuprofen in Healthy Elderly Volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28856569/),min,22,206662,DB01050,Ibuprofen
,28856569,terminal elimination half-life (t ½),"For cromolyn, the mean (±SD) maximum observed concentration (C max) in plasma was 46.69 ± 32.97 and 96.75 ± 46.22 ng/ml after single- and double-dose inhalation, respectively [time to C max (t max) ~22 min for each; terminal elimination half-life (t ½) ~1.8 h for each].",Pharmacokinetics of Cromolyn and Ibuprofen in Healthy Elderly Volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/28856569/),h,1.8,206663,DB01050,Ibuprofen
,28856569,plasma C max,"For ibuprofen, the plasma C max was 1090.98 ± 474.64 ng/ml and 2062.96 ± 655.13 ng/ml after single- and double-dose oral administration, respectively (t max ~1.6-1.8 h; t ½ ~1.9 h for each).",Pharmacokinetics of Cromolyn and Ibuprofen in Healthy Elderly Volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28856569/),[ng] / [ml],1090.98,206664,DB01050,Ibuprofen
,28856569,plasma C max,"For ibuprofen, the plasma C max was 1090.98 ± 474.64 ng/ml and 2062.96 ± 655.13 ng/ml after single- and double-dose oral administration, respectively (t max ~1.6-1.8 h; t ½ ~1.9 h for each).",Pharmacokinetics of Cromolyn and Ibuprofen in Healthy Elderly Volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28856569/),[ng] / [ml],2062.96,206665,DB01050,Ibuprofen
,28856569,t max,"For ibuprofen, the plasma C max was 1090.98 ± 474.64 ng/ml and 2062.96 ± 655.13 ng/ml after single- and double-dose oral administration, respectively (t max ~1.6-1.8 h; t ½ ~1.9 h for each).",Pharmacokinetics of Cromolyn and Ibuprofen in Healthy Elderly Volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28856569/),h,1.6-1.8,206666,DB01050,Ibuprofen
,28856569,t ½,"For ibuprofen, the plasma C max was 1090.98 ± 474.64 ng/ml and 2062.96 ± 655.13 ng/ml after single- and double-dose oral administration, respectively (t max ~1.6-1.8 h; t ½ ~1.9 h for each).",Pharmacokinetics of Cromolyn and Ibuprofen in Healthy Elderly Volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28856569/),h,1.9,206667,DB01050,Ibuprofen
,28856569,C max,"For cromolyn, the CSF C max was 0.24 ± 0.08 ng/ml at 3.72 ± 0.70 h after single-dose administration and 0.34 ± 0.17 ng/ml at 3.45 ± 0.95 h after double-dose administration, and for ibuprofen, the CSF C max was 3.94 ± 1.29 ng/ml at 2.55 ± 0.96 h after single-dose administration and 8.93 ± 3.29 ng/ml at 3.15 ± 1.05 h after double-dose administration.",Pharmacokinetics of Cromolyn and Ibuprofen in Healthy Elderly Volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28856569/),[ng] / [ml],0.24,206668,DB01050,Ibuprofen
,28856569,C max,"For cromolyn, the CSF C max was 0.24 ± 0.08 ng/ml at 3.72 ± 0.70 h after single-dose administration and 0.34 ± 0.17 ng/ml at 3.45 ± 0.95 h after double-dose administration, and for ibuprofen, the CSF C max was 3.94 ± 1.29 ng/ml at 2.55 ± 0.96 h after single-dose administration and 8.93 ± 3.29 ng/ml at 3.15 ± 1.05 h after double-dose administration.",Pharmacokinetics of Cromolyn and Ibuprofen in Healthy Elderly Volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28856569/),[ng] / [ml],0.34,206669,DB01050,Ibuprofen
,28856569,C max,"For cromolyn, the CSF C max was 0.24 ± 0.08 ng/ml at 3.72 ± 0.70 h after single-dose administration and 0.34 ± 0.17 ng/ml at 3.45 ± 0.95 h after double-dose administration, and for ibuprofen, the CSF C max was 3.94 ± 1.29 ng/ml at 2.55 ± 0.96 h after single-dose administration and 8.93 ± 3.29 ng/ml at 3.15 ± 1.05 h after double-dose administration.",Pharmacokinetics of Cromolyn and Ibuprofen in Healthy Elderly Volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28856569/),[ng] / [ml],3.94,206670,DB01050,Ibuprofen
,28856569,C max,"For cromolyn, the CSF C max was 0.24 ± 0.08 ng/ml at 3.72 ± 0.70 h after single-dose administration and 0.34 ± 0.17 ng/ml at 3.45 ± 0.95 h after double-dose administration, and for ibuprofen, the CSF C max was 3.94 ± 1.29 ng/ml at 2.55 ± 0.96 h after single-dose administration and 8.93 ± 3.29 ng/ml at 3.15 ± 1.05 h after double-dose administration.",Pharmacokinetics of Cromolyn and Ibuprofen in Healthy Elderly Volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28856569/),[ng] / [ml],8.93,206671,DB01050,Ibuprofen
,34332199,recoveries,"In addition, the recoveries of niclosamide ranged between 87.8 and 99.6% and 102-104% for rat and dog plasma, respectively.",Bioanalysis of niclosamide in plasma using liquid chromatography-tandem mass and application to pharmacokinetics in rats and dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34332199/),%,87.8 and 99.6,207265,DB01050,Ibuprofen
,34332199,recoveries,"In addition, the recoveries of niclosamide ranged between 87.8 and 99.6% and 102-104% for rat and dog plasma, respectively.",Bioanalysis of niclosamide in plasma using liquid chromatography-tandem mass and application to pharmacokinetics in rats and dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34332199/),%,102-104,207266,DB01050,Ibuprofen
>,34332199,plasma protein binding,"Additionally, niclosamide presented high plasma protein binding (>99.8%) and low metabolic stability.",Bioanalysis of niclosamide in plasma using liquid chromatography-tandem mass and application to pharmacokinetics in rats and dogs. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34332199/),%,99.8,207267,DB01050,Ibuprofen
,6673979,extraction efficiency,"The hemodialysis systems used in this study yielded a mean extraction efficiency of 16.7% for ibuprofen, with a mean dialysis plasma clearance of 22.7 ml/min.",Absorption and disposition of ibuprofen in hemodialyzed uremic patients. ,E-Q38,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6673979/),%,16.7,209013,DB01050,Ibuprofen
,6673979,plasma clearance,"The hemodialysis systems used in this study yielded a mean extraction efficiency of 16.7% for ibuprofen, with a mean dialysis plasma clearance of 22.7 ml/min.",Absorption and disposition of ibuprofen in hemodialyzed uremic patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6673979/),[ml] / [min],22.7,209014,DB01050,Ibuprofen
,6673979,half-life,The half-life of ibuprofen (1.3-1.9 hr) was not significantly altered by hemodialysis.,Absorption and disposition of ibuprofen in hemodialyzed uremic patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6673979/),h,1.3-1.9,209015,DB01050,Ibuprofen
,6673979,protein binding,"Observations of extraction efficiency, drug recovery and half-life during dialysis suggested nondialyzability of ibuprofen, probably due to its extensive protein binding (approximately 90%).",Absorption and disposition of ibuprofen in hemodialyzed uremic patients. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6673979/),%,90,209016,DB01050,Ibuprofen
,15249757,distribution volume,"Assuming a one-compartment model with instantaneous input and first-order output, there was no significant difference in the median distribution volume (0.63 vs. 0.59 liters/kg), but the median serum half-life (16.4 vs. 12.4 h) of amikacin was significantly longer (p <0.02), and the clearance (0.36 vs. 0.6 ml/kg/min; p <0.005) of amikacin was significantly lower in infants who received ibuprofen-lysine.",Effects of co-administration of ibuprofen-lysine on the pharmacokinetics of amikacin in preterm infants during the first days of life. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15249757/),[l] / [kg],0.63,209564,DB01050,Ibuprofen
,15249757,distribution volume,"Assuming a one-compartment model with instantaneous input and first-order output, there was no significant difference in the median distribution volume (0.63 vs. 0.59 liters/kg), but the median serum half-life (16.4 vs. 12.4 h) of amikacin was significantly longer (p <0.02), and the clearance (0.36 vs. 0.6 ml/kg/min; p <0.005) of amikacin was significantly lower in infants who received ibuprofen-lysine.",Effects of co-administration of ibuprofen-lysine on the pharmacokinetics of amikacin in preterm infants during the first days of life. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15249757/),[l] / [kg],0.59,209565,DB01050,Ibuprofen
,15249757,serum half-life,"Assuming a one-compartment model with instantaneous input and first-order output, there was no significant difference in the median distribution volume (0.63 vs. 0.59 liters/kg), but the median serum half-life (16.4 vs. 12.4 h) of amikacin was significantly longer (p <0.02), and the clearance (0.36 vs. 0.6 ml/kg/min; p <0.005) of amikacin was significantly lower in infants who received ibuprofen-lysine.",Effects of co-administration of ibuprofen-lysine on the pharmacokinetics of amikacin in preterm infants during the first days of life. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15249757/),h,16.4,209566,DB01050,Ibuprofen
,15249757,serum half-life,"Assuming a one-compartment model with instantaneous input and first-order output, there was no significant difference in the median distribution volume (0.63 vs. 0.59 liters/kg), but the median serum half-life (16.4 vs. 12.4 h) of amikacin was significantly longer (p <0.02), and the clearance (0.36 vs. 0.6 ml/kg/min; p <0.005) of amikacin was significantly lower in infants who received ibuprofen-lysine.",Effects of co-administration of ibuprofen-lysine on the pharmacokinetics of amikacin in preterm infants during the first days of life. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15249757/),h,12.4,209567,DB01050,Ibuprofen
,15249757,clearance,"Assuming a one-compartment model with instantaneous input and first-order output, there was no significant difference in the median distribution volume (0.63 vs. 0.59 liters/kg), but the median serum half-life (16.4 vs. 12.4 h) of amikacin was significantly longer (p <0.02), and the clearance (0.36 vs. 0.6 ml/kg/min; p <0.005) of amikacin was significantly lower in infants who received ibuprofen-lysine.",Effects of co-administration of ibuprofen-lysine on the pharmacokinetics of amikacin in preterm infants during the first days of life. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15249757/),[ml] / [kg·min],0.36,209568,DB01050,Ibuprofen
,15249757,clearance,"Assuming a one-compartment model with instantaneous input and first-order output, there was no significant difference in the median distribution volume (0.63 vs. 0.59 liters/kg), but the median serum half-life (16.4 vs. 12.4 h) of amikacin was significantly longer (p <0.02), and the clearance (0.36 vs. 0.6 ml/kg/min; p <0.005) of amikacin was significantly lower in infants who received ibuprofen-lysine.",Effects of co-administration of ibuprofen-lysine on the pharmacokinetics of amikacin in preterm infants during the first days of life. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15249757/),[ml] / [kg·min],0.6,209569,DB01050,Ibuprofen
,11185632,Cmax,"Geometric mean Cmax values for acetaminophen and R-(-)- and S-(+)-ibuprofen enantiomers were similar with and without telmisartan coadministration (12.6 micrograms/mL vs. 14.1 micrograms/mL; 17.3 micrograms/mL vs. 16.7 micrograms/mL; 19.4 micrograms/mL vs. 19.5 micrograms/mL, respectively), and values for R-(-)- as well as S-(+)-ibuprofen were bioequivalent.",Pharmacokinetics of acetaminophen and ibuprofen when coadministered with telmisartan in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11185632/),[μg] / [ml],12.6,209874,DB01050,Ibuprofen
,11185632,Cmax,"Geometric mean Cmax values for acetaminophen and R-(-)- and S-(+)-ibuprofen enantiomers were similar with and without telmisartan coadministration (12.6 micrograms/mL vs. 14.1 micrograms/mL; 17.3 micrograms/mL vs. 16.7 micrograms/mL; 19.4 micrograms/mL vs. 19.5 micrograms/mL, respectively), and values for R-(-)- as well as S-(+)-ibuprofen were bioequivalent.",Pharmacokinetics of acetaminophen and ibuprofen when coadministered with telmisartan in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11185632/),[μg] / [ml],14.1,209875,DB01050,Ibuprofen
,11185632,Cmax,"Geometric mean Cmax values for acetaminophen and R-(-)- and S-(+)-ibuprofen enantiomers were similar with and without telmisartan coadministration (12.6 micrograms/mL vs. 14.1 micrograms/mL; 17.3 micrograms/mL vs. 16.7 micrograms/mL; 19.4 micrograms/mL vs. 19.5 micrograms/mL, respectively), and values for R-(-)- as well as S-(+)-ibuprofen were bioequivalent.",Pharmacokinetics of acetaminophen and ibuprofen when coadministered with telmisartan in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11185632/),[μg] / [ml],17.3,209876,DB01050,Ibuprofen
,11185632,Cmax,"Geometric mean Cmax values for acetaminophen and R-(-)- and S-(+)-ibuprofen enantiomers were similar with and without telmisartan coadministration (12.6 micrograms/mL vs. 14.1 micrograms/mL; 17.3 micrograms/mL vs. 16.7 micrograms/mL; 19.4 micrograms/mL vs. 19.5 micrograms/mL, respectively), and values for R-(-)- as well as S-(+)-ibuprofen were bioequivalent.",Pharmacokinetics of acetaminophen and ibuprofen when coadministered with telmisartan in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11185632/),[μg] / [ml],16.7,209877,DB01050,Ibuprofen
,11185632,Cmax,"Geometric mean Cmax values for acetaminophen and R-(-)- and S-(+)-ibuprofen enantiomers were similar with and without telmisartan coadministration (12.6 micrograms/mL vs. 14.1 micrograms/mL; 17.3 micrograms/mL vs. 16.7 micrograms/mL; 19.4 micrograms/mL vs. 19.5 micrograms/mL, respectively), and values for R-(-)- as well as S-(+)-ibuprofen were bioequivalent.",Pharmacokinetics of acetaminophen and ibuprofen when coadministered with telmisartan in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11185632/),[μg] / [ml],19.4,209878,DB01050,Ibuprofen
,11185632,Cmax,"Geometric mean Cmax values for acetaminophen and R-(-)- and S-(+)-ibuprofen enantiomers were similar with and without telmisartan coadministration (12.6 micrograms/mL vs. 14.1 micrograms/mL; 17.3 micrograms/mL vs. 16.7 micrograms/mL; 19.4 micrograms/mL vs. 19.5 micrograms/mL, respectively), and values for R-(-)- as well as S-(+)-ibuprofen were bioequivalent.",Pharmacokinetics of acetaminophen and ibuprofen when coadministered with telmisartan in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11185632/),[μg] / [ml],19.5,209879,DB01050,Ibuprofen
,31194730,AUCo/AUCp plasma,"The model was also able to describe disease-mediated changes in neonates and young children (<3m postnatal age) related to meningitis and sepsis (range AUCo/AUCp plasma: 1.64-1.66, range AUCo/AUCp CSF: 1.43-1.73).",Development of a physiologically-based pharmacokinetic pediatric brain model for prediction of cerebrospinal fluid drug concentrations and the influence of meningitis. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31194730/),,1.64-1.66,211062,DB01050,Ibuprofen
,31194730,AUCo/AUCp CSF,"The model was also able to describe disease-mediated changes in neonates and young children (<3m postnatal age) related to meningitis and sepsis (range AUCo/AUCp plasma: 1.64-1.66, range AUCo/AUCp CSF: 1.43-1.73).",Development of a physiologically-based pharmacokinetic pediatric brain model for prediction of cerebrospinal fluid drug concentrations and the influence of meningitis. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31194730/),,1.43-1.73,211063,DB01050,Ibuprofen
,6668554,binding capacity,"The binding capacity averaged 1231 microM (range 848-1658 microM), and the association constant averaged 1.76 X 10(5) M-1 (range 1.15 X 10(5) to 2.73 X 10(5) M-1).",Pharmacokinetics of ibuprofen in man--III: Plasma protein binding. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6668554/),μM,1231,211123,DB01050,Ibuprofen
,6668554,association constant,"The binding capacity averaged 1231 microM (range 848-1658 microM), and the association constant averaged 1.76 X 10(5) M-1 (range 1.15 X 10(5) to 2.73 X 10(5) M-1).",Pharmacokinetics of ibuprofen in man--III: Plasma protein binding. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6668554/),1/[M],1.76 X 10(5),211124,DB01050,Ibuprofen
,6668554,association constant,"The binding capacity averaged 1231 microM (range 848-1658 microM), and the association constant averaged 1.76 X 10(5) M-1 (range 1.15 X 10(5) to 2.73 X 10(5) M-1).",Pharmacokinetics of ibuprofen in man--III: Plasma protein binding. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6668554/),1/[M],2.73 X 10(5),211125,DB01050,Ibuprofen
,1505153,Time of maximum serum concentrations,"Time of maximum serum concentrations for ibuprofen was 54.05 minutes versus 27.0 minutes for acetaminophen, time to maximum temperature decrease was 183 minutes for ibuprofen and 133 minutes for acetaminophen.",Pharmacokinetics and pharmacodynamics of ibuprofen isomers and acetaminophen in febrile children. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1505153/),min,54.05,212929,DB01050,Ibuprofen
,1505153,Time of maximum serum concentrations,"Time of maximum serum concentrations for ibuprofen was 54.05 minutes versus 27.0 minutes for acetaminophen, time to maximum temperature decrease was 183 minutes for ibuprofen and 133 minutes for acetaminophen.",Pharmacokinetics and pharmacodynamics of ibuprofen isomers and acetaminophen in febrile children. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1505153/),min,27.0,212930,DB01050,Ibuprofen
,1505153,time to maximum temperature decrease,"Time of maximum serum concentrations for ibuprofen was 54.05 minutes versus 27.0 minutes for acetaminophen, time to maximum temperature decrease was 183 minutes for ibuprofen and 133 minutes for acetaminophen.",Pharmacokinetics and pharmacodynamics of ibuprofen isomers and acetaminophen in febrile children. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1505153/),min,183,212931,DB01050,Ibuprofen
,1505153,time to maximum temperature decrease,"Time of maximum serum concentrations for ibuprofen was 54.05 minutes versus 27.0 minutes for acetaminophen, time to maximum temperature decrease was 183 minutes for ibuprofen and 133 minutes for acetaminophen.",Pharmacokinetics and pharmacodynamics of ibuprofen isomers and acetaminophen in febrile children. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1505153/),min,133,212932,DB01050,Ibuprofen
,9608882,peak plasma concentration (Cmax),"In fact, the geometric mean peak plasma concentration (Cmax) and median peak time (tmax) were 12.04 micrograms/ml at 3.5 h with the new formulation, and 18.71 micrograms/ml at 1 h with the SCT, respectively.",Comparative bioavailability study of two oral formulations of ibuprofen. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9608882/),[μg] / [ml],12.04,214681,DB01050,Ibuprofen
,9608882,peak time (tmax),"In fact, the geometric mean peak plasma concentration (Cmax) and median peak time (tmax) were 12.04 micrograms/ml at 3.5 h with the new formulation, and 18.71 micrograms/ml at 1 h with the SCT, respectively.",Comparative bioavailability study of two oral formulations of ibuprofen. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9608882/),[μg] / [ml],18.71,214682,DB01050,Ibuprofen
,15324530,oral bioavailability,"Oxaprozin has a high oral bioavailability (95%), with peak plasma concentrations at 3 to 5 hours after dosing.",Oxaprozin: kinetic and dynamic profile in the treatment of pain. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15324530/),%,95,215232,DB01050,Ibuprofen
,25452230,bioavailability,"After intravenous and oral administration of ibuprofen and fexofenadine (BCS class II and III), the plasma concentration and pharmacokinetic parameters were evaluated by our method and a terminal blood sampling method, with the result that both methods gave comparable results (ibuprofen: 63.8 ± 4.0% and 64.4%, fexofenadine: 6.5 ± 0.7% and 7.9%, respectively, in bioavailability).",Using improved serial blood sampling method of mice to study pharmacokinetics and drug-drug interaction. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25452230/),%,6.5,216135,DB01050,Ibuprofen
,25452230,bioavailability,"After intravenous and oral administration of ibuprofen and fexofenadine (BCS class II and III), the plasma concentration and pharmacokinetic parameters were evaluated by our method and a terminal blood sampling method, with the result that both methods gave comparable results (ibuprofen: 63.8 ± 4.0% and 64.4%, fexofenadine: 6.5 ± 0.7% and 7.9%, respectively, in bioavailability).",Using improved serial blood sampling method of mice to study pharmacokinetics and drug-drug interaction. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25452230/),%,7.9,216136,DB01050,Ibuprofen
,10221372,time to achieve apparent maximum ibuprofen concentration (Tmax),"The time to achieve apparent maximum ibuprofen concentration (Tmax) ranged from 1-3 hours, with maximum concentrations ranging from 21-150 microg/ml (mean 83 microg/ml).",Pharmacokinetics of ibuprofen in patients with cystic fibrosis. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10221372/),h,1-3,217090,DB01050,Ibuprofen
,10221372,maximum concentrations,"The time to achieve apparent maximum ibuprofen concentration (Tmax) ranged from 1-3 hours, with maximum concentrations ranging from 21-150 microg/ml (mean 83 microg/ml).",Pharmacokinetics of ibuprofen in patients with cystic fibrosis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10221372/),[μg] / [ml],83,217091,DB01050,Ibuprofen
,10221372,Cl/F,"The Cl/F ranged from 21.1-114.7 ml/min/m2 (mean 45.5 ml/min/m2), a 5-fold difference.",Pharmacokinetics of ibuprofen in patients with cystic fibrosis. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10221372/),[ml] / [m2·min],45.5,217092,DB01050,Ibuprofen
,10221372,Tmax,"The Cl/F was not different among doses; however, Tmax differed by an average of 1.25 hours (range 0-2 hrs).",Pharmacokinetics of ibuprofen in patients with cystic fibrosis. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10221372/),h,1.25,217093,DB01050,Ibuprofen
,2376426,peak plasma ibuprofen concentration,"After 2 times 200 mg single dose, one preparation produced peak plasma ibuprofen concentration 30.0 +/- 2.1 micrograms/ml at 1.6 h and the other preparation 23.2 +/- 1.9 micrograms/ml at 2.3 h (p less than 0.05).","Pharmacokinetics of ibuprofen in man: a single-dose comparison of two over-the-counter, 200 mg preparations. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2376426/),[μg] / [ml],30.0,217518,DB01050,Ibuprofen
,2376426,peak plasma ibuprofen concentration,"After 2 times 200 mg single dose, one preparation produced peak plasma ibuprofen concentration 30.0 +/- 2.1 micrograms/ml at 1.6 h and the other preparation 23.2 +/- 1.9 micrograms/ml at 2.3 h (p less than 0.05).","Pharmacokinetics of ibuprofen in man: a single-dose comparison of two over-the-counter, 200 mg preparations. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2376426/),[μg] / [ml],23.2,217519,DB01050,Ibuprofen
,21794255,t(max),"The median t(max) was 1.25 h, and the average maximal plasma concentration was 40.7 mg/l.",[Study of the extent and rate of bioavailability of ibuprofen tablets]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21794255/),h,1.25,218028,DB01050,Ibuprofen
,21794255,maximal plasma concentration,"The median t(max) was 1.25 h, and the average maximal plasma concentration was 40.7 mg/l.",[Study of the extent and rate of bioavailability of ibuprofen tablets]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21794255/),[mg] / [l],40.7,218029,DB01050,Ibuprofen
,29717552,Peak ibuprofen plasma concentrations,Peak ibuprofen plasma concentrations decreased an average of 36.4 mcg/mL after initiation of lumacaftor/ivacaftor with a relative reduction of 41.7%.,Impact of a cystic fibrosis transmembrane conductance regulator (CFTR) modulator on high-dose ibuprofen therapy in pediatric cystic fibrosis patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29717552/),[mcg] / [ml],36.4,218316,DB01050,Ibuprofen
,29717552,peak plasma concentration,The average peak plasma concentration was 84.2 mcg/mL (SD = 10.9) prior to lumacaftor/ivacaftor initiation and 47.9 mcg/mL (SD = 16.4) following initiation (P = 0.0039).,Impact of a cystic fibrosis transmembrane conductance regulator (CFTR) modulator on high-dose ibuprofen therapy in pediatric cystic fibrosis patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29717552/),[mcg] / [ml],84.2,218317,DB01050,Ibuprofen
,29717552,peak plasma concentration,The average peak plasma concentration was 84.2 mcg/mL (SD = 10.9) prior to lumacaftor/ivacaftor initiation and 47.9 mcg/mL (SD = 16.4) following initiation (P = 0.0039).,Impact of a cystic fibrosis transmembrane conductance regulator (CFTR) modulator on high-dose ibuprofen therapy in pediatric cystic fibrosis patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29717552/),[mcg] / [ml],47.9,218318,DB01050,Ibuprofen
,26249766,Cmax,"The pharmacokinetic parameters (Algidrin® Pediátrico vs. Dalsy® (Mean±SD)) were: S-enantiomer: Cmax=22.39±5.33 vs. 19.97±3.19 μg/mL; AUC0t=74.83±16.69 vs. 74.64±14.80 μg×h/mL, and AUC0∞=77.46±19.33 vs. 76.98±17.13 μg×h/mL; and for R-enantiomer: Cmax=21.74±3.76 vs. 15.20±2.03 μg/mL; AUC0t=57.55±10.17 vs. 46.13±9.61 μg×h/mL, and AUC0∞ value was 58.49±10.57 vs.","Ibuprofen lysinate, quicker and less variable: relative bioavailability compared to ibuprofen base in a pediatric suspension dosage form. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26249766/),[μg] / [ml],22.39,222025,DB01050,Ibuprofen
,26249766,Cmax,"The pharmacokinetic parameters (Algidrin® Pediátrico vs. Dalsy® (Mean±SD)) were: S-enantiomer: Cmax=22.39±5.33 vs. 19.97±3.19 μg/mL; AUC0t=74.83±16.69 vs. 74.64±14.80 μg×h/mL, and AUC0∞=77.46±19.33 vs. 76.98±17.13 μg×h/mL; and for R-enantiomer: Cmax=21.74±3.76 vs. 15.20±2.03 μg/mL; AUC0t=57.55±10.17 vs. 46.13±9.61 μg×h/mL, and AUC0∞ value was 58.49±10.57 vs.","Ibuprofen lysinate, quicker and less variable: relative bioavailability compared to ibuprofen base in a pediatric suspension dosage form. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26249766/),[μg] / [ml],19.97,222026,DB01050,Ibuprofen
,26249766,AUC0t,"The pharmacokinetic parameters (Algidrin® Pediátrico vs. Dalsy® (Mean±SD)) were: S-enantiomer: Cmax=22.39±5.33 vs. 19.97±3.19 μg/mL; AUC0t=74.83±16.69 vs. 74.64±14.80 μg×h/mL, and AUC0∞=77.46±19.33 vs. 76.98±17.13 μg×h/mL; and for R-enantiomer: Cmax=21.74±3.76 vs. 15.20±2.03 μg/mL; AUC0t=57.55±10.17 vs. 46.13±9.61 μg×h/mL, and AUC0∞ value was 58.49±10.57 vs.","Ibuprofen lysinate, quicker and less variable: relative bioavailability compared to ibuprofen base in a pediatric suspension dosage form. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26249766/),[h·μg] / [ml],74.83,222027,DB01050,Ibuprofen
,26249766,AUC0t,"The pharmacokinetic parameters (Algidrin® Pediátrico vs. Dalsy® (Mean±SD)) were: S-enantiomer: Cmax=22.39±5.33 vs. 19.97±3.19 μg/mL; AUC0t=74.83±16.69 vs. 74.64±14.80 μg×h/mL, and AUC0∞=77.46±19.33 vs. 76.98±17.13 μg×h/mL; and for R-enantiomer: Cmax=21.74±3.76 vs. 15.20±2.03 μg/mL; AUC0t=57.55±10.17 vs. 46.13±9.61 μg×h/mL, and AUC0∞ value was 58.49±10.57 vs.","Ibuprofen lysinate, quicker and less variable: relative bioavailability compared to ibuprofen base in a pediatric suspension dosage form. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26249766/),[h·μg] / [ml],74.64,222028,DB01050,Ibuprofen
,26249766,AUC0∞,"The pharmacokinetic parameters (Algidrin® Pediátrico vs. Dalsy® (Mean±SD)) were: S-enantiomer: Cmax=22.39±5.33 vs. 19.97±3.19 μg/mL; AUC0t=74.83±16.69 vs. 74.64±14.80 μg×h/mL, and AUC0∞=77.46±19.33 vs. 76.98±17.13 μg×h/mL; and for R-enantiomer: Cmax=21.74±3.76 vs. 15.20±2.03 μg/mL; AUC0t=57.55±10.17 vs. 46.13±9.61 μg×h/mL, and AUC0∞ value was 58.49±10.57 vs.","Ibuprofen lysinate, quicker and less variable: relative bioavailability compared to ibuprofen base in a pediatric suspension dosage form. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26249766/),[h·μg] / [ml],77.46,222029,DB01050,Ibuprofen
,26249766,AUC0∞,"The pharmacokinetic parameters (Algidrin® Pediátrico vs. Dalsy® (Mean±SD)) were: S-enantiomer: Cmax=22.39±5.33 vs. 19.97±3.19 μg/mL; AUC0t=74.83±16.69 vs. 74.64±14.80 μg×h/mL, and AUC0∞=77.46±19.33 vs. 76.98±17.13 μg×h/mL; and for R-enantiomer: Cmax=21.74±3.76 vs. 15.20±2.03 μg/mL; AUC0t=57.55±10.17 vs. 46.13±9.61 μg×h/mL, and AUC0∞ value was 58.49±10.57 vs.","Ibuprofen lysinate, quicker and less variable: relative bioavailability compared to ibuprofen base in a pediatric suspension dosage form. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26249766/),[h·μg] / [ml],76.98,222030,DB01050,Ibuprofen
,26249766,Cmax,"The pharmacokinetic parameters (Algidrin® Pediátrico vs. Dalsy® (Mean±SD)) were: S-enantiomer: Cmax=22.39±5.33 vs. 19.97±3.19 μg/mL; AUC0t=74.83±16.69 vs. 74.64±14.80 μg×h/mL, and AUC0∞=77.46±19.33 vs. 76.98±17.13 μg×h/mL; and for R-enantiomer: Cmax=21.74±3.76 vs. 15.20±2.03 μg/mL; AUC0t=57.55±10.17 vs. 46.13±9.61 μg×h/mL, and AUC0∞ value was 58.49±10.57 vs.","Ibuprofen lysinate, quicker and less variable: relative bioavailability compared to ibuprofen base in a pediatric suspension dosage form. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26249766/),[μg] / [ml],21.74,222031,DB01050,Ibuprofen
,26249766,Cmax,"The pharmacokinetic parameters (Algidrin® Pediátrico vs. Dalsy® (Mean±SD)) were: S-enantiomer: Cmax=22.39±5.33 vs. 19.97±3.19 μg/mL; AUC0t=74.83±16.69 vs. 74.64±14.80 μg×h/mL, and AUC0∞=77.46±19.33 vs. 76.98±17.13 μg×h/mL; and for R-enantiomer: Cmax=21.74±3.76 vs. 15.20±2.03 μg/mL; AUC0t=57.55±10.17 vs. 46.13±9.61 μg×h/mL, and AUC0∞ value was 58.49±10.57 vs.","Ibuprofen lysinate, quicker and less variable: relative bioavailability compared to ibuprofen base in a pediatric suspension dosage form. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26249766/),[μg] / [ml],15.20,222032,DB01050,Ibuprofen
,26249766,AUC0t,"The pharmacokinetic parameters (Algidrin® Pediátrico vs. Dalsy® (Mean±SD)) were: S-enantiomer: Cmax=22.39±5.33 vs. 19.97±3.19 μg/mL; AUC0t=74.83±16.69 vs. 74.64±14.80 μg×h/mL, and AUC0∞=77.46±19.33 vs. 76.98±17.13 μg×h/mL; and for R-enantiomer: Cmax=21.74±3.76 vs. 15.20±2.03 μg/mL; AUC0t=57.55±10.17 vs. 46.13±9.61 μg×h/mL, and AUC0∞ value was 58.49±10.57 vs.","Ibuprofen lysinate, quicker and less variable: relative bioavailability compared to ibuprofen base in a pediatric suspension dosage form. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26249766/),[h·μg] / [ml],57.55,222033,DB01050,Ibuprofen
,26249766,AUC0t,"The pharmacokinetic parameters (Algidrin® Pediátrico vs. Dalsy® (Mean±SD)) were: S-enantiomer: Cmax=22.39±5.33 vs. 19.97±3.19 μg/mL; AUC0t=74.83±16.69 vs. 74.64±14.80 μg×h/mL, and AUC0∞=77.46±19.33 vs. 76.98±17.13 μg×h/mL; and for R-enantiomer: Cmax=21.74±3.76 vs. 15.20±2.03 μg/mL; AUC0t=57.55±10.17 vs. 46.13±9.61 μg×h/mL, and AUC0∞ value was 58.49±10.57 vs.","Ibuprofen lysinate, quicker and less variable: relative bioavailability compared to ibuprofen base in a pediatric suspension dosage form. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26249766/),[h·μg] / [ml],46.13,222034,DB01050,Ibuprofen
,26249766,AUC0∞,"The pharmacokinetic parameters (Algidrin® Pediátrico vs. Dalsy® (Mean±SD)) were: S-enantiomer: Cmax=22.39±5.33 vs. 19.97±3.19 μg/mL; AUC0t=74.83±16.69 vs. 74.64±14.80 μg×h/mL, and AUC0∞=77.46±19.33 vs. 76.98±17.13 μg×h/mL; and for R-enantiomer: Cmax=21.74±3.76 vs. 15.20±2.03 μg/mL; AUC0t=57.55±10.17 vs. 46.13±9.61 μg×h/mL, and AUC0∞ value was 58.49±10.57 vs.","Ibuprofen lysinate, quicker and less variable: relative bioavailability compared to ibuprofen base in a pediatric suspension dosage form. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26249766/),,58.49,222035,DB01050,Ibuprofen
,26249766,tmax,The tmax (Median) for S-enantiomer (active) were: 0.5 vs.,"Ibuprofen lysinate, quicker and less variable: relative bioavailability compared to ibuprofen base in a pediatric suspension dosage form. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26249766/),,0.5,222036,DB01050,Ibuprofen
,8205243,overall inversion efficiency,The derivatization procedure took place in 10 min with an overall inversion efficiency of 90.3%.,Resolution of the enantiomers of ibuprofen; comparison study of diastereomeric method and chiral stationary phase method. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8205243/),%,90.3,223204,DB01050,Ibuprofen
,3349598,flow rate,"After the organic layer is evaporated, the reconstituted residue is chromatographed at ambient temperature on a C18 reversed-phase column with a mobile phase of acetonitrile/water/acetic acid/triethylamine (55/45/0.1/0.02 by vol) at a flow rate of 1 mL/min.",Liquid-chromatographic assay of ibuprofen enantiomers in plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3349598/),[ml] / [min],1,223831,DB01050,Ibuprofen
,3349598,resolution factor,"The IB diastereoisomers, detected at 232 nm, are free of interfering peaks and have a resolution factor of 2.2.",Liquid-chromatographic assay of ibuprofen enantiomers in plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3349598/),,2.2,223832,DB01050,Ibuprofen
,29043849,area under time-concentration curve for ibuprofen (AUC0-360),"The mean preoperative area under time-concentration curve for ibuprofen (AUC0-360) was 4806 (SD 1104) min·mg/L, and after surgery it was 2141 (583) min·mg/L (mean difference 2664, 95% CI for difference 2003 to 3325, p < .001).",Absorption of ibuprofen orodispersible tablets in early postoperative phase - a pharmacokinetic study. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29043849/),[mg·min] / [l],4806,223957,DB01050,Ibuprofen
,29043849,area under time-concentration curve for ibuprofen (AUC0-360),"The mean preoperative area under time-concentration curve for ibuprofen (AUC0-360) was 4806 (SD 1104) min·mg/L, and after surgery it was 2141 (583) min·mg/L (mean difference 2664, 95% CI for difference 2003 to 3325, p < .001).",Absorption of ibuprofen orodispersible tablets in early postoperative phase - a pharmacokinetic study. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29043849/),[mg·min] / [l],2141,223958,DB01050,Ibuprofen
,29043849,maximum preoperative plasma concentration,"The mean of the maximum preoperative plasma concentration of ibuprofen was three times higher, 26.7 (7.7) mg/L, than the postoperative value of 8.6 (2.1) mg/L (mean diff. 18.1, 95% CI 13.9 to 22.4, p < .001).",Absorption of ibuprofen orodispersible tablets in early postoperative phase - a pharmacokinetic study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29043849/),[mg] / [l],26.7,223959,DB01050,Ibuprofen
,29043849,maximum preoperative plasma concentration,"The mean of the maximum preoperative plasma concentration of ibuprofen was three times higher, 26.7 (7.7) mg/L, than the postoperative value of 8.6 (2.1) mg/L (mean diff. 18.1, 95% CI 13.9 to 22.4, p < .001).",Absorption of ibuprofen orodispersible tablets in early postoperative phase - a pharmacokinetic study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29043849/),[mg] / [l],8.6,223960,DB01050,Ibuprofen
,29043849,Times to maximum concentration,Times to maximum concentration were similar pre- and postoperatively at 155 (58) minutes and 169 (113) minutes (p = .67).,Absorption of ibuprofen orodispersible tablets in early postoperative phase - a pharmacokinetic study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29043849/),min,155,223961,DB01050,Ibuprofen
,29043849,Times to maximum concentration,Times to maximum concentration were similar pre- and postoperatively at 155 (58) minutes and 169 (113) minutes (p = .67).,Absorption of ibuprofen orodispersible tablets in early postoperative phase - a pharmacokinetic study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29043849/),min,169,223962,DB01050,Ibuprofen
,24999866,detection limit,"The DAPAP-derivatization enabled the highly sensitive detection [detection limit, 0.15fmol (equivalent to 30fg of intact IBU) on the column] and complete separation (resolution 3.1) of the IBU enantiomers.",Enantioselective determination of ibuprofen in saliva by liquid chromatography/tandem mass spectrometry with chiral electrospray ionization-enhancing and stable isotope-coded derivatization. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24999866/),fmol,0.15,224194,DB01050,Ibuprofen
,20007794,time-corrected AUC,"The mean (sem) time-corrected AUC on rest and activity, respectively, were: combination group 22.3 (3.2) and 28.4 (3.4); acetaminophen group 33.0 (3.1) and 40.4 (3.3); and ibuprofen group 34.8 (3.2) and 40.2 (3.4); P<0.01 for each of the four comparisons of combination vs constituent drug.",Combined acetaminophen and ibuprofen for pain relief after oral surgery in adults: a randomized controlled trial. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20007794/),,22.3,224220,DB01050,Ibuprofen
,20007794,time-corrected AUC,"The mean (sem) time-corrected AUC on rest and activity, respectively, were: combination group 22.3 (3.2) and 28.4 (3.4); acetaminophen group 33.0 (3.1) and 40.4 (3.3); and ibuprofen group 34.8 (3.2) and 40.2 (3.4); P<0.01 for each of the four comparisons of combination vs constituent drug.",Combined acetaminophen and ibuprofen for pain relief after oral surgery in adults: a randomized controlled trial. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20007794/),,28.4,224221,DB01050,Ibuprofen
,20007794,time-corrected AUC,"The mean (sem) time-corrected AUC on rest and activity, respectively, were: combination group 22.3 (3.2) and 28.4 (3.4); acetaminophen group 33.0 (3.1) and 40.4 (3.3); and ibuprofen group 34.8 (3.2) and 40.2 (3.4); P<0.01 for each of the four comparisons of combination vs constituent drug.",Combined acetaminophen and ibuprofen for pain relief after oral surgery in adults: a randomized controlled trial. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20007794/),,33.0,224222,DB01050,Ibuprofen
,20007794,time-corrected AUC,"The mean (sem) time-corrected AUC on rest and activity, respectively, were: combination group 22.3 (3.2) and 28.4 (3.4); acetaminophen group 33.0 (3.1) and 40.4 (3.3); and ibuprofen group 34.8 (3.2) and 40.2 (3.4); P<0.01 for each of the four comparisons of combination vs constituent drug.",Combined acetaminophen and ibuprofen for pain relief after oral surgery in adults: a randomized controlled trial. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20007794/),,40.4,224223,DB01050,Ibuprofen
,20007794,time-corrected AUC,"The mean (sem) time-corrected AUC on rest and activity, respectively, were: combination group 22.3 (3.2) and 28.4 (3.4); acetaminophen group 33.0 (3.1) and 40.4 (3.3); and ibuprofen group 34.8 (3.2) and 40.2 (3.4); P<0.01 for each of the four comparisons of combination vs constituent drug.",Combined acetaminophen and ibuprofen for pain relief after oral surgery in adults: a randomized controlled trial. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20007794/),,34.8,224224,DB01050,Ibuprofen
,20007794,time-corrected AUC,"The mean (sem) time-corrected AUC on rest and activity, respectively, were: combination group 22.3 (3.2) and 28.4 (3.4); acetaminophen group 33.0 (3.1) and 40.4 (3.3); and ibuprofen group 34.8 (3.2) and 40.2 (3.4); P<0.01 for each of the four comparisons of combination vs constituent drug.",Combined acetaminophen and ibuprofen for pain relief after oral surgery in adults: a randomized controlled trial. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20007794/),,40.2,224225,DB01050,Ibuprofen
,16869817,clearance,"*The use of a variable slope sigmoidal model to describe the relationship between clearance and postmenstrual age predicted an adult clearance of 3.79 l h(-1) 70 kg(-1) (95% confidence interval 2.76, 4.98) from premature neonatal data.",Vancomycin pharmacokinetics in preterm neonates and the prediction of adult clearance. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16869817/),[l] / [70·h·kg],3.79,224340,DB01050,Ibuprofen
,16869817,volume of distribution (V),The population estimate for volume of distribution (V) was 39 l 70 kg(-1) (coefficient of variation 19.4%).,Vancomycin pharmacokinetics in preterm neonates and the prediction of adult clearance. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16869817/),[l] / [70·kg],39,224341,DB01050,Ibuprofen
,16869817,Clearance (CL),Clearance (CL) increased from 0.897 l h(-1) 70 kg(-1) at 24 weeks PMA to 2.02 l h(-1) 70 kg(-1) by 34 weeks PMA.,Vancomycin pharmacokinetics in preterm neonates and the prediction of adult clearance. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16869817/),[l] / [70·h·kg],0.897,224342,DB01050,Ibuprofen
,16869817,Clearance (CL),Clearance (CL) increased from 0.897 l h(-1) 70 kg(-1) at 24 weeks PMA to 2.02 l h(-1) 70 kg(-1) by 34 weeks PMA.,Vancomycin pharmacokinetics in preterm neonates and the prediction of adult clearance. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16869817/),[l] / [70·h·kg],2.02,224343,DB01050,Ibuprofen
,16869817,adult clearance,"The use of a variable slope sigmoidal model to describe the relationship between clearance and PMA predicted an adult clearance of 3.79 l h(-1) 70 kg(-1) (95% confidence interval 2.76, 4.98).",Vancomycin pharmacokinetics in preterm neonates and the prediction of adult clearance. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16869817/),[l] / [70·h·kg],3.79,224344,DB01050,Ibuprofen
,25145138,extraction recoveries,The extraction recoveries of flurbiprofen from human plasma were between 93.6 and 98.6%.,Determination of flurbiprofen in human plasma by gas chromatography with mass spectrometry and its pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25145138/),%,93.6 and 98.6,225562,DB01050,Ibuprofen
,25145138,LOD,"The LOD and LOQ of flurbiprofen were 0.03 and 0.10 microg/mL, respectively.",Determination of flurbiprofen in human plasma by gas chromatography with mass spectrometry and its pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25145138/),[μg] / [ml],0.03,225563,DB01050,Ibuprofen
,25145138,LOQ,"The LOD and LOQ of flurbiprofen were 0.03 and 0.10 microg/mL, respectively.",Determination of flurbiprofen in human plasma by gas chromatography with mass spectrometry and its pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25145138/),[μg] / [ml],0.10,225564,DB01050,Ibuprofen
,16207608,maximum solubility,"The poloxamer gel with menthol/ibuprofen ratio of 1:9 and higher than 15% poloxamer 188 showed the maximum solubility of ibuprofen, 1.2 mg/mL.",Enhanced oral bioavailability of ibuprofen in rats by poloxamer gel using poloxamer 188 and menthol. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16207608/),[mg] / [ml],1.2,225815,DB01050,Ibuprofen
,24695355,milk concentration,The mean ibuprofen milk concentration was 360 ± 160 mcg/L.,"Ibuprofen concentrations in human mature milk--first data about pharmacokinetics study in breast milk with AOR-10127 ""Antalait"" study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24695355/),[mcg] / [l],360,226278,DB01050,Ibuprofen
,24695355,fat milk concentration,"The mean fat milk concentration was 3.23 ± 1.15 g per 100 mL, and the mean milk protein concentration 0.87 ± 0.27 g per 100 mL.","Ibuprofen concentrations in human mature milk--first data about pharmacokinetics study in breast milk with AOR-10127 ""Antalait"" study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24695355/),[g] / [100·ml],3.23,226279,DB01050,Ibuprofen
,24695355,milk protein concentration,"The mean fat milk concentration was 3.23 ± 1.15 g per 100 mL, and the mean milk protein concentration 0.87 ± 0.27 g per 100 mL.","Ibuprofen concentrations in human mature milk--first data about pharmacokinetics study in breast milk with AOR-10127 ""Antalait"" study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24695355/),[g] / [100·ml],0.87,226280,DB01050,Ibuprofen
,24695355,transfer infant dose,"The ibuprofen transfer infant dose (theoretical infant dose) was 68 mcg·kg-1·d-1 (8-262 mcg·kg-1·d-1), and the relative infant dose was <0.38% (0.04%-1.53%) of the weight-adjusted maternal daily dose, which equals 0.2% of the infant dose.","Ibuprofen concentrations in human mature milk--first data about pharmacokinetics study in breast milk with AOR-10127 ""Antalait"" study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24695355/),[mcg] / [d·kg],68,226281,DB01050,Ibuprofen
,24695355,transfer infant dose,"The ibuprofen transfer infant dose (theoretical infant dose) was 68 mcg·kg-1·d-1 (8-262 mcg·kg-1·d-1), and the relative infant dose was <0.38% (0.04%-1.53%) of the weight-adjusted maternal daily dose, which equals 0.2% of the infant dose.","Ibuprofen concentrations in human mature milk--first data about pharmacokinetics study in breast milk with AOR-10127 ""Antalait"" study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24695355/),[mcg] / [d·kg],8,226282,DB01050,Ibuprofen
,9099319,apparent volume of distribution (AVd),"Data (mean +/- SEM) show that apparent volume of distribution (AVd) was 62.1 +/- 3.9 ml/kg, plasma t1/2 beta was 30.5 +/- 4.2 h, elimination rate constant (Kel) was 0.032 +/- 0.004 h-1, plasma clearance was 2.06 +/- 0.33 ml/kg/h and plasma concentration (Cp) at 1 h was 180.6 +/- 11.1 mg/l.",Pharmacokinetics and protein binding of intravenous ibuprofen in the premature newborn infant. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9099319/),[ml] / [kg],62.1,227260,DB01050,Ibuprofen
,9099319,plasma t1/2 beta,"Data (mean +/- SEM) show that apparent volume of distribution (AVd) was 62.1 +/- 3.9 ml/kg, plasma t1/2 beta was 30.5 +/- 4.2 h, elimination rate constant (Kel) was 0.032 +/- 0.004 h-1, plasma clearance was 2.06 +/- 0.33 ml/kg/h and plasma concentration (Cp) at 1 h was 180.6 +/- 11.1 mg/l.",Pharmacokinetics and protein binding of intravenous ibuprofen in the premature newborn infant. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9099319/),h,30.5,227261,DB01050,Ibuprofen
,9099319,elimination rate constant (Kel),"Data (mean +/- SEM) show that apparent volume of distribution (AVd) was 62.1 +/- 3.9 ml/kg, plasma t1/2 beta was 30.5 +/- 4.2 h, elimination rate constant (Kel) was 0.032 +/- 0.004 h-1, plasma clearance was 2.06 +/- 0.33 ml/kg/h and plasma concentration (Cp) at 1 h was 180.6 +/- 11.1 mg/l.",Pharmacokinetics and protein binding of intravenous ibuprofen in the premature newborn infant. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9099319/),1/[h],0.032,227262,DB01050,Ibuprofen
,9099319,plasma clearance,"Data (mean +/- SEM) show that apparent volume of distribution (AVd) was 62.1 +/- 3.9 ml/kg, plasma t1/2 beta was 30.5 +/- 4.2 h, elimination rate constant (Kel) was 0.032 +/- 0.004 h-1, plasma clearance was 2.06 +/- 0.33 ml/kg/h and plasma concentration (Cp) at 1 h was 180.6 +/- 11.1 mg/l.",Pharmacokinetics and protein binding of intravenous ibuprofen in the premature newborn infant. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9099319/),[ml] / [h·kg],2.06,227263,DB01050,Ibuprofen
,9099319,plasma concentration (Cp),"Data (mean +/- SEM) show that apparent volume of distribution (AVd) was 62.1 +/- 3.9 ml/kg, plasma t1/2 beta was 30.5 +/- 4.2 h, elimination rate constant (Kel) was 0.032 +/- 0.004 h-1, plasma clearance was 2.06 +/- 0.33 ml/kg/h and plasma concentration (Cp) at 1 h was 180.6 +/- 11.1 mg/l.",Pharmacokinetics and protein binding of intravenous ibuprofen in the premature newborn infant. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9099319/),[mg] / [l],180.6,227264,DB01050,Ibuprofen
,9099319,Cp,"In 10 neonates, IBU maintenance dose of 5 mg/kg once daily on days 2 and 3 generated mean Cp of 116.6 +/- 54.5 mg/l and 113.6 +/- 58.2 mg/l, respectively.",Pharmacokinetics and protein binding of intravenous ibuprofen in the premature newborn infant. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9099319/),[mg] / [l],116.6,227265,DB01050,Ibuprofen
,9099319,Cp,"In 10 neonates, IBU maintenance dose of 5 mg/kg once daily on days 2 and 3 generated mean Cp of 116.6 +/- 54.5 mg/l and 113.6 +/- 58.2 mg/l, respectively.",Pharmacokinetics and protein binding of intravenous ibuprofen in the premature newborn infant. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9099319/),[mg] / [l],113.6,227266,DB01050,Ibuprofen
,8329287,Cmax,"Comparing (S)- and (R)-ibuprofen within the group receiving the racemate significantly higher Cmax (20.3 +/- 5.3 vs 17.7 +/- 4.4 micrograms ml-1; P < 0.02; 95% confidence interval for differences (CI): 0.5-4.6), AUC (86.2 +/- 23.5 vs 67.6 +/- 26.6 micrograms ml-1 h; P < 0.001; CI: 9.5-27.6), mean residence time (4.5 +/- 1.1 vs 4.1 +/- 1.2 h; P < 0.01; CI: 0.1-0.6) and renal clearance (0.8 +/- 0.6 vs 0.0 +/- 0.0 ml min-1; P < 0.001; CI: 0.5-1.0) values were observed for the (S)-enantiomer.",Variability in the stereoselective disposition of ibuprofen in patients with rheumatoid arthritis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8329287/),[μg] / [ml],20.3,227813,DB01050,Ibuprofen
,8329287,Cmax,"Comparing (S)- and (R)-ibuprofen within the group receiving the racemate significantly higher Cmax (20.3 +/- 5.3 vs 17.7 +/- 4.4 micrograms ml-1; P < 0.02; 95% confidence interval for differences (CI): 0.5-4.6), AUC (86.2 +/- 23.5 vs 67.6 +/- 26.6 micrograms ml-1 h; P < 0.001; CI: 9.5-27.6), mean residence time (4.5 +/- 1.1 vs 4.1 +/- 1.2 h; P < 0.01; CI: 0.1-0.6) and renal clearance (0.8 +/- 0.6 vs 0.0 +/- 0.0 ml min-1; P < 0.001; CI: 0.5-1.0) values were observed for the (S)-enantiomer.",Variability in the stereoselective disposition of ibuprofen in patients with rheumatoid arthritis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8329287/),[μg] / [ml],17.7,227814,DB01050,Ibuprofen
,8329287,AUC,"Comparing (S)- and (R)-ibuprofen within the group receiving the racemate significantly higher Cmax (20.3 +/- 5.3 vs 17.7 +/- 4.4 micrograms ml-1; P < 0.02; 95% confidence interval for differences (CI): 0.5-4.6), AUC (86.2 +/- 23.5 vs 67.6 +/- 26.6 micrograms ml-1 h; P < 0.001; CI: 9.5-27.6), mean residence time (4.5 +/- 1.1 vs 4.1 +/- 1.2 h; P < 0.01; CI: 0.1-0.6) and renal clearance (0.8 +/- 0.6 vs 0.0 +/- 0.0 ml min-1; P < 0.001; CI: 0.5-1.0) values were observed for the (S)-enantiomer.",Variability in the stereoselective disposition of ibuprofen in patients with rheumatoid arthritis. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8329287/),[h·μg] / [ml],86.2,227815,DB01050,Ibuprofen
,8329287,AUC,"Comparing (S)- and (R)-ibuprofen within the group receiving the racemate significantly higher Cmax (20.3 +/- 5.3 vs 17.7 +/- 4.4 micrograms ml-1; P < 0.02; 95% confidence interval for differences (CI): 0.5-4.6), AUC (86.2 +/- 23.5 vs 67.6 +/- 26.6 micrograms ml-1 h; P < 0.001; CI: 9.5-27.6), mean residence time (4.5 +/- 1.1 vs 4.1 +/- 1.2 h; P < 0.01; CI: 0.1-0.6) and renal clearance (0.8 +/- 0.6 vs 0.0 +/- 0.0 ml min-1; P < 0.001; CI: 0.5-1.0) values were observed for the (S)-enantiomer.",Variability in the stereoselective disposition of ibuprofen in patients with rheumatoid arthritis. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8329287/),[h·μg] / [ml],67.6,227816,DB01050,Ibuprofen
,8329287,mean residence time,"Comparing (S)- and (R)-ibuprofen within the group receiving the racemate significantly higher Cmax (20.3 +/- 5.3 vs 17.7 +/- 4.4 micrograms ml-1; P < 0.02; 95% confidence interval for differences (CI): 0.5-4.6), AUC (86.2 +/- 23.5 vs 67.6 +/- 26.6 micrograms ml-1 h; P < 0.001; CI: 9.5-27.6), mean residence time (4.5 +/- 1.1 vs 4.1 +/- 1.2 h; P < 0.01; CI: 0.1-0.6) and renal clearance (0.8 +/- 0.6 vs 0.0 +/- 0.0 ml min-1; P < 0.001; CI: 0.5-1.0) values were observed for the (S)-enantiomer.",Variability in the stereoselective disposition of ibuprofen in patients with rheumatoid arthritis. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8329287/),h,4.5,227817,DB01050,Ibuprofen
,8329287,mean residence time,"Comparing (S)- and (R)-ibuprofen within the group receiving the racemate significantly higher Cmax (20.3 +/- 5.3 vs 17.7 +/- 4.4 micrograms ml-1; P < 0.02; 95% confidence interval for differences (CI): 0.5-4.6), AUC (86.2 +/- 23.5 vs 67.6 +/- 26.6 micrograms ml-1 h; P < 0.001; CI: 9.5-27.6), mean residence time (4.5 +/- 1.1 vs 4.1 +/- 1.2 h; P < 0.01; CI: 0.1-0.6) and renal clearance (0.8 +/- 0.6 vs 0.0 +/- 0.0 ml min-1; P < 0.001; CI: 0.5-1.0) values were observed for the (S)-enantiomer.",Variability in the stereoselective disposition of ibuprofen in patients with rheumatoid arthritis. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8329287/),h,4.1,227818,DB01050,Ibuprofen
,8329287,renal clearance,"Comparing (S)- and (R)-ibuprofen within the group receiving the racemate significantly higher Cmax (20.3 +/- 5.3 vs 17.7 +/- 4.4 micrograms ml-1; P < 0.02; 95% confidence interval for differences (CI): 0.5-4.6), AUC (86.2 +/- 23.5 vs 67.6 +/- 26.6 micrograms ml-1 h; P < 0.001; CI: 9.5-27.6), mean residence time (4.5 +/- 1.1 vs 4.1 +/- 1.2 h; P < 0.01; CI: 0.1-0.6) and renal clearance (0.8 +/- 0.6 vs 0.0 +/- 0.0 ml min-1; P < 0.001; CI: 0.5-1.0) values were observed for the (S)-enantiomer.",Variability in the stereoselective disposition of ibuprofen in patients with rheumatoid arthritis. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8329287/),[ml] / [min],0.8,227819,DB01050,Ibuprofen
,8329287,renal clearance,"Comparing (S)- and (R)-ibuprofen within the group receiving the racemate significantly higher Cmax (20.3 +/- 5.3 vs 17.7 +/- 4.4 micrograms ml-1; P < 0.02; 95% confidence interval for differences (CI): 0.5-4.6), AUC (86.2 +/- 23.5 vs 67.6 +/- 26.6 micrograms ml-1 h; P < 0.001; CI: 9.5-27.6), mean residence time (4.5 +/- 1.1 vs 4.1 +/- 1.2 h; P < 0.01; CI: 0.1-0.6) and renal clearance (0.8 +/- 0.6 vs 0.0 +/- 0.0 ml min-1; P < 0.001; CI: 0.5-1.0) values were observed for the (S)-enantiomer.",Variability in the stereoselective disposition of ibuprofen in patients with rheumatoid arthritis. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8329287/),[ml] / [min],0.0,227820,DB01050,Ibuprofen
,16723553,elimination half-life (t(1/2)),The mean elimination half-life (t(1/2)) was prolonged from 2.4 to 3.2 h (P < 0.01) by voriconazole.,Effects of the antifungals voriconazole and fluconazole on the pharmacokinetics of s-(+)- and R-(-)-Ibuprofen. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16723553/),h,2,228543,DB01050,Ibuprofen
,16723553,elimination half-life (t(1/2)),The mean elimination half-life (t(1/2)) was prolonged from 2.4 to 3.2 h (P < 0.01) by voriconazole.,Effects of the antifungals voriconazole and fluconazole on the pharmacokinetics of s-(+)- and R-(-)-Ibuprofen. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16723553/),h,3,228544,DB01050,Ibuprofen
,16723553,t(1/2),The mean t(1/2) of S-(+)-ibuprofen was prolonged from 2.4 to 3.1 h (P < 0.05) by fluconazole.,Effects of the antifungals voriconazole and fluconazole on the pharmacokinetics of s-(+)- and R-(-)-Ibuprofen. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16723553/),h,2.4,228545,DB01050,Ibuprofen
,16723553,t(1/2),The mean t(1/2) of S-(+)-ibuprofen was prolonged from 2.4 to 3.1 h (P < 0.05) by fluconazole.,Effects of the antifungals voriconazole and fluconazole on the pharmacokinetics of s-(+)- and R-(-)-Ibuprofen. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16723553/),h,3.1,228546,DB01050,Ibuprofen
,16723553,AUC ratios,"The geometric mean S-(+)-ibuprofen AUC ratios in the voriconazole and fluconazole phases were 2.01 (90% confidence interval [CI], 1.80 to 2.22) and 1.82 (90% CI, 1.72 to 1.91), respectively, i.e., above the bioequivalence acceptance upper limit of 1.25.",Effects of the antifungals voriconazole and fluconazole on the pharmacokinetics of s-(+)- and R-(-)-Ibuprofen. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16723553/),,2.01,228547,DB01050,Ibuprofen
,16723553,AUC ratios,"The geometric mean S-(+)-ibuprofen AUC ratios in the voriconazole and fluconazole phases were 2.01 (90% confidence interval [CI], 1.80 to 2.22) and 1.82 (90% CI, 1.72 to 1.91), respectively, i.e., above the bioequivalence acceptance upper limit of 1.25.",Effects of the antifungals voriconazole and fluconazole on the pharmacokinetics of s-(+)- and R-(-)-Ibuprofen. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16723553/),,1.82,228548,DB01050,Ibuprofen
,10497140,First order degradation half-lives,"First order degradation half-lives of 26 and 0. 5 h were observed on incubation in buffer of pH 7.4 for the 1-O-acylglucuronides of telmisartan and diclofenac, respectively.",Disposition and chemical stability of telmisartan 1-O-acylglucuronide. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10497140/),h,26,228719,DB01050,Ibuprofen
,10497140,First order degradation half-lives,"First order degradation half-lives of 26 and 0. 5 h were observed on incubation in buffer of pH 7.4 for the 1-O-acylglucuronides of telmisartan and diclofenac, respectively.",Disposition and chemical stability of telmisartan 1-O-acylglucuronide. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10497140/),h,0. 5,228720,DB01050,Ibuprofen
,10497140,clearance,"After i.v. dosing to rats, telmisartan 1-O-acylglucuronide was rapidly cleared from plasma with a clearance of 180 ml/min/kg, compared with 15.6 ml/min/kg for the parent compound.",Disposition and chemical stability of telmisartan 1-O-acylglucuronide. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10497140/),[ml] / [kg·min],180,228721,DB01050,Ibuprofen
,10497140,clearance,"After i.v. dosing to rats, telmisartan 1-O-acylglucuronide was rapidly cleared from plasma with a clearance of 180 ml/min/kg, compared with 15.6 ml/min/kg for the parent compound.",Disposition and chemical stability of telmisartan 1-O-acylglucuronide. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10497140/),[ml] / [kg·min],15.6,228722,DB01050,Ibuprofen
,7575754,relative bioavailability,A mean relative bioavailability of 0.96 (B) and 1.01 (C) was determined for the test formulation.,Pharmacokinetics of ibuprofen following a single administration of a suspension containing enteric-coated microcapsules. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7575754/),,0.96,228847,DB01050,Ibuprofen
,7575754,relative bioavailability,A mean relative bioavailability of 0.96 (B) and 1.01 (C) was determined for the test formulation.,Pharmacokinetics of ibuprofen following a single administration of a suspension containing enteric-coated microcapsules. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7575754/),,1.01,228848,DB01050,Ibuprofen
,7575754,maximum plasma concentration,"For the test formulation, the highest mean maximum plasma concentration (54.3 micrograms/ml) was measured with a corresponding tmax of 1.9 h.",Pharmacokinetics of ibuprofen following a single administration of a suspension containing enteric-coated microcapsules. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7575754/),[μg] / [ml],54.3,228849,DB01050,Ibuprofen
,7575754,tmax,"For the test formulation, the highest mean maximum plasma concentration (54.3 micrograms/ml) was measured with a corresponding tmax of 1.9 h.",Pharmacokinetics of ibuprofen following a single administration of a suspension containing enteric-coated microcapsules. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7575754/),h,1.9,228850,DB01050,Ibuprofen
,7575754,peak plasma concentrations,"For the reference formulations, mean peak plasma concentrations of 45.2 micrograms/ml after 2.6 h (B) and 25.7 micrograms/ml after 5.6 h (C) were observed.",Pharmacokinetics of ibuprofen following a single administration of a suspension containing enteric-coated microcapsules. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7575754/),[μg] / [ml],45.2,228851,DB01050,Ibuprofen
,7575754,peak plasma concentrations,"For the reference formulations, mean peak plasma concentrations of 45.2 micrograms/ml after 2.6 h (B) and 25.7 micrograms/ml after 5.6 h (C) were observed.",Pharmacokinetics of ibuprofen following a single administration of a suspension containing enteric-coated microcapsules. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7575754/),[μg] / [ml],25.7,228852,DB01050,Ibuprofen
,7575754,lagtime,"Despite the enteric coating of the microcapsules, a very short lagtime of 0.03 h was determined for the suspension.",Pharmacokinetics of ibuprofen following a single administration of a suspension containing enteric-coated microcapsules. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7575754/),h,0.03,228853,DB01050,Ibuprofen
,7575754,tlag,"For the other rapid release formulation (B), the lagtime was in a similar magnitude (0.11 h), while the absorption from the sustained-release tablet was clearly decelerated (tlag = 0.97 h).",Pharmacokinetics of ibuprofen following a single administration of a suspension containing enteric-coated microcapsules. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7575754/),h,0.97,228854,DB01050,Ibuprofen
,8527289,elimination half-lives,"The estimated elimination half-lives of (R)- and (S)-ibuprofen were 1.7 h and 2.5 h in plasma and 3.9 h and 7.9 h in CSF, respectively.",Stereoselective disposition of ibuprofen enantiomers in human cerebrospinal fluid. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8527289/),h,1.7,230778,DB01050,Ibuprofen
,8527289,elimination half-lives,"The estimated elimination half-lives of (R)- and (S)-ibuprofen were 1.7 h and 2.5 h in plasma and 3.9 h and 7.9 h in CSF, respectively.",Stereoselective disposition of ibuprofen enantiomers in human cerebrospinal fluid. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8527289/),h,2.5,230779,DB01050,Ibuprofen
,8527289,elimination half-lives,"The estimated elimination half-lives of (R)- and (S)-ibuprofen were 1.7 h and 2.5 h in plasma and 3.9 h and 7.9 h in CSF, respectively.",Stereoselective disposition of ibuprofen enantiomers in human cerebrospinal fluid. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8527289/),h,3.9,230780,DB01050,Ibuprofen
,8527289,elimination half-lives,"The estimated elimination half-lives of (R)- and (S)-ibuprofen were 1.7 h and 2.5 h in plasma and 3.9 h and 7.9 h in CSF, respectively.",Stereoselective disposition of ibuprofen enantiomers in human cerebrospinal fluid. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8527289/),h,7.9,230781,DB01050,Ibuprofen
,8527289,AUCCSF/AUCplasma ratios,"The AUCCSF/AUCplasma ratios (0, 8 h) were 0.009 and 0.015 for the (R)- and (S)-forms, respectively.",Stereoselective disposition of ibuprofen enantiomers in human cerebrospinal fluid. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8527289/),,0.009,230782,DB01050,Ibuprofen
,8527289,AUCCSF/AUCplasma ratios,"The AUCCSF/AUCplasma ratios (0, 8 h) were 0.009 and 0.015 for the (R)- and (S)-forms, respectively.",Stereoselective disposition of ibuprofen enantiomers in human cerebrospinal fluid. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8527289/),,0.015,230783,DB01050,Ibuprofen
,28749581,IC50,Physiologically based pharmacokinetic (PBPK) modeling reproduced the renal clearance of baricitinib and the inhibitory effect of probenecid using the in vitro IC50 value of 4.4 μM.,Prediction of Transporter-Mediated Drug-Drug Interactions for Baricitinib. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28749581/),μM,4.4,231753,DB01050,Ibuprofen
,28749581,IC50,"Using ibuprofen and diclofenac in vitro IC50 values of 4.4 and 3.8 μM toward OAT3, 1.2 and 1.0 AUC(0-∞) ratios of baricitinib were predicted.",Prediction of Transporter-Mediated Drug-Drug Interactions for Baricitinib. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28749581/),μM,4.4,231754,DB01050,Ibuprofen
,28749581,IC50,"Using ibuprofen and diclofenac in vitro IC50 values of 4.4 and 3.8 μM toward OAT3, 1.2 and 1.0 AUC(0-∞) ratios of baricitinib were predicted.",Prediction of Transporter-Mediated Drug-Drug Interactions for Baricitinib. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28749581/),μM,3.8,231755,DB01050,Ibuprofen
,28749581,AUC(0-∞) ratios,"Using ibuprofen and diclofenac in vitro IC50 values of 4.4 and 3.8 μM toward OAT3, 1.2 and 1.0 AUC(0-∞) ratios of baricitinib were predicted.",Prediction of Transporter-Mediated Drug-Drug Interactions for Baricitinib. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28749581/),,1.2,231756,DB01050,Ibuprofen
,28749581,AUC(0-∞) ratios,"Using ibuprofen and diclofenac in vitro IC50 values of 4.4 and 3.8 μM toward OAT3, 1.2 and 1.0 AUC(0-∞) ratios of baricitinib were predicted.",Prediction of Transporter-Mediated Drug-Drug Interactions for Baricitinib. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28749581/),,1.0,231757,DB01050,Ibuprofen
less,3228575,Tmax,Concentration-time data for both enantiomers were in agreement and indicated that drug was absorbed much more quickly from Tablet B than from the Tablet A; enantiomer Tmax values were less than 1.3 h from Tablet B but longer than 4 h from the Tablet A (p less than 0.001).,Comparative human study of ibuprofen enantiomer plasma concentrations produced by two commercially available ibuprofen tablets. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3228575/),h,1.3,231978,DB01050,Ibuprofen
longer,3228575,Tmax,Concentration-time data for both enantiomers were in agreement and indicated that drug was absorbed much more quickly from Tablet B than from the Tablet A; enantiomer Tmax values were less than 1.3 h from Tablet B but longer than 4 h from the Tablet A (p less than 0.001).,Comparative human study of ibuprofen enantiomer plasma concentrations produced by two commercially available ibuprofen tablets. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3228575/),h,4,231979,DB01050,Ibuprofen
,22301864,brain-targeting index,"In the pharmacokinetic study, prodrug 1 exhibited a brain-targeting index of 11.19 {DTI=(AUC(brain)/AUC(plasma))(1)/(AUC(brain)/AUC(plasma))(dexibuprofen)}.",In vitro and in vivo investigation of dexibuprofen derivatives for CNS delivery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22301864/),,11.19,233559,DB01050,Ibuprofen
,17386653,flow rate,"The mobile phase used was methanol-triethylamine (pH 7.0; 0.3% v/v in Milli-Q water) (60:40%, v/v) at a flow rate of 1.0 mL min(-1).",High-performance liquid chromatography and pharmacokinetics of aceclofenac in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17386653/),[ml] / [min],1.0,235092,DB01050,Ibuprofen
,17386653,recovery,"The mean recovery of aceclofenac and IS were 84.62+/-3.23 and 89.19+/-1.57%, respectively and the method was found to be precise, accurate, and specific during the study.",High-performance liquid chromatography and pharmacokinetics of aceclofenac in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17386653/),%,84.62,235093,DB01050,Ibuprofen
,17386653,recovery,"The mean recovery of aceclofenac and IS were 84.62+/-3.23 and 89.19+/-1.57%, respectively and the method was found to be precise, accurate, and specific during the study.",High-performance liquid chromatography and pharmacokinetics of aceclofenac in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17386653/),%,89.19,235094,DB01050,Ibuprofen
,2083147,plasma half-life,"The plasma elimination of (R)-ibuprofen was found to be more rapid than that of the S-enantiomer [plasma half-life: (R) 2.03 h; (S) 3.05 h; 2P less than 0.001], resulting in a progressive enrichment in the plasma content of this isomer, some 64% of the total area under the plasma concentration time curves (AUC) being due to the pharmacologically active enantiomer.",Interindividual variability in the enantiomeric disposition of ibuprofen following the oral administration of the racemic drug to healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2083147/),h,2.03,235958,DB01050,Ibuprofen
,2083147,plasma half-life,"The plasma elimination of (R)-ibuprofen was found to be more rapid than that of the S-enantiomer [plasma half-life: (R) 2.03 h; (S) 3.05 h; 2P less than 0.001], resulting in a progressive enrichment in the plasma content of this isomer, some 64% of the total area under the plasma concentration time curves (AUC) being due to the pharmacologically active enantiomer.",Interindividual variability in the enantiomeric disposition of ibuprofen following the oral administration of the racemic drug to healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2083147/),h,3.05,235959,DB01050,Ibuprofen
,8368610,volume of distribution at steady state,"Harmonic mean volume of distribution at steady state was 0.14 (range, 0.12 to 0.17) L/kg, elimination half-life was 1.55 (range, 1.33 to 1.73) hours, and total clearance was 86.2 (range, 68.8 to 106.2) ml/kg/h.",Pharmacokinetics of ibuprofen in lactating dairy cows. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8368610/),[l] / [kg],0.14,236648,DB01050,Ibuprofen
,8368610,elimination half-life,"Harmonic mean volume of distribution at steady state was 0.14 (range, 0.12 to 0.17) L/kg, elimination half-life was 1.55 (range, 1.33 to 1.73) hours, and total clearance was 86.2 (range, 68.8 to 106.2) ml/kg/h.",Pharmacokinetics of ibuprofen in lactating dairy cows. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8368610/),h,1.55,236649,DB01050,Ibuprofen
,8368610,total clearance,"Harmonic mean volume of distribution at steady state was 0.14 (range, 0.12 to 0.17) L/kg, elimination half-life was 1.55 (range, 1.33 to 1.73) hours, and total clearance was 86.2 (range, 68.8 to 106.2) ml/kg/h.",Pharmacokinetics of ibuprofen in lactating dairy cows. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8368610/),[ml] / [h·kg],86.2,236650,DB01050,Ibuprofen
,8368610,oral bioavailability,"Harmonic mean oral bioavailability was 99% (range, 79 to 112).",Pharmacokinetics of ibuprofen in lactating dairy cows. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8368610/),%,99,236651,DB01050,Ibuprofen
,23585306,t1/2,"The main pharmacokinetics parameters of test and reference were as follows: t1/2 was (1.94±0.38) h and (1.95±0.28) h; Cmax was (33.41±7.83) μg · mL- 1 and (31.08±9.30) μg · mL- 1; AUC0-12 was (91.44±19.26) μg · mL-1 · h and (84.75±24.45) μg · mL-1 · h; AUC0-∞ was (92.82±19.94) μg · mL-1 · h and (85.97±24.99) μg · mL-1 · h; median Tmax was 0.5 h (range, 0.25, 2) and 0.5 h (range, 0.25, 1.5).",Pharmacokinetic and bioequivalence studies of ibuprofen suspension after a single-dose administration in healthy Chinese volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23585306/),h,1.94,236986,DB01050,Ibuprofen
,23585306,t1/2,"The main pharmacokinetics parameters of test and reference were as follows: t1/2 was (1.94±0.38) h and (1.95±0.28) h; Cmax was (33.41±7.83) μg · mL- 1 and (31.08±9.30) μg · mL- 1; AUC0-12 was (91.44±19.26) μg · mL-1 · h and (84.75±24.45) μg · mL-1 · h; AUC0-∞ was (92.82±19.94) μg · mL-1 · h and (85.97±24.99) μg · mL-1 · h; median Tmax was 0.5 h (range, 0.25, 2) and 0.5 h (range, 0.25, 1.5).",Pharmacokinetic and bioequivalence studies of ibuprofen suspension after a single-dose administration in healthy Chinese volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23585306/),h,1.95,236987,DB01050,Ibuprofen
,23585306,Cmax,"The main pharmacokinetics parameters of test and reference were as follows: t1/2 was (1.94±0.38) h and (1.95±0.28) h; Cmax was (33.41±7.83) μg · mL- 1 and (31.08±9.30) μg · mL- 1; AUC0-12 was (91.44±19.26) μg · mL-1 · h and (84.75±24.45) μg · mL-1 · h; AUC0-∞ was (92.82±19.94) μg · mL-1 · h and (85.97±24.99) μg · mL-1 · h; median Tmax was 0.5 h (range, 0.25, 2) and 0.5 h (range, 0.25, 1.5).",Pharmacokinetic and bioequivalence studies of ibuprofen suspension after a single-dose administration in healthy Chinese volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23585306/),1·ml-·μg,33.41,236988,DB01050,Ibuprofen
,23585306,Cmax,"The main pharmacokinetics parameters of test and reference were as follows: t1/2 was (1.94±0.38) h and (1.95±0.28) h; Cmax was (33.41±7.83) μg · mL- 1 and (31.08±9.30) μg · mL- 1; AUC0-12 was (91.44±19.26) μg · mL-1 · h and (84.75±24.45) μg · mL-1 · h; AUC0-∞ was (92.82±19.94) μg · mL-1 · h and (85.97±24.99) μg · mL-1 · h; median Tmax was 0.5 h (range, 0.25, 2) and 0.5 h (range, 0.25, 1.5).",Pharmacokinetic and bioequivalence studies of ibuprofen suspension after a single-dose administration in healthy Chinese volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23585306/),1·ml-·μg,31.08,236989,DB01050,Ibuprofen
,23585306,AUC0-12,"The main pharmacokinetics parameters of test and reference were as follows: t1/2 was (1.94±0.38) h and (1.95±0.28) h; Cmax was (33.41±7.83) μg · mL- 1 and (31.08±9.30) μg · mL- 1; AUC0-12 was (91.44±19.26) μg · mL-1 · h and (84.75±24.45) μg · mL-1 · h; AUC0-∞ was (92.82±19.94) μg · mL-1 · h and (85.97±24.99) μg · mL-1 · h; median Tmax was 0.5 h (range, 0.25, 2) and 0.5 h (range, 0.25, 1.5).",Pharmacokinetic and bioequivalence studies of ibuprofen suspension after a single-dose administration in healthy Chinese volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23585306/),[h·μg] / [ml],91.44,236990,DB01050,Ibuprofen
,23585306,AUC0-12,"The main pharmacokinetics parameters of test and reference were as follows: t1/2 was (1.94±0.38) h and (1.95±0.28) h; Cmax was (33.41±7.83) μg · mL- 1 and (31.08±9.30) μg · mL- 1; AUC0-12 was (91.44±19.26) μg · mL-1 · h and (84.75±24.45) μg · mL-1 · h; AUC0-∞ was (92.82±19.94) μg · mL-1 · h and (85.97±24.99) μg · mL-1 · h; median Tmax was 0.5 h (range, 0.25, 2) and 0.5 h (range, 0.25, 1.5).",Pharmacokinetic and bioequivalence studies of ibuprofen suspension after a single-dose administration in healthy Chinese volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23585306/),[h·μg] / [ml],84.75,236991,DB01050,Ibuprofen
,23585306,AUC0-∞,"The main pharmacokinetics parameters of test and reference were as follows: t1/2 was (1.94±0.38) h and (1.95±0.28) h; Cmax was (33.41±7.83) μg · mL- 1 and (31.08±9.30) μg · mL- 1; AUC0-12 was (91.44±19.26) μg · mL-1 · h and (84.75±24.45) μg · mL-1 · h; AUC0-∞ was (92.82±19.94) μg · mL-1 · h and (85.97±24.99) μg · mL-1 · h; median Tmax was 0.5 h (range, 0.25, 2) and 0.5 h (range, 0.25, 1.5).",Pharmacokinetic and bioequivalence studies of ibuprofen suspension after a single-dose administration in healthy Chinese volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23585306/),[h·μg] / [ml],92.82,236992,DB01050,Ibuprofen
,23585306,AUC0-∞,"The main pharmacokinetics parameters of test and reference were as follows: t1/2 was (1.94±0.38) h and (1.95±0.28) h; Cmax was (33.41±7.83) μg · mL- 1 and (31.08±9.30) μg · mL- 1; AUC0-12 was (91.44±19.26) μg · mL-1 · h and (84.75±24.45) μg · mL-1 · h; AUC0-∞ was (92.82±19.94) μg · mL-1 · h and (85.97±24.99) μg · mL-1 · h; median Tmax was 0.5 h (range, 0.25, 2) and 0.5 h (range, 0.25, 1.5).",Pharmacokinetic and bioequivalence studies of ibuprofen suspension after a single-dose administration in healthy Chinese volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23585306/),[h·μg] / [ml],85.97,236993,DB01050,Ibuprofen
,23585306,Tmax,"The main pharmacokinetics parameters of test and reference were as follows: t1/2 was (1.94±0.38) h and (1.95±0.28) h; Cmax was (33.41±7.83) μg · mL- 1 and (31.08±9.30) μg · mL- 1; AUC0-12 was (91.44±19.26) μg · mL-1 · h and (84.75±24.45) μg · mL-1 · h; AUC0-∞ was (92.82±19.94) μg · mL-1 · h and (85.97±24.99) μg · mL-1 · h; median Tmax was 0.5 h (range, 0.25, 2) and 0.5 h (range, 0.25, 1.5).",Pharmacokinetic and bioequivalence studies of ibuprofen suspension after a single-dose administration in healthy Chinese volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23585306/),h,0.5,236994,DB01050,Ibuprofen
,23585306,Tmax,"The main pharmacokinetics parameters of test and reference were as follows: t1/2 was (1.94±0.38) h and (1.95±0.28) h; Cmax was (33.41±7.83) μg · mL- 1 and (31.08±9.30) μg · mL- 1; AUC0-12 was (91.44±19.26) μg · mL-1 · h and (84.75±24.45) μg · mL-1 · h; AUC0-∞ was (92.82±19.94) μg · mL-1 · h and (85.97±24.99) μg · mL-1 · h; median Tmax was 0.5 h (range, 0.25, 2) and 0.5 h (range, 0.25, 1.5).",Pharmacokinetic and bioequivalence studies of ibuprofen suspension after a single-dose administration in healthy Chinese volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23585306/),h,0.5,236995,DB01050,Ibuprofen
,2252842,clearance,"There was 50 +/- 4% inversion of (R)-ibuprofen, a figure similar to that observed in man and (R)-ibuprofen had a higher clearance (12.6 +/- 1.3 ml/min/kg) than (S)-ibuprofen (7.7 +/- 0.7 ml/min/kg; P less than 0.01).",Stereoselective disposition of ibuprofen and flurbiprofen in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2252842/),[ml] / [kg·min],12.6,238141,DB01050,Ibuprofen
,2252842,clearance,"There was 50 +/- 4% inversion of (R)-ibuprofen, a figure similar to that observed in man and (R)-ibuprofen had a higher clearance (12.6 +/- 1.3 ml/min/kg) than (S)-ibuprofen (7.7 +/- 0.7 ml/min/kg; P less than 0.01).",Stereoselective disposition of ibuprofen and flurbiprofen in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2252842/),[ml] / [kg·min],7.7,238142,DB01050,Ibuprofen
,2252842,clearance,"The clearance of (R)-flurbiprofen after racemate (2.3 +/- 0.1 ml/min/kg) was higher than its clearance when administered alone (1.7 +/- 0.2 ml/min/kg; P less than 0.01), indicating a pharmacokinetic interaction between the enantiomers (most probably at plasma protein binding sites).",Stereoselective disposition of ibuprofen and flurbiprofen in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2252842/),[ml] / [kg·min],2.3,238143,DB01050,Ibuprofen
,2252842,clearance,"The clearance of (R)-flurbiprofen after racemate (2.3 +/- 0.1 ml/min/kg) was higher than its clearance when administered alone (1.7 +/- 0.2 ml/min/kg; P less than 0.01), indicating a pharmacokinetic interaction between the enantiomers (most probably at plasma protein binding sites).",Stereoselective disposition of ibuprofen and flurbiprofen in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2252842/),[ml] / [kg·min],1.7,238144,DB01050,Ibuprofen
,30897305,tmax,"Taken after a meal, ibuprofen in the FDC reached tmax earlier than ibuprofen lysinate (median 1.25 vs 1.63 hours), and Cmax was approximately 13% higher, with comparable AUC, suggesting that the profile of ibuprofen was in favor of the FDC compared with ibuprofen lysinate.","Pharmacokinetic Properties of Ibuprofen (IBU) From the Fixed-Dose Combination IBU/Caffeine (400/100 mg; FDC) in Comparison With 400 mg IBU as Acid or Lysinate Under Fasted and Fed Conditions-Data From 2 Single-Center, Single-Dose, Randomized Crossover Studies in Healthy Volunteers. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30897305/),h,1.25,238723,DB01050,Ibuprofen
,30897305,tmax,"Taken after a meal, ibuprofen in the FDC reached tmax earlier than ibuprofen lysinate (median 1.25 vs 1.63 hours), and Cmax was approximately 13% higher, with comparable AUC, suggesting that the profile of ibuprofen was in favor of the FDC compared with ibuprofen lysinate.","Pharmacokinetic Properties of Ibuprofen (IBU) From the Fixed-Dose Combination IBU/Caffeine (400/100 mg; FDC) in Comparison With 400 mg IBU as Acid or Lysinate Under Fasted and Fed Conditions-Data From 2 Single-Center, Single-Dose, Randomized Crossover Studies in Healthy Volunteers. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30897305/),h,1.63,238724,DB01050,Ibuprofen
,31480005,LD50,The LD50 was estimated to be approximately 5000 mg/kg.,"Design, synthesis and pharmacological evaluation of CVIB, a codrug of carvacrol and ibuprofen as a novel anti-inflammatory agent. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31480005/),[mg] / [kg],5000,239738,DB01050,Ibuprofen
,9743814,absolute bio-availability,The absolute bio-availability is 15 and 12% for rats and humans respectively.,Anti-inflammatory activity of chondroitin sulfate. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9743814/),%,15,240564,DB01050,Ibuprofen
,9743814,absolute bio-availability,The absolute bio-availability is 15 and 12% for rats and humans respectively.,Anti-inflammatory activity of chondroitin sulfate. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9743814/),%,12,240565,DB01050,Ibuprofen
,11673749,volume of distribution of the central compartment (Vd(c)),Between the first and third doses (day 3 and day 5) there was a significant decrease of the volume of distribution of the central compartment (Vd(c)) (0.244 versus 0.171 L/kg; P =.03) and area under the plasma concentration-time curve (524 versus 447 mg.,Ibuprofen pharmacokinetics in preterm infants with patent ductus arteriosus. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11673749/),[l] / [kg],0.244,240889,DB01050,Ibuprofen
,11673749,volume of distribution of the central compartment (Vd(c)),Between the first and third doses (day 3 and day 5) there was a significant decrease of the volume of distribution of the central compartment (Vd(c)) (0.244 versus 0.171 L/kg; P =.03) and area under the plasma concentration-time curve (524 versus 447 mg.,Ibuprofen pharmacokinetics in preterm infants with patent ductus arteriosus. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11673749/),[l] / [kg],0.171,240890,DB01050,Ibuprofen
,11673749,area under the plasma concentration-time curve,Between the first and third doses (day 3 and day 5) there was a significant decrease of the volume of distribution of the central compartment (Vd(c)) (0.244 versus 0.171 L/kg; P =.03) and area under the plasma concentration-time curve (524 versus 447 mg.,Ibuprofen pharmacokinetics in preterm infants with patent ductus arteriosus. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11673749/),mg,524,240891,DB01050,Ibuprofen
,11673749,area under the plasma concentration-time curve,Between the first and third doses (day 3 and day 5) there was a significant decrease of the volume of distribution of the central compartment (Vd(c)) (0.244 versus 0.171 L/kg; P =.03) and area under the plasma concentration-time curve (524 versus 447 mg.,Ibuprofen pharmacokinetics in preterm infants with patent ductus arteriosus. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11673749/),mg,447,240892,DB01050,Ibuprofen
,28898054,T1/2,"The entities were functionalized with a 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) chelator via a l-lysine and β-alanine linker moiety using solid-phase peptide chemistry and labeled with 177Lu (T1/2 = 6.65 days), a clinically established radiometal.","Synthesis, Radiolabeling, and Characterization of Plasma Protein-Binding Ligands: Potential Tools for Modulation of the Pharmacokinetic Properties of (Radio)Pharmaceuticals. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28898054/),d,6.65,241701,DB01050,Ibuprofen
,28898054,"T1/2,β","177Lu-DOTA-PPB-01 showed the slowest blood clearance (T1/2,β: >15 h) followed by 177Lu-DOTA-PPB-03 (T1/2,β: ∼2.33 h) and 177Lu-DOTA-PPB-02 (T1/2,β: ∼1.14 h), which was excreted relatively fast.","Synthesis, Radiolabeling, and Characterization of Plasma Protein-Binding Ligands: Potential Tools for Modulation of the Pharmacokinetic Properties of (Radio)Pharmaceuticals. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/28898054/),h,∼2.33,241702,DB01050,Ibuprofen
,30054639,trough concentration,"Simulations of this dosing regimen show an (S)-ibuprofen trough concentration of 43 mg L-1 is reached at 48 h, which we assumed the target through concentration.",Simulation-based suggestions to improve ibuprofen dosing for patent ductus arteriosus in preterm newborns. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30054639/),[mg] / [l],43,242260,DB01050,Ibuprofen
,17657761,recovery,"Following SPE procedure, recovery of the chiral analytes from the two media was in the ranges of 82-87%, 90-95% and 70-76% for ibuprofen, 2'-hydroxy-ibuprofen and 2'-carboxy-ibuprofen enantiomers, respectively.",Enantioselective CE method for pharmacokinetic studies on ibuprofen and its chiral metabolites with reference to genetic polymorphism. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17657761/),%,82-87,243281,DB01050,Ibuprofen
,17657761,recovery,"Following SPE procedure, recovery of the chiral analytes from the two media was in the ranges of 82-87%, 90-95% and 70-76% for ibuprofen, 2'-hydroxy-ibuprofen and 2'-carboxy-ibuprofen enantiomers, respectively.",Enantioselective CE method for pharmacokinetic studies on ibuprofen and its chiral metabolites with reference to genetic polymorphism. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17657761/),%,90-95,243282,DB01050,Ibuprofen
,17657761,recovery,"Following SPE procedure, recovery of the chiral analytes from the two media was in the ranges of 82-87%, 90-95% and 70-76% for ibuprofen, 2'-hydroxy-ibuprofen and 2'-carboxy-ibuprofen enantiomers, respectively.",Enantioselective CE method for pharmacokinetic studies on ibuprofen and its chiral metabolites with reference to genetic polymorphism. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17657761/),%,70-76,243283,DB01050,Ibuprofen
,18243606,solubility,"Furthermore, the formula of ibuprofen-loaded gelatin microcapsule at the ratio of gelatin/ibuprofen/sodium lauryl sulfate/water/ethanol of 4/0.5/0.6/30/70 showed ibuprofen solubility of about 290microg/ml and ethanol content of about 160microg/mg.",Novel gelatin microcapsule with bioavailability enhancement of ibuprofen using spray-drying technique. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18243606/),[μg] / [ml],290,244597,DB01050,Ibuprofen
,3365913,ratio of,Concentrations of the active S-enantiomer in synovial fluid exceeded those of the R-enantiomer at all times in all patients with the ratio of S to R concentrations being 2.1 +/- 0.3 (mean +/- SE).,Stereoselective disposition of ibuprofen enantiomers in synovial fluid. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3365913/),,2.1,245731,DB01050,Ibuprofen
,7833229,half-lives,Mean (+/- s.d.) half-lives were 1.6 +/- 0.5 h for S(+) and 1.5 +/- 0.5 h for R(-) and mean (+/- s.d.) AUC values were 31.5 +/- 14.3 mg l-1 h for S(+) and 36.6 +/- 13.8 mg l-1 h for R(-).,Stereoselective disposition of ibuprofen enantiomers in infants. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7833229/),h,1.6,247019,DB01050,Ibuprofen
,7833229,half-lives,Mean (+/- s.d.) half-lives were 1.6 +/- 0.5 h for S(+) and 1.5 +/- 0.5 h for R(-) and mean (+/- s.d.) AUC values were 31.5 +/- 14.3 mg l-1 h for S(+) and 36.6 +/- 13.8 mg l-1 h for R(-).,Stereoselective disposition of ibuprofen enantiomers in infants. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7833229/),h,1.5,247020,DB01050,Ibuprofen
,7833229,AUC,Mean (+/- s.d.) half-lives were 1.6 +/- 0.5 h for S(+) and 1.5 +/- 0.5 h for R(-) and mean (+/- s.d.) AUC values were 31.5 +/- 14.3 mg l-1 h for S(+) and 36.6 +/- 13.8 mg l-1 h for R(-).,Stereoselective disposition of ibuprofen enantiomers in infants. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7833229/),[h·mg] / [l],31.5,247021,DB01050,Ibuprofen
,7833229,AUC,Mean (+/- s.d.) half-lives were 1.6 +/- 0.5 h for S(+) and 1.5 +/- 0.5 h for R(-) and mean (+/- s.d.) AUC values were 31.5 +/- 14.3 mg l-1 h for S(+) and 36.6 +/- 13.8 mg l-1 h for R(-).,Stereoselective disposition of ibuprofen enantiomers in infants. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7833229/),[h·mg] / [l],36.6,247022,DB01050,Ibuprofen
,23468008,relative oral bioavailability,"The pharmacokinetic study in beagle dogs showed improved absorption of ibuprofen from cubic nanoparticles compared to that of pure ibuprofen, with evidence of a longer half-life and a relative oral bioavailability of 222% (P < 0.05).","Cubic phase nanoparticles for sustained release of ibuprofen: formulation, characterization, and enhanced bioavailability study. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23468008/),%,222,247091,DB01050,Ibuprofen
,10233203,"area under serum drug concentration (AUC (0, 2 h)","During the first 2 h after the 200 mg dose, dental extraction resulted in a significant reduction of the area under serum drug concentration (AUC (0, 2 h) mg l-1 h) from 5.6+/-2.9 to 1.6+/-1.8 (P<0.01) and from 5.5+/-3.0 to 2.1+/-2.0 (P<0.05) for S and R-ibuprofen, respectively.",Pain-mediated altered absorption and metabolism of ibuprofen: an explanation for decreased serum enantiomer concentration after dental surgery. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10233203/),[h·mg] / [l],5.6,247758,DB01050,Ibuprofen
,10233203,"area under serum drug concentration (AUC (0, 2 h)","During the first 2 h after the 200 mg dose, dental extraction resulted in a significant reduction of the area under serum drug concentration (AUC (0, 2 h) mg l-1 h) from 5.6+/-2.9 to 1.6+/-1.8 (P<0.01) and from 5.5+/-3.0 to 2.1+/-2.0 (P<0.05) for S and R-ibuprofen, respectively.",Pain-mediated altered absorption and metabolism of ibuprofen: an explanation for decreased serum enantiomer concentration after dental surgery. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10233203/),[h·mg] / [l],1.6,247759,DB01050,Ibuprofen
,10233203,"area under serum drug concentration (AUC (0, 2 h)","During the first 2 h after the 200 mg dose, dental extraction resulted in a significant reduction of the area under serum drug concentration (AUC (0, 2 h) mg l-1 h) from 5.6+/-2.9 to 1.6+/-1.8 (P<0.01) and from 5.5+/-3.0 to 2.1+/-2.0 (P<0.05) for S and R-ibuprofen, respectively.",Pain-mediated altered absorption and metabolism of ibuprofen: an explanation for decreased serum enantiomer concentration after dental surgery. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10233203/),[h·mg] / [l],5.5,247760,DB01050,Ibuprofen
,10233203,"area under serum drug concentration (AUC (0, 2 h)","During the first 2 h after the 200 mg dose, dental extraction resulted in a significant reduction of the area under serum drug concentration (AUC (0, 2 h) mg l-1 h) from 5.6+/-2.9 to 1.6+/-1.8 (P<0.01) and from 5.5+/-3.0 to 2.1+/-2.0 (P<0.05) for S and R-ibuprofen, respectively.",Pain-mediated altered absorption and metabolism of ibuprofen: an explanation for decreased serum enantiomer concentration after dental surgery. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10233203/),[h·mg] / [l],2.1,247761,DB01050,Ibuprofen
,10233203,"AUC (0, 2 h)","Similar observations were made following the 600 mg dose for AUC (0, 2 h) of S-ibuprofen (from 14.2+/-6.1 to 7.2+/-5.5 mg l-1 h, P<0.05) with no significant difference for R-ibuprofen (from 14.4+/-9.5 to 5.8+/-7. 1).",Pain-mediated altered absorption and metabolism of ibuprofen: an explanation for decreased serum enantiomer concentration after dental surgery. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10233203/),[h·mg] / [l],14.2,247762,DB01050,Ibuprofen
,10233203,"AUC (0, 2 h)","Similar observations were made following the 600 mg dose for AUC (0, 2 h) of S-ibuprofen (from 14.2+/-6.1 to 7.2+/-5.5 mg l-1 h, P<0.05) with no significant difference for R-ibuprofen (from 14.4+/-9.5 to 5.8+/-7. 1).",Pain-mediated altered absorption and metabolism of ibuprofen: an explanation for decreased serum enantiomer concentration after dental surgery. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10233203/),[h·mg] / [l],7.2,247763,DB01050,Ibuprofen
,10233203,"AUC (0, 2 h)","Similar observations were made following the 600 mg dose for AUC (0, 2 h) of S-ibuprofen (from 14.2+/-6.1 to 7.2+/-5.5 mg l-1 h, P<0.05) with no significant difference for R-ibuprofen (from 14.4+/-9.5 to 5.8+/-7. 1).",Pain-mediated altered absorption and metabolism of ibuprofen: an explanation for decreased serum enantiomer concentration after dental surgery. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10233203/),,14.4,247764,DB01050,Ibuprofen
,10233203,"AUC (0, 2 h)","Similar observations were made following the 600 mg dose for AUC (0, 2 h) of S-ibuprofen (from 14.2+/-6.1 to 7.2+/-5.5 mg l-1 h, P<0.05) with no significant difference for R-ibuprofen (from 14.4+/-9.5 to 5.8+/-7. 1).",Pain-mediated altered absorption and metabolism of ibuprofen: an explanation for decreased serum enantiomer concentration after dental surgery. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10233203/),[h·mg] / [l],5.8,247765,DB01050,Ibuprofen
,11203270,t50%,"t50% of the in vitro release was 4.5 and 5 h for the mini-tablet and Ibu-slow formulations, respectively.",Bioavailability of ibuprofen from matrix mini-tablets based on a mixture of starch and microcrystalline wax. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11203270/),h,4.5,248697,DB01050,Ibuprofen
,11203270,t50%,"t50% of the in vitro release was 4.5 and 5 h for the mini-tablet and Ibu-slow formulations, respectively.",Bioavailability of ibuprofen from matrix mini-tablets based on a mixture of starch and microcrystalline wax. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11203270/),h,5,248698,DB01050,Ibuprofen
,11203270,t50%Cmax,"Both formulations behaved in vivo as sustained-release formulation; their HVDt50%Cmax value was determined at 5.6 and 5.1 h for the mini-tablet and Ibu-slow formulations, respectively.",Bioavailability of ibuprofen from matrix mini-tablets based on a mixture of starch and microcrystalline wax. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11203270/),h,5.6,248699,DB01050,Ibuprofen
,11203270,t50%Cmax,"Both formulations behaved in vivo as sustained-release formulation; their HVDt50%Cmax value was determined at 5.6 and 5.1 h for the mini-tablet and Ibu-slow formulations, respectively.",Bioavailability of ibuprofen from matrix mini-tablets based on a mixture of starch and microcrystalline wax. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11203270/),h,5.1,248700,DB01050,Ibuprofen
,11203270,relative bioavailability,"A significantly higher value of Cmax was seen for the mini-tablet formulation, resulting in a relative bioavailability of 116 +/- 22.6% compared to the Ibu-slow matrix.",Bioavailability of ibuprofen from matrix mini-tablets based on a mixture of starch and microcrystalline wax. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11203270/),%,116,248701,DB01050,Ibuprofen
,8866042,Cmax,Cmax (+/-SE) increased from 9.88 +/- 0.48 mg L-1 (fasting) to 11.36 +/- 0.88 mg L-1 (postprandial) and AUC0-48 (+/-SE) increased from 120.78 +/- 9.64 mg h L-1 (fasting) to 149.73 +/- 12.24 mg h L-1 (postprandial).,The effect of food on the bioavailability of ibuprofen and flurbiprofen from sustained release formulations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8866042/),[mg] / [l],9.88,250506,DB01050,Ibuprofen
,8866042,Cmax,Cmax (+/-SE) increased from 9.88 +/- 0.48 mg L-1 (fasting) to 11.36 +/- 0.88 mg L-1 (postprandial) and AUC0-48 (+/-SE) increased from 120.78 +/- 9.64 mg h L-1 (fasting) to 149.73 +/- 12.24 mg h L-1 (postprandial).,The effect of food on the bioavailability of ibuprofen and flurbiprofen from sustained release formulations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8866042/),[mg] / [l],11.36,250507,DB01050,Ibuprofen
,8866042,AUC0-48,Cmax (+/-SE) increased from 9.88 +/- 0.48 mg L-1 (fasting) to 11.36 +/- 0.88 mg L-1 (postprandial) and AUC0-48 (+/-SE) increased from 120.78 +/- 9.64 mg h L-1 (fasting) to 149.73 +/- 12.24 mg h L-1 (postprandial).,The effect of food on the bioavailability of ibuprofen and flurbiprofen from sustained release formulations. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8866042/),[h·mg] / [l],120.78,250508,DB01050,Ibuprofen
,8866042,AUC0-48,Cmax (+/-SE) increased from 9.88 +/- 0.48 mg L-1 (fasting) to 11.36 +/- 0.88 mg L-1 (postprandial) and AUC0-48 (+/-SE) increased from 120.78 +/- 9.64 mg h L-1 (fasting) to 149.73 +/- 12.24 mg h L-1 (postprandial).,The effect of food on the bioavailability of ibuprofen and flurbiprofen from sustained release formulations. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8866042/),[h·mg] / [l],149.73,250509,DB01050,Ibuprofen
,8866042,time to peak (tmax),The mean (+/-SE) time to peak (tmax) was also significantly delayed from 3.85 +/- 0.27 h to 8.70 +/- 0.89 h.,The effect of food on the bioavailability of ibuprofen and flurbiprofen from sustained release formulations. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8866042/),h,3.85,250510,DB01050,Ibuprofen
,8866042,time to peak (tmax),The mean (+/-SE) time to peak (tmax) was also significantly delayed from 3.85 +/- 0.27 h to 8.70 +/- 0.89 h.,The effect of food on the bioavailability of ibuprofen and flurbiprofen from sustained release formulations. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8866042/),h,8.70,250511,DB01050,Ibuprofen
,8866042,concentration of the first peak (Cpeak 1),"Although food did not affect the bioavailability of this formulation, there was a statistically significant increase in the mean (+/-SE) concentration of the first peak (Cpeak 1) from 14.21 +/- 1.38 mg L-1 (fasting) to 20.14 +/- 1.38 mg L-1 (with food).",The effect of food on the bioavailability of ibuprofen and flurbiprofen from sustained release formulations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8866042/),[mg] / [l],14.21,250512,DB01050,Ibuprofen
,8866042,concentration of the first peak (Cpeak 1),"Although food did not affect the bioavailability of this formulation, there was a statistically significant increase in the mean (+/-SE) concentration of the first peak (Cpeak 1) from 14.21 +/- 1.38 mg L-1 (fasting) to 20.14 +/- 1.38 mg L-1 (with food).",The effect of food on the bioavailability of ibuprofen and flurbiprofen from sustained release formulations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8866042/),[mg] / [l],20.14,250513,DB01050,Ibuprofen
,10749518,apparent volume of distribution,"Celexocib is extensively protein bound, primarily to plasma albumin, and has an apparent volume of distribution of 455+/-166L in humans.",Clinical pharmacokinetics and pharmacodynamics of celecoxib: a selective cyclo-oxygenase-2 inhibitor. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10749518/),l,455,252478,DB01050,Ibuprofen
,10749518,elimination half-life,Celecoxib is metabolised primarily by the cytochrome P450 (CYP) 2C9 isoenzyme and has an elimination half-life of about 11 hours in healthy individuals.,Clinical pharmacokinetics and pharmacodynamics of celecoxib: a selective cyclo-oxygenase-2 inhibitor. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10749518/),h,11,252479,DB01050,Ibuprofen
,2670397,elimination half-life,"Even though diclofenac has a relatively short elimination half-life in plasma (1.5 hours), it persists in synovial fluid.",Diclofenac sodium. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2670397/),h,1.5,252500,DB01050,Ibuprofen
,3993392,Initial,"Initial and terminal kinetic half-lives were about 0.6 and 13.4 min., respectively.","Ibuprofen, pharmacokinetics and pharmacodynamics in the isolated rabbit heart. ",k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3993392/),min,0.6,252725,DB01050,Ibuprofen
,3993392,terminal kinetic half-lives,"Initial and terminal kinetic half-lives were about 0.6 and 13.4 min., respectively.","Ibuprofen, pharmacokinetics and pharmacodynamics in the isolated rabbit heart. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3993392/),min,13.4,252726,DB01050,Ibuprofen
,3993392,Vd beta,Vd beta was about 82 ml/g myocardial tissue.,"Ibuprofen, pharmacokinetics and pharmacodynamics in the isolated rabbit heart. ",Vb-Q62,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3993392/),[ml] / [g],82,252727,DB01050,Ibuprofen
,34416778,peak times,"Previous studies have described the pharmacokinetic profiles of ibuprofen suppository and the mean peak times of ibuprofen suppository were around 1.8 hours, indicating a slower rate of absorption.",Rectal Administration of Ibuprofen: Comparison of Enema and Suppository Form. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34416778/),h,1.8,253659,DB01050,Ibuprofen
,34416778,Tmax,"This study showed that Tmax for ibuprofen enema was less than half that of ibuprofen suppository (median 40 min vs. 90 min, respectively; p-value=0.0003).",Rectal Administration of Ibuprofen: Comparison of Enema and Suppository Form. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34416778/),min,40,253660,DB01050,Ibuprofen
,34416778,Tmax,"This study showed that Tmax for ibuprofen enema was less than half that of ibuprofen suppository (median 40 min vs. 90 min, respectively; p-value=0.0003).",Rectal Administration of Ibuprofen: Comparison of Enema and Suppository Form. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34416778/),min,90,253661,DB01050,Ibuprofen
>,12807998,peak plasma concentration (Cmax),"Long-term treatment with ibuprofen twice daily, at doses that achieve peak plasma concentration (Cmax) >50 microg/ml, slows progression of lung disease in patients with cystic fibrosis (CF).",Effect of ibuprofen on neutrophil migration in vivo in cystic fibrosis and healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12807998/),[μg] / [ml],50,253937,DB01050,Ibuprofen
>,12807998,Cmax,Previous data suggest that Cmax >50 microg/ml is associated with a reduction in neutrophil (PMN) migration into the lung and that lower concentrations are associated with an increase in PMN migration.,Effect of ibuprofen on neutrophil migration in vivo in cystic fibrosis and healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12807998/),[μg] / [ml],50,253938,DB01050,Ibuprofen
,12807998,Cmax,"To estimate the threshold concentration at which ibuprofen is associated with a decrease in PMN migration in vivo, we measured the PMN content of oral mucosal washes in 35 healthy (age 19-40 years) and 16 CF (age 18-32 years) subjects who took ibuprofen twice daily for 10 days in doses that achieved Cmax 8 to 90 microg/ml.",Effect of ibuprofen on neutrophil migration in vivo in cystic fibrosis and healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12807998/),[μg] / [ml],8 to 90,253939,DB01050,Ibuprofen
>,12807998,Cmax,"Cmax >50 microg/ml was associated with a 31 +/- 7% (mean +/- S.E.M.) reduction in PMNs in CF (n = 11, p < 0.001) and 25 +/- 6% reduction in PMNs in healthy subjects (n = 16, p < 0.001).",Effect of ibuprofen on neutrophil migration in vivo in cystic fibrosis and healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12807998/),[μg] / [ml],50,253940,DB01050,Ibuprofen
<,12807998,Cmax,Cmax <50 microg/ml was associated with an increase in PMNs of approximately 40%.,Effect of ibuprofen on neutrophil migration in vivo in cystic fibrosis and healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12807998/),[μg] / [ml],50,253941,DB01050,Ibuprofen
>,12807998,Cmax,"These results suggest that Cmax >50 microg/ml and twice daily dosing of ibuprofen are required to decrease PMN migration, and reinforce the current recommendation that pharmacokinetics should be performed in CF patients prescribed ibuprofen.",Effect of ibuprofen on neutrophil migration in vivo in cystic fibrosis and healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12807998/),[μg] / [ml],50,253942,DB01050,Ibuprofen
>,14581063,extraction efficiency,The mean extraction efficiency was >92%.,Stereospecific high-performance liquid chromatographic analysis of ibuprofen in rat serum. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14581063/),%,92,254603,DB01050,Ibuprofen
,24478225,extraction recoveries,The extraction recoveries of naproxen from human plasma were between 93.0 and 98.9%.,Determination of naproxen in human plasma by GC-MS. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24478225/),%,93.0 and 98.9,255220,DB01050,Ibuprofen
,24478225,LOD,"The LOD and LOQ of naproxen were 0.03 and 0.10 μg/mL, respectively.",Determination of naproxen in human plasma by GC-MS. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24478225/),[μg] / [ml],0.03,255221,DB01050,Ibuprofen
,24478225,LOQ,"The LOD and LOQ of naproxen were 0.03 and 0.10 μg/mL, respectively.",Determination of naproxen in human plasma by GC-MS. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24478225/),[μg] / [ml],0.10,255222,DB01050,Ibuprofen
,26334726,relative bioavailability,The relative bioavailability of paracetamol (93.78%) and ibuprofen (96.45%) confirmed the pharmacokinetic equivalence of the oral and IV formulations of the fixed-dose combination.,Pharmacokinetics and Bioavailability of a Fixed-Dose Combination of Ibuprofen and Paracetamol after Intravenous and Oral Administration. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26334726/),%,93.78,259716,DB01050,Ibuprofen
,26334726,relative bioavailability,The relative bioavailability of paracetamol (93.78%) and ibuprofen (96.45%) confirmed the pharmacokinetic equivalence of the oral and IV formulations of the fixed-dose combination.,Pharmacokinetics and Bioavailability of a Fixed-Dose Combination of Ibuprofen and Paracetamol after Intravenous and Oral Administration. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26334726/),%,96.45,259717,DB01050,Ibuprofen
,20515527,flow rate,The mobile phase was a mixture of methanol and water containing 1.0% glacial acetic acid (70:30 v/v) at a flow rate of 1.0 mL/min.,A simple and sensitive HPLC method for quantification of the metabolin of meclofenoxate in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20515527/),[ml] / [min],1.0,259730,DB01050,Ibuprofen
,20515527,recovery,"The mean recovery of chlorophenoxyacetic acid and IS were (79.54 +/- 6.33)% and (78.48 +/- 2.14)%, respectively, and the method was found to be precise, accurate, and specific during the study.",A simple and sensitive HPLC method for quantification of the metabolin of meclofenoxate in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20515527/),%,79.54,259731,DB01050,Ibuprofen
,20515527,recovery,"The mean recovery of chlorophenoxyacetic acid and IS were (79.54 +/- 6.33)% and (78.48 +/- 2.14)%, respectively, and the method was found to be precise, accurate, and specific during the study.",A simple and sensitive HPLC method for quantification of the metabolin of meclofenoxate in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20515527/),%,78.48,259732,DB01050,Ibuprofen
,24858390,oral bioavailability (AUC0⟶t),"In experiments with rats, oral bioavailability (AUC0⟶t) of ibuprofen in the microemulsions was similar for the different formulations (6779.0-7413.3 min μg/mL) and significantly higher than that of an ibuprofen suspension (4830.9 min μg/mL).",Optimizing surfactant content to improve oral bioavailability of ibuprofen in microemulsions: just enough or more than enough? ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24858390/),[min·μg] / [ml],6779.0-7413.3,260621,DB01050,Ibuprofen
,24858390,oral bioavailability (AUC0⟶t),"In experiments with rats, oral bioavailability (AUC0⟶t) of ibuprofen in the microemulsions was similar for the different formulations (6779.0-7413.3 min μg/mL) and significantly higher than that of an ibuprofen suspension (4830.9 min μg/mL).",Optimizing surfactant content to improve oral bioavailability of ibuprofen in microemulsions: just enough or more than enough? ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24858390/),[min·μg] / [ml],4830.9,260622,DB01050,Ibuprofen
,17284505,AUC,"S(+)-ibuprofen mean +/- SD AUC and maximum concentration (C(max)) values were 131.6 +/- 26.8 microg x h/mL and 31.8 +/- 7.33 microg/mL, respectively, for control samples and 122.4 +/- 32.9 microg x h/mL and 33.6 +/- 7.83 microg/mL, respectively, after St.",Effects of St. John's wort supplementation on ibuprofen pharmacokinetics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17284505/),[h·μg] / [ml],131.6,261010,DB01050,Ibuprofen
,17284505,AUC,"S(+)-ibuprofen mean +/- SD AUC and maximum concentration (C(max)) values were 131.6 +/- 26.8 microg x h/mL and 31.8 +/- 7.33 microg/mL, respectively, for control samples and 122.4 +/- 32.9 microg x h/mL and 33.6 +/- 7.83 microg/mL, respectively, after St.",Effects of St. John's wort supplementation on ibuprofen pharmacokinetics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17284505/),[h·μg] / [ml],122.4,261011,DB01050,Ibuprofen
,17284505,maximum concentration (C(max)),"S(+)-ibuprofen mean +/- SD AUC and maximum concentration (C(max)) values were 131.6 +/- 26.8 microg x h/mL and 31.8 +/- 7.33 microg/mL, respectively, for control samples and 122.4 +/- 32.9 microg x h/mL and 33.6 +/- 7.83 microg/mL, respectively, after St.",Effects of St. John's wort supplementation on ibuprofen pharmacokinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17284505/),[μg] / [ml],31.8,261012,DB01050,Ibuprofen
,17284505,maximum concentration (C(max)),"S(+)-ibuprofen mean +/- SD AUC and maximum concentration (C(max)) values were 131.6 +/- 26.8 microg x h/mL and 31.8 +/- 7.33 microg/mL, respectively, for control samples and 122.4 +/- 32.9 microg x h/mL and 33.6 +/- 7.83 microg/mL, respectively, after St.",Effects of St. John's wort supplementation on ibuprofen pharmacokinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17284505/),[μg] / [ml],33.6,261013,DB01050,Ibuprofen
,17284505,AUC,"R(-)-ibuprofen mean AUC and C(max) values were 85.1 +/- 26.6 microg x h/mL and 28.4 +/- 8.72 microg/mL, respectively, for control samples and 87.7 +/- 30.1 microg x h/mL and 30.0 +/- 8.97 microg/mL, respectively, for St. John's wort treatment samples.",Effects of St. John's wort supplementation on ibuprofen pharmacokinetics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17284505/),[h·μg] / [ml],85.1,261014,DB01050,Ibuprofen
,17284505,AUC,"R(-)-ibuprofen mean AUC and C(max) values were 85.1 +/- 26.6 microg x h/mL and 28.4 +/- 8.72 microg/mL, respectively, for control samples and 87.7 +/- 30.1 microg x h/mL and 30.0 +/- 8.97 microg/mL, respectively, for St. John's wort treatment samples.",Effects of St. John's wort supplementation on ibuprofen pharmacokinetics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17284505/),[h·μg] / [ml],87.7,261015,DB01050,Ibuprofen
,17284505,C(max),"R(-)-ibuprofen mean AUC and C(max) values were 85.1 +/- 26.6 microg x h/mL and 28.4 +/- 8.72 microg/mL, respectively, for control samples and 87.7 +/- 30.1 microg x h/mL and 30.0 +/- 8.97 microg/mL, respectively, for St. John's wort treatment samples.",Effects of St. John's wort supplementation on ibuprofen pharmacokinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17284505/),[μg] / [ml],28.4,261016,DB01050,Ibuprofen
,17284505,C(max),"R(-)-ibuprofen mean AUC and C(max) values were 85.1 +/- 26.6 microg x h/mL and 28.4 +/- 8.72 microg/mL, respectively, for control samples and 87.7 +/- 30.1 microg x h/mL and 30.0 +/- 8.97 microg/mL, respectively, for St. John's wort treatment samples.",Effects of St. John's wort supplementation on ibuprofen pharmacokinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17284505/),[μg] / [ml],30.0,261017,DB01050,Ibuprofen
,28756848,bioavailability,"After intravenous and oral administration of ibuprofen and fexofenadine (BCS class II and III), the plasma concentration and pharmacokinetic parameters were evaluated by our method and a terminal blood sampling method, with the result that both methods gave comparable results (ibuprofen: 63.8±4.0% and 64.4%, fexofenadine: 6.5±0.7% and 7.9%, respectively, in bioavailability).",Using Improved Serial Blood Sampling Method of Mice to Study Pharmacokinetics and Drug-Drug Interaction. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28756848/),%,6.5,261614,DB01050,Ibuprofen
,28756848,bioavailability,"After intravenous and oral administration of ibuprofen and fexofenadine (BCS class II and III), the plasma concentration and pharmacokinetic parameters were evaluated by our method and a terminal blood sampling method, with the result that both methods gave comparable results (ibuprofen: 63.8±4.0% and 64.4%, fexofenadine: 6.5±0.7% and 7.9%, respectively, in bioavailability).",Using Improved Serial Blood Sampling Method of Mice to Study Pharmacokinetics and Drug-Drug Interaction. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28756848/),%,7.9,261615,DB01050,Ibuprofen
,12296989,oral clearance,3. The oral clearance of (S)-ibuprofen was significantly greater than that of the R-enantiomer (74.5 +/- 18.1 versus 57.1 +/- 11.7 ml min(-1); p < 0.05) and the clearance of (R)-ibuprofen via inversion was ca two fold that via alternative pathways.,Stereoselectivity of ibuprofen metabolism and pharmacokinetics following the administration of the racemate to healthy volunteers. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12296989/),[ml] / [min],74.5,261707,DB01050,Ibuprofen
,12296989,oral clearance,3. The oral clearance of (S)-ibuprofen was significantly greater than that of the R-enantiomer (74.5 +/- 18.1 versus 57.1 +/- 11.7 ml min(-1); p < 0.05) and the clearance of (R)-ibuprofen via inversion was ca two fold that via alternative pathways.,Stereoselectivity of ibuprofen metabolism and pharmacokinetics following the administration of the racemate to healthy volunteers. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12296989/),[ml] / [min],57.1,261708,DB01050,Ibuprofen
,2775619,total area under the plasma concentration-time curve,"Following alkaline hydrolysis of glucuronide conjugates, the urinary recoveries of ibuprofen and its major metabolites were measured by h.p.l.c. 3. There was no difference (P greater than 0.05, two-tailed Student's t-test; data expressed as mean +/- s.d.) between C and T phases in the total area under the plasma concentration-time curve of R(-)-ibuprofen (C 4514 +/- 1063 mg 1(-1) min vs T 4665 +/- 1435 mg 1(-1) min) and S(+)-ibuprofen (C 6460 +/- 1063 mg 1(-1) min vs T 6886 +/- 1207 mg 1(-1) min).",Lack of effect of cimetidine on the pharmacokinetics of R(-)- and S(+)-ibuprofen. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2775619/),mg·min,4514,262798,DB01050,Ibuprofen
,2775619,total area under the plasma concentration-time curve,"Following alkaline hydrolysis of glucuronide conjugates, the urinary recoveries of ibuprofen and its major metabolites were measured by h.p.l.c. 3. There was no difference (P greater than 0.05, two-tailed Student's t-test; data expressed as mean +/- s.d.) between C and T phases in the total area under the plasma concentration-time curve of R(-)-ibuprofen (C 4514 +/- 1063 mg 1(-1) min vs T 4665 +/- 1435 mg 1(-1) min) and S(+)-ibuprofen (C 6460 +/- 1063 mg 1(-1) min vs T 6886 +/- 1207 mg 1(-1) min).",Lack of effect of cimetidine on the pharmacokinetics of R(-)- and S(+)-ibuprofen. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2775619/),mg·min,4665,262799,DB01050,Ibuprofen
,2775619,total area under the plasma concentration-time curve,"Following alkaline hydrolysis of glucuronide conjugates, the urinary recoveries of ibuprofen and its major metabolites were measured by h.p.l.c. 3. There was no difference (P greater than 0.05, two-tailed Student's t-test; data expressed as mean +/- s.d.) between C and T phases in the total area under the plasma concentration-time curve of R(-)-ibuprofen (C 4514 +/- 1063 mg 1(-1) min vs T 4665 +/- 1435 mg 1(-1) min) and S(+)-ibuprofen (C 6460 +/- 1063 mg 1(-1) min vs T 6886 +/- 1207 mg 1(-1) min).",Lack of effect of cimetidine on the pharmacokinetics of R(-)- and S(+)-ibuprofen. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2775619/),mg·min,6460,262800,DB01050,Ibuprofen
,2775619,total area under the plasma concentration-time curve,"Following alkaline hydrolysis of glucuronide conjugates, the urinary recoveries of ibuprofen and its major metabolites were measured by h.p.l.c. 3. There was no difference (P greater than 0.05, two-tailed Student's t-test; data expressed as mean +/- s.d.) between C and T phases in the total area under the plasma concentration-time curve of R(-)-ibuprofen (C 4514 +/- 1063 mg 1(-1) min vs T 4665 +/- 1435 mg 1(-1) min) and S(+)-ibuprofen (C 6460 +/- 1063 mg 1(-1) min vs T 6886 +/- 1207 mg 1(-1) min).",Lack of effect of cimetidine on the pharmacokinetics of R(-)- and S(+)-ibuprofen. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2775619/),mg·min,6886,262801,DB01050,Ibuprofen
,32291553,viscosity,"pH of this nanogels was found within the range of 6.1-7.2, whereas the viscosity was found 310.13 to 6361 cps.",Novel Enhanced Therapeutic Efficacy of Dapoxetine HCl by Nano-Vesicle Transdermal Gel for Treatment of Carrageenan-Induced Rat Paw Edema. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32291553/),cps,310.13 to 6361,263521,DB01050,Ibuprofen
,32291553,permeation flux,"The ex vivo skin permeation gels showed permeation flux range, 5.9 ± 0.80 to 17.92 ± 1.13 μg/cm2 h.",Novel Enhanced Therapeutic Efficacy of Dapoxetine HCl by Nano-Vesicle Transdermal Gel for Treatment of Carrageenan-Induced Rat Paw Edema. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32291553/),[μg] / [cm2·h],5.9,263522,DB01050,Ibuprofen
,32291553,permeation flux,"The ex vivo skin permeation gels showed permeation flux range, 5.9 ± 0.80 to 17.92 ± 1.13 μg/cm2 h.",Novel Enhanced Therapeutic Efficacy of Dapoxetine HCl by Nano-Vesicle Transdermal Gel for Treatment of Carrageenan-Induced Rat Paw Edema. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32291553/),[μg] / [cm2·h],17.92,263523,DB01050,Ibuprofen
,32291553,permeation flux,"The highest permeation flux (17.92 ± 1.13 μg/cm2 h) was observed, which was 3.14-folds higher than that of the plain DH gel (10.72 ± 0.84 μg/cm2 h.",Novel Enhanced Therapeutic Efficacy of Dapoxetine HCl by Nano-Vesicle Transdermal Gel for Treatment of Carrageenan-Induced Rat Paw Edema. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32291553/),[μg] / [cm2·h],17.92,263524,DB01050,Ibuprofen
,32291553,permeation flux,"The highest permeation flux (17.92 ± 1.13 μg/cm2 h) was observed, which was 3.14-folds higher than that of the plain DH gel (10.72 ± 0.84 μg/cm2 h.",Novel Enhanced Therapeutic Efficacy of Dapoxetine HCl by Nano-Vesicle Transdermal Gel for Treatment of Carrageenan-Induced Rat Paw Edema. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32291553/),[μg] / [cm2·h],10.72,263525,DB01050,Ibuprofen
,8582471,relative bioavailability,"The second study showed that the mean relative bioavailability of dexibuprofen to ibuprofen racemate was 0.66, thus enabling the estimation of clinically useful dexibuprofen doses from the usual doses of the racemate.",Comparison of the bioavailability of dexibuprofen administered alone or as part of racemic ibuprofen. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8582471/),,0.66,264354,DB01050,Ibuprofen
,14698588,maximum solubility,"The poloxamer gel with menthol/ibuprofen ratio of 1:9 and higher than 15% poloxamer 188 showed the maximum solubility of ibuprofen, 1.2mg/ml.",Enhanced rectal bioavailability of ibuprofen in rats by poloxamer 188 and menthol. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14698588/),[mg] / [ml],1.2,264524,DB01050,Ibuprofen
,10885587,time to reach maximum drug concentration (tmax),"Absorption of ibuprofen from suspension was adequately described by a first-order process; however, a model with 2 parallel first-order input sites was used for the drug given as effervescent granules, leading to time to reach maximum drug concentration (tmax) values of 0.9 and 1.9 hours for suspension and granules, respectively.",Pharmacokinetic-Pharmacodynamic Modelling of the antipyretic effect of two oral formulations of ibuprofen. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10885587/),h,0.9,266061,DB01050,Ibuprofen
,10885587,time to reach maximum drug concentration (tmax),"Absorption of ibuprofen from suspension was adequately described by a first-order process; however, a model with 2 parallel first-order input sites was used for the drug given as effervescent granules, leading to time to reach maximum drug concentration (tmax) values of 0.9 and 1.9 hours for suspension and granules, respectively.",Pharmacokinetic-Pharmacodynamic Modelling of the antipyretic effect of two oral formulations of ibuprofen. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10885587/),h,1.9,266062,DB01050,Ibuprofen
,10885587,Emax (,"The estimates (with percentage coefficients of variation in parentheses) of Emax (maximum inhibition of the zero-order synthesis rate of the factor causing fever), EC50 (plasma concentration eliciting half of Emax), n (slope parameter) and k(out) (first order rate constant of degradation) were 0.055 (10), 6.16 (14) mg/L, 2.71 (18) and 1.17 (23) h(-1), respectively, where To is the estimate of the basal temperature, 38.8 (1) degrees C.",Pharmacokinetic-Pharmacodynamic Modelling of the antipyretic effect of two oral formulations of ibuprofen. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10885587/),[mg] / [l],0.055,266063,DB01050,Ibuprofen
,10885587,maximum inhibition of the zero-order synthesis rate,"The estimates (with percentage coefficients of variation in parentheses) of Emax (maximum inhibition of the zero-order synthesis rate of the factor causing fever), EC50 (plasma concentration eliciting half of Emax), n (slope parameter) and k(out) (first order rate constant of degradation) were 0.055 (10), 6.16 (14) mg/L, 2.71 (18) and 1.17 (23) h(-1), respectively, where To is the estimate of the basal temperature, 38.8 (1) degrees C.",Pharmacokinetic-Pharmacodynamic Modelling of the antipyretic effect of two oral formulations of ibuprofen. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10885587/),[mg] / [l],0.055,266064,DB01050,Ibuprofen
,10885587,first order rate constant of degradation,"The estimates (with percentage coefficients of variation in parentheses) of Emax (maximum inhibition of the zero-order synthesis rate of the factor causing fever), EC50 (plasma concentration eliciting half of Emax), n (slope parameter) and k(out) (first order rate constant of degradation) were 0.055 (10), 6.16 (14) mg/L, 2.71 (18) and 1.17 (23) h(-1), respectively, where To is the estimate of the basal temperature, 38.8 (1) degrees C.",Pharmacokinetic-Pharmacodynamic Modelling of the antipyretic effect of two oral formulations of ibuprofen. ,Kdeg-Q12,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10885587/),1/[h],2.71,266065,DB01050,Ibuprofen
,10885587,first order rate constant of degradation,"The estimates (with percentage coefficients of variation in parentheses) of Emax (maximum inhibition of the zero-order synthesis rate of the factor causing fever), EC50 (plasma concentration eliciting half of Emax), n (slope parameter) and k(out) (first order rate constant of degradation) were 0.055 (10), 6.16 (14) mg/L, 2.71 (18) and 1.17 (23) h(-1), respectively, where To is the estimate of the basal temperature, 38.8 (1) degrees C.",Pharmacokinetic-Pharmacodynamic Modelling of the antipyretic effect of two oral formulations of ibuprofen. ,Kdeg-Q12,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10885587/),1/[h],1.17,266066,DB01050,Ibuprofen
,15220011,time to onset of analgesia,"The median time to onset of analgesia was 24 minutes for etoricoxib 120, 180, and 240 mg, and 30 minutes for etoricoxib 60 mg and ibuprofen.","Etoricoxib in acute pain associated with dental surgery: a randomized, double-blind, placebo- and active comparator-controlled dose-ranging study. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15220011/),min,24,266197,DB01050,Ibuprofen
,15220011,time to onset of analgesia,"The median time to onset of analgesia was 24 minutes for etoricoxib 120, 180, and 240 mg, and 30 minutes for etoricoxib 60 mg and ibuprofen.","Etoricoxib in acute pain associated with dental surgery: a randomized, double-blind, placebo- and active comparator-controlled dose-ranging study. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15220011/),min,30,266198,DB01050,Ibuprofen
>,15220011,duration of analgesic effect,"The duration of analgesic effect was >24 hours for etoricoxib 120, 180, and 240 mg, and 12.1 hours for etoricoxib 60 mg.","Etoricoxib in acute pain associated with dental surgery: a randomized, double-blind, placebo- and active comparator-controlled dose-ranging study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15220011/),h,24,266199,DB01050,Ibuprofen
,15220011,duration of analgesic effect,"The duration of analgesic effect was >24 hours for etoricoxib 120, 180, and 240 mg, and 12.1 hours for etoricoxib 60 mg.","Etoricoxib in acute pain associated with dental surgery: a randomized, double-blind, placebo- and active comparator-controlled dose-ranging study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15220011/),h,12.1,266200,DB01050,Ibuprofen
,15220011,duration of effect,"The duration of effect was significantly longer with all 4 etoricoxib doses compared with ibuprofen (10.1 hours; P < 0.05 etoricoxib 60 mg; < or = 0.001etoricoxib 120, 180, and 240 mg) and compared with placebo (2.1 hours; P < = 0.001).","Etoricoxib in acute pain associated with dental surgery: a randomized, double-blind, placebo- and active comparator-controlled dose-ranging study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15220011/),h,10.1,266201,DB01050,Ibuprofen
,15220011,duration of effect,"The duration of effect was significantly longer with all 4 etoricoxib doses compared with ibuprofen (10.1 hours; P < 0.05 etoricoxib 60 mg; < or = 0.001etoricoxib 120, 180, and 240 mg) and compared with placebo (2.1 hours; P < = 0.001).","Etoricoxib in acute pain associated with dental surgery: a randomized, double-blind, placebo- and active comparator-controlled dose-ranging study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15220011/),h,2.1,266202,DB01050,Ibuprofen
,33779002,T½,The T½ of S-IBU in the newborn was much longer than in adults (41.8 vs.,Ibuprofen enantiomers in premature neonates with patent ductus arteriosus: Preliminary data on an unexpected pharmacokinetic profile of S(+)-ibuprofen. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33779002/),,41.8,269081,DB01050,Ibuprofen
,33779002,T½,"≈2 h), whereas the T½ of R-IBU appeared to be the same (2.3 h).",Ibuprofen enantiomers in premature neonates with patent ductus arteriosus: Preliminary data on an unexpected pharmacokinetic profile of S(+)-ibuprofen. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33779002/),h,2.3,269082,DB01050,Ibuprofen
,9728897,clearances,"When subjects were pretreated with clofibrate, clearances of R-ibuprofen and 13C-S-ibuprofen increased significantly from 55.0 and 66.4 ml/min to 186.2 and 106.7 ml/min (p < 0.01), respectively.",Effect of clofibrate on the chiral inversion of ibuprofen in healthy volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9728897/),[ml] / [min],55.0,270674,DB01050,Ibuprofen
,9728897,clearances,"When subjects were pretreated with clofibrate, clearances of R-ibuprofen and 13C-S-ibuprofen increased significantly from 55.0 and 66.4 ml/min to 186.2 and 106.7 ml/min (p < 0.01), respectively.",Effect of clofibrate on the chiral inversion of ibuprofen in healthy volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9728897/),[ml] / [min],66.4,270675,DB01050,Ibuprofen
,9728897,clearances,"When subjects were pretreated with clofibrate, clearances of R-ibuprofen and 13C-S-ibuprofen increased significantly from 55.0 and 66.4 ml/min to 186.2 and 106.7 ml/min (p < 0.01), respectively.",Effect of clofibrate on the chiral inversion of ibuprofen in healthy volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9728897/),[ml] / [min],186.2,270676,DB01050,Ibuprofen
,9728897,clearances,"When subjects were pretreated with clofibrate, clearances of R-ibuprofen and 13C-S-ibuprofen increased significantly from 55.0 and 66.4 ml/min to 186.2 and 106.7 ml/min (p < 0.01), respectively.",Effect of clofibrate on the chiral inversion of ibuprofen in healthy volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9728897/),[ml] / [min],106.7,270677,DB01050,Ibuprofen
,9728897,clearance,"This increase was similarly reflected in the clearance by inversion of R-ibuprofen (control, 36.0 ml/min; treated, 118.8 ml/min; p < 0.01), as well as in the clearance by noninversion (control, 19.0 ml/min; treated, 67.4 ml/min; p < 0.01).",Effect of clofibrate on the chiral inversion of ibuprofen in healthy volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9728897/),[ml] / [min],36.0,270678,DB01050,Ibuprofen
,9728897,clearance,"This increase was similarly reflected in the clearance by inversion of R-ibuprofen (control, 36.0 ml/min; treated, 118.8 ml/min; p < 0.01), as well as in the clearance by noninversion (control, 19.0 ml/min; treated, 67.4 ml/min; p < 0.01).",Effect of clofibrate on the chiral inversion of ibuprofen in healthy volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9728897/),[ml] / [min],118.8,270679,DB01050,Ibuprofen
,9728897,clearance,"This increase was similarly reflected in the clearance by inversion of R-ibuprofen (control, 36.0 ml/min; treated, 118.8 ml/min; p < 0.01), as well as in the clearance by noninversion (control, 19.0 ml/min; treated, 67.4 ml/min; p < 0.01).",Effect of clofibrate on the chiral inversion of ibuprofen in healthy volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9728897/),[ml] / [min],19.0,270680,DB01050,Ibuprofen
,9728897,clearance,"This increase was similarly reflected in the clearance by inversion of R-ibuprofen (control, 36.0 ml/min; treated, 118.8 ml/min; p < 0.01), as well as in the clearance by noninversion (control, 19.0 ml/min; treated, 67.4 ml/min; p < 0.01).",Effect of clofibrate on the chiral inversion of ibuprofen in healthy volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9728897/),[ml] / [min],67.4,270681,DB01050,Ibuprofen
,9728897,Unbound clearance,"Unbound clearance values significantly increased for R-ibuprofen (control, 19.5 L/min; treated, 38.7 L/min) but not for 13C-S-ibuprofen (11.8 versus 10.6 L/min, respectively).",Effect of clofibrate on the chiral inversion of ibuprofen in healthy volunteers. ,CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9728897/),[l] / [min],19.5,270682,DB01050,Ibuprofen
,9728897,Unbound clearance,"Unbound clearance values significantly increased for R-ibuprofen (control, 19.5 L/min; treated, 38.7 L/min) but not for 13C-S-ibuprofen (11.8 versus 10.6 L/min, respectively).",Effect of clofibrate on the chiral inversion of ibuprofen in healthy volunteers. ,CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9728897/),[l] / [min],38.7,270683,DB01050,Ibuprofen
,9728897,Unbound clearance,"Unbound clearance values significantly increased for R-ibuprofen (control, 19.5 L/min; treated, 38.7 L/min) but not for 13C-S-ibuprofen (11.8 versus 10.6 L/min, respectively).",Effect of clofibrate on the chiral inversion of ibuprofen in healthy volunteers. ,CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9728897/),[l] / [min],11.8,270684,DB01050,Ibuprofen
,9728897,Unbound clearance,"Unbound clearance values significantly increased for R-ibuprofen (control, 19.5 L/min; treated, 38.7 L/min) but not for 13C-S-ibuprofen (11.8 versus 10.6 L/min, respectively).",Effect of clofibrate on the chiral inversion of ibuprofen in healthy volunteers. ,CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9728897/),[l] / [min],10.6,270685,DB01050,Ibuprofen
,15606441,plasma half-life,"Thus, after administration of 400 mg ibuprofen, the plasma half-life (95% confidence intervals) for individuals with genotypes CYP2C8*1/*1, CYP2C8*1/*3 and CYP2C8*3/*3, was 2.0 h (1.8-2.2), 4.2 h (1.9-6.5; P < 0.05) and 9.0 h (7.8-10.2; P < 0.002), respectively.",The effect of the cytochrome P450 CYP2C8 polymorphism on the disposition of (R)-ibuprofen enantiomer in healthy subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15606441/),h,2.0,271031,DB01050,Ibuprofen
,15606441,plasma half-life,"Thus, after administration of 400 mg ibuprofen, the plasma half-life (95% confidence intervals) for individuals with genotypes CYP2C8*1/*1, CYP2C8*1/*3 and CYP2C8*3/*3, was 2.0 h (1.8-2.2), 4.2 h (1.9-6.5; P < 0.05) and 9.0 h (7.8-10.2; P < 0.002), respectively.",The effect of the cytochrome P450 CYP2C8 polymorphism on the disposition of (R)-ibuprofen enantiomer in healthy subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15606441/),h,4.2,271032,DB01050,Ibuprofen
,15606441,plasma half-life,"Thus, after administration of 400 mg ibuprofen, the plasma half-life (95% confidence intervals) for individuals with genotypes CYP2C8*1/*1, CYP2C8*1/*3 and CYP2C8*3/*3, was 2.0 h (1.8-2.2), 4.2 h (1.9-6.5; P < 0.05) and 9.0 h (7.8-10.2; P < 0.002), respectively.",The effect of the cytochrome P450 CYP2C8 polymorphism on the disposition of (R)-ibuprofen enantiomer in healthy subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15606441/),h,9.0,271033,DB01050,Ibuprofen
,1304448,FBL,Similar FBL values were observed in both groups (group A vs B): during the first week the FBL values were (mean +/- SD) 0.40 +/- 0.23 ml/day vs 0.55 +/- 0.53 ml/day on days 1-3 and 0.40 +/- 0.21 ml/day vs 0.37 +/- 0.13 ml/day on days 4-7.,Unaltered ibuprofen-induced faecal blood loss upon coadministration of moclobemide. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1304448/),[ml] / [d],0.40,274100,DB01050,Ibuprofen
,1304448,FBL,Similar FBL values were observed in both groups (group A vs B): during the first week the FBL values were (mean +/- SD) 0.40 +/- 0.23 ml/day vs 0.55 +/- 0.53 ml/day on days 1-3 and 0.40 +/- 0.21 ml/day vs 0.37 +/- 0.13 ml/day on days 4-7.,Unaltered ibuprofen-induced faecal blood loss upon coadministration of moclobemide. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1304448/),[ml] / [d],0.55,274101,DB01050,Ibuprofen
,1304448,FBL,Similar FBL values were observed in both groups (group A vs B): during the first week the FBL values were (mean +/- SD) 0.40 +/- 0.23 ml/day vs 0.55 +/- 0.53 ml/day on days 1-3 and 0.40 +/- 0.21 ml/day vs 0.37 +/- 0.13 ml/day on days 4-7.,Unaltered ibuprofen-induced faecal blood loss upon coadministration of moclobemide. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1304448/),[ml] / [d],0.40,274102,DB01050,Ibuprofen
,1304448,FBL,Similar FBL values were observed in both groups (group A vs B): during the first week the FBL values were (mean +/- SD) 0.40 +/- 0.23 ml/day vs 0.55 +/- 0.53 ml/day on days 1-3 and 0.40 +/- 0.21 ml/day vs 0.37 +/- 0.13 ml/day on days 4-7.,Unaltered ibuprofen-induced faecal blood loss upon coadministration of moclobemide. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1304448/),[ml] / [d],0.37,274103,DB01050,Ibuprofen
,1304448,FBL,"The increase in FBL during the second week was comparable in both groups, with and without moclobemide (days 8-10: 0.78 +/- 0.59 ml/day vs 0.80 +/- 0.58 ml/day; days 11-14: 1.49 +/- 0.95 ml/day vs 1.28 +/- 0.62 ml/day).",Unaltered ibuprofen-induced faecal blood loss upon coadministration of moclobemide. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1304448/),[ml] / [d],0.78,274104,DB01050,Ibuprofen
,1304448,FBL,"The increase in FBL during the second week was comparable in both groups, with and without moclobemide (days 8-10: 0.78 +/- 0.59 ml/day vs 0.80 +/- 0.58 ml/day; days 11-14: 1.49 +/- 0.95 ml/day vs 1.28 +/- 0.62 ml/day).",Unaltered ibuprofen-induced faecal blood loss upon coadministration of moclobemide. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1304448/),[ml] / [d],0.80,274105,DB01050,Ibuprofen
,1304448,FBL,"The increase in FBL during the second week was comparable in both groups, with and without moclobemide (days 8-10: 0.78 +/- 0.59 ml/day vs 0.80 +/- 0.58 ml/day; days 11-14: 1.49 +/- 0.95 ml/day vs 1.28 +/- 0.62 ml/day).",Unaltered ibuprofen-induced faecal blood loss upon coadministration of moclobemide. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1304448/),[ml] / [d],1.49,274106,DB01050,Ibuprofen
,1304448,FBL,"The increase in FBL during the second week was comparable in both groups, with and without moclobemide (days 8-10: 0.78 +/- 0.59 ml/day vs 0.80 +/- 0.58 ml/day; days 11-14: 1.49 +/- 0.95 ml/day vs 1.28 +/- 0.62 ml/day).",Unaltered ibuprofen-induced faecal blood loss upon coadministration of moclobemide. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1304448/),[ml] / [d],1.28,274107,DB01050,Ibuprofen
